ID,title,actual_duration,status,study_type,arm_group_type,intervention_type,interventional_type_model,phase,fda_regulated_drug,fda_regulated_device,enrollment_count
IRST174.22,What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?,2187 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,60000
GCO 17-2188,Increasing African Immigrant Womens Participation in Breast Cancer Screening,1212 days,Recruiting,Interventional,Other,Behavioral,Single Group Assignment,Not Applicable,No,No,168
233756,The HIFUB Study (HIFU in Breast Cancer),184 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,15
D16196,A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers,1047 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,18
RO1912-30902,RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients,762 days,Unknown status,Interventional,"Other, Experimental",Radiation,Parallel Assignment,Not Applicable,No,No,166
UMCC 2021.087,Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid,354 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,40
LNs Staging of Breast cancer,Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer.,1157 days,Unknown status,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,50
SA18i0002,The Effect of a Patient Decision Aids for Breast Cancer Screening,487 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,3269
494936,Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening,4666 days,Recruiting,Interventional,Experimental,Genetic,Single Group Assignment,Not Applicable,No,No,80
042210,Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer,1842 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,16
(818)109A-57,Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy,959 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,70
21 SEIN 01,Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.,485 days,Completed,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,61
18-181,Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening,2677 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,100
catheter guided chemo-infusion,Catheter Guided Chemo-infusion in Breast Cancer,761 days,Not yet recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,50
2020/132,Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS),245 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Single Group Assignment,Not Applicable,No,No,150
17-689,Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening,1931 days,"Active, not recruiting",Interventional,Experimental,"Device, Device",Single Group Assignment,Not Applicable,No,Yes,82
831804,[18F] F-GLN by PET/CT in Breast Cancer,2067 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,30
154/2019,Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery,1546 days,Suspended,Interventional,"Experimental, Other",Other,Parallel Assignment,Not Applicable,No,No,36
Amr Ahmed,"The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism",395 days,Not yet recruiting,Interventional,"Experimental, Experimental",Combination Product,Parallel Assignment,Early Phase 1,Yes,No,200
2022-11-076-002,Comparison of Ultrasound and Breast MRI for Breast Cancer Detection,1827 days,Not yet recruiting,Interventional,"Experimental, Experimental",Diagnostic Test,Crossover Assignment,Not Applicable,No,No,1464
Health Literacy of Breast Ca,The Effect of Breast Cancer Screening Training,318 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,60
ZY(2018-2020)-CCCX-2005-04,Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer,1467 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,200
22IC7498,Behavioural Science Messages in Breast Cancer Screening,184 days,Completed,Interventional,"Active Comparator, Experimental, Experimental","Behavioral, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,34047
18 SEIN 11,"Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.",2369 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Phase 2,No,No,55
17-447,Imaging With [11C]Martinostat in Breast Cancer,1734 days,Withdrawn,Interventional,Experimental,"Drug, Device",Single Group Assignment,Phase 1,Yes,No,0
22-509,Breast Cancer Survivor Educational Intervention,184 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,15
ID-BCRPS-02-20220913,The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population,108 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,20
17-01549,Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer,2376 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,Yes,170
202101073,Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool,133 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,1277
"estPerMed 1, Breast",Personalised Risk-based Breast Cancer Prevention and Screening,792 days,Unknown status,Interventional,"Active Comparator, Active Comparator, No Intervention",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,28389
68824072019,Risk Reduction Program for Women Having High Risk of Breast Cancer,1249 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,77
20220303swj0211,The Psychology Intervention on Disease Acceptance and Quality of Life in Breast Cancer Patients,731 days,Not yet recruiting,Interventional,"Experimental, Other",Behavioral,Parallel Assignment,Not Applicable,No,No,90
RC20_0532,Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid,731 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,66000
KMUHIRB-E(I)-20200041,"Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment",696 days,Completed,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,73
4452,Development of a Horizontal Data Integration Classifier for Noninvasive Early Diagnosis of Breast Cancer,1412 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Diagnostic Test, Diagnostic Test",Sequential Assignment,Not Applicable,No,No,367
SK-421-BRCA,A Digital Solution for Breast Cancer Patients,413 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,66
autotaxin1,Autotaxin: a Potential Biomarker for Breast Cancer.,804 days,Completed,Interventional,"Active Comparator, Sham Comparator",Biological,Parallel Assignment,Not Applicable,No,No,110
DS8201-A-U302,"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",2062 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,524
CCR 5113,PIONEER Study of Lifestyle Intervention to Reduced Breast Cancer Risk,1171 days,"Active, not recruiting",Interventional,"No Intervention, No Intervention, Experimental, Experimental, Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,240
ICO-N-2017-02,Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse,919 days,Terminated,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,50
medicin,Autotaxin (ATX) as a Marker for Breast Cancer,549 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Diagnostic Test, Radiation, Diagnostic Test, Diagnostic Test, Radiation, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Other, Other",Parallel Assignment,Not Applicable,No,No,100
METCZ20200211,Magnetic Tracer in the Sentinel Node Procedure in Breast Cancer: the Non-radioactive Alternative for Radio-isotopes,192 days,Completed,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,40
2020-A00058-31,Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening,2161 days,Recruiting,Interventional,"Other, Other, Other",Other,Parallel Assignment,Not Applicable,No,No,1100
351-19,mULM to Support Breast Cancer Diagnosis and Therapy,949 days,Recruiting,Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,74
PekingUPH10B004,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients,2099 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,46
CD3-MUC1 in breast cancer,Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer,412 days,Withdrawn,Interventional,"Experimental, Active Comparator, No Intervention","Biological, Procedure",Parallel Assignment,Phase 2,No,No,0
LCCC 1829,Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA,4422 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,500
2022-080,"Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer",1091 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
20218,A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy,1372 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,13
LA LEAST,Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer,3508 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,290
2015-004027-31,HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer,1759 days,Recruiting,Interventional,"Other, Other",Radiation,Parallel Assignment,Not Applicable,No,No,24
BREACE,Exercise in Older Women With Breast Cancer During Systemic Therapy,1842 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,100
495077,18F-FDG PET/CT Imaging for Breast Cancer,3606 days,Recruiting,Interventional,"Other, Other",Other,Parallel Assignment,Not Applicable,No,No,300
CCR4684,"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours",1880 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,58
211753,BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity,876 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,500
1705018188,Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer,1450 days,Terminated,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,Yes,14
22-136,"A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer",1096 days,Recruiting,Interventional,Experimental,"Diagnostic Test, Radiation, Procedure",Single Group Assignment,Phase 1,No,No,60
RECO_CT29B,Investigation of Urinary Biomarkers for the Detection of Breast Cancer,467 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,200
D8531C00002,A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy,4921 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,4300
SOLTI-1910,Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.,799 days,Recruiting,Interventional,"Experimental, Active Comparator",Drug,Parallel Assignment,Phase 2,No,No,63
Targeted axillary dissection,Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy,609 days,Not yet recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Phase 4,No,No,30
2021-0215,BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer,842 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,40
17-398,Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer,462 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,45
IC 2018-01,Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer,788 days,Completed,Interventional,"Experimental, Experimental","Diagnostic Test, Diagnostic Test",Sequential Assignment,Not Applicable,No,No,15
IC 2020 08,Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer.,329 days,Completed,Interventional,"Experimental, Experimental","Diagnostic Test, Diagnostic Test",Sequential Assignment,Not Applicable,No,No,35
PI17/00834,Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening,1066 days,Completed,Interventional,,Other,Single Group Assignment,Not Applicable,No,No,387
PekingUMCH-FAPI-BC-1,Characterizing Breast Cancer With 68Ga-FAPI PET/CT,974 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,100
PekingUMCH-FAPI-BC-2,Characterizing Breast Cancer With Al18F-NOTA-FAPI-04 PET/CT,416 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,100
180034,ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma,1359 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,30
IRB17-0721,Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,1662 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,74
BCL IDE,Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer,920 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,Yes,448
REO 027,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer,1118 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Drug, Drug, Drug",Parallel Assignment,Early Phase 1,No,No,26
V3-MOMMO-01,Open Label Immunotherapy Trial for Breast Cancer,548 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,Phase 2,No,No,20
077-2019,Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Locally-Advanced Breast Cancer,1430 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,20
Juçara Phd Thesis,Emotional Evaluation and Reconstructed Breast Satisfaction,973 days,Unknown status,Interventional,"Experimental, Active Comparator","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,110
18 SEIN 08,The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.,315 days,Terminated,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,4
2021-012,Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE),731 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,58
CASE12119,Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer,1068 days,Recruiting,Interventional,"Experimental, Active Comparator","Genetic, Genetic, Other, Other, Device",Parallel Assignment,Not Applicable,No,Yes,100
18-124,ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer,4026 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,82
EFC16133,"Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity",238 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,3
s66248,Identifying Prognostic Variables for Persistent Upper Limb Dysfunctions After Breast Cancer Treatment,1012 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,250
964635,The Benefit of Surgery in Stage IV of Breast Cancer,395 days,Unknown status,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,212
SCCC-11118; STU-2018-0015,Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer,2195 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,61
2019402,Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners,580 days,Not yet recruiting,Interventional,"Experimental, Experimental, Other","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,102
RADIO-SLEEP,Sleep Disorders Prior to and During a Course of Radiotherapy for Breast Cancer,394 days,Not yet recruiting,Interventional,Experimental,"Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,No,51
19-001,Individualizing Surveillance Mammography for Older Breast Cancer Survivors,777 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,45
UCaenNormandie,A Randomized Cluster Trial to Evaluate a Mobile Mammography Unit in Breast Cancer Screening in France (Mammobile),930 days,Enrolling by invitation,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,91982
17-552,Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening,2082 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,Yes,910
CCR5348,Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer,2191 days,Not yet recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,400
STUDY00011606,Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women,85 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, No Intervention","Other, Other, Other, Other",Factorial Assignment,Not Applicable,No,No,500
03/21,A Prospective Single-center Cohort Study Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients,304 days,Not yet recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,31
AHQU-2021007,Genetic Predictors of Response to Acupuncture for Cancer-related Fatigue Among Breast Cancer Patients After Chemotherapy,578 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,60
D8530C00003,"A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer",949 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,132
2019-05-157,Genetic Characteristics of Metastatic Breast Cancer Patients,1841 days,Recruiting,Interventional,Other,Diagnostic Test,Sequential Assignment,Not Applicable,No,No,300
200056,"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",171 days,Terminated,Interventional,"Experimental, Experimental, Experimental","Biological, Drug, Biological, Biological",Sequential Assignment,Phase 1,Yes,No,1
182-20-CA,18F-fluoroestradiol (FES) PET/CT for Breast Cancer,1064 days,Recruiting,Interventional,"Experimental, Experimental",Diagnostic Test,Parallel Assignment,Phase 2,Yes,No,124
Shengjing-LCG008,Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy,2191 days,Not yet recruiting,Interventional,"Experimental, Other","Drug, Drug",Parallel Assignment,Phase 3,No,No,450
NeoRadUKD,NeoRad Breast Cancer Study,3835 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,1826
STUDY19060359,Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania,2348 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,1650
UEM0002,Synergic Effects of Physical Activity and Probiotic on Gut Immune System and Quality of Life of Breast Cancer Survivors.,456 days,Withdrawn,Interventional,"Experimental, Experimental, Placebo Comparator","Other, Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,0
004181,Together After Cancer,1155 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,480
21 SEIN 09,"Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.",1074 days,Recruiting,Interventional,Other,"Other, Other",Single Group Assignment,Not Applicable,No,No,120
CINEICC-3-IAT,Mind Programme for Women With Breast Cancer,972 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,154
Bakircay University,Training With Mobile Application in Breast Cancer,97 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,64
21149002,The Effect of Virtual Reality on Anxiety and Fatigue in Women With Breast Cancer Receiving Adjuvant Chemotherapy,240 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,66
AAAU1629,FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments,427 days,Not yet recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,55
BC-NEO-IIT-SHR1316-SHR6390-RT,Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment,702 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Radiation",Parallel Assignment,Not Applicable,No,No,24
IRB202100182 -N,All-extremity Exercise During Breast Cancer Chemotherapy,396 days,Recruiting,Interventional,"Experimental, Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,68
2019-KY-001-003,PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer,1279 days,Completed,Interventional,Experimental,Drug,Sequential Assignment,"Phase 1, Phase 2",No,No,15
AbantIBU,Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery,457 days,Withdrawn,Interventional,"Experimental, Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,0
121K686,Online Group Therapy for Breast Cancer,259 days,Recruiting,Interventional,"Experimental, Active Comparator, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,51
NADOPTIC,Monitoring Response to NAC and Prediction of pCR in Breast Cancer Patients Using Optical Imaging,1096 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,20
Pro00020917,Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer,1796 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,39
Breast Cancer,"Effects of Continuous and Interval Physical Training Through the Intensity of the Incremental Shuttle Walk Test, on Functional Capacity and Quality of Life in Women With Malignant Breast Cancer During Chemotherapy Treatment",1075 days,Not yet recruiting,Interventional,"Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,60
BSU,The Effect of Metformin on Breast Cancer Patients,488 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,80
URomLS Prot.0930/2021Rif. 6528,To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study),148 days,Completed,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,20
SOLTI-1716,Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression,1564 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,46
LCCC 1749,Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging,2817 days,Recruiting,Interventional,Experimental,"Behavioral, Other",Single Group Assignment,Not Applicable,No,No,100
GIMI-IRB-20005,Multi-4SCAR-T Therapy Targeting Breast Cancer,1308 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,100
202302017,Cryoablation vs Lumpectomy in T1 Breast Cancers,2741 days,Not yet recruiting,Interventional,"Experimental, Active Comparator, Other, Experimental","Device, Procedure",Parallel Assignment,Not Applicable,No,Yes,256
2015-4-6-003,Prevention of Sequelae Pain After Breast Cancer Surgery by Self-massages and Self Stretching. Impact of Learning Workshops.,1615 days,Recruiting,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,144
FIRST,FreezIng bReaST Cancer in Brazil: a Before-after Study,669 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,30
147/19,Breast Cancer: Feasibility of an Educational Intervention,344 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,224
STUDY00001641,Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women,869 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,320
PetrovRIO,Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB),3351 days,Recruiting,Interventional,"Experimental, Experimental",Procedure,Single Group Assignment,Not Applicable,No,No,60
wanghaibo,Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer,1635 days,Not yet recruiting,Interventional,Experimental,Biological,Single Group Assignment,Early Phase 1,No,No,10
852-20,"Breast Cancer, Reasoning, and Activity Intervention",1609 days,Withdrawn,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,0
2020[84],HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody,1498 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Early Phase 1,No,No,40
IBCSG 59-19,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,2623 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,400
33293720.9.0000.5505,Tele-rehabilitation in Women With Breast Cancer During COVID-19 Pandemic.,1005 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,60
199080,Prospective Trial of Digital Breast Tomosynthesis (DBT) in Breast Cancer Screening.,2023 days,Recruiting,Interventional,"Experimental, Active Comparator","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,100000
SLN SPECT,Sentinel Lymph Node Identification in Patients With Breast Cancer Using SPECT/CT,1523 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Device, Device",Sequential Assignment,Not Applicable,No,No,4
SOLTI-1907,Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer,1442 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,55
SDS-HER-01-2018,Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer,190 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,18
APHP211502,Breast Cancer Prevention and Screening Membership,3593 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,189
SCHBCC-N024,Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer,1826 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,186
CELC-G-301,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),1461 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,701
DBCG Proton trial,The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer,6209 days,Recruiting,Interventional,"Active Comparator, Experimental",Radiation,Parallel Assignment,Not Applicable,No,Yes,1502
OOTR-N016/KBCRN-B-003/HT-PAB,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",891 days,Completed,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,141
710/2021,The Effect of Arm Exercises on Arm Oedema After Breast Cancer Surgery,773 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,30
KL166-IIS-001,HER2-positive Breast Cancer Project Initiated by Investigators,944 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,48
N19ASC,Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy,2738 days,Not yet recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,340
SNBvsPET/MRI 2,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,1687 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,247
dingxwyh01,Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer,669 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Not Applicable,No,No,50
SNUH_FMI,Molecular Profiling in Young (<50 Years of Age) Patients With Metastatic Breast Cancer,669 days,Unknown status,Interventional,Other,Genetic,Single Group Assignment,Not Applicable,No,No,200
2022/0035986,Vocational Rehabilitation for the Return to Work of Breast Cancer Patients: a Feasibility Study,723 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,25
RF-2013-02358165,Axillary Reverse Mapping (ARM) in Breast Cancer Surgery to Prevent Lymphedema. (ARMtrial),1049 days,Unknown status,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,300
18-516,GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,2484 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,47
19-147,Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer,406 days,Completed,Interventional,Experimental,"Diagnostic Test, Other",Single Group Assignment,Phase 1,Yes,No,6
dingxwyh02,The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer,669 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Not Applicable,No,No,50
19 SEIN 14,E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer.,509 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,45
AURORA,New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA),730 days,Unknown status,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,20
BR02/03/21,Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer,1486 days,Recruiting,Interventional,Experimental,Device,Sequential Assignment,Phase 1,No,No,26
2018-9529,TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer,1998 days,Recruiting,Interventional,"Other, Other","Device, Procedure",Parallel Assignment,Not Applicable,No,Yes,75
REaCT-HER TIME,Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy,627 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,20
SOLTI-1911,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,2981 days,Recruiting,Interventional,"Experimental, Other","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,530
IC 2018-08,Breast Cancer Risk After Diagnostic Gene Sequencing,863 days,Completed,Interventional,Experimental,"Genetic, Genetic, Behavioral",Single Group Assignment,Not Applicable,No,No,405
AHQU-2021006,Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer,735 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,59
V2011201,Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer,438 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,0
HCB-ONC001 (ML41519),Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy,2260 days,Recruiting,Interventional,"Experimental, No Intervention",Biological,Single Group Assignment,Phase 2,No,No,17
IRB-300002157,RAD 1802: Pilot Trial of Dose Adapted Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI),2295 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,Yes,40
Shengjing-LCG009,Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients,2205 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
OTT-19-06,"A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer",433 days,Completed,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,No,No,40
FAST feasibility in CU,Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer,1969 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,20
BC001,Moving on After Breast Cancer Plus- for Breast Cancer Survivors,1213 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,354
UT BCS ECS Study,Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors,218 days,Withdrawn,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,0
19-509,Genetic Testing for All Breast Cancer Patients (GET FACTS),1370 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,400
19-277,Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients,1252 days,"Active, not recruiting",Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,34
UW 20-064,Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy,2999 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,30
20-1039,Couples QOL in Metastatic Breast Cancer,1338 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,112
UC-0105/1701,SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer,1709 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,31
18-1025,Coping Together After Breast Cancer,1438 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,240
09.2019.984,Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema,85 days,Unknown status,Interventional,Experimental,Combination Product,Single Group Assignment,Not Applicable,No,No,22
O4M-B001,Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients,122 days,Unknown status,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,No,125
TaiHao TVGH2020-07-006AC#1,Evaluation of TaiHao Breast Ultrasound Diagnosis Software RN-CES Descartes,60 days,"Active, not recruiting",Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,3
STGKS001,Artificial Intelligence in Large-scale Breast Cancer Screening,1340 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,No,55579
19-086,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",2012 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,77
CNER 202107/05,eHealth Intervention for Medication Adherence in Breast Cancer Survivors,512 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,15
Optimune Trial,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,1506 days,Terminated,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,64
1808019498,Converting HR+ Breast Cancer Into an Individualized Vaccine,2114 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator","Radiation, Drug, Biological",Parallel Assignment,Phase 2,Yes,No,100
HYGEE,Evaluation of the Impact of the Use of Hypnotherapy Performed by a Virtual Reality Toolalong the Care Pathway of Patients Undergoing Breast Cancer Treatment.,1080 days,"Active, not recruiting",Interventional,"No Intervention, Experimental",Device,Parallel Assignment,Not Applicable,No,No,27
STU-2018-0370,Infrared Imaging for Breast Cancer Modeling,1084 days,Completed,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,11
Prix Ruban Rose/2021/FF-01,Personalized Follow-up After Breast Cancer Surgery Via Electronic Patient Reported Outcomes,455 days,Completed,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,20
Pyrotinib neoadjuvant,Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer,899 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Combination Product, Combination Product",Parallel Assignment,Phase 2,No,No,80
FUSCC-OMIT,A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT),1917 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,172
SMC 2021-02-102,"Selective Omission of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm studyTrial",2652 days,Enrolling by invitation,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,178
BSMMU/2019/8874,Effect of Vitamin C and E in Breast Cancer Patients Undergoing Chemotherapy,341 days,Unknown status,Interventional,"No Intervention, Active Comparator",Drug,Parallel Assignment,Not Applicable,No,No,80
99mTc-ADAPT6 vs 99mTc-DARPinG3,Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3,265 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Not Applicable,No,No,15
Telemonitoring BCS,"Effect of Telemonitoring on Functionality, Quality of Life and Risk of Lymphedema in Breast Cancer Survivors",122 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,30
CCTG MA.39,Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer,3501 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Radiation, Other",Parallel Assignment,Phase 3,No,Yes,2140
19/317-2101,Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients,1454 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,2000
2021-1116,Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks,2526 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 3,No,No,400
SPT-2021-002,Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer,1390 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 4,No,No,70
s66248-aim2,Identifying Prognostic Variables for Persistent UL Dysfunctions After Breast Cancer Treatment -Reliability and Validity,1012 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,150
BGB-290-201,Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China,1027 days,Completed,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,88
10038,Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*),5479 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Biological",Sequential Assignment,Phase 1,Yes,No,69
Pro00085352,Examining Bioactivity of PVSRIPO in Invasive Breast Cancer,1250 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Early Phase 1,Yes,No,6
EORTC 1745-ETF-BCG,Adjuvant Palbociclib in Elderly Patients With Breast Cancer,4857 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,366
4523,Acupuncture Treatment of Vasomotor Symptoms in Breast Cancer Patients,1126 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,90
17-455,The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer,2536 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Crossover Assignment,Phase 2,Yes,No,100
01AB21- PIK3CA,Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.,1040 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,40
ICO-N-2017-12,Clinico-biological Data Collection Study of Metastatic Breast Cancer,6581 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Procedure, Biological, Behavioral",Parallel Assignment,Not Applicable,No,No,300
Optimune Trial Add-on,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,731 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,360
2018396H,TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer,1096 days,Unknown status,Interventional,"Experimental, Active Comparator",Drug,Parallel Assignment,Phase 2,No,No,200
PROICM 2020-05 SKY,Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.,1632 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,108
GEICAM/2019-01,Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients,4532 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,200
MA-BC-Ⅱ-040,Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer,639 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,35
2019-1183,A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer,2046 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 1,No,Yes,70
IJB-NERABRAIN-ODN-007,Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer,0 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,0
19-066,Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer,2017 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention, Experimental",Device,Parallel Assignment,Not Applicable,No,Yes,214
EH18-203,The MEDITATE-BC Study: Mindfulness-Enhanced Decision Intervention To Aid Treatment Election - Breast Cancer,459 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,22
A211801,Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation,4299 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Other",Parallel Assignment,Phase 3,Yes,No,300
CAAE: 39277420.8.0000.5313,Adaptations to Breast Cancer and Exercise Using Telehealth (ABRACE: Telehealth),758 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,36
D361DC00001,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),2797 days,Recruiting,Interventional,"Experimental, Placebo Comparator, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,700
PekingUMCH-NM25,99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer,390 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,34
5354-CL-1201,A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery,416 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 2,Yes,No,132
2019-228,Prophylactic Irradiation to the Contralateral Breast for BCAs Patients,2526 days,Recruiting,Interventional,"No Intervention, Experimental",Radiation,Parallel Assignment,Not Applicable,No,No,323
800646,Intervening on Womens Health for Rural Young Breast Cancer Survivors,928 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Sequential Assignment,Not Applicable,No,No,135
NP 1521/19,Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer,1826 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Other",Parallel Assignment,Not Applicable,No,No,86
DARE,"DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer",2135 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,100
[2019]52,HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02,975 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,10
NOV2016PhD818,Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.,298 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,41
GEICAM/2017-01_IBCSG 62-20_BIG,Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET),1813 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Biological, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,300
PekingUMCH-FES-BC-1,Characterizing Breast Cancer With 18F-FES PET/CT,1340 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,50
GCO 17-00563,Integrated Intervention for Breast Cancer Survivors With Diabetes,582 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,60
EudraCT 2020-005200-19,Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC),694 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,40
D9673C00007,A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer,962 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 3,Yes,No,500
J21125,Cardiometabolic Screening Program,1824 days,Recruiting,Interventional,Other,"Other, Other, Behavioral, Behavioral, Other, Other, Behavioral, Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,450
UBRS20139,Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling,1074 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,22
TQB3616-III-03,Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer,1402 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,1946
20 SEIN 13,Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer,1084 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,200
20190283,SABER Study for Selected Early Stage Breast Cancer,1822 days,Recruiting,Interventional,Experimental,Radiation,Sequential Assignment,Not Applicable,No,Yes,18
NCC3075,Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer,1095 days,Not yet recruiting,Interventional,"Experimental, Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 2,No,No,60
19900601,Effect of Lymphedema Prevention Program Based on Theory of Knowledge-attitude-practice on Postoperative Breast Cancer Patients,282 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Factorial Assignment,Not Applicable,No,No,108
DBCG RT Recon,Delayed-immediate Versus Delayed Breast Reconstruction in Breast Cancer Patients With Mastectomy and Radiation Therapy,5053 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,590
PROICM 2019-11 PRA,A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer,4380 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other, Radiation",Parallel Assignment,Phase 3,No,No,400
SPHIC-TR-BCa2022-01,A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer,1096 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 1,No,No,24
SRMBCNabP2022,Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer,436 days,Not yet recruiting,Interventional,"Active Comparator, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,No,No,30
C3441020,Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer,758 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,61
FDRT-BC009,FSRT in Breast Cancer Patients With Brain Metastases,1096 days,Unknown status,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,170
18-223,Olaparib + Sapacitabine in BRCA Mutant Breast Cancer,2456 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,10
MCC-20897,DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer,964 days,Recruiting,Interventional,Experimental,"Biological, Biological",Sequential Assignment,Phase 1,Yes,No,30
IIT2018-01-McArthur-IPI,Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer,2393 days,Recruiting,Interventional,Experimental,"Drug, Drug, Procedure, Procedure",Single Group Assignment,Phase 2,Yes,No,80
BCHRD201,AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer,365 days,Unknown status,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,100
BrIMA,Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer,379 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,160
ChanghaiHTB,Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy,3195 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Procedure, Procedure, Drug",Sequential Assignment,Not Applicable,No,No,362
2018-00838; ch20Weber2,Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS),6691 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Procedure, Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,1500
WSG-AM09,A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1),651 days,Completed,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,46
UC-0107/1903,Patients Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer,1431 days,Recruiting,Interventional,"Other, Other, No Intervention","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,250
AHQU-2021005,Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxanes Chemotherapy in Breast Cancer,730 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,54
BC-2019,The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target,1765 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,300
19-188,"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",986 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,30
SP00049673,Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB,522 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,49
17-512,Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer,2708 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,78
SCBCS025,"Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China",1488 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,34
19-239,Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.,1880 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,75
LC2019L06,Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy,2860 days,Recruiting,Interventional,"Experimental, No Intervention","Drug, Drug",Parallel Assignment,Phase 2,No,No,286
HNCH-BC003,Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients,746 days,Withdrawn,Interventional,"Experimental, Active Comparator","Combination Product, Other",Parallel Assignment,Phase 2,No,No,0
02AB21-TucErBit,"A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer",921 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,30
IRB-48150,68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer,1918 days,Suspended,Interventional,Experimental,"Drug, Procedure, Procedure, Device",Single Group Assignment,"Phase 1, Phase 2",Yes,Yes,20
IUSCC-0613,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,859 days,Completed,Interventional,Experimental,"Drug, Drug",Sequential Assignment,Phase 1,Yes,No,18
16-145,Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy,1842 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Procedure",Parallel Assignment,Not Applicable,No,Yes,98
State University of São Paulo,Aerobic Training in Treatment for Breast Cancer,883 days,Completed,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,6
21-440,Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer,476 days,Recruiting,Interventional,"Experimental, Experimental","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,20
YM107109E,Breast Cancer Self-Management Mobile Care Application Intervention in the Quality of Life,176 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,112
GEICAM/2020-08,Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer,1242 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,49
2023-09,Feasibility of Carbon-Dye Marking of Axillary Lymph Nodes Before Neoadjuvant Chemotherapy in Patients With Breast Cancer,388 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,50
ARV-471-BC-201,A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery,472 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Procedure",Parallel Assignment,Phase 2,Yes,No,150
18-333,A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy,2160 days,"Active, not recruiting",Interventional,Experimental,"Device, Device",Single Group Assignment,Not Applicable,No,Yes,30
MA-BC-II-024,Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),1476 days,Not yet recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,420
GNC-035-103,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer",734 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,29
DS8201-A-U301,DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02],2223 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,600
M18DMB,ModraDoc006/r in Patients With Breast Cancer,649 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,12
ZNJC201935,Nomogram to Predict Breast Cancer Related Lymphedema,2576 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,600
SCHBCC0N026,A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC,711 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,20
MUKDEN-09,"Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer",1816 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,236
RGT-419B_01-101,"First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer",908 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,48
21-003046,"Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer",695 days,Recruiting,Interventional,Experimental,"Procedure, Drug",Single Group Assignment,Phase 2,Yes,No,50
SSGJ-302H-mBC-IIT-01,Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC,725 days,Recruiting,Interventional,"Active Comparator, Experimental",Drug,Parallel Assignment,Phase 4,No,No,60
KY2019-070,Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,3151 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 3,No,No,316
D8530C00001,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,2013 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,403
BT006,Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases,895 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,10
1R01CA236860-01A1,Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors,1794 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,250
310-17-SZMC,Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer,789 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,15
CINDERELLA,Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.,914 days,Not yet recruiting,Interventional,"Experimental, Other",Device,Parallel Assignment,Not Applicable,No,No,1030
2017-01282 (BASEC),Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer,23 days,Terminated,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,1
RP-20-013,Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer,1004 days,Withdrawn,Interventional,"Experimental, Experimental",Drug,Single Group Assignment,Phase 4,Yes,No,0
CCR5214,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",1096 days,Not yet recruiting,Interventional,"Experimental, Active Comparator, Active Comparator, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,324
MCC-21757,Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer,1458 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Phase 2,No,Yes,86
K2022-025-01,A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer,1096 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,63
0720222005,The Postoperative Radiotherapy in N1 Breast Cancer Patients,4170 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,1106
D967UC00001,"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",3170 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,1134
PLEASURABLE,"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer",2404 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,59
21822,"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer",1290 days,Withdrawn,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,0
CTNZ-2017-01,Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy,858 days,Completed,Interventional,"Other, Other","Drug, Drug",Crossover Assignment,Phase 2,No,No,160
20-649,"Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer",3055 days,Recruiting,Interventional,Experimental,"Drug, Drug, Radiation",Single Group Assignment,Phase 2,Yes,No,32
Qassim QDs-VELD,Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer,1185 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 1,No,No,30
HR-BLTN-III-EBC,A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,1846 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,1192
14-833-02,Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study,583 days,Completed,Interventional,"Active Comparator, Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,153
17-519,Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis,2709 days,"Active, not recruiting",Interventional,Experimental,"Drug, Procedure",Single Group Assignment,Phase 2,Yes,No,45
Radiotherapy in Breast Cancer,Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients,545 days,Completed,Interventional,"Experimental, Active Comparator",Radiation,Parallel Assignment,Phase 3,No,No,100
STML-ELA-0222,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,1315 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,322
H-41818,Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer,3924 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,34
CLUE-BCL,Evaluation of the Treatment Response in Breast Cancer Related Lymphedema,153 days,Completed,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,30
nihan25,Women on Breast Cancer Health Belıefs and Screenıng Behavıors,243 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,200
2020-0927,Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer,1114 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,300
2020FES,16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer,365 days,Unknown status,Interventional,Experimental,Radiation,Single Group Assignment,"Phase 1, Phase 2",No,No,8
SCLND0919,Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer Patients With Ipsilateral Supraclavicular Lymph Node Metastasis,1158 days,Unknown status,Interventional,"Experimental, Active Comparator","Procedure, Radiation",Parallel Assignment,Not Applicable,No,No,180
PUMA-NER-6203,A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib,546 days,Completed,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,6
KBCSG-24,Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NAC (OPTIMIST),3082 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,533
AHQU-2021001,Effect of Oxygen Inhalation on Fatigue After Chemotherapy of Breast Cancer in High Altitude Area,670 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,102
Fenofibrate in Breast Cancer,Fenofibrate Role in Breast Cancer Patients,396 days,Recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,50
AHQU-2021003,Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer,729 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,34
2018LS148,BAriaTric Surgery After Breast Cancer Treatment (BATS),672 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Procedure, Behavioral",Parallel Assignment,Not Applicable,No,No,40
PekingUMCH-BCa093,68Ga PET/CT Imaging in Breast Cancer Patients,777 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,"Phase 1, Phase 2",No,No,50
ADA,"An Integrative Intervention Based on Physical Activity, Nutrition and Supportive Care (the ADA Program) to Improve the Quality of Life of Breast Cancer Survivors",1066 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,160
514-0213/21-5000,Insulin Sensitivity After Breast Cancer,1857 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Not Applicable,No,No,24
CentroHLOBreastUnit,HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer,731 days,Unknown status,Interventional,"Experimental, No Intervention, Other, Other",Drug,Parallel Assignment,Phase 4,No,No,90
CCR4965,Evaluating a Digital Tool for Supporting Breast Cancer Patients,1186 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,165
GCO 21-0699,"Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",1068 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,60
DBCG RT Natural Trial,Partial Breast Versus no Irradiation for Women With Early Breast Cancer,6205 days,Recruiting,Interventional,"Active Comparator, No Intervention",Radiation,Parallel Assignment,Not Applicable,No,No,926
IPNCb-01,Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer,760 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
CSPC-KAL-BC-12,Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer,2010 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,250
003-2017,Stereotactic Body Radiation Therapy for Breast Cancer,1826 days,Recruiting,Interventional,Experimental,Radiation,Sequential Assignment,Not Applicable,No,No,24
Breast cancer treatment,The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer,335 days,Not yet recruiting,Interventional,"Placebo Comparator, Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 4,No,No,100
18-561,NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,1503 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,30
Vitamin D and breast cancer,Vitamin D and Calcium Supplementation in Breast Cancer,334 days,Not yet recruiting,Interventional,"No Intervention, Experimental",Drug,Parallel Assignment,"Phase 2, Phase 3",No,No,40
SYSEC-KY-KS-2021-182,Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer,364 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,64
CASE6119,Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer,700 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Biological",Parallel Assignment,Early Phase 1,Yes,No,30
KX-ORAX-CN-007,A PK Study of Oraxol in Breast Cancer Patients,597 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,24
NCC2018M-042,Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ),1035 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,40
55791222.0.0000.5313,Water and Land-based Aerobic Training in Breast Cancer Survivors,1094 days,Not yet recruiting,Interventional,"Experimental, Experimental, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,48
UF-BRE-002,Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients,1095 days,Withdrawn,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,0
GIM21 - LiqERBcept,Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial),1162 days,Completed,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,48
BREAST-SK-001,"Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.",1096 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,28
LR19/011/50551,Increasing Knowledge of Alcohol as a Risk Factor for Breast Cancer Among Women Attending Breast Screening Services,300 days,Completed,Interventional,"Experimental, Other","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,558
STU00201961A,A Research Study for Latina Women Undergoing Breast Cancer Treatment,1025 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,51
18-641,"Young, Empowered & Strong (YES): The Young Womens Breast Cancer Study 2- Focus on Intervention Pilot",119 days,Completed,Interventional,"Experimental, Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,30
CLEE011O12301C,A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer,2730 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Other",Parallel Assignment,Phase 3,Yes,No,5101
HIRSLANDEN 01 SAKK 23/18,Intelligent Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer,1749 days,Recruiting,Interventional,Experimental,Procedure,Sequential Assignment,Not Applicable,No,No,420
CCH-IRB-190414-P,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study,881 days,Recruiting,Interventional,"Experimental, Active Comparator, Active Comparator","Device, Procedure, Procedure",Parallel Assignment,Not Applicable,No,Yes,180
348455,Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer,2009 days,"Active, not recruiting",Interventional,Other,Behavioral,Single Group Assignment,Not Applicable,No,No,41
SOLTI-2101,Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype,1799 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,456
Zz123456.,The Effect of the Mobile Application-based Support Program on the Outcomes of Breast Cancer Patients in the Pandemic,580 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,100
GBG102 - SASCIA,Sacituzumab Govitecan in Primary HER2-negative Breast Cancer,3075 days,Recruiting,Interventional,"Experimental, Other","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,1332
FWA00015574/6-01-2019/korany,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,254 days,Completed,Interventional,"Experimental, Other","Drug, Drug",Parallel Assignment,Phase 2,No,No,250
UI-ROD-OCTU02,MicroRNA Profiles in Triple Negative Breast Cancer,610 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,42
PN-301-21,"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer",1372 days,Recruiting,Interventional,"Experimental, Active Comparator","Biological, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,146
ROCK,Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer,2192 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,25
SOLTI-1805,"A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression",859 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Early Phase 1,No,No,80
KY20202075-F-2,Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer,973 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
06805118.2.1001.5404,Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Early Breast Cancer,4018 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,800
AN.MCME.CR.12,Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation,1096 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,25
MedOPP293,Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer,2400 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,393
iOM-110383,A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,90 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,0
IRST174.25,Partial Breast Re-irradiation in Women in Women With Locally Recurrent Breast Cancer Previously Treated With Conservative Surgery and Whole Breast Irradiation,3258 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,68
EUROPA,ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer,3287 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Drug",Parallel Assignment,Phase 3,No,No,926
HM022BC3C01,A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer,864 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,339
UF-BRE-007,Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,1016 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,74
SOLTI-2103,NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial,2805 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,120
SOLTI-1503,Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer,2330 days,"Active, not recruiting",Interventional,Experimental,"Biological, Drug",Single Group Assignment,Early Phase 1,No,No,28
LQ009,Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study,2010 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,500
BGB-900-2001-IIT,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",820 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 2,No,No,96
CLEE011H2301,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer,2788 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,0
ONAWA (SOLTI-1802),Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer,175 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,10
1,Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction,2500 days,Recruiting,Interventional,"Experimental, No Intervention",Radiation,Parallel Assignment,Not Applicable,No,No,120
STUDY00010776,REJOIN Trial for Older Breast Cancer Survivors,899 days,Recruiting,Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,24
CASE13119,Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer,610 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Biological, Other",Parallel Assignment,Not Applicable,No,No,100
ZX-2021-FES-ESTROTIMP-4,Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer,1209 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,152
2017-0499,"Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",1382 days,Completed,Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Phase 1,Yes,No,24
IIT-UM2018001,Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation,1246 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,44
UPCC 17120,Telehealth Weight Loss Program for Breast Cancer Survivors,865 days,"Active, not recruiting",Interventional,Experimental,"Behavioral, Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,22
Shengjing_002,Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer,1125 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,420
IRB-57723,Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer,1824 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,25
3764,Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis,1186 days,Unknown status,Interventional,Experimental,Radiation,Single Group Assignment,Early Phase 1,No,No,30
D8530C00006,"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer",1186 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,10
115858,SIGNAL During a COVID-19 Pandemic,914 days,Withdrawn,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,0
CCH-IRB-190414-R,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy for Breast Cancer,862 days,Unknown status,Interventional,"Experimental, Active Comparator, Active Comparator","Device, Procedure, Procedure",Parallel Assignment,Not Applicable,No,Yes,900
UCCS20110,Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer,703 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,Phase 1,No,No,10
2019-004559-35,Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial),2586 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Procedure",Single Group Assignment,Phase 2,No,No,27
KARMA Kontrast,KARMA Kontrast - a Controlled Trial Evaluating Contrast Enhanced Mammography in Early Detection of Breast Cancer,568 days,Unknown status,Interventional,Other,Combination Product,Single Group Assignment,Not Applicable,No,No,420
ACE-Breast-03,"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)",1701 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,31
FMBSUREC/10102021/Rabie,Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients,1157 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,"Phase 2, Phase 3",No,No,60
2020-535,Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy,1703 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,332
EF141,Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy,638 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,0
STUDY00001225,The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project,1534 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Parallel Assignment,Phase 2,No,No,452
CCR5119,KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer,2389 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,No,No,184
3475-756,"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",4411 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Biological, Drug, Drug, Drug, Drug, Drug, Drug, Radiation, Procedure",Parallel Assignment,Phase 3,Yes,No,1240
2022-0055,A Study for the Neoadjuvant Treatment of Breast Cancer,1989 days,Recruiting,Interventional,"Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 4,No,No,1576
WEFITTER,Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib,344 days,Recruiting,Interventional,"Active Comparator, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,68
ARO-2015-1,Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer,1578 days,Recruiting,Interventional,"No Intervention, Experimental",Radiation,Parallel Assignment,Not Applicable,No,No,564
HNCH-MBC11,Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer,943 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,71
SOLTI-1507,Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients,2008 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,No,No,15
DKFZ-2019-008,Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE),2406 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, No Intervention","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,240
20170328,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,1248 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,31
SHPD005,Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer,1643 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Procedure",Parallel Assignment,Phase 2,No,No,196
20-124,YES Study - Newly Diagnosed/Metastatic Intervention,2723 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,400
LaPemERLA,Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole,1415 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,40
Pro00020138,Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer,1909 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,28
18-394,DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC,4318 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,100
2019SABE028,The Effect of Early Rehabilitation After Breast Cancer Surgery on Physical and Psychosocial Functions,518 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Other",Parallel Assignment,Not Applicable,No,No,42
IIBSP-PRO-2021-10,Prehabilitation for Breast Cancer Surgery,730 days,Recruiting,Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,64
SYSUCC-015,Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer,2577 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,520
REO 026-1,Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer,628 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,15
2019.429,Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients,230 days,Completed,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,122
CP7-005,A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients,1522 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Other, Other, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,170
2021/193780(REK),Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole,731 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,100
123123,Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients,1726 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,196
JTU-6H-20211011001,Effect of ALND With Vein Branches Reservation on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer,821 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,288
CIMS-4FMFES-2021-3966,4FMFES-PET Imaging of ER+ Advanced Breast Cancers,1155 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Phase 2,No,No,150
SOLTI-1718,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,494 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,12
HLX11-BC301,A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer,1345 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,900
Zoledronic Acid In Breast Ca,Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole,730 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 3,Yes,No,50
Tacrolimus_2020,Tacrolimus as Treatment of Breast Cancer-Related Lymphedema,471 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,20
KSRAD001,Using AI to Select Women for Supplemental MRI in Breast Cancer Screening,1552 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,2500
Stage 2 compression therapy,Adjustable Compression Wrap Versus Compression Sleeve to Control Breast Cancer-related Lymphedema,578 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,Yes,72
CASE5120,Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer,1068 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,72
PROICM 2020-07 VIS,Professional Life After Breast Cancer: Feasibility of a Coaching Program for an Adapted Return to Work,595 days,Recruiting,Interventional,Other,"Other, Other",Single Group Assignment,Not Applicable,No,No,25
CL1-81694-003,S 81694 Plus Paclitaxel in Metastatic Breast Cancer,886 days,Completed,Interventional,"Experimental, Active Comparator, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,22
Shengjing-LCG005,Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer,1960 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,110
2020.KB.SAG.069,The Effect of Mobile Lymphedema Self-Care Support Program on Self-Care in Women With Breast Cancer-related Lymphedema,91 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
INNOVBC,A Guided Internet-delivered Individually-tailored ACT-influenced CBT Intervention to Improve Psychosocial Outcomes in Breast Cancer,668 days,Unknown status,Interventional,"Experimental, Other",Behavioral,Parallel Assignment,"Phase 2, Phase 3",No,No,128
R20-003,Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Breast Cancer,761 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,20
MedOPP319,CB-103 Plus NSAI In Luminal Advanced Breast Cancer,725 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,80
WO39391,A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer,2579 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,2300
20-157,Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD),1080 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Radiation, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,Yes,120
2021.693,mHealth Usage Among Nigeria Women Diagnosed With Breast Cancer Receiving Chemotherapy,456 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,126
GENEXAN,GENe EXpression After Regional or General ANesthesia in Patients Undergoing Breast Cancer Surgery,365 days,Unknown status,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,100
HSC20160245H,Improving Adherence to EHT Among Breast Cancer Patients,1490 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,108
GRO-06-001,ABUS for Early-stage Breast Cancer,1096 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,675
REC-H-PHBSU-21010,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,487 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,100
YOUNGBC-22,"Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer",487 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,72
16D.674,Prospective Breast Cancer Biospecimen Collection,988 days,Unknown status,Interventional,Other,"Procedure, Other, Other",Single Group Assignment,Not Applicable,No,No,200
SMC- 5725-18,The Breast Cancer Personalized Nutrition Study,2329 days,Recruiting,Interventional,"Experimental, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,200
2000025837,Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer,1286 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,6
2020/33,Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer,2512 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,40
DS8201-A-U305,A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05),3679 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,1600
2018.016,Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA,2385 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,164
HE071-CSP-021,A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer,1084 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,73
PREDIX II HER2,Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer,769 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,6
ATADEK 2022-17/27,The Effect of Wearable Vibration Therapy on Shoulder Functionality in Individuals Receiving Adjuvant Radiotherapy After Breast Cancer Surgery,106 days,Recruiting,Interventional,"Active Comparator, Experimental","Device, Other",Parallel Assignment,Not Applicable,No,No,38
CHIR-01-sentinel,Sentinel Lymph Node Biopsy in Patients With Breast Cancer After Neoadjuvant Therapy,1064 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,61
R.20.05.834,Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.,1060 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,120
MCC-20902,Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer,1519 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,13
D3615C00001,Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer,1513 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,818
SMC-2019-05-021 (2),Real-time Interactive Digital Healthcare System in Patients With Breast Cancer; Randomized Controlled Trial,595 days,Completed,Interventional,"Experimental, Active Comparator","Device, Other",Parallel Assignment,Not Applicable,No,No,100
17/209,The Tomosynthesis Trial in Bergen - Part 2,1977 days,"Active, not recruiting",Interventional,Other,Radiation,Single Group Assignment,Not Applicable,No,No,31082
1563/2018,Randomized Clinical Trial Comparing Rehabilitation Robotic Versus Conventional After Breast Cancer Surgery,519 days,Unknown status,Interventional,"Experimental, Active Comparator","Device, Other",Parallel Assignment,Not Applicable,No,No,108
18-603,"Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors",765 days,Completed,Interventional,"Experimental, Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,100
2021-0170,Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer,1246 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,190
PUMCH-SBSBC,Survival Benefits of Statins in Breast Cancer Patients,1919 days,Recruiting,Interventional,"Experimental, Other","Drug, Behavioral",Parallel Assignment,Phase 3,No,No,314
B27IB3856,UCLA Breast Cancer Survivor Health Promotion Research Study,426 days,Recruiting,Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,30
2018.08.ST,Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma,1104 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,7
YYS-20200305,Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer,649 days,Completed,Interventional,"Placebo Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,80
CAN04CLIN005,Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.,1663 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,116
ORIN1001-001,ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer,1405 days,"Active, not recruiting",Interventional,"Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",Yes,No,150
Breast Cancer-RISS,Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries,182 days,Completed,Interventional,"Active Comparator, No Intervention",Drug,Parallel Assignment,Phase 4,No,No,50
STML-ELA-0322,"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study",731 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,80
HNCH-BC010,A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer,873 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,456
22SCH740,STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER),1461 days,Not yet recruiting,Interventional,Other,Drug,Single Group Assignment,Phase 2,Yes,No,36
eMOUVOIR-1901,Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients,1444 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,1133
20G.605,Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer,1133 days,Recruiting,Interventional,Experimental,"Procedure, Drug, Procedure",Single Group Assignment,Early Phase 1,Yes,No,25
19-002792,Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients,2633 days,Recruiting,Interventional,"Active Comparator, Experimental",Procedure,Parallel Assignment,Not Applicable,No,No,20
UT BCS Sleep Study,Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors,168 days,Withdrawn,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,0
919PP17,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,243 days,Completed,Interventional,"No Intervention, Experimental",Drug,Parallel Assignment,Phase 2,No,No,100
H-50349,Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer,2390 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,185
B002-101,B002 in Patients With HER2-positive Breast Cancer,1064 days,Completed,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,23
"2016-051-000001, 2563",Investigating Barriers for Decision Making in a Danish Breast Cancer Screening Context,132 days,Recruiting,Interventional,"Other, Other, Other","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,3000
MCC-21378,Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,1431 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Drug, Drug, Biological",Sequential Assignment,Phase 1,Yes,No,28
010006,Integrin α6-targeted SPECT Imaging of Breast Cancer,479 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,9
2021-0358,A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC),1139 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,20
LACUDY,Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient,70 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Not Applicable,No,No,60
CSPC-DMS-BC-17,Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer,458 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,40
UC-0105/1815,"Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis",1987 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,186
NCC3340,A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer,851 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,26
YOMA,Effects of Yoga on the Quality of Life of Breast Cancer Patients,937 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,138
2022-7735,Life After Breast Cancer - Impact of a Life Coach,716 days,Not yet recruiting,Interventional,"Experimental, Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,120
IRB00130428,The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer,1740 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Diagnostic Test, Diagnostic Test",Parallel Assignment,Phase 2,Yes,Yes,30
HR BLTN 014,Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer,1125 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,41
GS-US-595-6184,Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy,2942 days,Recruiting,Interventional,"Experimental, Active Comparator","Biological, Biological, Drug",Parallel Assignment,Phase 3,Yes,No,1514
C4891023,TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B),1680 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,Phase 2,Yes,No,35
SYSU-2022-02,"Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.",547 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,28
GO40987,"A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer",669 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Procedure",Parallel Assignment,Phase 1,Yes,No,75
HR-BLTN-008,"Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer",1241 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,86
HNCH-MBC08-BM02,Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases,733 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,100
SNF4,Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer,1581 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,145
MA-BC-II-006,Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC),1379 days,Recruiting,Interventional,Experimental,"Biological, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,20
17/013,Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer,1765 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Radiation, Drug",Parallel Assignment,Phase 2,No,No,54
SNF3,PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer,1581 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,200
2020 - 176,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,334 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,60
HR-TNBC-HN100,SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer,1096 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,39
2018-68-1461,Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer,2161 days,Recruiting,Interventional,"Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,1560
STU00206180,A Web-Based Tool to Improve Breast Cancer Survivorship,1068 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,84
2019-09-09,Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer,2192 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental",Procedure,Parallel Assignment,Not Applicable,No,No,120
UBRS20013,Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer,1096 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,20
HR-BLTN-014,Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer,609 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,20
SPI-POZ-101,A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer,278 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,6
EC/TMC/108/17,Hypo-Fractionated Radiotherapy in Breast Cancer,1827 days,Unknown status,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,30
SGRT-BC,Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer,1826 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,"Phase 2, Phase 3",No,No,556
CMUH108-REC3-090,A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy,817 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,10
RC48-C012,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,1187 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,366
261\\2021,Real-time Tele-monitoring Versus Routine Monitoring of Breast Cancer Patients Receiving Adjuvant Systemic Therapy,700 days,Not yet recruiting,Interventional,"No Intervention, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,150
ERIBRAIN-IPC 2017-014,Eribulin in Brain Metastases From HER2-negative Breast Cancer,413 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,0
CYH33-G103,"Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer",609 days,Unknown status,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,No,No,228
OTT 18-02,Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT),935 days,Completed,Interventional,"Active Comparator, Active Comparator",Combination Product,Parallel Assignment,Phase 4,No,No,262
SYSA1901-002,Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer,1139 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,560
YBCSG-21-03,Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer,802 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,92
EBaran,The Effect of Complex Decongestive Physiotherapy on Sensory Parameters in Breast Cancer Related Lymphedema.,734 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,30
2019-0088,Proton Accelerated Partial Breast Irradiation,372 days,Withdrawn,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,0
R20-030,Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI,1339 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 1,Yes,No,25
NL77000.029.21,Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients,4572 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,100
MUKDEN 07,A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients,2176 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,61
OstacoliMIND&BC,Mindful-life: Mindfulness Based Intervention vs Cognitive Behavioral Therapy in Patients With Breast Cancer,364 days,Unknown status,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,100
NCC3286,A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway,853 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Single Group Assignment,Phase 2,No,No,64
HR-BLTN-010,A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer,1065 days,Unknown status,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,60
CMUH106-REC3-137,Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors,1374 days,Completed,Interventional,"Experimental, Experimental, Experimental",Drug,Crossover Assignment,Not Applicable,No,No,54
2010134480,Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients,712 days,Unknown status,Interventional,"Other, Other","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,Yes,100
DS8201-A-U303,Trastuzumab Deruxtecan (DS-8201a) Versus Investigators Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04],1525 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,557
H18-02581,"Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers",1819 days,Not yet recruiting,Interventional,Experimental,"Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,No,50
SMX 22-002,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,1188 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,400
18-371,"Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial",2147 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Device, Other",Parallel Assignment,Not Applicable,No,Yes,80
K171005J,"Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility",555 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,186
X-XJTU1AFLSY-93,"Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038",882 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,209
2019/2452,Impact of a Breast cAncer Survivorship Interprofessional Community Care Model,506 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,70
J1836,"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer",1874 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,33
20-104,"Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)",133 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,31
SCHBCC-N030,Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS),2556 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 2,No,No,356
D967JC00001,A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer,1828 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,245
LMengmeng,An Online Psychosocial Intervention for Fear of Cancer Recurrence in Breast Cancer Survivors,456 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,244
NCC1888,Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib,742 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,68
XZP-3287-3002,A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer,1399 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,372
R21-072,Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI),1523 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,20
HCI131027,Functional Precision Oncology for Metastatic Breast Cancer,1627 days,Recruiting,Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,15
SCHBCC-N025,A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS),1066 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,46
ERC/2020/10/11 (26/10/2020),Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model,692 days,Recruiting,Interventional,"No Intervention, Experimental","Device, Other, Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,Yes,4100
19-055,A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients,2730 days,Recruiting,Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Phase 1,Yes,No,20
20F.259,Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation,1211 days,Recruiting,Interventional,Experimental,"Procedure, Drug",Single Group Assignment,"Phase 2, Phase 3",Yes,No,200
2019/1318,Exercise in Breast Cancer Survivors,905 days,Completed,Interventional,"Experimental, No Intervention, Other",Behavioral,Parallel Assignment,Not Applicable,No,No,210
BC-P29,Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT,2982 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,136
Smart,An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy,275 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,108
RS-NAT01,Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy,1155 days,Unknown status,Interventional,"Active Comparator, No Intervention, Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,No,No,80
2021/32,The Effect of Self-compassion on Breast Cancer,184 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,70
SMX 20-001,Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,864 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,29
BOMB,Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis,2427 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Radiation, Other",Parallel Assignment,Not Applicable,No,No,183
XuzhouMedSch3,Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery,499 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,100
MC220301,Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer,1446 days,Recruiting,Interventional,Experimental,"Procedure, Drug, Other, Procedure",Single Group Assignment,Phase 2,Yes,No,100
FUSCC-TNBC-BLIS,Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer,1034 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,192
TeMP 2021,The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.,2195 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,130
D931CC00001,Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer,1491 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Combination Product",Parallel Assignment,Phase 2,Yes,No,80
WuhanU,Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP,2084 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,20
Stage 1 Compression Therapy,Adjustable Compression Wrap Versus Compression Bandage Reduce to Breast Cancer-related Lymphedema,548 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,Yes,72
4298,mHealth for Breast Cancer Survivors With Insomnia,330 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,76
018-745,LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer,1548 days,"Active, not recruiting",Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,Yes,No,10
20-371,Niraparib + Dostarlimab In BRCA Mutated Breast Cancer,3133 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,62
HBMUFH-101,A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer,853 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,300
2019-KY-051,Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer,2192 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,185
GCX-BCT-06,Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy,3643 days,Recruiting,Interventional,"Active Comparator, No Intervention",Drug,Parallel Assignment,Not Applicable,No,No,194
213355,Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer,719 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,21
2022-0056,A Study for the Adjuvant Treatment of Breast Cancer,1989 days,Recruiting,Interventional,"Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 4,No,No,2413
20192755,Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer,1317 days,Completed,Interventional,"No Intervention, Active Comparator",Drug,Parallel Assignment,Phase 2,No,No,100
K3_K1_2,An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain,1257 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,88
MEDOPP437,PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin,1461 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,28
D9670C00001,"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigators Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",2156 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,850
ACR A4707,Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts,1402 days,Not yet recruiting,Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,2032
OTT 20-11 (IT-02),INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer,706 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 2,Yes,No,90
PREBCA,Progressive Relaxation Training in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy,335 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,44
OBU-SC-BB-BC-II-010,"Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer",1125 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,216
20-09022641,Combined Immunotherapies in Metastatic ER+ Breast Cancer,1814 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Radiation, Drug, Drug",Parallel Assignment,Phase 2,Yes,Yes,102
SaglikBilimleriU_DU,Investigation of the Effect of Education on Symptom Management on Symptom Management in Patients With Breast Cancer,274 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,52
mTPVB SPPB Ver 2,Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer Surgery,730 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,100
SYSKY-2023-129-01,Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer,1019 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,170
UW20035,Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer,891 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,15
ID-TMS-02-20201012,CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population,1276 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Drug,Single Group Assignment,Not Applicable,No,No,150
ACE-Breast-07,ARX788 in Breast Cancer With Low Expression of HER2,618 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,54
CABC012,Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer,1435 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,97
2019-053,Intervention to Promote Breast Cancer Screening Among American Indian Women,1550 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,142
SNB vs PET/MRI 1,Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI,1610 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,110
AITIC,Artificial Intelligence in Breast Cancer Screening Programs in Córdoba (AITIC),700 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,27000
NIHR 128311,Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy,3289 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,1900
Pro00104868,Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer,1795 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,18
STUDY00000023,TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer,1719 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,24
2022/0132,The Effect of Myofascial Chain Release Techniques on Shoulder Joint Range of Motion in Breast Cancer Survivors,549 days,Not yet recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,48
GMI-1359-210,A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer,643 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,4
SHERO,"Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer",3651 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,60
MA-BC-II-023,Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy,1120 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,100
0494-22-RMB,A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.,1832 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,30
ICO-A-2018-10,Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery,1310 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,140
REG-074-2020,Pre-operative Exercise During Neoadjuvant Chemotherapy in Patients With Breast Cancer,1042 days,Recruiting,Interventional,"Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,120
Woman health,Whole Body Vibration Training and Breast Cancer Risk Factors,397 days,Completed,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,40
CSIIT-C39,Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer,425 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,40
99mTc-ZHER2,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.,434 days,Enrolling by invitation,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 1,No,No,30
HCC 22-003,Preoperative Irradiation for Stage I Breast Cancer,1666 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,Yes,24
CSIIT-C03,Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy,762 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,20
IBCSG 55-17,To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH),1415 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,144
WO42633,A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy,4923 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,1700
2022-05093-02,The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.,3942 days,Recruiting,Interventional,"No Intervention, Experimental",Radiation,Parallel Assignment,Not Applicable,No,No,1350
NRG-BR007,"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)",7329 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Other, Drug",Parallel Assignment,Phase 3,No,No,1670
CLP0008,Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients,1917 days,Recruiting,Interventional,"Experimental, No Intervention",Combination Product,Parallel Assignment,Phase 2,Yes,Yes,323
18-040,Topical Calcipotriene Treatment for Breast Cancer Immunoprevention,2458 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 1,Yes,No,120
UPCC 01121,Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer,2526 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,96
Molecular imaging of HER2,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3,602 days,Completed,Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 1,No,No,30
OP-1250-002,A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients,721 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,30
GEICAM/2018-06,"Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)",2680 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,315
26272819.3.0000.0068,Breast Cancer and Intrauterine Contraception,877 days,Recruiting,Interventional,"Active Comparator, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,90
SA20I0060,Supervised Resistance TRaining amONG Women at Risk of Breast Cancer Related Lymphedema,547 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,106
1094/2020,Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy,1963 days,Withdrawn,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,0
WO42133,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",446 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Procedure",Parallel Assignment,Phase 2,Yes,No,221
110-163-F,A Study Evaluating Near-infrared Zone II Imaging in Sentinel Lymph Node Mapping in Breast Cancer Patients,364 days,Recruiting,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,30
MUKDEN 06,A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients,1682 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,150
KN035-TH-HER2,KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer,853 days,Unknown status,Interventional,Experimental,"Biological, Biological, Drug",Single Group Assignment,Phase 2,No,No,59
COSMOPOLITAN,Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer,2404 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,202
21-VIN-0166/SAN-0647,"A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer",196 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Crossover Assignment,Phase 1,Yes,No,70
ISB 1302-103,Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer,107 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Biological, Biological, Biological, Biological, Biological, Biological, Biological",Parallel Assignment,"Phase 1, Phase 2",Yes,No,1
0063-17,A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients,2213 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,657
M16-735,A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),274 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,2
19-524,Effects of Exercise in Patients With Metastatic Breast Cancer,2731 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,350
HR-BLTN-002,A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physicians Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,868 days,Unknown status,Interventional,"Experimental, Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,256
CTO-IUSCC-0684,Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer,1552 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,Phase 1,Yes,No,38
Tele-Relax,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,680 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,52
NCC1865,A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer,1278 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
A5481126,Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy,758 days,Completed,Interventional,"Other, Other",Device,Single Group Assignment,Not Applicable,No,No,99
KCSG BR18-16,Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer,1218 days,"Active, not recruiting",Interventional,"Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",No,No,90
LY01005/CT-CHN-303,Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®,684 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,188
IFG-08-2019,Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON),720 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 4,No,No,108
XZP-3287-3001,A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer,2907 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,300
GEP,Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC),753 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,160
2019/2632,An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery,712 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,112
UMMCHTNBC,Telemonitoring Hypertension and Breast Cancer,211 days,Not yet recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,40
BTCRC-BRE18-337,"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",1506 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,37
J18138,Automated Method for Breast Cancer Detection,649 days,Terminated,Interventional,Other,"Procedure, Device",Single Group Assignment,Not Applicable,No,Yes,116
19-09020752,CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,3224 days,Withdrawn,Interventional,"Active Comparator, Active Comparator","Radiation, Drug, Drug",Parallel Assignment,Phase 2,Yes,Yes,0
RC31/21/0368,Impact of Adjuvant Hormone Therapy on Bone and Cardiovascular Risk,118 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,102
20-503,Feasibility of Fasting & Exercise in Pts With HR+ MBC,927 days,"Active, not recruiting",Interventional,Experimental,"Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,30
PGG-BCA2121 / MK-3475-C99,Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA),1893 days,"Active, not recruiting",Interventional,Experimental,"Biological, Biological",Single Group Assignment,Phase 2,Yes,No,50
ACTRN1261000928213,A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.,1473 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,200
Pro2020002182,Breast Cancer and Resistance Exercise Program,1492 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,50
160178,"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",1612 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,22
MRG002-004,A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer,823 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,350
BC-Pyrotinib-NVB,Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer,401 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,30
SYSUCC-016,GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer,730 days,Recruiting,Interventional,"Experimental, Other","Drug, Drug",Parallel Assignment,Phase 3,No,No,306
19-396,Liquid Biopsies and Imaging in Breast Cancer,1064 days,Unknown status,Interventional,Other,"Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,No,100
Shengjing-LJY07,Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer,2009 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Procedure,Parallel Assignment,Not Applicable,No,No,500
HMPL-012-SPRING-R103,Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer,853 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,45
CA209-7FL,"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",1517 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Biological, Drug, Other, Drug, Drug, Drug, Procedure",Parallel Assignment,Phase 3,Yes,No,521
NCC2021291,A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN),2202 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,102
20-2338,Effects of Pinkwashed Alcohol Ads in an Online RCT,8 days,Completed,Interventional,"Other, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,602
22-5307,Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease,973 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,15
CEP0431/2018 arm 2,LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2),1432 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator","Procedure, Procedure, Drug",Parallel Assignment,Not Applicable,No,No,195
MA-BC-II-035,Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer,1552 days,Enrolling by invitation,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,94
F2017000 (UAB 17112),Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer,1942 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,40
22040,Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer,1887 days,Recruiting,Interventional,Experimental,"Drug, Behavioral",Single Group Assignment,Phase 2,Yes,No,83
CTMS 17-0037,Imipramine on ER+ve and Triple Negative Breast Cancer,1335 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,17
D0816R00025,Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer,853 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,162
MedOPP238,POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer,0 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,0
BTCRC-BRE19-409,"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",1419 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,44
2020-0342,Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer,611 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,106
25IB-0023,Exercise Study for Breast Cancer Survivors,372 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
919PP18,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),973 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,70
18-002,A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy,2170 days,"Active, not recruiting",Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Phase 1,Yes,No,31
ZYYY-BC-001,Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer,822 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
CAAE: 82691818.0.0000.5154,Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.,586 days,Unknown status,Interventional,"Other, Experimental, Experimental, Experimental","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,80
PMD-026-1-001,Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer,1569 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,50
18432,Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease,1610 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Other, Other, Other, Behavioral",Parallel Assignment,Not Applicable,No,No,42
2020-KY-140,Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer,3713 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,516
21-159,ATEMPT 2.0: Adjuvant T-DM1 vs TH,2511 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,500
2020-KY-125,Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer,1461 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,71
CAAE 42627521600005274,Surgical Pre-habilitation in Breast Cancer.,728 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,248
20201101.2,"Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer",1461 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,57
SYSUCC-008,Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer,210 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,35
SURVIVE,Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer,4742 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Diagnostic Test, Diagnostic Test, Diagnostic Test, Other",Parallel Assignment,Not Applicable,No,No,3500
4352,Evaluating the Impact of Evidence-based Information About Mammography on Breast Cancer Screening Decisions,700 days,Unknown status,Interventional,"Experimental, Experimental, Sham Comparator","Other, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,209
SPHIC-TR-BCa2022-02,A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction,2061 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,67
KCSG BR22-20,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",2222 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,202
CRE2018013,Effects of Exercise Training at Different Timeline on Shoulder Dysfunction After Breast Cancer Modified Radical Mastectomy,629 days,Completed,Interventional,"Active Comparator, Experimental, Experimental, Experimental","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,200
IRB_00137018,A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors,1013 days,Recruiting,Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,72
2022-0353,Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors,870 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Phase 1,No,No,62
MCC-19765,Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases,1810 days,"Active, not recruiting",Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Phase 1,Yes,No,14
LCCC 1931,LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+),1921 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,100
4-2018-0264,Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16),395 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
2018/TMC/133/IRB/31,One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer,3653 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,2100
BRE 354,A Study of U3-1402 in Subjects With Metastatic Breast Cancer,941 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 2,Yes,No,120
IR-1.1,Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway,2191 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,270
SYSUCC-017,Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer,925 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
IB 2015-01,High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study,939 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,15
20-5215.0,An Impact Assessment of a Culturally Tailored Online Psychosocial Program for Chinese Immigrant Women With Breast Cancer,791 days,Recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,100
MEN1611-01,MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer,1473 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,62
SGNTUC-028,A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer,1941 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,650
SYSUCC-020,"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.",911 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,73
BC-RWS,Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer,387 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,500
C4891001,A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.,1900 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,560
CCR4884,PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer,1420 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,45
2016-0537,Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer,2894 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Other, Drug, Drug, Biological, Biological",Parallel Assignment,"Phase 1, Phase 2",Yes,No,43
69HCL21_1085,Evaluation of the Diagnostic Performance of a Bra Prototype to Detect Breast Cancer,153 days,Recruiting,Interventional,"Active Comparator, Experimental",Device,Parallel Assignment,Not Applicable,No,No,81
SGNTUC-025,A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer,1795 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,70
AIRC IG-23118,Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer,2770 days,Recruiting,Interventional,Experimental,"Radiation, Radiation",Single Group Assignment,"Phase 1, Phase 2",No,No,79
3-2021-0026,"Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)",2159 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,59
STU-2022-0385,Real-time Intraoperative Breast Cancer Visualization for Margin Assessment,1443 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Device, Procedure",Sequential Assignment,"Phase 1, Phase 2",Yes,Yes,97
BC-P26,Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer,183 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,104
KOTK/2022/12550,Patient-centered Breast Cancer Teleprehabilitation,579 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,50
SCHBCC-N029,Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer,1796 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,319
PUMCH-MIRC213,99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer,480 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Single Group Assignment,Early Phase 1,No,No,30
TMS01190510,Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels,663 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,151
1752/20,Local Therapy for ER/PR-positive Oligometastatic Breast Cancer,3652 days,Recruiting,Interventional,"No Intervention, Experimental","Radiation, Procedure, Other",Parallel Assignment,Phase 2,No,No,74
IMAP-CM,Randomized and Multicenter Study to Evaluate a Customizable Support Breast Cancer Material,296 days,Completed,Interventional,"Experimental, Sham Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,125
SRB_201808_163,Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE),3627 days,Recruiting,Interventional,"Active Comparator, Experimental, No Intervention","Drug, Other",Parallel Assignment,Phase 4,No,No,565
SMC 2020-11-051,Effect of Prophylactic Medical Compression Therapy on the Reduction of Breast Cancer-related Lymphedema in Patients With Adjuvant Docetaxel Chemotherapy: a Randomized Controlled Study,1754 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,150
2016-A01344-47,Adapted Physical Activity for Breast Cancer HER2 Positive Patient,2318 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,70
1807187-2,Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE),2448 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,808
Lilly-I3Y-US-I026,Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer,406 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,44
D8532C00001,A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease,2926 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,1342
RG1121129,"Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial",309 days,Completed,Interventional,"Experimental, Experimental, Experimental","Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,27
21-123,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,1096 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Dietary Supplement, Dietary Supplement, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,106
UC-BCG-2103,Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk,4403 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,696
Ketogenic Diet,Effects of Ketogenic Diet in Overweight and Obese Women With Breast Cancer,1096 days,Not yet recruiting,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,56
20-172,Taking AIM at Breast Cancer,1767 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,300
CMUH108-REC1-113,Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients,1169 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,300
ALT-P7,"Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients",1100 days,Completed,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,27
2019-7-Non-NSU Health,Assessing the Utility of Tissue Dielectric Constant (TDC) Measurements to Differentiate Breast Cancer From Healthy Breasts,1057 days,Completed,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,Yes,60
I236,CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer,1901 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,37
GCO 17-1585,Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer,485 days,Terminated,Interventional,"Active Comparator, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,7
PRO00028602,Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer,1233 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,30
D0816C00018,To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.,1360 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 3,Yes,No,256
HUB-PSI-CAMAD,Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression,50 days,Terminated,Interventional,"Experimental, Experimental","Drug, Behavioral",Parallel Assignment,Phase 2,No,No,40
REP0121,To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer,804 days,Withdrawn,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,0
SBMASTER,The MASTER Study (MAmmary Cancer STatin ER Positive Study),5110 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,3360
AMCI-001,PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer,1669 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,160
Fukui-2019-1,Exercise Post-Diagnosis of Breast Cancer,2561 days,Recruiting,Interventional,"Active Comparator, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,165
PRO00028925,"Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer",2105 days,Recruiting,Interventional,"Other, Experimental","Other, Other",Parallel Assignment,Phase 2,Yes,No,56
K160913J,Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer,2832 days,"Active, not recruiting",Interventional,Experimental,"Genetic, Biological, Other",Single Group Assignment,Not Applicable,No,No,73
N-20180090,Analgesic Effect of Resistance Training for Breast Cancer Survivors,409 days,Completed,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,20
FDRT-BC016,Neoadjuvant Radiation in Locally Advanced Breast Cancer,1736 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,50
RF-2016-02363686,Tomosynthesis as Primary Test for Breast Cancer Screening,2542 days,Recruiting,Interventional,"Experimental, Active Comparator","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,8000
A231901CD,Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions,2177 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Active Comparator","Other, Other, Procedure, Other, Other, Other, Other, Other, Other",Factorial Assignment,Not Applicable,No,No,700
UPCC 10117,"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (GLACIER)",259 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,0
22/409-3611,Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients,2922 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,65
BC-CIH-H-RWS,H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study,943 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,40
4-2020-1453,"Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing (MUTATION2)",518 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,52
IRB15-1005,Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer,212 days,Withdrawn,Interventional,"Experimental, Other, Other, Other, Other, Other","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,0
LCCC1820,Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer,98 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,0
GC101-21K177,Study on TIL for the Treatment of Advanced Breast Cancer,1127 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Early Phase 1,No,No,50
2019.046,Lifestyles and Breast Cancer,1647 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,766
2020-004696-41,Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy,1073 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental, No Intervention, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,210
V3002401,Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer,656 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,210
2021-0768,A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer,1602 days,Recruiting,Interventional,Experimental,"Procedure, Radiation, Procedure",Single Group Assignment,Phase 2,No,No,36
FDRT-BC008,Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer,3712 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,1494
TILS001 trial,Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS,1893 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,20
SYSEC-KY-KS-2022-056,Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast Cancer,416 days,Not yet recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,200
S1709-101-888,Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer,1645 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,54
ARV-471-mBC-102,"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",511 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,32
BR01/02/21,"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor",1313 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,120
MA-BC-II-020,Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer,1675 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,490
NL68820.091.19,Minimal Invasive Breast Cancer Excision Using Vacuum Assisted Biopsy Under Ultrasound Guidance,851 days,Recruiting,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,170
6010121027,Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy,910 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,120
FS-1502-III1-01,FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer,1037 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Biological, Biological",Parallel Assignment,Phase 3,No,No,314
2020-0708,"Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study",1713 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,240
20-347,"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer",3520 days,Recruiting,Interventional,Experimental,"Combination Product, Drug",Single Group Assignment,Phase 2,Yes,No,375
NCC2493,Radiotherapy for Extracranial Oligometastatic Breast Cancer,1850 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Radiation",Parallel Assignment,Phase 3,No,No,170
ICO 13-001,Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer,1676 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Early Phase 1,No,No,60
2018-A01128-47,EMDR Psychotherapy for Anxious-depressive Symptoms in Breast Cancer Patient,2649 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,190
SCBCG-006,A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients,3812 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 3,No,No,794
LRP/PegGCSF/2016/004,Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer,309 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 4,Yes,No,138
GRACE,GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer,457 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,75
21-600,Early Intervention,760 days,Not yet recruiting,Interventional,Experimental,"Device, Device",Single Group Assignment,Not Applicable,No,Yes,40
114,The Effect of Reiki on Symptom Control and Quality of Life in Breast Cancer Patients,211 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,52
IIT2018-17-McArthur-TCDRT,"Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer",1826 days,Withdrawn,Interventional,"Active Comparator, Experimental","Drug, Radiation, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,0
20 KHCC 91,SBRT for Breast Cancer Oligometastases,2191 days,Recruiting,Interventional,Other,Radiation,Single Group Assignment,Not Applicable,No,No,50
SYSUCC-019,"Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial",853 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,126
IIT-CRM2020001,Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature,1334 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,55
2020-154,Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema,2535 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Procedure",Parallel Assignment,Not Applicable,No,No,104
CTO-IUSCC-0715,Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs,904 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,62
SP0048722,Optimizing Quality of Life in Women Living With Metastatic Breast Cancer,684 days,Completed,Interventional,"Experimental, Active Comparator, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,31
38341220.8.0000.0072,"Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery",2128 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Radiation, Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,36
Neo-ACT,Physical Exercise During Preoperative Chemotherapy for Breast Cancer,1848 days,Recruiting,Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,712
CH-BC-059,A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）,1908 days,Enrolling by invitation,Interventional,"Experimental, Active Comparator","Drug, Other, Genetic, Drug",Parallel Assignment,Phase 3,Yes,No,300
07102022_SR,Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer,273 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator",Behavioral,Parallel Assignment,Not Applicable,No,No,15
GO42784,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physicians Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",4469 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,4100
New theory(Tamoxifen&retinoic),"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.",122 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Sham Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,160
145314,Safety and Efficacy of Ga68 Αvβ3 IAC PET/CT for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients,731 days,Not yet recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,"Phase 1, Phase 2",Yes,No,25
20-505,A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer,1351 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Radiation",Parallel Assignment,Phase 2,Yes,No,34
RadiaAce001,The Effect of RadiaAce Gel in the Prevention and Treatment of Radiation Dermatitis in Breast Cancer Patients,444 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,120
Neo-program 2021.02.23,Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant Treatment,501 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,132
ARV-471-mBC-101,A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer,1641 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,215
275078,Digitally Distributed Yoga for Women Treated for Breast Cancer,2557 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,250
IIT-2017-NeoPACT,Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer,2250 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,121
2021000247,"Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.",4004 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",Yes,No,40
REaCT-70,Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer,1109 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Phase 4,No,No,100
BTCRC-BRE16-042,"Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients",2407 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,47
TVD-101-002B,Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor (HR)-Positive and Human Epidermal Receptor 2 (HER2)-Negative Breast Cancer,754 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,53
20-0140-A,MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study,303 days,Withdrawn,Interventional,"Experimental, Active Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,No,0
CA209-929,"Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients",469 days,Terminated,Interventional,"Experimental, Experimental, Experimental","Biological, Biological",Single Group Assignment,Phase 2,Yes,No,5
Glnz87?,The Effect of Guided Imagery Based on the Health Promotion Model on the Quality of Life in Breast Cancer Patients,287 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,68
GIM24-PALBO-BP,Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy,1476 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,168
18-115,Physiotherapy Program for Breast Cancer Women Following Surgery: A Pilot Clinical Trial,884 days,Completed,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,23
IBISCO Trial,Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer,1460 days,Recruiting,Interventional,"Experimental, No Intervention",Radiation,Parallel Assignment,Not Applicable,No,No,30
NBC Che001,Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy,481 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,160
IC 2021-08,Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment,635 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,200
AI Yoga Study on Facebook - 1,Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors,45 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,38
6222/22.03.2017,Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer,365 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,30
EUBREAST-01,Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST,2879 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,350
1216-4-011,Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients,536 days,Completed,Interventional,"Placebo Comparator, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,60
UPCC 15121,Breast Cancer Outreach Among Primary Care Patients,182 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,24680
OMERIC-1904,Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer,1088 days,Recruiting,Interventional,,Procedure,Single Group Assignment,Not Applicable,No,No,25
18-217,Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job,1820 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,546
ACE-Breast-06,ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases,716 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,32
CHLOBREASTASP,"Breast Cancer Active Surveillance, Alternative Option, Aspirin Included",1825 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,60
CTO-IUSCCC-0781,Exercise in Metastatic Breast Cancer: EMBody,1736 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Phase 2,No,No,100
TT420X2101,Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer,1087 days,"Active, not recruiting",Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,48
201808046,Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma,2761 days,"Active, not recruiting",Interventional,Experimental,"Radiation, Procedure",Single Group Assignment,Not Applicable,No,Yes,77
Versión 4- 20/09/2020,Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors,456 days,Completed,Interventional,Other,Drug,Single Group Assignment,Phase 4,No,No,10
HS-10352-102,A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer,1449 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 1,No,No,224
CSPC-KAL-BC-16,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer,1035 days,Unknown status,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,414
REaCT-Wellness,A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer,1412 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Phase 4,No,No,228
NEXT-BRCA,Implementing Exercise Into Clinical Practice in Breast Cancer Care,1550 days,"Active, not recruiting",Interventional,"Experimental, Experimental, No Intervention","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,85
MedOPP167,Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients,701 days,Terminated,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 2,No,No,22
LPM-008,The LightPath® and 68Ga-RM2 in Breast Cancer Study,1797 days,Not yet recruiting,Interventional,"Other, Experimental, Experimental","Combination Product, Drug",Sequential Assignment,Phase 3,No,No,80
DATOS-20220624-ASJF-Efecto car,Cardioprotective Effect of Acute Exercise in Breast Cancer Patients,617 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,40
NSABP FB-13,Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer,831 days,Completed,Interventional,Experimental,"Drug, Drug, Drug, Diagnostic Test",Single Group Assignment,Phase 2,Yes,No,24
202207198RINB,Can ILR Reduce the Risk of Arm Lymphedema?,1995 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,240
FZPL-Ⅲ-303,A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physicians Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation,1813 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,474
SYSUCC 019,Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients,1295 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,47
BCSPilot01,A Combined Exercise Training Program for Women Living With Breast Cancer,210 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,36
2014CB543202-03,Acupuncture for Breast Cancer Related Lymphedema,517 days,Unknown status,Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,60
578-21-FB,Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy,3470 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,46
107CS-6,Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer,1346 days,Unknown status,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,72
BRE 381,Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,1218 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,36
2022-009,Thero2-01S22 in HER2-positive Breast Cancer,1461 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator, Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,320
KCT 005,"A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery",213 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,20
G1T28-212,"Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer",479 days,Completed,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug, Biological",Single Group Assignment,Phase 2,Yes,No,24
SCHBCC-NO28,Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer,3661 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,94
ID-RCB 2022-A01488-35,Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI,1461 days,Not yet recruiting,Interventional,"No Intervention, Experimental",Device,Crossover Assignment,Not Applicable,No,No,5000
PI-2021-3,Design and Evaluation of the Effects of a Physical Therapy Program With Digital Support in Patients With Breast Cancer,1003 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,92
2021-KY-124-001,Aesthetic Outcomes of Oncoplastic Breast Surgery for Breast Cancer in the Upper Inner Quadrant,287 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,109
MA-BC-Ⅱ-021,Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer,646 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Procedure, Drug, Procedure",Parallel Assignment,Phase 2,No,No,60
DFP22-0020,Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer,519 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,52
CCM 1505,Coronary Artery Calcium and Cardiovascular Risk Factors Analysis After RT or Breast Cancer,800 days,Recruiting,Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,100
PER.CIN.BN.95.III,Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer,655 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,214
21-5021,Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN),1166 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,1150
C4891006,TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A),1570 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,35
2021-0840,Acupuncture for Psychoneurological Symptoms Among Breast Cancer Survivors,1307 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,8
OV-121,Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP,1776 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
042110,CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage,2062 days,"Active, not recruiting",Interventional,"Active Comparator, Other","Drug, Other",Single Group Assignment,Early Phase 1,Yes,No,34
BC-09638,GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.,1806 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 4,No,No,160
2018-0601,Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women,1355 days,Recruiting,Interventional,"Placebo Comparator, Experimental, Placebo Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,232
D967JC00002,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,966 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,139
UKM14_0016,Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography,2461 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,99689
RJBC-HFRNI,Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment,3205 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,801
m-VCAP1,Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer,516 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
19-133,An Online Research Study: BrainHealth in Breast Cancer Survivors,731 days,Recruiting,Interventional,"Experimental, Placebo Comparator",Behavioral,Crossover Assignment,Not Applicable,No,No,200
CLEE011A2206,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",2296 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,327
CASE3118,Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer,1691 days,"Active, not recruiting",Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,13
2020(55),Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer,3530 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,214
WO40324,"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",1981 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Procedure, Radiation, Drug",Parallel Assignment,Phase 3,Yes,No,500
ML39208,A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment,311 days,Completed,Interventional,Experimental,"Device, Drug",Single Group Assignment,Phase 2,No,No,56
18/028,"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer",1894 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,No,No,36
A231701CD,Increasing Patients Engagement in Breast Cancer Surgery Decision-Making,1750 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Other, Other",Crossover Assignment,Not Applicable,No,No,598
FDRT-BC017,Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer,2141 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,1650
AC699-001,Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer,733 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,60
2020-495,Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer,2556 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,260
CTRIAL-IE 17-13,Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer,356 days,Terminated,Interventional,Other,"Drug, Drug",Single Group Assignment,Phase 1,No,No,2
00005038,Family History and Breast Cancer Education Trial,547 days,Completed,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,196
H-43432,Sitravatinib in Metastatic Breast Cancer,468 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,3
HCRN BRE18-334,"Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer",4543 days,Recruiting,Interventional,"Experimental, Active Comparator, Active Comparator","Drug, Drug, Drug, Drug, Other",Parallel Assignment,Phase 2,Yes,No,197
ACT16105,Phase 2 Study of Amcenestrant (SAR439859) Versus Physicians Choice in Locally Advanced or Metastatic ER-positive Breast Cancer,1438 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,290
OSU-22013,Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer,1236 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,1000
I-3364822,Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer,2130 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Other, Other, Procedure, Other",Parallel Assignment,Not Applicable,No,No,130
ICO-N-2019-04,[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers,405 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,13
20140299,Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,1355 days,Completed,Interventional,"Experimental, Experimental","Biological, Biological",Single Group Assignment,Phase 1,Yes,No,36
CS003-BC,Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer,486 days,Recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug",Sequential Assignment,Phase 2,No,No,58
2020-005722-28,Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer,1857 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,100
MD-127-2019,Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study),790 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,204
2020-07-064-002,Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors,431 days,Completed,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,28
UC-BCG-2204,Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer,1096 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 3,No,No,100
PYHOPE-BC-104,Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer,1093 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,60
TMZ-TNBC,Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC),1705 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,40
STUDY-20-01174,Increasing Breast Cancer Screening in Chinese Immigrants,530 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,99
SIM-1907-02-SERD-101,"Phase I Study to Evaluate SCR-6852 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer",1209 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,No,No,146
20-151,Refining Local-Regional Therapy for IBC,2373 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,50
RJBC-SHF RNI,Adjuvant Regional Nodal Radiation Therapy for One Week in Breast Cancer,2220 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,197
HREBA.CC-21-0429,Exercise Rehabilitation Via a Mobile Application for Individuals With Breast Cancer Undergoing Chemotherapy,253 days,Recruiting,Interventional,"Active Comparator, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,30
UW17107,ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer,823 days,Terminated,Interventional,"Experimental, Experimental","Drug, Dietary Supplement",Parallel Assignment,Phase 2,Yes,No,4
NL63209 041 18,MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer,4625 days,Withdrawn,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,0
2020-AHL-001,"Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer",854 days,Not yet recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 1,Yes,No,40
202201100,A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors,474 days,Recruiting,Interventional,Experimental,"Other, Procedure",Single Group Assignment,Not Applicable,No,No,14
SAMuhammad,Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt,731 days,Unknown status,Interventional,"Active Comparator, Active Comparator",Drug,Single Group Assignment,"Phase 2, Phase 3",No,No,45
2019-A02195-52,Immunomonitoring of Breast Cancer Patients During Systemic Treatment,1461 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,150
ShantouCH02,Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index,1247 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,64
PekingUPH10B003,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients,2104 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,46
CTMS# 19-0028,Effects of Creatine Supplementation in Breast Cancer Survivors,1432 days,Recruiting,Interventional,"Experimental, No Intervention",Dietary Supplement,Parallel Assignment,Not Applicable,No,No,30
NEO-01,OA for Breast Cancer NAC Response,645 days,Completed,Interventional,Experimental,Device,Sequential Assignment,Not Applicable,No,Yes,20
NL58040.091.16,Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance,527 days,Terminated,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,22
LQ006,Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer,987 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,35
MCC-19-15740,Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters),1401 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,460
K180603J,Advanced MR Techniques for Breast Cancer Detection,1827 days,Withdrawn,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,0
ABLE02,A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer,1438 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,244
MCC-21-BRE-54,"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",5339 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Sequential Assignment,Phase 2,Yes,No,70
HUM00140468,Acupressure for Pain and Opioid Use Among Breast Cancer Patients,395 days,Terminated,Interventional,"Active Comparator, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,8
CLEE011A3201C,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,1479 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Combination Product, Combination Product, Combination Product, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,223
2/108/7,What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?,395 days,Unknown status,Interventional,Experimental,"Other, Other, Other",Single Group Assignment,Not Applicable,No,No,25
EOC202A1101,Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer,1166 days,Completed,Interventional,Experimental,"Biological, Drug",Single Group Assignment,Phase 1,No,No,12
18-2562.cc,Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey,1676 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,370
19-586,Prolonged Nightly Fasting in Breast Cancer Survivors,711 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,40
2014CB543202-02,Warm Acupuncture for Breast Cancer Related Lymphedema,1073 days,Completed,Interventional,"Experimental, Experimental, No Intervention","Other, Other",Parallel Assignment,Not Applicable,No,No,108
IB 2017-05,Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.,1096 days,Unknown status,Interventional,"Experimental, Active Comparator",Behavioral,Parallel Assignment,Phase 3,No,No,320
On4Rehab Pilot Trial,Physical Exercise for Breast Cancer Survivors: Face-to-face Versus Home-based,152 days,Completed,Interventional,"Active Comparator, Experimental",Other,Parallel Assignment,Not Applicable,No,No,12
IIT-0005,Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting,735 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Drug",Parallel Assignment,Phase 2,No,No,52
PROTECT,Prospective Surveillance for Breast Cancer-Related Lymphedema,1427 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,250
NCC2129,Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer,1129 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,108
001,Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer,1034 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,60
SYSU-CSCO-2020,Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab,1827 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,27
IRB18-0970,A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer,2478 days,Recruiting,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,400
2019-09-023,Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial,1825 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental",Procedure,Single Group Assignment,Not Applicable,No,No,1380
Shengjing-LCG004,Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT,1960 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,1498
MedOPP168,"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer",1037 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,5
I239,CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer,1108 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,15
IRB00158622,Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings,780 days,Completed,Interventional,"Active Comparator, Sham Comparator, Other","Other, Other, Other",Factorial Assignment,Not Applicable,No,No,102
RFTMBCPW,Fulvestrant in Metastatic Breast Cancer,1157 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 4,No,No,30
s63338,The Added Value of a Third Supervised Training Session to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study,240 days,Completed,Interventional,"Active Comparator, Experimental, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,62
2017-0071,"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer",2325 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,54
20200628GD,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,753 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,30
ANLO-BC,Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer,924 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,134
SHR-A1811-III-306,SHR-A1811 Versus Investigators Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial,1127 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,528
REO 028,A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study,1482 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental, Experimental","Drug, Biological, Drug",Parallel Assignment,Phase 2,Yes,No,48
LQ007,Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer,987 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,32
2019-KY-049,Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer,1085 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,46
D9268C00001,"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigators Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",1397 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,733
ET17-203 DISCO,Efficacy of Exercise Using Connected Activity Trackers and Therapeutic Education in Localized Breast Cancer,1589 days,Completed,Interventional,"Experimental, Experimental, Experimental, No Intervention","Device, Behavioral",Factorial Assignment,Not Applicable,No,No,436
EC/2017/0200,Intra-operative PET-CT: a Novel Approach to Determine Excision Margins in Lumpectomy Breast Cancer.,2190 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,100
200277,Focused Ultrasound and Gemcitabine in Breast Cancer,1070 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Device, Other",Parallel Assignment,Phase 1,Yes,Yes,48
CFT / sp123,A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer,547 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,42
2021-1201,3D Printed Breast Models in the Surgical Management of Breast Cancer,1308 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Diagnostic Test,Single Group Assignment,Phase 2,No,No,200
FDRT-BC012,Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer,2190 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,"Phase 1, Phase 2",No,No,120
99mTc- RM26,Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26,850 days,Enrolling by invitation,Interventional,"Experimental, Experimental",Diagnostic Test,Parallel Assignment,Phase 1,No,No,10
2103254164,Pioglitazone Therapy Targeting Fatigue in Breast Cancer,464 days,Recruiting,Interventional,"Active Comparator, Active Comparator, No Intervention","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,30
MA-BC-II-026,Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),1635 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,35
OBU-BC-II-079,Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer,547 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,65
BCD-178-2,Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer,1097 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,336
SHR6390-Ib/II-201,A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,1561 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,146
AAAT4412,Breast Elasticity Imaging During Neoadjuvant Chemotherapy,931 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,50
N19MIM,Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial,3326 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Biological, Biological",Parallel Assignment,Phase 2,No,No,38
CA209-7A8,A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,648 days,Completed,Interventional,"Experimental, Experimental, Active Comparator","Biological, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,23
CFT/sp123,"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer",546 days,Withdrawn,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,0
EVER-132-002,Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC),1194 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,331
KY20192081-F-1,Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer,1096 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,100
AC682-001,A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer,658 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,30
ATOS-Z-201,(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer,868 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,174
UC-0140/1711 - UCBG3-06,Study on Androgen Receptor and Triple Negative Breast Cancer,1589 days,Completed,Interventional,"Experimental, Other","Drug, Drug",Parallel Assignment,Phase 2,No,No,94
2018-05-0155,Improving Brain Function After Breast Cancer Study,489 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,36
SBU-PCWRT-BREAST,Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer,2574 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Early Phase 1,No,Yes,25
2021.240,Effectiveness of Mobile Messenger-initiated Reminder on Biannual Mammography Adherence in Breast Cancer Screening,730 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,600
HNCH-BC008,Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer,2530 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,1979
PLATO study,PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate,3341 days,Recruiting,Interventional,Experimental,"Drug, Drug, Genetic",Single Group Assignment,Phase 2,No,No,122
RSRB00066846,"A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer",1457 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,32
KC19EESI0325,Real-time Interactive Digital Healthcare System in Post Operation Patients With Breast Cancer; Pilot Study,189 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,20
16-007764,Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography,241 days,Withdrawn,Interventional,Other,"Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,Yes,0
114421,Understanding and Addressing Patient and Provider Preferences Around Discussions of Cost of Breast Cancer Care,742 days,Completed,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,100
18-621,Tucatinib + Abemaciclib + Herceptin for HER2+ MBC,86 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,0
IRB-59141,Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer,372 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,30
STOP-BC Trial,Sulindac and Breast Density in Women at Risk of Developing Breast Cancer,2264 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,150
SYSU005,Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation,1446 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,61
ZN-c5-002,A Study of ZN-c5 in Participants With Breast Cancer,508 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,35
Fudan University,NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy,1156 days,Unknown status,Interventional,"Experimental, No Intervention","Drug, Drug",Parallel Assignment,Phase 3,No,No,316
18-8214-BO,Effectiveness of Ear Acupuncture to Improve Insomnia in Women With Breast Cancer,252 days,Completed,Interventional,"Experimental, Active Comparator","Procedure, Behavioral",Parallel Assignment,Not Applicable,No,No,52
1711-048-898,Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer,1744 days,Recruiting,Interventional,"Experimental, Active Comparator",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,460
HR-BLTN-001,Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC,641 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,79
2021-A03091-40,Evaluation of the Interest of a Postural and Functional Analysis for the Follow-up of the Adapted Motor Activity of Patients Treated for Breast Cancer,1216 days,Not yet recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,60
P.T.REC/012/002968,RESISTANCE VERSUS AEROBIC EXERCISES ON Breast Cancer Patients,110 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Device, Other",Parallel Assignment,Not Applicable,No,No,60
IIT-2021-ASSET,Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer,796 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,18
4-2020-1131,Talazoparib Maintenance Therapy in Triple-negative Breast Cancer,1096 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,206
145358,"A Phase I/II Multicenter, Open-Label Study of Lu-177-αvβ3-IAC, for the Treatment of Angiogenic Breast Cancer Patients.",578 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,100
UMCC 2018.016,The ConnectedCancerCare Pilot Study (CCC),387 days,Completed,Interventional,"Experimental, Other","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,66
TP.102.17.22.PAR,Pilot Clinical Evaluation of a Microwave Imaging System for Breast Cancer Detection,632 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,103
EFC15935,Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer,1171 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,1068
BC-NEO-IIT-SHR6390,SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.,606 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,20
GDWCH-001,Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer,1155 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,73
SMC-2018-10-062,Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast Cancer,708 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,44
SMX 18001,Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,1595 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,100
NRG-BR008,Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer,5074 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Radiation, Drug",Parallel Assignment,Phase 3,No,No,1300
TEBICA002,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,915 days,Completed,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,5
CWCD118B12201,Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer,2133 days,Not yet recruiting,Interventional,"Experimental, Active Comparator, Active Comparator, Other","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,250
CALORIE,Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy,731 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,50
S2010,"Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study",1860 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Procedure, Procedure, Behavioral, Other, Other",Parallel Assignment,Not Applicable,No,No,540
2019-A01592-55,Transcutaneous Breast Cancer Diagnosis by Canine Odorology,1517 days,Suspended,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,450
ABY-025-MI301,A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer,2628 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,160
202202045MIPA,Olaparib Maintenance Therapy in Metastatic Breast Cancer,1115 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,300
22-07025006,Diabetes Care for Breast Cancer Patients,1379 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,76
2019/044,Evaluation of the Effect of Mediterranean Diet on Breast Cancer Patients,456 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,25
B2017-11,Neoadjuvant Goserelin for Triple Negative Breast Cancer,1826 days,Unknown status,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,No,No,180
Pro00088926,Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer,1334 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,320
Tmab-TK006-102b,Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases,365 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,30
Ahead-BC-20170323,Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer,731 days,Unknown status,Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Phase 2,No,No,30
21090645,Omega-3 and Vitamin D Supplementation in Breast Cancer Women,254 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, No Intervention","Dietary Supplement, Dietary Supplement, Combination Product",Parallel Assignment,Early Phase 1,No,No,88
18-0234,The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,518 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,88
P20CA217199-9492018,A Community Dance Intervention Engaging Breast Cancer Survivors in a Middle-income Country,549 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,64
Pro00107216,The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer,607 days,Withdrawn,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,0
HREBA.CC 19-0363,Rise Up After Breast Cancer,243 days,Completed,Interventional,Experimental,"Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,12
AHQU-2021004,Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer,589 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,52
H20-03123,Breast Cancer Endocrine Therapy FITness (BE-FIT) Trial.,1021 days,Recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,132
SYS-C-201801-5010,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,4383 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,210
15-017,Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer,1390 days,Unknown status,Interventional,Experimental,"Other, Other",Single Group Assignment,Not Applicable,No,No,190
ZN-c5-003,A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer,711 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,14
M14ABC,"A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients",1508 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,9
18-004803,Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes,397 days,Terminated,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,1
34615/4/21,The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer,513 days,Completed,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,66
CLAG525B2101,"A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer",1241 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,88
MINERVA,Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management,1435 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 4,Yes,No,300
LACOG 0419,Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer,3145 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,494
CHB18.04,Quality of Life and Sexuality of Patients Over 65 Years Undergoing Adjuvant Treatment for Breast Cancer,1186 days,Completed,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,14
CSIIT-C21,A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer,731 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,70
BOOG 2018-01,Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study,4812 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,462
AMC2020-17,Upper Limb Function After Breast Cancer Surgery: the Role of Post-operative Physical Therapy Intervention,427 days,Completed,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,160
KY20222062-C-1,"Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer",425 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,20
20201540,Prospective Evaluation of Targeted Axillary Dissection (TAD),1096 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,45
RCVDBCIIR005,Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer,549 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,20
STUDY00003282,Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer,1317 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,50
IRB-2022-348,Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery,422 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,116
LCCC 1639,"Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC",317 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,5
SCHBCC-N034,Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D),1825 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 2,No,No,356
2022-0431,A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC),273 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,25
CBYL719C1201,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer,2507 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,50
SYSA1802-CSP-006,A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC),730 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,79
KY2019-023,Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,2693 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,53
MEDOPP447,Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer,870 days,Withdrawn,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,0
GE-226-004,Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer,366 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Diagnostic Test, Diagnostic Test",Sequential Assignment,Phase 1,Yes,No,12
2021P002871,Optimizing Functional Recovery of Breast Cancer Survivors,1311 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,300
CABC - Kreftfor project - SEB,Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions,5463 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Placebo Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,390
201708076,Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer,532 days,Completed,Interventional,"Experimental, Active Comparator","Other, Procedure, Behavioral, Procedure, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,30
TWT-203,"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer",1162 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,44
CO41101,A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.,1191 days,Completed,Interventional,"Experimental, Experimental, Active Comparator, Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,242
EA1183,"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study",2707 days,Recruiting,Interventional,Experimental,"Procedure, Other, Procedure",Single Group Assignment,Phase 2,No,No,134
WO42312,"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physicians Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)",1095 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,303
NHP,Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer,729 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,50
JU 2020/1732-51,Digi-Do - a Digital Information Tool to Help Patients Diagnosed With Breast Cancer,1216 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,80
NCCH1607,"PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY",2608 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,180
NL69081.041.19,The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial,1465 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 3,No,No,120
AAAS2359,Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition,366 days,Unknown status,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,90
HSEARS20210816002,The Effects of a Nurse-led mHealth Program for Symptom Self-management of Breast Cancer Patients Undergoing Chemotherapy,266 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,76
D926XC00001,A Study of Dato-DXd With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03),2676 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,1075
HRS-8080-I-101,A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults,1260 days,Enrolling by invitation,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,156
ONA-XR-103,Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer,1245 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,67
2022-0315,Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,3613 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 1,Yes,No,37
KCSG BR19-13,High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx),1817 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,578
STU00216520,Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia,1411 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Phase 3,No,No,452
20805,BATs in Patients With Breast Cancer and Leptomeningeal Metastases,1022 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,3
ICO-2020-25,Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients,984 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,12
HRS-1358-I-101,A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer,874 days,Enrolling by invitation,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,102
IRFMN-BRC-7103,Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer,1968 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,54
BL-M02D1-101,A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors,712 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,No,No,26
RJBC1901,Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,234 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Procedure",Parallel Assignment,Phase 2,No,No,12
PELICAN-IPC 2015-016,Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer,2472 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,81
852000,FES BPET-DBT in Newly Diagnosed Breast Cancer,1006 days,Not yet recruiting,Interventional,Experimental,"Device, Drug",Single Group Assignment,Early Phase 1,Yes,Yes,20
YO41137,"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer",2106 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Procedure, Radiation, Drug",Parallel Assignment,Phase 3,Yes,No,200
BC2,A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer,2495 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,172
CO40016,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",1824 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,580
ADIGYN,Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer,3511 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,1000
NICSO-GINSENG,American Ginseng for the Prevention of Moderate-severe Fatigue in Breast Cancer Patients,611 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,290
ATADEK-2018 / 9,KİNECT® - Video Games Based Physiotherapy Programme in Patients With Breast Cancer Surgery,336 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,34
UW22095,Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer,1081 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,100
HREBA.CC-18-0657,Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer,1713 days,Enrolling by invitation,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,50
NSABP FB-12,Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling,1995 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug, Diagnostic Test",Single Group Assignment,Phase 2,Yes,Yes,64
4469,PIK3CA in HER2+ BC and pCR Trial,487 days,"Active, not recruiting",Interventional,Experimental,Genetic,Single Group Assignment,Not Applicable,No,No,58
STUDY00018504,"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer",2941 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Procedure, Drug, Drug, Biological, Drug, Other, Drug",Parallel Assignment,Phase 2,Yes,No,132
YOUNGBC-19,Chidamide in Combination With Abemaciclib and Fulvestrant in Breast Cancer Patients Previously Treated With Palbociclib,304 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,44
CCR5316,A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer,3077 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,1100
STUDY00000675,Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer,1264 days,Recruiting,Interventional,Experimental,"Procedure, Drug, Drug, Procedure",Single Group Assignment,Phase 1,Yes,No,20
FILBLAU1022,Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy,580 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Biological, Biological",Parallel Assignment,Phase 3,No,No,60
CBYL719C2303,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.",1759 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Crossover Assignment,Phase 3,No,No,234
BC-IIT-SHR6390-FMTN,A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.,857 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,35
LV,"Breast Cancer, Omics, and Precision Medicine",699 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Biological,Factorial Assignment,Phase 2,No,No,200
CAPRICE-IPC 2020-053,A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr,1736 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,72
HMPL-012-SPRING-R101,An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer,1096 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,63
2107239-9,Reverse Triple Negative Immune Resistant Breast Cancer,244 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,30
Breast PTC,Postoperative Identification of Tumor Cells at the Lumpectomy Site of Patients With Early Breast Cancer,1839 days,Suspended,Interventional,,Procedure,Single Group Assignment,Not Applicable,No,No,20
201900115B0,Evaluation of the Effects of the Couple-based Family Nursing for Women With Breast Cancer,299 days,Completed,Interventional,"Experimental, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,70
2021-A02664-37,Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.,858 days,Recruiting,Interventional,Other,Biological,Single Group Assignment,Not Applicable,No,No,165
EF 160,Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer,1704 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,68
D20148,Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI),1115 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,28
CBYL719C2202,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",399 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,2
TRIO036,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer",678 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,19
EG017,To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.,1217 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,81
2019000486,"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer",1614 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,12
Alpha-Lipoic Acid,Alpha-Lipoic Acid in Breast Cancer Patients,609 days,Completed,Interventional,"Experimental, Experimental","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,64
VICC BREP 1898,Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer,1810 days,"Active, not recruiting",Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Phase 1,Yes,Yes,20
MD.22.07.674,Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients,654 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 3,No,No,116
07-2021/EK OUSA,Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery,760 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,120
I241,Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer,1952 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Other, Drug, Drug",Parallel Assignment,Phase 2,No,No,484
853.4,"Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer",316 days,Unknown status,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,12
173-18-CA,Perioperative Mindfulness Proposal,1614 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,24
1400,Tahini and Dermatitis in Breast Cancer,68 days,Not yet recruiting,Interventional,"Active Comparator, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,50
NCC2167,Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine,1369 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Active Comparator","Drug, Biological, Biological, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,138
UW 18-526,The Effect of Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy,585 days,Completed,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,30
H-1905-141-1035,Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer,2143 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,180
EUBREAST-2 INDAX,Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy,3286 days,Withdrawn,Interventional,"Experimental, Experimental","Procedure, Radiation",Parallel Assignment,Phase 3,No,No,0
HRHB-CB001,"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer",1461 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Biological",Parallel Assignment,"Phase 2, Phase 3",No,No,280
NSABP FB-14,Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer,1885 days,"Active, not recruiting",Interventional,Experimental,"Biological, Biological",Single Group Assignment,Phase 2,Yes,No,29
ADG106-T6002,"A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer",2815 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,66
1812850942,Telephone Support for Metastatic Breast Cancer Patients,1552 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,250
RJBC1801,Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer,1279 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,100
UTAR- 8068/000,A Systemic Approach to Study the Traditional Chinese Medicine as an Adjuvant Treatment in Breast Cancer Patients,710 days,Recruiting,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,30
SH APBI RISE,Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr,1856 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,Yes,91
TOL2506A,Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer,1399 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 3,Yes,No,250
2019-A02500-57,Management of Cognitive Difficulties After Cancer Treatments in Women Treated for Breast Cancer: Feasibility Study (Step 1 of the Cog-Stim Protocol),749 days,Completed,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,20
JCOG1919E,A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer,1621 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,280
Prix Ruban Rose/2020/FF-03,Multidisciplinary Care Pathway With Electronic Patient Reported Outcomes (ePRO) Post-operative Follow-up of Breast Cancer Surgery Complications to Optimize Patient Quality of Life,707 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,50
SBU-SBRT-BREAST-NO-SX,Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery,2568 days,"Active, not recruiting",Interventional,Experimental,Radiation,Single Group Assignment,Early Phase 1,No,Yes,15
E7389-M065-401,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",457 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,200
IUSCC-0680,Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors,1430 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,Yes,72
HCRN BRE20-468,"Ribociclib And Endocrine Treatment of Physicians Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",1905 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,200
UPCC 04119,BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy,1333 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator, Other","Radiation, Drug, Procedure",Parallel Assignment,"Phase 1, Phase 2",Yes,No,27
2021-04,Smart Bra for Diagnosing Breast Cancer,214 days,Not yet recruiting,Interventional,"Other, Other",Device,Parallel Assignment,Not Applicable,No,No,70
18-000718,"Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients",2165 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Behavioral, Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,200
MOST Pain,Optimizing Psychological Treatment for Pain After Breast Cancer,761 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,185
AQUAFIT-2018,Water-based Versus Land-based Exercise for Breast Cancer Survivors,971 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,28
Moderate Dose Omega-3,Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer,1120 days,Unknown status,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,11
Pro00104863,"Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer",365 days,Withdrawn,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,0
MA40,Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,2221 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Other",Parallel Assignment,Phase 3,No,No,250
HR-BLTN-003,Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer,1649 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,100
Velocity,Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer,545 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Behavioral, Drug",Parallel Assignment,Phase 3,Yes,No,20
KN026-201,Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer,2192 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,68
GBG105,"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer",1460 days,Recruiting,Interventional,"Experimental, Other","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,170
KN026-208,Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,555 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
27600,Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer,1553 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,176
RnaDx-BRV-BC- 01,RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy,2740 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,594
ZN-c5-001,A Study of ZN-c5 in Subjects With Breast Cancer,1475 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,181
2020-A00398-31,Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer,1654 days,Recruiting,Interventional,Other,Biological,Single Group Assignment,Not Applicable,No,No,85
CSIIT-C10,Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors,326 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,20
ICON CA209-9FN,Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer,3397 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,82
31052019,Implementation of a CDSS in Oncology Patients During COVID-19,400 days,Completed,Interventional,"Active Comparator, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,44
iOM-110393,Self-efficacy Coaching for Women With Breast Cancer,251 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,46
201711073,"MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",882 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental","Biological, Drug, Drug, Drug, Procedure, Procedure, Procedure",Sequential Assignment,Phase 1,Yes,No,0
L21-076,Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers,1247 days,Not yet recruiting,Interventional,"No Intervention, Experimental, Experimental","Device, Combination Product",Single Group Assignment,"Phase 1, Phase 2",Yes,Yes,36
2020-007,Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy (PROTECT-04),342 days,Completed,Interventional,"Experimental, Other",Other,Parallel Assignment,Not Applicable,No,No,30
19-300,Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer,1827 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,Yes,400
RAD1901-308,Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer,1910 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,466
LAE205INT3101,Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer,1046 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Single Group Assignment,Phase 1,Yes,No,20
201900180,89Zr-atezolizumab PET Scan and Lobular Breast Cancer,865 days,Terminated,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,1
201911047,Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,170 days,Terminated,Interventional,Experimental,"Device, Drug, Drug, Other, Other, Drug, Device, Procedure, Procedure",Single Group Assignment,Phase 1,Yes,Yes,1
CAAP CA,Light Emitting Diode for theTreatment of Genitourinary Syndrome of Menopause Associated With Breast Cancer Treatment,733 days,Unknown status,Interventional,"Experimental, Sham Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,74
BCT 2102,Tucatinib Together With Pembrolizumab and Trastuzumab,909 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,50
OCOG-2019-RHEAL,Hypofractionated LocoRegional Radiotherapy in Breast Cancer,2515 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,588
KY20223267-1,PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer,1460 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,100
SGNTUC-016,A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer,1672 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,565
GUMPTION,Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer,699 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,100
MA-BC-II-018,"Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial",2812 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,140
SCHBCC-N041,SNF Platform Study of HR+/ HER2-advanced Breast Cancer,1432 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,140
1401,Grape Juice and Dermatitis in Breast Cancer,68 days,Not yet recruiting,Interventional,"Active Comparator, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,50
IBIO-301,A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer,2014 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,200
FUSCC-T-sunflower,Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower),1216 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,126
BTP-66732,"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer",1156 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,267
CSIIT-C18,Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer,761 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Not Applicable,No,No,82
CLOVER,Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer,2678 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,2172
LOXO-PIK-21001,A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors,1086 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,400
SPI-GCF-104,"Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer",1937 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Biological, Biological, Biological, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,90
HNCH-BC006,Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer,1199 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,558
2019-0550,Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer,2606 days,"Active, not recruiting",Interventional,Other,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,13
NL74126.091.20,Adherence Improving Self-Management Strategy (AIMS) in Breast Cancer Patients Using Adjuvant Endocrine Treatment (AET),748 days,Unknown status,Interventional,"Experimental, Experimental, Other, Other","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,64
ALTERBC008,A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer,729 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,32
IOM-050371,Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line,1651 days,Completed,Interventional,"Experimental, Active Comparator","Combination Product, Combination Product",Parallel Assignment,Phase 3,No,No,41
IRB-2021-04,Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy,1257 days,Recruiting,Interventional,"Other, No Intervention",Behavioral,Factorial Assignment,Not Applicable,No,No,40
DPMBC301,Compare the Efficacy and the Safety of Doxorubicin and Cyclophosphamide Followed by Taxotere Versus Doxorubicin and Cyclophosphamide Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer,1034 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,320
SYHX2011-001,A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer,213 days,Not yet recruiting,Interventional,"Experimental, Experimental",Drug,Crossover Assignment,Phase 1,No,No,28
21-225,A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery,1443 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,"Phase 1, Phase 2",Yes,No,49
KCSG-BR18-13/TR-03,Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer,729 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,15
ICPS002/20,Radiofrequency Ablation (RFA) in Breast Tumors,1689 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,30
21-698,Alcohol and Breast Cancer (ABC) Trial,753 days,Recruiting,Interventional,"Experimental, Experimental","Other, Other",Crossover Assignment,Not Applicable,No,No,20
20P.020,"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer",1106 days,Withdrawn,Interventional,Experimental,"Drug, Biological, Biological, Biological, Other, Other",Single Group Assignment,"Phase 1, Phase 2",Yes,No,0
RJBC2001,"Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer",2770 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Procedure",Parallel Assignment,Phase 2,No,No,216
H-2009-079-1157,Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency,1446 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,70
GB491-005,A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer,974 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,10
012342QM,Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer,2162 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,87
GDWCH002(TNBC),ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer,943 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
HR-BLTN 015,A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.,671 days,Unknown status,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,59
HER2BRAIN,TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN),1460 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,120
HNCH-MBC10,A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer,731 days,Not yet recruiting,Interventional,"Experimental, Other","Drug, Drug",Parallel Assignment,Phase 2,No,No,60
IC 2020-20,Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy,1077 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,300
2017-004909-41,Prevention of Cardiac Dysfunction During Breast Cancer Therapy,2435 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 2,No,No,214
2022JC-55,Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.,1825 days,Not yet recruiting,Interventional,"Experimental, Sham Comparator, No Intervention","Other, Other",Parallel Assignment,Not Applicable,No,No,90
ICO-2020-28,Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases,790 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,52
2021-0974,Time Restricted Eating During Chemotherapy for Breast Cancer,1308 days,Recruiting,Interventional,"Experimental, No Intervention, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,40
HNCH-MBC12,Study of SHR-A1811 in HER2-positive Advanced Breast Cancer With Brain Metastases,1126 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,75
Twisted Pink Foundation,Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer,3589 days,Recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,Yes,No,15
HORMONOVILLE,Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer,794 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,133
ET17-093 BreastImmune03,Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease,1613 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,95
1910208-9,Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer,889 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,55
CSPC-KAL-BC-11,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer,578 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,520
1503144-7,"Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)",821 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,178
IRB00022667,Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening,945 days,Not yet recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,350
TOL2506A-EXT,"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study",1982 days,Enrolling by invitation,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 3,Yes,No,250
IKP275 / GBG91,Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients,601 days,Completed,Interventional,"No Intervention, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,356
BELIEVE@BC,Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer,1249 days,Not yet recruiting,Interventional,"No Intervention, Experimental",Device,Parallel Assignment,Not Applicable,No,No,120
GCC 1926,GammaPod Dose Escalation Radiation for Early Stage Breast Cancer,2634 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator",Radiation,Sequential Assignment,Not Applicable,No,Yes,50
HIFU202207,To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer,851 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Procedure, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,20
BO40747,A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer,1686 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,454
KA22053,The 24 Hour Effects of Remedial Exercises With and Without Compression Therapy on Breast Cancer-related Lymphedema,208 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Single Group Assignment,Not Applicable,No,No,34
BOOG-2017-01,"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.",2969 days,"Active, not recruiting",Interventional,"Other, Active Comparator, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,100
GO39869,"Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",1186 days,Completed,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,14
P2100-SUR-S11,"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",1725 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Drug, Drug, Radiation",Parallel Assignment,Phase 1,Yes,No,18
BC-IIT-FMTN-SHR6390-ET,"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer",1514 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,65
2022JC-55-1,Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.,1826 days,Not yet recruiting,Interventional,"Active Comparator, Sham Comparator, No Intervention","Other, Other",Parallel Assignment,Not Applicable,No,No,90
XJTU1AF-CRF-2020-006,Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer,1153 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,120
SPY LNM 01,A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer,633 days,Completed,Interventional,Experimental,"Combination Product, Combination Product",Single Group Assignment,Phase 3,Yes,Yes,151
2018-062,Reducing Metabolic Syndrome Among Breast Cancer Survivors,677 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,7
CBYL719A0US03T,"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",675 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,25
QUILT-3.067,QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.,1752 days,"Active, not recruiting",Interventional,Experimental,"Drug, Biological, Biological, Biological, Biological, Biological, Biological, Biological, Biological, Biological, Biological, Drug, Drug, Drug, Drug, Drug, Drug, Procedure",Single Group Assignment,"Phase 1, Phase 2",Yes,No,79
1808189-7,Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer,432 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,60
17041,A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer,1757 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,72
TSL-CM-TSL1502-Ⅱ,A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations,1429 days,Not yet recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,125
QL1701-002,"A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer",1250 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,474
FAVOR,"Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer",2129 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,493
60905722.0.0000.0072,Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy,2996 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,36
197520,Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer,2912 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,65
17249,A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body,286 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,5
Onkologikoa,PFMT Educational Intervention for Patients With Advancer Breast Cancer,585 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,42
ET17-057,Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer,2065 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,90
21-018,A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer,700 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,23
ShandongCHI-20,Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer,1095 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,100
AL-2001,Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.,1706 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,60
kazuma,"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study",1523 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,204
308-2017,Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer,3641 days,Recruiting,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,120
Pro00107615,TOPS for African American Breast Cancer Survivors,445 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,26
AC682-002,A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer,792 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,150
PRO00037175,Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer,1763 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,36
55516,Effectiveness of Aerobic Exercises and Laughter Yoga Compared With Yoga in Anxiety/Depression Levels in Breast Cancer,205 days,Completed,Interventional,"Experimental, Experimental, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,198
MA-BC-II-007,Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer,1612 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,261
48347821.8.0000.5249,The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients,548 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Not Applicable,No,No,44
OBU-BC-II-086,"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy",945 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,30
200218,Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design,1070 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,314
2017 0105,Health Benefits of HIT for Breast Cancer Patients,244 days,Withdrawn,Interventional,"Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,0
MYBC,Multidisciplinary Shared Decision Making of Fertility Preservation in Young Women With Breast Cancer,2557 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,4100
D-FR-01070-003,Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer,107 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,4
MUKDEN01,"Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial",2347 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,89
R174-A11507-17-S52,Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression,640 days,Withdrawn,Interventional,"Experimental, Experimental, Placebo Comparator","Dietary Supplement, Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,0
000001,Reliability and Reproducibility of Bandaging in Breast Cancer,729 days,Completed,Interventional,"Experimental, Experimental",Other,Crossover Assignment,Not Applicable,No,No,23
BG01-2102,Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer,1081 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,552
19-004343,"Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot",1015 days,Enrolling by invitation,Interventional,Experimental,Genetic,Single Group Assignment,Not Applicable,No,Yes,250
Shandong CHI-11,Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer,1796 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,200
NCC2225,Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer,1021 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,100
NCC-006461,Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer,1308 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,40
OZM-103,A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer,129 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,0
SCHBCC-NO27,Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients,448 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,60
2020/482,"Supervised Exercise, Sleep in Patients With Non Metastatic Breast Cancer",845 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,60
TUXEDO-1,Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases,1095 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,15
CIBI375Y008,"A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations",1096 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,20
NL76658.029.21,Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer,720 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Not Applicable,No,No,15
SCHBCC-N032,"Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer",1096 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,37
OE861801,A Phase I Study of LX-039 Tablets,1289 days,Enrolling by invitation,Interventional,"Experimental, Experimental",Drug,Single Group Assignment,Phase 1,No,No,68
1808189-8,Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer,253 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,78
4-2018-0765,"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",1603 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,95
LB,Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer,1018 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,80
CSIIT-C34,Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer,1028 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,90
19-886,RCT of CBD for Anxiety in Advanced Breast Cancer,760 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 2,Yes,No,50
FACILE,FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer,2527 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,194
RP6530-2101,"Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer",414 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,40
GEICAM/2021-08,Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab,2070 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,41
SYHX2011-002,A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound),489 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,454
ZDWY.XBZL.002,Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer,915 days,Not yet recruiting,Interventional,Other,Drug,Single Group Assignment,Phase 2,No,No,58
BO41843,"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",2351 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,992
HSEARS20180509004,Acupuncture for Joint Symptoms in Patients With Breast Cancer,1067 days,Terminated,Interventional,"Experimental, Sham Comparator, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,64
Shandong CHI-10,Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer,1894 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,200
erector-spinae,Postoperative Analgesia in Breast Cancer Surgery: Safety and Efficiency of Ultrasound Guided Erector Spinae Plane Block,195 days,Completed,Interventional,"Active Comparator, Placebo Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,60
OnkoFit I,Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Adjuvant Radiotherapy of Breast Cancer,1826 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,201
103089,A Window Trial on Curcumin for Invasive Breast Cancer Primary Tumors,1310 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,22
SHR6390-III-301,A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,1296 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,357
17575,A Study of LY3484356 in Women With Breast Cancer Before Having Surgery,569 days,Completed,Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 1,Yes,No,86
IMMU-132-09,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physicians Choice in Participants With HR+/HER2- Metastatic Breast Cancer,1973 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,543
2017-IIT-HER2-Aspire,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,2557 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,3
QL1209-301,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.,760 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Procedure",Parallel Assignment,Phase 3,No,No,544
17395,"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer",1284 days,Withdrawn,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 4,Yes,No,0
D967RC00001,"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",1705 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,624
2019-A01323-54,Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer,1601 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,342
UPCC 10119,ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer,2587 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 2,Yes,No,66
WO41554,"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer",2060 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",Yes,No,400
2020-0198,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,2327 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,56
UC-0109/1805,My Personalized Breast Screening,2358 days,Recruiting,Interventional,"Other, Experimental","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,85000
SHR-1210-III-318,"A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.",1266 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,780
H21089,Breathing Exercise for Chronic Pain Management in Breast Cancer Survivors,364 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,72
CSPC-DMS-BC-11,Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer,1147 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
0379520202023,Pain Neuroscience Education and Graded Exposure to Movement in Breast Cancer Survivors,820 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,62
S63893,Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity,1460 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, No Intervention","Drug, Drug",Parallel Assignment,Early Phase 1,No,No,0
KM10B,Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physicians Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer,1293 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,119
TriMix-Breast,Intratumoral TriMix Injections in Early Breast Cancer Patients,2240 days,Recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug",Sequential Assignment,Phase 1,No,No,36
19-486,A Study of the Bodys Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer,1458 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other, Other",Parallel Assignment,Phase 2,No,No,62
UC-GMP-2206,Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib,2557 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,162
SYSUCC-003,Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer,1383 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,228
2021-005,Consequences of Eccentric Cycling on Exercise-related Neuromuscular Responses and Biomarkers in Breast Cancer Patients,157 days,Completed,Interventional,Experimental,"Other, Other, Other",Single Group Assignment,Not Applicable,No,No,12
MRG002-009,A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients,557 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,99
CBYL719G12301,Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation,1356 days,Recruiting,Interventional,"Experimental, Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,511
TCF20-BRE-01,Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376,1774 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,No,No,75
GS-US-586-6144,Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer,1114 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 2,Yes,No,144
PMC_TTAC-0001_05,TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer,1392 days,"Active, not recruiting",Interventional,Experimental,Drug,Sequential Assignment,Phase 1,No,No,11
EOC103A3101,"Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer",1751 days,"Active, not recruiting",Interventional,"Active Comparator, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,375
CO41012,A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,1415 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,20
SYM013,Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients,1087 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,100
SHR6390-III-302,A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,1625 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,426
Pro2021000838,"Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care",731 days,Not yet recruiting,Interventional,"Active Comparator, No Intervention",Behavioral,Crossover Assignment,Not Applicable,No,No,910
CSPC-DMS-BC-K07,Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer,2233 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,372
SGNLVA-002,Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer,2499 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,211
WO43919,"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy",2130 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,400
EMBRAVE-001,Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients,1096 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,Yes,No,100
I 72218,A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity,751 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,30
FCN-437c-III201,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",1096 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,434
MCC-20899,Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases,1127 days,Recruiting,Interventional,"Experimental, Experimental","Radiation, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,31
2021-TNBC-01,Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer,1138 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,30
FCN-437c-III202,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",851 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,312
breast-202204,Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer,545 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,30
20150288,Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors,1826 days,Withdrawn,Interventional,"Experimental, Active Comparator, Active Comparator, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",Yes,No,0
P170927J,Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment,1095 days,Not yet recruiting,Interventional,"Active Comparator, Experimental, Experimental","Device, Device, Device",Parallel Assignment,Not Applicable,No,No,330
HBBL-01,Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study,1096 days,Unknown status,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,No,No,80
PCZCTP-220702-001,"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer",486 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,12
ERC-260,Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer,394 days,Withdrawn,Interventional,"Placebo Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,0
POL6326-009,"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer",991 days,Unknown status,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,384
911,"Effects of Green Coffee Extract Supplementation on Leptin, Ghrelin, Adiponectin,Anthropometric Measurements, Lipid Profile in Breast Cancer Survivors",518 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,50
IRB#18853,Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening,1351 days,Recruiting,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,Yes,210
EAGER-001,Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer,640 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,40
206010,Vaccination of Triple Negative Breast Cancer Patients,1445 days,Completed,Interventional,"Active Comparator, Experimental","Biological, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,24
UKFC-PU-2019-01-08,Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients,844 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental, Experimental","Dietary Supplement, Dietary Supplement, Other",Parallel Assignment,"Phase 1, Phase 2",No,No,324
2018-001705-91,Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer,642 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,48
KA-20007,"The Effect of Oral Cryotherapy on Anticipatory, Acute and Late Nausea and Vomiting in Breast Cancer Patients",300 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,54
Arise-FJ-B02,Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer,821 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,20
SYSU-2021,Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer,1467 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,78
SHR-A1811-II-202,A Phase Ib/II Study of SHR-A1811 Injection in HER2 Positive Breast Cancer,1318 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,402
2019-A03112-55,Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study,909 days,"Active, not recruiting",Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,55
017-396,Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer,1057 days,Completed,Interventional,"Experimental, Experimental",Dietary Supplement,Sequential Assignment,Not Applicable,No,No,16
G1T28-213,Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer,952 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,30
Shengjing-LCG012,A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer,619 days,Recruiting,Interventional,"Experimental, Other","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,100
NK/7784/Study/249,Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis,1826 days,Recruiting,Interventional,"Active Comparator, Experimental",Radiation,Parallel Assignment,Phase 3,No,No,98
CL0006,Intraoperative Detection of Residual Cancer in Breast Cancer,794 days,Completed,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,Yes,Yes,234
ZEN003694-004,A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer,1771 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,179
TED15954,Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer,1528 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,10
s2192648,Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients,545 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,60
UC-0140/1812,"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.",2897 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,158
MAMA_MOVE_Gaia After Treatment,Effects of a Physical Exercise Program in Quality of Life of Breast Cancer Survivors,1280 days,Completed,Interventional,"Experimental, No Intervention",Other,Crossover Assignment,Not Applicable,No,No,80
GS-US-569-6172,Study of Sacituzumab Govitecan-hziy (SG) in Japanese Participants With Advanced Solid Tumors or Triple-negative Breast Cancer,985 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,52
HNCH-BC011,Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer,2568 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,369
NCC3397,Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer,1826 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Other, Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,300
IC 2020-10,Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer,1531 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 2,No,No,214
CTMX-2009-002,Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer,852 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,125
2020-006106-23,Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva),1273 days,Suspended,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,200
HR-NeoBC-HN003,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.,578 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,48
17320,"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",363 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 4,Yes,No,4
PALBOBIN,Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer,986 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,24
202103030005,Evaluation and Re-evaluation of Post-mastectomy Pain Syndrome by Breast Cancer EDGE Task Force Outcomes,397 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,10
2018.451,"FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET",1538 days,"Active, not recruiting",Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,40
D8530C00002,A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer,1134 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,240
MA-BC-II-033,The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis,2009 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,53
17-428,Olaparib In Metastatic Breast Cancer,1734 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,114
NL81896.078.22,Tamoxifen Prediction Study in Patients With ER+ Breast Cancer,303 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,100
SDX-0103,Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer,1467 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,52
CO42177,"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer",891 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,83
MO39874,A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer,1825 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 3,Yes,No,184
202007016,Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer,2019 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Biological, Biological, Procedure, Procedure, Procedure",Parallel Assignment,"Phase 1, Phase 2",Yes,No,15
B003-101,B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer,1582 days,"Active, not recruiting",Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,45
DOUBLE,Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer,1003 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,61
REaCT-5G,"A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy",905 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,233
STUDY00019489,177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer,475 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,10
CO40151,A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,1491 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,140
TQB2450-Ib-07,A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC),601 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,30
R19-149,Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging,1582 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,20
2021/609,Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer,821 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,40
BOOG-2017-02,Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer,1946 days,Withdrawn,Interventional,"No Intervention, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,0
AK117-203,A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer,586 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,80
HR-NeoBC-HN002,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.,700 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,75
AND019-MN-101,A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer,939 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,61
SKB264-Ⅲ-03,"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer",935 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 3,No,No,254
495573096,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer,730 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,268
ESPB in breast cancer surgery,Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery,608 days,"Active, not recruiting",Interventional,"Placebo Comparator, Experimental, Experimental","Procedure, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,60
SI 475/2019,Analgesic Effect of Adding Thoracic Paravertebral Nerve Blocks to Modified PEC Block in Breast Cancer Surgery,943 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,100
JS001-026-III-TNBC,Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment,2202 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,531
CBYL719CIN01,"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment",828 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 4,No,No,100
SPORT-DS,Single Pre-Operative Radiation Therapy - With Delayed Surgery for Low Risk Breast Cancer,1735 days,"Active, not recruiting",Interventional,Experimental,Radiation,Single Group Assignment,Phase 1,No,No,20
WO43571,"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)",3741 days,Recruiting,Interventional,"Other, Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,812
2020-0232,Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC),2183 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,12
TQB2450-III-06,A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC),760 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,332
CASE5119,Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer,658 days,Recruiting,Interventional,"Active Comparator, Experimental","Dietary Supplement, Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,150
AH150201,"Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c",1232 days,Unknown status,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,78
EVER-132-001,Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments,920 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,80
99mTc-ADAPT6 in breast cancer,99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes,608 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,30
MOST Pain Pilot,Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study,153 days,Completed,Interventional,"No Intervention, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,31
TBDBreast50,Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer,0 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,0
I237,CFI-400945 in Patients With Advanced/Metastatic Breast Cancer,1652 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,51
KarolinskaUD,"OptiBra Study, Optimal Postoperative Bra After Breastcancer Surgery",376 days,Unknown status,Interventional,"Active Comparator, Experimental",Other,Factorial Assignment,Phase 3,No,No,200
QUILT-3.058,A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies,464 days,Terminated,Interventional,Experimental,"Biological, Biological, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,3
20200225,Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI),813 days,Recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,36
SCCC-03121; STU-2021-0657,"CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer",1442 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,45
BC-Fluzoparib,Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer,1422 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,40
NCC1969,Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer,1360 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,35
HX008-Ib/II-TNBC-01,A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer,870 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,31
STUDY00004350,A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy,727 days,Not yet recruiting,Interventional,Experimental,"Other, Other, Other, Other",Single Group Assignment,Not Applicable,No,No,30
14/2021,Efficacy of Expressive Writing on Quality of Life Among Breast Cancer Survivors in Oman: A Double Blind Randomized Controlled Trial,1094 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,64
HNCH-MBC07,Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure,1268 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,87
HR-BLTN-III-NeoBC,Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer,1408 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,355
SYSU-2022-UCAN,Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer,1806 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,349
19-113,Exercise Treatment With Standard Therapy for Metastatic Breast Cancer,1511 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Other,Parallel Assignment,Phase 1,No,No,53
B013-301,Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer,1486 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 2, Phase 3",No,No,450
4CAST,Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer,1126 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,65
811,"Effects of Green Coffee Extract Supplementation on Adropin, Irisin, Vaspine,Systemic Inflammation and Oxidative Stress in Breast Cancer Survivors",607 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,50
SHR1210-III-322,A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),1147 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,581
BC- T-DM1,Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy,1058 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Not Applicable,No,No,50
HERMIONE-7,"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)",1424 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,31
RG1006427,Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors,615 days,Completed,Interventional,"Active Comparator, Experimental","Behavioral, Other, Behavioral, Other, Other",Parallel Assignment,Phase 2,No,No,90
22-x354,ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer,2679 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Active Comparator","Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,174
CO41863,A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,134 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,1
21030,Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer,335 days,Withdrawn,Interventional,Experimental,"Device, Other, Other",Single Group Assignment,Not Applicable,No,Yes,0
BAT-8001-002-CR,The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer,1279 days,Unknown status,Interventional,"Experimental, Active Comparator","Biological, Drug, Drug",Parallel Assignment,Phase 3,No,No,410
MedOPP190,"Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)",929 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,14
Combined CTH and HT in MBC,"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study",886 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,124
KN046-203,A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer,1569 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Biological, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,52
DZ2019HE001,"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer",1318 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,23
S62794,"Preventing Taxane-related Peripheral Neuropathy, Pain and Nail Toxicity: A Prospective Self-controlled Trial Comparing Hilotherapy With Frozen Gloves in Early Breast Cancer",519 days,Completed,Interventional,"Active Comparator, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,62
SHR6390-SHR1020-I-101-BC,A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer,736 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,76
IIT2022-07-YUAN-IB-TNBC,Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer,1279 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,41
MA-BC-II-047,Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study,1125 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,No,No,30
FUSCC,Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA),1642 days,Not yet recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator, Other","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,338
222.20,SBRT in Early Breast Cancer in Elderly Women,1034 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Radiation,Sequential Assignment,Phase 1,No,No,30
NCC201711008,Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,490 days,Unknown status,Interventional,,Drug,Single Group Assignment,Phase 2,No,No,14
2019-0634,Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women,404 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,62
ShandongCHI-06,Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy,2618 days,Not yet recruiting,Interventional,"No Intervention, Experimental",Drug,Parallel Assignment,Phase 2,No,No,200
NCC2474,Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer,821 days,Unknown status,Interventional,"Experimental, Active Comparator","Biological, Drug, Drug, Drug, Device",Parallel Assignment,Phase 2,No,No,55
MK 3475-318,Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.,803 days,Completed,Interventional,"Other, Other, Other, Other, Other, Other",Drug,Single Group Assignment,Early Phase 1,No,No,54
Medical Research Institute,"US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation",422 days,Completed,Interventional,"Experimental, Active Comparator, Placebo Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,60
MCLA-128-CL02,MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer,2222 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,101
HNCH-HER2-MBC001,Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.,555 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,46
P170929J,PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers,2922 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,12
GB491-004,GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer,873 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,270
MORE-T trial,Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients,2628 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Diagnostic Test, Procedure",Parallel Assignment,Phase 2,No,No,238
IJB-LOB-2019,Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE),1264 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,65
MS200647_0020,Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer,634 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,11
262840,CIPN in Early Stage Breast Cancer Patients,585 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,48
U025,Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer,1428 days,Completed,Interventional,Experimental,"Drug, Drug, Drug, Procedure",Single Group Assignment,Phase 1,Yes,No,100
Soh-Med-21_10_18,One Week Adjuvant Radiotherapy for Breast Cancer,730 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,100
SPH4336-301,Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer,596 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,374
HCB/2019/0786,Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy,669 days,"Active, not recruiting",Interventional,"Sham Comparator, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,84
2019-185-AGH,Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer,1416 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Device,Parallel Assignment,Phase 2,No,Yes,40
EC2019/0127,Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment,710 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Device,Parallel Assignment,Not Applicable,No,No,40
REaCT-OGF,Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy,914 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 4,No,No,240
NCI-2021-08921,Metformin and Nightly Fasting in Women With Early Breast Cancer,670 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Procedure, Drug, Other, Other, Other",Parallel Assignment,Phase 2,Yes,No,120
AIs with chemotherapy in MBC,Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer,640 days,Not yet recruiting,Interventional,,Drug,Single Group Assignment,Phase 2,No,No,70
CTRIAL-IE 22-01,Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study),1827 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,80
SIBP-01-3,A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer,761 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,580
20-068,MARGetuximab Or Trastuzumab (MARGOT),2544 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,171
19-002448,Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer,1192 days,"Active, not recruiting",Interventional,Experimental,"Other, Other, Other",Single Group Assignment,Phase 1,No,No,100
UC Laser,Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors,1534 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Device",Parallel Assignment,Not Applicable,No,Yes,70
TEMPLATE,Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study,735 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,265
CO42867,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,1959 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Active Comparator, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,510
GBG 93,"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).",1856 days,Recruiting,Interventional,"Experimental, Active Comparator",Drug,Parallel Assignment,Phase 4,No,No,150
2022-0500,Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors or Chemotherapy in Luminal B/HER2-negative Breast Cancer (DAPATH),1126 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,120
IJB-LBC-NEOCHECKRAY-2018,"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:",2262 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Radiation, Drug",Parallel Assignment,Phase 2,No,No,147
HR-MBC-HN001,A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer,1501 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,78
MCC-19803,Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer,621 days,Terminated,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 2,Yes,No,17
20-130,Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer,1727 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Active Comparator","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,152
BG01-2001,PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer,127 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,No,No,16
ROGABREAST,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",860 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,9
18291,A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer,844 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 1,No,No,24
SYSU-2021-UCAN,Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer,2922 days,Not yet recruiting,Interventional,"Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug",Factorial Assignment,Phase 3,No,No,512
18040334,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,598 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,60
Labra-001,Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy,335 days,Completed,Interventional,"Sham Comparator, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,71
M19-992,"A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy",140 days,Terminated,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,4
2021-1122,"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer",974 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 4,No,No,402
SYSKY-2022-105-01,Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer,853 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,132
CS2-19004,Chemotherapy - Induced Peripheral Neuropathy,380 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,22
I2I1,Connecting Breast Cancer Survivors for Exercise,265 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,108
2019-01-064,TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery,1253 days,Unknown status,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,67
SHR-A1811-206,A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.,698 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,300
FOENIX-MBC2 TAS-120-201,A Study of TAS-120 in Patients With Metastatic Breast Cancer,1400 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,168
IRB18-1178,Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer,1598 days,Recruiting,Interventional,"Experimental, Other, Other, Other, Other","Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 2,Yes,No,60
ML43171,"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physicians Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)",1336 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,320
UC-BCG-2011,Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer,1291 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,55
CSIIT-C41,Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy,550 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,23
MO43110,A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer,1178 days,Recruiting,Interventional,"Other, Other, Experimental, Experimental, Other","Drug, Drug, Drug, Drug, Drug, Procedure, Radiation",Parallel Assignment,Phase 3,Yes,No,330
SHR-1210-III-327,A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer,516 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,104
EOC202A2102,"HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy",1126 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator","Biological, Drug",Parallel Assignment,Phase 2,No,No,50
IEO 675,Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer,518 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,46
MP-05-2021-2605,Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer,673 days,Recruiting,Interventional,Experimental,"Procedure, Diagnostic Test",Single Group Assignment,Not Applicable,No,No,98
7339-009,Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009),2230 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Biological, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,460
MC1831,"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer",1707 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Procedure, Procedure, Biological",Single Group Assignment,Phase 2,Yes,No,38
D933LC00001,A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer,1652 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,210
MA-BC-II-042,Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer,1499 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,80
2020-1190,Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer,923 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Other, Device, Behavioral, Other, Other",Single Group Assignment,Not Applicable,No,No,30
HRS8807-I-101,"A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer",1162 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Device, Drug",Single Group Assignment,Phase 1,No,No,90
2019-00673; sp19Kurzeder,Digoxin Induced Dissolution of CTC Clusters,693 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,9
BreCLIM-2018-116-31M,BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases,3652 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Drug",Parallel Assignment,Phase 3,No,No,200
TQ-B3525-I-02,"A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer",427 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,42
HKUCTR-2709,Use of Superparamagnetic Iron Oxide (SPIO) in Sentinel Lymph Node Detection for Breast Cancer,2168 days,Recruiting,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,300
MUKDEN5,Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer,1071 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,130
Prevention of neuropathy,Photobiomodulation for Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer,720 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator, Placebo Comparator","Device, Device, Device",Parallel Assignment,Not Applicable,No,No,186
TQB3616-II-01,A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer,726 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,120
s17-00995,MBSR During AI Therapy for Breast Cancer,869 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,23
SHR9549-I-101,SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer,446 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,4
3-2019-0140,Effects of Mediterranean Diet Based Intervention in Breast Cancer Patients,731 days,Unknown status,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,78
IRB00109957,THRIVE Breast Cancer App Study,1323 days,Completed,Interventional,"No Intervention, Active Comparator, Active Comparator","Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,313
IRB18-00912,Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery,1547 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,202
0392-18-HMO,CO2 Laser Therapy for the Treatment of GSM in Patients With Breast Cancer,1642 days,"Active, not recruiting",Interventional,"Active Comparator, Sham Comparator",Device,Sequential Assignment,Not Applicable,No,No,60
UW19046,FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer,1137 days,Recruiting,Interventional,Experimental,"Drug, Diagnostic Test",Single Group Assignment,Early Phase 1,Yes,No,12
I 73718,Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer,1544 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug, Biological, Drug",Single Group Assignment,Phase 1,Yes,No,9
HCB/2020/0971,Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer Survivors,941 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,150
FJD-LCO2-19-01,A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.,1127 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Device, Combination Product",Parallel Assignment,Not Applicable,No,No,98
MC01/05/20; IST-325 (KPT),Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START),1706 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,63
KROG 21-07,Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients,3927 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,622
22012020,Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer,392 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,37
2020-1267,Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion,1383 days,"Active, not recruiting",Interventional,Experimental,"Procedure, Procedure, Other, Drug",Single Group Assignment,Not Applicable,No,Yes,89
HER2BAT,A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone,1421 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,130
ARIANNA (SOLTI-1502),Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC,861 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,34
PROICM 2019-05 MAC,Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery,1140 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,75
BLI-1401-2-01,"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.",546 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,44
20221120,A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause,1096 days,Not yet recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 2,Yes,No,20
CLEAR,Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer,2556 days,Recruiting,Interventional,Experimental,"Procedure, Radiation, Procedure",Single Group Assignment,Phase 2,No,No,110
2.777.676,Photobiomodulation for Breast Cancer Radiodermatitis,1028 days,Completed,Interventional,"No Intervention, Experimental",Device,Parallel Assignment,"Phase 2, Phase 3",No,No,48
IC 2017-06,Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer,1278 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,200
CO40115,A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer,2223 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental, Experimental, Active Comparator, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,133
111-009-F,A Study for Optimization of 6% Hydroxyethyl Starch Based Indocyanine Green Near-infrared Fluorescence Navigated Sentinel Lymph Node Biopsy for Breast Cancer Patients,364 days,Recruiting,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Phase 1,No,No,24
21129002,Topical Menthol Application in Chemotherapy-Related Peripheral Neuropathy in Patients With Breast Cancer,274 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,60
MCC-20915,"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab",1434 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Drug, Drug, Drug, Procedure",Sequential Assignment,Phase 2,Yes,No,34
PMCT-IMSLNB-MIT,Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique,914 days,Unknown status,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,350
V2000701,Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer,659 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,186
University Brunswick,Physical Activity Levels and Functional Improvement in Breast Cancer Survivors,933 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,20
1605576856,Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients,728 days,Recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,40
3475-B49,Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49),2590 days,Recruiting,Interventional,"Experimental, Active Comparator","Biological, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,800
2018-0287,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",1792 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,124
SABO 21-01,Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer,1929 days,Recruiting,Interventional,"Experimental, No Intervention",Radiation,Parallel Assignment,Not Applicable,No,No,345
UW20037,Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study),1243 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,39
20201101,Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study),1461 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,300
ZJCH-CK19B,A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer,595 days,Unknown status,Interventional,"No Intervention, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,388
IPI-549-03,Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3),958 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,91
2017-0500,M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer,1575 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,38
APG2575XU103,"A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer",779 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,65
BLTN-NeoBC1115,Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer,517 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,20
22-259,A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer,1096 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,Yes,40
UW18099,Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer,3152 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,Yes,30
17384,A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer,1005 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,2450
BL-B01D1-104,A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors,721 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,36
M21CSM,COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study,6422 days,"Active, not recruiting",Interventional,Other,"Procedure, Radiation, Other",Single Group Assignment,Phase 2,No,No,118
4-2022-0600,Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction,2800 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,790
22239,Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors,780 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Procedure, Drug, Drug, Other, Other",Parallel Assignment,Phase 2,Yes,No,88
202107015,"Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing",1850 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Device, Other",Parallel Assignment,Not Applicable,No,Yes,55
20171,Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer,868 days,Recruiting,Interventional,Experimental,"Other, Drug",Single Group Assignment,Not Applicable,No,No,26
HS-10352-101,Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer,1087 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,54
NNG17.2,Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients,1113 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,128
2019-40016-06,Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy,580 days,Unknown status,Interventional,"Active Comparator, Other",Drug,Factorial Assignment,Not Applicable,No,No,50
IRB-52869,Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer,1352 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,150
D9266C00001,"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)",713 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,118
2017/78,"Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)",3288 days,Not yet recruiting,Interventional,Experimental,Drug,Sequential Assignment,"Phase 1, Phase 2",No,No,85
ICRG0201,"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.",1259 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,80
SHR-A1811-III-301,"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane",886 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,269
IRB-63041,Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer,1446 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,40
U21-02-4401,Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition,1423 days,Recruiting,Interventional,,Drug,Single Group Assignment,Phase 2,Yes,No,74
GS-US-592-6173,"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",1652 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,440
SCO-120-19-22,A Study in Patients With Advanced Breast Cancer,591 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,167
GS-US-592-6238,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physicians Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer,1746 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,540
CBYL719C2201,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer,1653 days,Recruiting,Interventional,"Experimental, Placebo Comparator, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,135
TQB3616-III-01,TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail,623 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,287
19/218,Increasing Access to Breast Cancer Screening Among Immigrants,3547 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,11355
CHANGEABLE,Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer,835 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,37
19-3032.cc,Combined Modality Exercise and Appetite in Breast Cancer Survivors,472 days,Terminated,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,3
SCT200IITNBC,Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer,529 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,Phase 2,No,No,30
651,Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.,2922 days,Recruiting,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,850
H3B-6545-J081-103,"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",1156 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,No,No,33
2019-00174 Neoadj Breast Pilot,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",457 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,0
MO40628,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,1393 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Crossover Assignment,Phase 2,Yes,No,160
NNG17.1,Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.,634 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 1,No,No,50
STUDY00004618,A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening,207 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Other, Behavioral, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,140
19959,Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors,730 days,Unknown status,Interventional,"Active Comparator, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,52
AIPAC-003,Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy,1594 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Placebo Comparator","Biological, Drug, Other",Parallel Assignment,"Phase 2, Phase 3",Yes,No,849
18-1068,Clinician Communication About Sexual Health,248 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,32
SuleymanDU-SALMAN-F-001,The Effect of Mobile Application-based Information About Before and After Surgery,151 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,82
IIBSP-SIL-2017-70,Evaluation of a New Technique to Fill the Defect Generated After Conservative Surgery in Breast Cancer,895 days,Completed,Interventional,"Experimental, Active Comparator","Device, Procedure",Parallel Assignment,Not Applicable,No,No,100
Shoulder exercise cancer,Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery,322 days,Completed,Interventional,"Experimental, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,465
NCI-2022-00004,Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body,1558 days,Recruiting,Interventional,Experimental,"Drug, Dietary Supplement",Single Group Assignment,"Phase 1, Phase 2",Yes,No,18
GC-627-05,Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,693 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,393
LCCC 2104,Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN),1096 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Drug",Parallel Assignment,Phase 2,Yes,Yes,90
2021SQGH00743,The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer,1825 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,40
N21CPB-IRBd22-103,Communication in Breast Cancer Care,209 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,40
UPNA-CUMACA-B2022,Web-based Intervention for Long-term Breast Cancer Survivors,517 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,182
rosuva2020,Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients,1095 days,Recruiting,Interventional,"No Intervention, Active Comparator",Drug,Parallel Assignment,Phase 3,No,No,50
213831,Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease,2983 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,800
Pro00109917,Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors,432 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,30
GCO 17-2320,Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer,634 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,9
MA-BC-II-025,Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer,2373 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,206
CPO-NBP-2002,NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy,580 days,Not yet recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,60
INT/2020/VOICE,"Implementation, Effectiveness and Impact of a Value Based Intervention for Patients With Breast or Lung Cancer",1641 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,1161
N assisted,A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab,2085 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,300
SYSKY-2022-024-01,Construction and Effect Evaluation of Malignant Fungating Wounds Care Regimen for Breast Cancer Patients,767 days,Recruiting,Interventional,Experimental,Procedure,Sequential Assignment,Not Applicable,No,No,50
PROSOM-K,Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep,791 days,Completed,Interventional,"Other, Other, Other","Other, Drug",Parallel Assignment,Not Applicable,No,No,75
NL62441.068.17,PET-MRI for Axillary Staging in Node Negative Breast Cancer Patients,2108 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,125
EP0062-101,Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer,821 days,Not yet recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,128
KY2022-044-B,"CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial",2452 days,Recruiting,Interventional,"Active Comparator, Other",Device,Parallel Assignment,Not Applicable,No,No,484
SUGBG-2021001,Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide,911 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,50
PI2018_843_0061,Feasibility of Total Mastectomy in Ambulatory Care,1155 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,50
2110244-11,Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery,547 days,Recruiting,Interventional,"Experimental, Sham Comparator, Sham Comparator",Device,Parallel Assignment,Phase 4,No,No,186
HSM/VGH-2019-12-009CC,Web-based Oncofertility Support Tool for Reproductive-age Women With Breast Cancer,582 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,54
2021-A01550-41,Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer,1070 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,354
2449PT,Effect of Exercise Mode in Breast Cancer-Related Lymphedema,476 days,Completed,Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,52
20220430GD,Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation,2431 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,66
StrataXRT,A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients,260 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,50
TQB3909-Ib/II-01,A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer,274 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,65
"S-20200021, 19-16321",An Individualised Treatment vs. a Minimal Program in Women With Late-term Shoulder Impairments After Breast Cancer.,189 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,31
Exo-LCR-1807,Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.,1553 days,Withdrawn,Interventional,Experimental,"Procedure, Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,0
AGO/2019/003,Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer,158 days,Withdrawn,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,0
C4891016,A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC),246 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,6
MCC-19220,PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient,730 days,Withdrawn,Interventional,Experimental,"Diagnostic Test, Biological, Diagnostic Test",Single Group Assignment,Early Phase 1,Yes,No,0
2020-A01916-33,Adapted Fencing in Breast Cancer: a Pilot Study,356 days,Recruiting,Interventional,"Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,24
BR-003,Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors,701 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,122
2021/156064(REK),Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients,4581 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Dietary Supplement, Dietary Supplement",Parallel Assignment,Phase 2,Yes,No,60
MedOPP199,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -",238 days,Completed,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,66
RECHMPL21_0680,Impact of Video Information Support on Preoperative Anxiety in Breast Cancer Surgery,1014 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,200
18459,A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer,3438 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,6000
PRO00030295,Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors,1002 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,40
DBCG RT SDM,Shared Decision Making With Breast Cancer Patients,1244 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,678
NBK 171/1/2021,Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a Window of Opportunity Study,1800 days,Not yet recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,126
NCC1787,Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer,1126 days,Unknown status,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,50
UCI 19-145 [HS# 1459],"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",2314 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,20
18496,"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",1753 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Other, Other",Parallel Assignment,"Phase 1, Phase 2",Yes,No,28
INT214/22,Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial,731 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental",Dietary Supplement,Parallel Assignment,Phase 2,No,No,145
201906,Psychological Interventions to Prevent Late Effects in Breast Cancer,1553 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,200
BL-M07D1-101,A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors,723 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,26
22-250,TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients,1414 days,Recruiting,Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,270
HCI130492,Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics,1551 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,34
E7090-J081-102,A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer,1299 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,No,No,72
Folio No.03-2022,Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae,126 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,26
S63330,FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.,1521 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,150
CA209-8H3,"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients",2190 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,138
A171601,"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer",2178 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug, Other, Other",Single Group Assignment,Phase 2,Yes,No,93
OP-1250-001,"A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer",1205 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,94
21-091,A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer,730 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,50
CARDIEJERCAN,Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients,372 days,Not yet recruiting,Interventional,"No Intervention, Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,90
RIBBS 2019/37,Risk-Based Breast Screening in Young Women,2203 days,"Active, not recruiting",Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,10270
CCR5234,Digital Delivery of Information About Genetic Testing for Breast Cancer,514 days,"Active, not recruiting",Interventional,"Experimental, No Intervention, Experimental, No Intervention","Other, Other",Sequential Assignment,Not Applicable,No,No,1000
2574,Prospective Thinking in Hormone-Responsive Breast Cancer,415 days,Completed,Interventional,"Experimental, Sham Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,89
IFG-06-2019,Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer,918 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,82
439-21,High-intensity Exercise After Treatment,489 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,7
VHIO20002,A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020,1066 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Biological, Drug",Single Group Assignment,Phase 1,No,No,20
H-45698,Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ),1371 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,57
FDRT-BC010,Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases,1318 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,"Phase 1, Phase 2",No,No,39
D8666C00004,To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.,583 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,0
17-0310,Narrative Visualization for Breast Cancer Survivors Physical Activity,1307 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,40
OTT 17-02,Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients,398 days,Completed,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,124
MC1835-ACCRU-BR-1701,"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",1791 days,Recruiting,Interventional,"Experimental, Placebo Comparator, Experimental","Biological, Biological, Other, Biological, Biological, Biological",Parallel Assignment,Phase 2,Yes,No,480
CCR4772,PRELUDE Study of Lymphatic Surgery to Treat Breast Cancer Related Lymphoedema,901 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,64
UC-BCG-2205,Treatment for Breast Cancer Patients With Meninges Invaded by Tumor Cells,1277 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,30
21094,CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer,774 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,78
PECP,The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer,730 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,100
11066,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,1264 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator","Behavioral, Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,375
CBYL719A03201,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,195 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,2
SDO-006-20-01,To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer,276 days,Withdrawn,Interventional,"Active Comparator, Active Comparator",Drug,Crossover Assignment,Phase 1,Yes,No,0
22-655,STOP-HER2: Stopping Trastuzumab in HER2+ MBC,4628 days,Not yet recruiting,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Phase 2,No,No,82
CL0007,Investigation of Novel Surgical Imaging for Tumor Excision,912 days,Completed,Interventional,"Experimental, No Intervention",Combination Product,Parallel Assignment,Phase 3,Yes,Yes,406
MO39193,A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer,2454 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,572
HSR210410,Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer,1614 days,Not yet recruiting,Interventional,"Other, Other, Other, Other","Drug, Drug, Radiation, Radiation",Parallel Assignment,"Phase 2, Phase 3",Yes,No,45
ALTER-BC-003,AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer,609 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,42
NL67422.041.18,Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer,610 days,Unknown status,Interventional,Experimental,"Drug, Procedure, Drug",Single Group Assignment,Phase 1,Yes,No,12
AL-TNBC-01,A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer,1204 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,67
300007016,"Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations",821 days,Recruiting,Interventional,"Experimental, Active Comparator",Behavioral,Parallel Assignment,Not Applicable,No,No,40
QUILT-3.057,QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine,1187 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Biological, Biological, Biological, Biological, Biological, Biological, Drug, Biological, Biological, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,0
2021-0261,Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer,381 days,Completed,Interventional,"Active Comparator, Experimental, Experimental, Experimental","Drug, Device, Other",Parallel Assignment,Phase 3,Yes,Yes,167
H3B-6545-G000-102,A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer,1460 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Sequential Assignment,Phase 1,Yes,No,36
NCI-2018-01581,"Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer",2209 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure, Drug, Procedure, Biological, Drug, Procedure, Drug, Biological, Drug, Biological",Parallel Assignment,Phase 2,Yes,No,70
CAR202,A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC,1008 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,38
SIB16134,Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer,436 days,Withdrawn,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,0
2020-11/15,"The Effect of Art Therapy on Pain, Emesis, Anxiety and Quality of Life, Breast Cancer",401 days,Completed,Interventional,"Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,60
20D.876,SABR-CaRe in Early Stage Breast Cancer,1592 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Radiation, Procedure, Other, Other, Procedure, Other",Parallel Assignment,Phase 2,No,No,80
41494,Feasibility of a Remotely-Delivered Yoga Intervention on Cognitive Function in Breast Cancer Survivors,226 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,18
19D.799,A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer,134 days,Recruiting,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,30
21-110,Anti-anxiety Biotics for Breast Cancer Survivors,285 days,Completed,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,3
GM1-CIPN-202,"A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer",986 days,Not yet recruiting,Interventional,"Experimental, Experimental, Placebo Comparator",Drug,Parallel Assignment,"Phase 2, Phase 3",No,No,150
HSaleem,Kinesiology Taping Technique in Post-mastectomy Breast Cancer Related Lymphedema,330 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,50
220493,Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment,334 days,Unknown status,Interventional,Other,Drug,Single Group Assignment,Not Applicable,No,No,28
2020-q12,Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer,1500 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,40
1280-0022,The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread,1260 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,103
112626,Three Fraction Radiation to Induce Immuno-Oncologic Response,1521 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,40
0124-18-TLV,Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor,882 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,40
BL2014084,"This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment",486 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,60
RLY-2608-101,"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer",1362 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,190
CLEE011A2207,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",2394 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,376
21050,An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis,797 days,Recruiting,Interventional,Experimental,"Other, Procedure, Device, Biological, Biological",Single Group Assignment,Phase 4,Yes,Yes,10
55054,Inspiratory Muscle Training in Obese Breast Cancer Survivors,2191 days,Not yet recruiting,Interventional,"Experimental, Sham Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,78
PILOT 171548,RISE - Reduce Sitting Time Among Breast Cancer Survivors,315 days,"Active, not recruiting",Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,21
Pro00109777,Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib,740 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,48
22-225,ETHAN - ET for Male BC,4808 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,60
ShandongCHI-04,The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy,730 days,Unknown status,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,200
1710018694,Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients,2967 days,Recruiting,Interventional,Other,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,41
MC1733,A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer,1422 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,33
294-2018,Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients,544 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
29747,T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer,1477 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,54
IFG-NIB-01,Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC,1036 days,Completed,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,53
PRESSODOU-1809,Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery,1253 days,Recruiting,Interventional,"Experimental, Sham Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,120
WSG-AM08,"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC",2951 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 3,No,No,1670
MRG002-005,A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC),629 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,66
HLX10-013-TNBCneo,to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC),2548 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Sequential Assignment,Phase 3,No,No,522
INT 192/19,Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer,1457 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Dietary Supplement, Drug, Drug",Parallel Assignment,Phase 2,No,No,30
IRB-53650,"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer",374 days,Terminated,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,4
VICC BRE 17107,Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer,884 days,Terminated,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,12
2017-004938-28,Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure,850 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
Pro00103625,Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,1202 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,18
2017/01,Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients,1087 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator",Other,Parallel Assignment,Phase 3,No,No,150
G0F9119N,CoMoon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy,760 days,Completed,Interventional,"No Intervention, Experimental",Device,Parallel Assignment,Not Applicable,No,No,77
NCI-2018-01519,Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer,3184 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Radiation",Parallel Assignment,Phase 2,Yes,No,300
OP_1413,Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer,1431 days,Recruiting,Interventional,"No Intervention, Experimental",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,220
2020-001,"Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer",1067 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,53
NCI-2022-07265,"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial",1336 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental","Drug, Procedure, Procedure, Procedure, Drug, Procedure",Parallel Assignment,Phase 2,Yes,No,95
G1T28-208,"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)",1289 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,194
ZZBGCART-016,EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer,1096 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Early Phase 1,No,No,30
21-038,Fulvestrant + Neratinib In Breast Cancer,1096 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,25
STUDY00004257,"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",956 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Early Phase 1,Yes,No,40
09.2019.865,Responsiveness of Outcome Scales in Breast Cancer Related Lymphedema,224 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
I-3010822,"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer",1431 days,Not yet recruiting,Interventional,"Experimental, Experimental","Procedure, Procedure, Drug, Procedure, Biological, Procedure, Biological, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,12
UMCC 2021.056,An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer Survivors,202 days,Completed,Interventional,"Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,30
BOOG 2019-01,"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer",1375 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,50
AZV2022,The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors,1091 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, No Intervention","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,440
RF-2016-02362383,Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer,1536 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,112
HYPART,HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).,2700 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,1018
UTD-1-BM-II,"The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.",1096 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,43
2018/14-01,A New Mindfulness Intervention Called Mindfulness Based Swinging Technique (MBST) for Women With Breast Cancer,1421 days,Completed,Interventional,"Experimental, Active Comparator",Behavioral,Crossover Assignment,Not Applicable,No,No,156
UC-0140/1814,"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients",2922 days,Recruiting,Interventional,Other,"Drug, Other",Single Group Assignment,Not Applicable,No,No,200
NBG-19-01; SWEBCG 19-01,"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC",5671 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,920
bakircaymzeren07,Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema,165 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,40
2021SCR,Cone Beam Breast CT for Breast Cancer Screening,730 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,Yes,1024
Lymphedema Rehabilitation,New Therapeutic Approach in Upper Limb Lymphedema Secondary to Breast Cancer: Activity-oriented Proprioceptive Antiedema Therapy (TAPA),915 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,42
IRB-30000320,"Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors",2053 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,126
VMA-253-18,Fish Oil and EPO in Breast Cancer,1947 days,Recruiting,Interventional,"Experimental, No Intervention",Dietary Supplement,Parallel Assignment,Not Applicable,No,No,60
9764,"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",2386 days,Withdrawn,Interventional,Experimental,"Drug, Drug, Other, Drug, Other, Other, Drug, Drug",Single Group Assignment,Phase 4,Yes,No,0
EA1211,"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial",690 days,Not yet recruiting,Interventional,Experimental,"Drug, Procedure, Other, Procedure, Procedure",Single Group Assignment,Phase 2,No,No,235
11B1920N_BCS-PAIN,The Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors,1267 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,200
ShandongCHI-13,Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer,212 days,Unknown status,Interventional,"Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,600
3-2020-0448,Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence,3258 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,532
Pro2020001306,Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer,988 days,Recruiting,Interventional,Experimental,"Other, Other, Radiation, Procedure, Radiation, Other",Single Group Assignment,Not Applicable,No,Yes,55
17502,A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer,1848 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,500
2861/20,Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer,2617 days,Recruiting,Interventional,"Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Other",Factorial Assignment,Phase 2,Yes,No,80
GY202201,Efficacy of Acupuncture Treatment for Breast Cancer-associated Insomnia,955 days,Recruiting,Interventional,"Experimental, Sham Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,264
WO40181,"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",973 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,103
BMTN,Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer,960 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,54
20190304-01H,"Breaststroke Swimming After Breast Cancer Treatment/Surgery as a Means of Treatment for Seroma, Lymphedema, and Chronic Arm and Chest Pain",1095 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,128
30388,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",2052 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,20
STUDY00146320,Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens,1509 days,Recruiting,Interventional,"Experimental, Other",Drug,Parallel Assignment,Phase 2,Yes,No,120
SM-88-001,Study of SM-88 in Advanced Cancers,365 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,0
2022-A00437-36,Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer,1704 days,Not yet recruiting,Interventional,"Experimental, Active Comparator, Active Comparator",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,75
2.073.549,Pilates and Dance to Breast Cancer Patients Undergoing Treatment,1094 days,Completed,Interventional,"Experimental, Experimental, No Intervention","Other, Other",Factorial Assignment,Not Applicable,No,No,74
2-114-18,Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?,414 days,Unknown status,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,16
NCI-2020-02319,Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer,1238 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Procedure, Drug, Drug, Procedure",Sequential Assignment,"Phase 1, Phase 2",Yes,No,106
P170407J,Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer,1006 days,Completed,Interventional,Other,Drug,Single Group Assignment,Phase 2,No,No,8
QF-SC10914-203,A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients,748 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,78
D926PC00001,"A Study of Dato-DXd Versus Investigators Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)",1297 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,600
IRB00376235,The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer,1887 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,250
HCRN BRE18-360,Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physicians Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases,1637 days,Recruiting,Interventional,Experimental,"Drug, Radiation, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,41
19-1974.cc,Appetite and Exercise in Breast Cancer Survivors,729 days,Completed,Interventional,"Other, Other","Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,21
H19-02480,BREast Cancer And Sexuality Treatment,1425 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,120
HS-10342-201,A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer,822 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,20
IRB202000746,"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",3287 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Other","Drug, Combination Product, Combination Product",Parallel Assignment,"Phase 1, Phase 2",Yes,No,65
2020-01-mp-BUS,Multi-parametric Breast Ultrasound Imaging as a Potential Biomarker for Breast Cancer,393 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,100
CBCSG041,Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction,1856 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,80
PILHLE-001,"Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial",2557 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,48
WEBAPPAC,Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer,1642 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,438
21-579,Low-field MRI for Breast Cancer Screening,731 days,Not yet recruiting,Interventional,"Active Comparator, Experimental",Device,Parallel Assignment,Not Applicable,No,Yes,40
A011801,"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial",5228 days,Recruiting,Interventional,"Active Comparator, Experimental","Biological, Drug, Drug, Other, Other",Parallel Assignment,Phase 3,Yes,No,1031
Maple Tree Exercise,Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients,831 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,70
ERC/2019/10/05,Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria,1364 days,Recruiting,Interventional,"Experimental, Experimental","Procedure, Other",Parallel Assignment,Not Applicable,No,No,600
22145,Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer,112 days,Completed,Interventional,"Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 2,No,No,60
ICS Maugeri - CE 2202,Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer,1125 days,Completed,Interventional,"Active Comparator, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,49
TCHP,Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer,730 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,100
19-001881,Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors,1129 days,Recruiting,Interventional,Experimental,"Drug, Other",Single Group Assignment,Phase 2,Yes,No,24
STU-2020-1043,Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib,1347 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,60
041-2018,Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer,1717 days,Completed,Interventional,"No Intervention, Experimental",Combination Product,Parallel Assignment,"Phase 2, Phase 3",No,No,63
RESCREEN,Optimized Rehabilitation Following Primary Breast Cancer Surgery,2543 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,643
NCI-2019-00048,"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer",1102 days,Withdrawn,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,0
IRB-57111,Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients,2056 days,"Active, not recruiting",Interventional,"Active Comparator, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,31
2022-0959,Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery,1949 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Single Group Assignment,"Phase 2, Phase 3",No,No,225
I 60517,Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice,1301 days,Completed,Interventional,"Active Comparator, Experimental","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,174
OSU-21185,Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors,412 days,Recruiting,Interventional,Experimental,"Behavioral, Other, Other",Single Group Assignment,Not Applicable,No,No,40
A221803,Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy,1295 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Device, Other, Other",Parallel Assignment,Phase 3,No,Yes,216
IndonesiaU2022,The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer,897 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,26
STUDY00003100,Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts,1138 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 4,Yes,No,36
FM-17-B01,Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer,3203 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Procedure",Parallel Assignment,Phase 3,No,No,650
STUDY00007842,Music as a Perioperative Therapy in Breast Cancer Patients,840 days,Withdrawn,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,0
STUDY00001007,Peer Support For Young Adult Women With High Breast Cancer Risk,1782 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,560
20-133,A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer,1439 days,"Active, not recruiting",Interventional,Experimental,Procedure,Single Group Assignment,Early Phase 1,No,No,30
H19094,Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients,337 days,Completed,Interventional,"Other, Experimental","Other, Behavioral",Parallel Assignment,Not Applicable,No,No,72
16-185671,Integrative Approaches to Cancer Survivorship: Project 3,653 days,Completed,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,30
M18BEL,Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO,2652 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 2,No,No,80
"UPCC# 15122, IRB # 852205",CAR T Cells in Mesothelin-Expressing Breast Cancer,5474 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Device",Sequential Assignment,Phase 1,Yes,Yes,12
HCC 20-243,Apollo Device for Metastatic Breast Cancer (MBC),1854 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,30
Alaa_Negm_MSc_2023,"Effect of Kinesiotaping Augmented By Resistive Exercise on Fatigue, Physical Strength, Quality of Life in Breast Cancer Survivors",120 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,40
SunYatsenU2H-LQ3,"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC",4381 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, No Intervention","Drug, Drug",Parallel Assignment,Phase 2,No,No,460
BYEC20211201,Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC,869 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,128
18-140,Sexual Health and Rehabilitation After Ovarian Suppression Treatment,365 days,Completed,Interventional,Experimental,"Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,20
2022-0378,Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care,1980 days,Recruiting,Interventional,"Other, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,220
20-221,Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity,1768 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,160
IRB-58571,Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer,265 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,100
BPI-1178-2019-001,A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer,1369 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,122
E-HHC-2016-0245,Adaptive Symptom Care Using Fish-Based Nutritional Directives Post Breast Cancer,1444 days,Suspended,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,150
21656,"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer",785 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,405
UC-0140/1901,Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer,2912 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,378
ACCRU-BR-1801,T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer,462 days,Withdrawn,Interventional,"Active Comparator, Experimental","Drug, Biological",Parallel Assignment,Phase 2,Yes,No,0
HE072-CSP-002,Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance,1096 days,Not yet recruiting,Interventional,"Experimental, Experimental",Drug,Single Group Assignment,Phase 1,No,No,136
17-00890,Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC),1460 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,8
2020-01,Exercise Therapy During Radiotherapy,182 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,40
TransRosaLEE-IPC 2021-075,"Trans-RosaLEE Study: a Biomarker-directed, Translational Study",1734 days,Not yet recruiting,Interventional,Experimental,"Genetic, Genetic, Genetic, Genetic",Single Group Assignment,Not Applicable,No,No,241
2000024495,Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer,1500 days,"Active, not recruiting",Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,400
UMCC 2021.109,Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer,552 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Sequential Assignment,Phase 4,Yes,No,22
TROIKA,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients",1424 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,503
HMCC-BR22-001,Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC),2151 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,36
I 1680021,Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer,975 days,Not yet recruiting,Interventional,Experimental,"Biological, Procedure, Procedure, Procedure, Biological, Other",Single Group Assignment,Phase 2,Yes,No,19
NCC1692,Anlotinib in Metastatic HER2 Negative Breast Cancer,612 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,26
0201263,Hypofractionation And Ultra-Hypofractionation In Adjuvant Radiotherapy For Breast Cancer,731 days,Unknown status,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,100
19/002,"Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer",1674 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,31
NCI-2019-06461,"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",1302 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Biological, Biological",Parallel Assignment,"Phase 1, Phase 2",Yes,No,12
HNCH-BC001,The TP Regimen in the Treatment of Early Triple Negative Breast Cancer,1464 days,Completed,Interventional,"Placebo Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,212
S-169,Complementary and Alternative Medicine on Mental Health in Breast Cancer Patients,486 days,Unknown status,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Other,Parallel Assignment,Phase 1,No,No,250
HCI103657,Merestinib on Bone Metastases in Subjects With Breast Cancer,529 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,2
HS627-III,Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel,508 days,Unknown status,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,408
17782,A Study of Abemaciclib in Indian Women With Advanced Breast Cancer,739 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 4,Yes,No,200
LQ004,Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer,578 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,29
2021-A03166-35,Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer.,915 days,Not yet recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,32
AAAS9859,Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI),1198 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,36
249571,Mini-AFTERc Intervention for Fear of Cancer Recurrence,446 days,Unknown status,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,133
2022/050,Telerehabilitation in Survival Breast Cancer Patients,436 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,69
BR01/01/22,Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer,1461 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,51
UMCC 2020.122,"Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",849 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,25
CA048-001,A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread,692 days,Completed,Interventional,"Experimental, Experimental, Experimental","Biological, Biological, Drug",Single Group Assignment,Phase 1,Yes,No,12
NCI-2022-10810,"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer",1454 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Procedure, Drug, Procedure, Drug, Biological",Single Group Assignment,Phase 1,Yes,No,24
RG1004302,Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer,1760 days,Recruiting,Interventional,Experimental,"Drug, Biological",Single Group Assignment,Phase 1,Yes,No,24
Pro00100093,A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer,2102 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Experimental","Biological, Biological",Parallel Assignment,Phase 2,Yes,No,39
0201-21,Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors,1126 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,70
CORE,Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity,30 days,Terminated,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,2
ENZENO-C-101,ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study),919 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,106
19206,Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.,1360 days,Recruiting,Interventional,Experimental,"Drug, Other",Single Group Assignment,Phase 2,Yes,No,40
S00748-NIM,Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial,364 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,36
STUDY00002373,Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy,973 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Device, Procedure, Other",Parallel Assignment,Phase 2,No,Yes,50
ATENTO19,Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO),730 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,56
SCHBCC-N048,Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.,1386 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,223
3-2020-0343,Primary Surgical Prevention of Breast Cancer-related Lymphedema,2555 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,72
KSF2-1707,Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer,3571 days,"Active, not recruiting",Interventional,Experimental,"Procedure, Biological, Procedure",Single Group Assignment,Not Applicable,No,No,132
UW 19-045,Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy,865 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,138
22-074,A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer,1824 days,Recruiting,Interventional,"Experimental, Experimental, Placebo Comparator","Drug, Drug, Other",Sequential Assignment,Phase 2,Yes,No,55
lithium and breast cancer,Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients,669 days,Completed,Interventional,"No Intervention, Experimental",Drug,Parallel Assignment,Phase 3,No,No,50
18549,Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema,1808 days,"Active, not recruiting",Interventional,Experimental,"Other, Behavioral, Behavioral, Other, Other",Single Group Assignment,Not Applicable,No,No,19
EGC002,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,1192 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,807
Multimodal Project,Multimodal Project,243 days,Not yet recruiting,Interventional,"Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,80
201710109,Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,1297 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Biological, Device, Procedure",Parallel Assignment,Phase 1,Yes,No,18
2016-003518-28,Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer,1096 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Drug, Drug",Parallel Assignment,Phase 3,No,No,142
BR01/02/19,Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA),1875 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,86
XJLL-KY20212136,RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer,1404 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,20
2017-073,The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer,1909 days,"Active, not recruiting",Interventional,Experimental,"Other, Drug",Single Group Assignment,Phase 2,Yes,No,24
CMUH107-REC3-102,Yoga for Aromatase Inhibitor-related Knee Pain Relief in Breast Cancer Patients,179 days,Completed,Interventional,"Active Comparator, Placebo Comparator",Other,Crossover Assignment,Not Applicable,No,No,60
HBO001,Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy,1766 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Procedure, Drug, Dietary Supplement",Parallel Assignment,Phase 2,Yes,No,60
RG1718047,"Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer",1308 days,Withdrawn,Interventional,Experimental,"Biological, Drug",Single Group Assignment,Phase 2,Yes,No,0
2020-006,Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients,246 days,Completed,Interventional,"Other, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,13
TX05-03,"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer",952 days,Completed,Interventional,"Experimental, Active Comparator","Biological, Biological, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,809
2016/65,Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer,2556 days,"Active, not recruiting",Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,47
22-490,VS-6766+Abema+Fulv in Met HR+/HER- BC,2106 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,63
19P.117,Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences,1595 days,"Active, not recruiting",Interventional,Experimental,"Drug, Procedure, Other, Other",Single Group Assignment,Phase 1,No,No,3
HCRN BRE19-433,"A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer",1187 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Radiation",Single Group Assignment,Phase 2,Yes,No,1
S2020-09,Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor,984 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,300
J17118,Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC,2173 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,100
EQ132-201,A Study of Lerociclib in Participants With Advanced Breast Cancer,1592 days,Recruiting,Interventional,Other,Drug,Single Group Assignment,Phase 2,Yes,No,100
UW21062,Remote Electronic Assessment of Survivors With Feedback Communication and Directed Referrals,338 days,Completed,Interventional,"Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,30
ACT16106,"Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer",479 days,Terminated,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,105
2018/8361/I,MUltimodal Targeted Axillary Surgery,1119 days,Recruiting,Interventional,Other,"Diagnostic Test, Diagnostic Test, Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,160
427 BC SDM,Enhancing Shared Decision-Making in Breast Cancer,1481 days,Completed,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,140
20210901-jiangchunling,A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases,944 days,Recruiting,Interventional,"Experimental, Active Comparator",Combination Product,Parallel Assignment,Phase 2,No,No,362
2023-3181,Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery,392 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,68
01,Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer,297 days,Recruiting,Interventional,"Experimental, Sham Comparator, Other","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,51
CHUV-DO-0009-CyberImmunoBreast,CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC),1698 days,Recruiting,Interventional,"Experimental, Experimental","Radiation, Drug",Parallel Assignment,Phase 2,No,No,40
PEMBRACA,Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA),1510 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,22
170115,T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,1899 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,12
ANG1005-CLN-07,ANG1005 in Leptomeningeal Disease From Breast Cancer,822 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,150
IJB-EBC-Decrescendo-2020,De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade,2600 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 2,Yes,No,1065
FASCINATE-N,Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy,1035 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,716
Manual Therapy BCS,Effects of Manual Therapy on Chronic Pain and Functionality of Breast Cancer Survivors,118 days,Terminated,Interventional,"Experimental, Sham Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,10
KUH5101090,"The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients",0 days,Withdrawn,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,0
17471,Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer,2024 days,"Active, not recruiting",Interventional,Experimental,"Drug, Other, Other, Other, Drug",Single Group Assignment,Phase 2,Yes,No,2
BAIBU-FTR-ED-001,Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema,1082 days,Completed,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,21
STUDY00018239,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,930 days,Completed,Interventional,Experimental,"Biological, Drug",Single Group Assignment,Phase 1,Yes,No,3
NCO-21001,Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma,665 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,100
16-015,Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib,1283 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Early Phase 1,Yes,No,7
2170-29-02/1-2,The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks,975 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Device, Device, Drug, Procedure",Parallel Assignment,Not Applicable,No,No,100
GBG 97,Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer,1599 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,150
DOT-1871-KIE-0120-I,Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW,638 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,0
IIT-2017-MM-BRST-Her2noRT,Omission of Radiation in Patients With Her-2 Positive Breast Cancer,3233 days,Recruiting,Interventional,"Experimental, No Intervention, No Intervention",Radiation,Parallel Assignment,Not Applicable,No,Yes,78
KaratayUHaticeTEZ,The Effect of Training Given by Mobile Application to Women Undergoing Breast Surgery,183 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,81
YBCSG-21-01,Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab,1142 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,240
UniUrb_21/10.07.2019,Movement and Health Beyond Care (MoviS),2154 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,172
Shengjing-LJY02,DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast,2527 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,200
2016-6346,Comparison of Healthy Diets on Breast Cancer Markers,795 days,Completed,Interventional,"Active Comparator, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,11
N19TON,Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients,2489 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,52
Soh-Med-23-02-16,Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients,853 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 1,No,No,100
SIMR_onc19_IIS_DAndre_Ashwaga,Ashwagandha for Cognitive Dysfunction,1035 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Crossover Assignment,Phase 2,Yes,No,80
PROICM 2018-02 SKY,Feasibility Study: Yoga Educational Project,333 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,24
GRASPA-TNBC-2018-02,Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2),1022 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,27
NCI-2016-01293,Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer,1905 days,"Active, not recruiting",Interventional,Experimental,"Procedure, Drug, Procedure",Single Group Assignment,Phase 1,Yes,No,39
BOOG 2021-01 SEQUEL-Breast,SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast),2099 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,130
2020-1138,A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients,423 days,Completed,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,392
432-17,Facilitating Oncology Patient-Clinician Communication Via E-health Innovations,688 days,Completed,Interventional,Other,Behavioral,Single Group Assignment,Not Applicable,No,No,31
20170770,"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",2514 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,162
YX2021-070(F1),Effect of Intravenous S-ketamine on Opioid Consumption,638 days,Recruiting,Interventional,"Placebo Comparator, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,825
LCI-BRE-MTN-NIR-001,LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer,1736 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,0
1B-16-11,Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer,2192 days,Withdrawn,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Behavioral, Behavioral, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,0
7119-001,A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001),2799 days,"Active, not recruiting",Interventional,Experimental,"Drug, Biological, Drug",Single Group Assignment,Phase 2,Yes,No,56
PRO2,Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy or Antibody-drug Conjugate Therapy.,578 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,585
KTI-21-01,Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC),549 days,Not yet recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,Yes,Yes,15
CDX-ONC-101,"A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer",746 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Biological,Sequential Assignment,Phase 1,Yes,No,24
ICL-2022-1,Personalized Preventive Support for Cognitive Impairment in Non-Metastatic Breast Cancer (EFACog),793 days,Not yet recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,56
1070741-1,Subclinical Lymphedema Treatment Study,2801 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,267
MO42319,A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC),3129 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Other",Parallel Assignment,Phase 3,Yes,No,96
2021-1031,"A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer",796 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,36
MCC-19337,HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer,2248 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Experimental","Biological, Drug, Procedure",Parallel Assignment,Early Phase 1,Yes,No,32
18175,"A Study of Imlunestrant, Investigators Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",2157 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,860
4090,Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.,463 days,Completed,Interventional,"Experimental, Experimental",Device,Parallel Assignment,Not Applicable,No,Yes,29
2021332GD,Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy,791 days,Not yet recruiting,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,350
18238,Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer,1438 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,350
21152,Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer,443 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Other, Other, Other",Parallel Assignment,Phase 1,Yes,No,200
BLTN-Ig,Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer,1271 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,No,No,97
I 62218,Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer,1605 days,"Active, not recruiting",Interventional,Experimental,"Procedure, Procedure, Drug, Biological, Drug, Biological",Single Group Assignment,Early Phase 1,Yes,No,8
Pro00080769,Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA),1365 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,45
E2019316,A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer,761 days,Unknown status,Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Phase 4,No,No,43
22-364,Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer,1826 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Phase 2,No,No,140
ISK-N103,"Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer",593 days,Withdrawn,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,0
NCI-2019-02752,Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer,1472 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,204
STao-003,Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer,1463 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,184
OSU-17122,Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors,1761 days,Recruiting,Interventional,Experimental,"Other, Other, Other, Other, Other, Other",Single Group Assignment,Not Applicable,No,No,30
SKB264-Ⅱ-07,SKB264 +/- KL-A167 in Recurrent or Metastatic Triple-negative Breast Cancer,731 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,95
LonghuaH,Clinical Study on Auricular Points Sticking Plus Chinese Medication for Hot Flashes in Breast Cancer Women,331 days,Unknown status,Interventional,"Active Comparator, Sham Comparator",Other,Parallel Assignment,Not Applicable,No,No,92
OTT 18-01,Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL),1857 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 4,No,No,211
PTC-breastNAT,PTC Guiding Neoadjuvant Treatment in Breast Cancer,790 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Diagnostic Test,Parallel Assignment,Phase 2,No,No,40
ZL-1302-002,A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC,597 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,120
MCC-21-18633,Entertainment Media to Deliver Educational Messages About Mammography in Saudi Arabia,32 days,Completed,Interventional,"Experimental, Active Comparator, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,240
Fudan-P1-201701,PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients,1325 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Combination Product, Combination Product, Combination Product, Combination Product",Parallel Assignment,Phase 1,No,No,31
2018-0473,Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer,1673 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other, Procedure",Parallel Assignment,Not Applicable,No,No,545
2019-0638,Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer,1123 days,Recruiting,Interventional,Experimental,"Procedure, Other, Other, Other, Other, Other, Other, Other",Single Group Assignment,Not Applicable,No,No,30
NCC1786,Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer,2251 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,No,No,60
ZG-2021-002,ZetaFuse™ Bone Graft in the Repair of Bone Defects From Metastatic Breast Cancer in the Spinal Vertebral Body,365 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,10
NU 19B07,"SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer",0 days,Withdrawn,Interventional,Experimental,"Drug, Biological, Genetic",Single Group Assignment,Phase 1,Yes,No,0
LUT-RD-02-01,LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients,531 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,28
MEDOPP445,Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED,1041 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,50
OSU-18174,A QoL Intervention for Young African American Breast Cancer Survivors,425 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,30
ICR-CTSU/2017/10065,PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer,2239 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,81
VICC BRE 18108,A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer,2124 days,Recruiting,Interventional,"Experimental, Active Comparator","Dietary Supplement, Drug",Single Group Assignment,Early Phase 1,Yes,No,36
RIGAIN,RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer,4151 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,540
Survey_App,Anonymous Survey of Breast Cancer Patients Concerning Their Use of Medical Apps,334 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,200
DR210090_SILENCE,Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea,700 days,Not yet recruiting,Interventional,"Experimental, Sham Comparator","Device, Drug, Device",Parallel Assignment,Not Applicable,No,No,338
OSU-21035,Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors,1525 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,360
19-031,ADVANCE (A Pilot Trial),1461 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,41
20-166,Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,2446 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,110
INCMNSZ REF 1239,Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients,1369 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug, Procedure, Drug",Single Group Assignment,Phase 2,No,No,20
OSU-20101,A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer,944 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,40
UW18063,Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS,2189 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,12
N201912134,A Patient-centered Continuous and Interdisciplinary Shared Decision Making Approach for Breast Cancer Rehabilitation,365 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,264
IRST174.21,"Yoga on QOL Physiological Distress&Fatigue, on Patients Affected by Breast Cancer in Adjuvant Radiotherapy",976 days,Unknown status,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,120
OSU-18201,Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer,1817 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,Yes,61
H-1912-010-086,To Assess the Efficacy of the LYMPHA in the Prevention of Lymphedema Following Axillary Dissection for Breast Cancer,725 days,Unknown status,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,34
DAN-22220205,A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer,818 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,30
UPCC 21118,"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",1264 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,54
MA-BC-II-002,Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer,1288 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,208
I 2612022,Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer,1461 days,Not yet recruiting,Interventional,Experimental,"Procedure, Procedure, Procedure, Biological, Drug, Other",Single Group Assignment,Phase 2,Yes,No,25
M21CAR,DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy,5418 days,Not yet recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,595
IFOM-CPT008/2022/PO007,Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel,1052 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,37
RG1122380,STEMVAC in Patients With Early Stage Triple Negative Breast Cancer,530 days,Recruiting,Interventional,Experimental,"Biological, Biological",Single Group Assignment,Phase 2,Yes,No,33
4070,A Study Evaluating FT-SW in Unilateral Breast Cancer-Related Lymphedema Patients,16 days,Terminated,Interventional,"Active Comparator, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,Yes,2
RG1003977,Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants,1193 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,102
20190812,Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy,395 days,Completed,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,No,No,216
BabesBolyaiOncovox,A Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients - a Randomised Clinical Trial,167 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,140
CADPT01A12101C,Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).,1467 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Biological, Drug, Drug, Biological, Biological",Single Group Assignment,Phase 1,Yes,No,64
V2011801,P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .,547 days,Withdrawn,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,0
R.18.02.33,Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy,2557 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Drug, Procedure, Procedure",Parallel Assignment,Phase 3,No,No,370
MCC-19-14621,Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx,1074 days,Completed,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,12
I-19-04120,Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer,1104 days,Recruiting,Interventional,Experimental,"Biological, Biological",Single Group Assignment,Phase 2,Yes,No,23
042001,"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study",1174 days,Recruiting,Interventional,Experimental,"Biological, Other, Other, Biological",Single Group Assignment,Phase 2,Yes,No,25
767/29-09-2017,Vaginal Laser Therapy in Breast Cancer Survivors,609 days,Unknown status,Interventional,"Experimental, Placebo Comparator",Device,Parallel Assignment,Not Applicable,No,No,50
WSG-AM12,NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer,1919 days,Not yet recruiting,Interventional,"Experimental, Experimental, Other, Other","Drug, Drug",Crossover Assignment,Phase 2,No,No,402
STUDY00002985,Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer,1166 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,40
CSIIT-C37,Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer,489 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,60
i 67518,Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Survivors,788 days,Terminated,Interventional,"Experimental, Active Comparator","Other, Behavioral, Other, Other",Parallel Assignment,Not Applicable,No,No,10
HCI153239,"Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC",1728 days,Suspended,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Phase 2,No,No,80
268-2017,Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control,1352 days,Completed,Interventional,"Other, Other",Device,Parallel Assignment,Not Applicable,No,No,40
16-304,Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma,4383 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator",Radiation,Parallel Assignment,Not Applicable,No,Yes,400
2019-A02374-53,"Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer",987 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,220
2022-191,Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients,1552 days,Not yet recruiting,Interventional,"Experimental, Sham Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,1206
NCI-2017-02320,"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer",0 days,Withdrawn,Interventional,"Active Comparator, Experimental","Drug, Drug, Other, Drug",Parallel Assignment,Phase 2,Yes,No,0
GIM25-CAPT,Atezolizumab Plus CArboplatin Plus Nab-paclitaxel,1461 days,Recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,No,No,104
ELA-0121,Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer,1188 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,106
APPI2-PT-2020-AIMSS,Targeted Physiotherapeutic Treatment for Aromatase Inhibitor-associated Musculoskeletal Pain in Breast Cancer Survivors,1142 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,120
EDP1503-101,"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",1047 days,Completed,Interventional,"Experimental, Experimental, Experimental","Biological, Biological",Parallel Assignment,Phase 1,Yes,No,69
187519,"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer",1483 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Drug, Drug, Biological, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,150
OnerCengiz,The Effect of Mindfulness Program on Spiritual Well-BeingBreast Cancer Patients,274 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,70
PH-CP026,PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy,1275 days,Completed,Interventional,"Placebo Comparator, Experimental","Drug, Drug, Procedure",Parallel Assignment,Phase 2,No,No,67
B1432020000025,"Pain, Nutrition and Glycemic Response in Chronic Low Back Pain and Breast Cancer Survivors",819 days,Completed,Interventional,"Experimental, Experimental, Active Comparator","Other, Other",Crossover Assignment,Not Applicable,No,No,159
IFG-05-2019,Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO,1282 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,89
CTP-BRST-01,Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases,2864 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,30
A221801,"Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial",1703 days,Not yet recruiting,Interventional,"Experimental, Sham Comparator","Device, Device, Other, Other",Parallel Assignment,Phase 3,No,Yes,250
2016-0538,Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer,1668 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,28
2018/455,Stochastic Modulated Vibrations on Autonomic Nervous System of Breast Cancer Patients During Radiotherapy,485 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Device, Other",Parallel Assignment,Not Applicable,No,No,130
MC2031,"Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer",664 days,Withdrawn,Interventional,Experimental,"Drug, Procedure, Drug",Single Group Assignment,Early Phase 1,Yes,No,0
9988,Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors,453 days,Completed,Interventional,"Active Comparator, Experimental","Behavioral, Other, Other, Device, Other, Other",Parallel Assignment,Not Applicable,No,No,20
TN.32.1.17.SATF,Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.,575 days,Completed,Interventional,"Experimental, Experimental, Experimental",Device,Parallel Assignment,Not Applicable,No,No,25
KN026-US-I-001,KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer,1292 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,22
MC1931,Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer,1495 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,29
CBTMMUH,Effect of Perioperative CBT on Chronic Persistent Postsurgical Pain Among Breast Cancer Patients,640 days,Completed,Interventional,"Active Comparator, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,48
20180259-01H,Mid-point Transverse Process to Pleura Block for Breast Cancer Surgery: A Randomized Controlled Trial,1460 days,Recruiting,Interventional,"Active Comparator, Experimental, Sham Comparator","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,150
PHRI.SCHOLAR-2,Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction,1614 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,130
2017-0502,M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer,2342 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,20
OSU-18317,Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer,1117 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Other, Other",Parallel Assignment,Phase 1,Yes,No,20
e-OTCAT20,Telehealth Program to Prevent Cancer and Chemotherapy-related Cognitive Impairment.,1094 days,Enrolling by invitation,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,98
23-050,A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction,1827 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Other",Parallel Assignment,Phase 2,Yes,No,50
19447,Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors,365 days,Withdrawn,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,0
20G.093,"Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial",652 days,Completed,Interventional,Experimental,"Other, Device, Other, Other, Other",Single Group Assignment,Not Applicable,No,No,39
ANI251_BCS-PI,PI-targeted PNE+MI Compared to BIOMEDICAL Education in BCS,1096 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,156
NCI-2019-05187,"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer",1461 days,Recruiting,Interventional,Experimental,"Drug, Procedure, Other, Other, Radiation",Single Group Assignment,Phase 1,Yes,No,42
OUMK59829,Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer,1825 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Procedure",Single Group Assignment,Phase 2,No,No,23
STUDY00000057,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",1705 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,19
239531,Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors,1090 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Combination Product",Parallel Assignment,Phase 2,Yes,No,60
Castle06(BC),Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy,701 days,Recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,No,No,15
STUDY02000934_1,A Single Arm Pilot Study to Refine a Novel Approach to Exercise Promotion Based on Affect-regulation,307 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,37
IFG-01-2022,"Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients",1450 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,1000
PI-0171-2020,Pain Treatment in a Breast Cancer Population. PaiNEd Study.,515 days,Recruiting,Interventional,"Experimental, Active Comparator, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,72
STU-2019-0529,Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM),875 days,Terminated,Interventional,Experimental,"Procedure, Drug",Single Group Assignment,Phase 4,Yes,No,6
NBC Sur001,Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for cN+ Breast Cancer,1314 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,100
RG1718049,Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy,698 days,Terminated,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,15
ESPvsPECS/AOP,Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery,365 days,Withdrawn,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,0
MP-12-2021-2565,Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS),2641 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,No,80
S1703,S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer,7109 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,1320
OSU-19152,EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer,450 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Other",Crossover Assignment,Not Applicable,No,Yes,30
2018-11-128,Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer,1460 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Not Applicable,No,No,136
OSU-20340,Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer,671 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Other, Other",Parallel Assignment,Early Phase 1,Yes,No,50
PAXMAN,Cooling Cap Trial to Prevent Permanent Chemotherapy-induced Alopecia in Breast Cancer Patients,615 days,Completed,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,Yes,170
MC210303,Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer,1452 days,Not yet recruiting,Interventional,Experimental,"Other, Procedure, Procedure, Device",Single Group Assignment,Not Applicable,No,Yes,5
NL80749.058.22 DIRECT 2,"Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer",3288 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Phase 3,No,No,240
2020-01097,Effect of Heavy-load Resistance Training During Chemotherapy on Muscle Cellular Outcomes,1488 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,40
NCI-2022-04956,"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer",1096 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Procedure, Procedure, Procedure, Procedure, Drug, Biological",Sequential Assignment,Phase 1,Yes,No,57
IRB-2022-329,Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency,1033 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,50
N20ESP,Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block in Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction - a Non-inferiority Trial,578 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Other",Parallel Assignment,Not Applicable,No,No,100
UZBRU_VHH1_3,Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients,2071 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,55
17753,T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer,1546 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Biological, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,25
Exactis-03,Combination of Olaparib and Navitoclax in Women With HGSC and TNBC,901 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,No,No,36
35945/10/22,Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients,731 days,Enrolling by invitation,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",Yes,No,56
2019-5382,Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk,1621 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,400
IRB00105944,"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",1644 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug, Radiation, Drug",Single Group Assignment,Phase 2,Yes,No,38
IRB202201483,Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors,204 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,28
MC18C3,Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer,894 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Drug",Parallel Assignment,Phase 2,Yes,No,18
2022-376,Digital Cognitive Behavioral Therapy for Insomnia for Chronic Insomnia in Breast Cancer Survivors,853 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,264
20-002712,Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer,1560 days,Recruiting,Interventional,Experimental,"Other, Other, Biological",Single Group Assignment,Phase 1,Yes,No,20
Gabapentin RCT,Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy,729 days,Unknown status,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,"Phase 2, Phase 3",Yes,No,46
167514,Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib,1483 days,Completed,Interventional,Experimental,"Drug, Biological, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,11
FS-CY1502-Ph1-01,Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.,2060 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,297
G1T48-01,"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer",1604 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,107
PH-CP032,PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients,169 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,36
2018-0062,Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer,1707 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,60
URomLS-2019a,The Recovery of Reaching Movement in Breast Cancer Survivors: Two Different Rehabilitative Protocols in Comparison,557 days,Completed,Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,66
ODO-TE-B201,"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC",857 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,152
MAMMoutreach,Opt-in vs. Opt-out for Breast Cancer Screening,135 days,Not yet recruiting,Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,871
20-222,Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy,701 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,30
20-001275,"Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",1817 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Procedure, Biological",Parallel Assignment,Phase 2,Yes,No,88
OSU-22083,Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer,748 days,Recruiting,Interventional,Experimental,"Procedure, Other, Procedure, Other",Single Group Assignment,Not Applicable,No,No,40
CF22200A,Effects of an Exercise Intervention on Taxane-induced Peripheral Neuropathy in Breast Cancer Survivors,395 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,88
2018-0550,Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy,1812 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,6
3543,Effectiveness of Ultrasound Guided PECS Block on Opioid Consumption and Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.,606 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Procedure, Other",Parallel Assignment,Not Applicable,No,No,70
EstroTEP COMPARE,Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES,397 days,Unknown status,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,25
2020-0715,Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer,2487 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Biological, Biological",Single Group Assignment,Phase 2,Yes,No,30
NCI-2019-06088,Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones,1281 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure, Procedure, Drug, Radiation",Parallel Assignment,Phase 2,Yes,No,70
MA-BC-II-037,Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02),1322 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,120
LCZ696ABM001.001,Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM),1826 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 4,No,No,600
2018-0127,Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer,870 days,Unknown status,Interventional,"Experimental, No Intervention","Drug, Procedure, Procedure",Parallel Assignment,Early Phase 1,Yes,No,50
S2007,Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases,2177 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 2,Yes,No,44
19-004024,RBX7455 Before Surgery for the Treatment of Operable Breast Cancer,1934 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,30
115300-20-52703,Early Rehabilitation for Breast Cancer - A Randomized Control Trial,639 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,32
MC1635,Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery,1969 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Radiation, Other, Radiation",Parallel Assignment,Phase 2,Yes,No,82
IIT2019-21-Basho-TOPAZ,TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases,731 days,Withdrawn,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,0
81603703,Effects of Infrared Laser Moxibustion on Cancer-related Fatigue in Breast Cancer Patients,1133 days,Completed,Interventional,"Experimental, Sham Comparator, No Intervention","Device, Device",Parallel Assignment,Not Applicable,No,No,140
BTCRC BRE15-024,Ribociclib and Bicalutamide in AR+ TNBC,2309 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,37
2021-375,Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients,201 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,76
3474028/2019,Effects of the Anchor System in the Postural Stability,1461 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,80
2020-0245,"Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial",346 days,Withdrawn,Interventional,Experimental,"Drug, Biological, Radiation",Single Group Assignment,Phase 1,Yes,No,0
18-000427,"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted",1818 days,"Active, not recruiting",Interventional,Experimental,"Biological, Biological, Biological",Single Group Assignment,Phase 1,Yes,No,6
CASE11119,Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program,1059 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,60
ZLYNXM202014,Identification and Preservation of Arm Lymphatics,1928 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,1200
19.07,ImmunoBreast - A Phase Ib Study,1125 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,"Phase 1, Phase 2",No,No,20
REaCT-Low Risk HER-2,A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer,1106 days,Completed,Interventional,"Active Comparator, Placebo Comparator",Drug,Parallel Assignment,Phase 3,No,No,51
PRO00035701,"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer",2263 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,0
REaCT-CHRONO,Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance,762 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Phase 4,No,No,247
Acu-CIPN,Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer,1186 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Drug",Parallel Assignment,Not Applicable,No,No,102
202104085,Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma,2879 days,Recruiting,Interventional,"Experimental, Experimental",Radiation,Parallel Assignment,Not Applicable,No,Yes,130
ZL-MG-BC-001,A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC,245 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,16
P170104J,"A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer",1435 days,Unknown status,Interventional,Other,Drug,Single Group Assignment,Phase 2,No,No,54
Pro00104214,Well-Being After Breast Cancer Surgery,1422 days,Recruiting,Interventional,"Experimental, Active Comparator, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,564
CLEE011AIT01,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",2341 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 3,No,No,287
MedOPP150,"First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC",1152 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,100
ODO-TE-B202,Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC,715 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,294
Study00146761,Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers,759 days,Recruiting,Interventional,"Experimental, Other",Drug,Parallel Assignment,Early Phase 1,Yes,No,20
17-546,Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC,2751 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,33
DRACARYS,Dragonboat Activity for Breast Cancer,138 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,32
RIPH2_BREYSSE_ETAPH,"Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer",1088 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,300
I 60217,Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects,1704 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,200
21-001819,"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",1090 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Active Comparator","Drug, Drug, Drug, Biological, Other, Drug, Biological, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,18
ARC-2 (AB928CSP0002),A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies,991 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,35
RJ-101-RCT-001,Study to Investigate the Effect of AB-101 in Breast Cancer Survivors,460 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Early Phase 1,Yes,No,3
SCHBCC-N046,FUSCC Refractory TNBC Platform Study (FUTURE2.0),1188 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,120
2021-1151-002,OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk,3617 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,418
Aqua POLO-IPC 2019-028,Feasibility Study of an Adapted and Supported Water Polo Program to Reduce Fatigue Related to Cancer and Improve Psychological and Social Recovery in Patients With Breast Cancer Remission,291 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,24
OSU-20408,An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors,1156 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral, Other, Other",Parallel Assignment,Not Applicable,No,No,40
21D.625,Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery,643 days,Suspended,Interventional,Experimental,"Other, Other",Single Group Assignment,Not Applicable,No,No,55
TNBC-NEO,Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC,2548 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,0
13/21,Continuous Pectoral Nerve Block in Breast Cancer Surgery,108 days,Completed,Interventional,"Active Comparator, Sham Comparator","Procedure, Other",Parallel Assignment,Not Applicable,No,No,48
NCI-2017-01960,Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer,1379 days,Completed,Interventional,Experimental,"Drug, Other",Sequential Assignment,Phase 1,Yes,No,24
USB_22 Trial,Serratus Anterior Plane Block to Prevent Chronic Postoperative Pain in Breast Cancer,364 days,Recruiting,Interventional,"Experimental, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,94
CSIIT-C25,Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC,731 days,Recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,No,No,59
SAKK 95/17,Activity Program During Aromatase Inhibitor Therapy,2440 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,375
2018-A01019-46,Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer,1287 days,Completed,Interventional,"Active Comparator, Sham Comparator","Drug, Other",Parallel Assignment,Not Applicable,No,No,140
Fisioterapia en Linfedema,Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer,240 days,Completed,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,28
2019-0752,Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations,1425 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,8
STUDY00003705,Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer,163 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,27
CL 2775,Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients,574 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Placebo Comparator","Drug, Drug, Other",Parallel Assignment,Phase 4,No,No,132
STUDY00003782,RAGE Inhibition to Decrease Therapy Cardiotoxicity in Women With Early Breast Cancer,550 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,48
UEM Quirón,Effects of a Physical Exercise Intervention During Neoadjuvant Chemotherapy in Women With Breast Cancer,792 days,Unknown status,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,80
MUST-02-001,Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening,657 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,1333
IB2022-04,Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.,669 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,164
D5336C00001,To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.,2032 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,273
CE 193/17,"Oxidative Stress, Anxiety and Depression in Breast Cancer Patients: Impact of Music Therapy",698 days,Completed,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,60
IRAS 314460,CLI and FAR for Intraoperative Margin Assessment,793 days,Not yet recruiting,Interventional,Other,Procedure,Single Group Assignment,Phase 2,No,No,60
UPCC12118,Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab,1971 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 1,Yes,No,69
LCCC 1716,PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo,439 days,Terminated,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,Yes,1
YL202-INT-101-01,A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer,1077 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,80
227/KEPK/IX/2022,The Effectiveness of Lymphatic Bypass Supermicrosurgery,634 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,140
OFA,Opioid Free Anesthesia in Breast Cancer Surgery,622 days,Completed,Interventional,"Experimental, Sham Comparator","Procedure, Drug, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,80
STUDY00021243,Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer,1119 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,25
HNCH-2022KY59,UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases,1065 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,30
Prevention of radiodermatitis,Photobiomodulation for Prevention of Radiodermatitis in Women With Breast Cancer Undergoing Adjuvant Radiotherapy,731 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental",Device,Parallel Assignment,Not Applicable,No,No,148
D3614C00001,Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC,1564 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,924
AH150202-1,"Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin",1095 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 2,No,No,70
D8530C00007,AZD9833 China PK Study,731 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,No,No,30
21-194,"A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer",730 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,28
MedOPP100,A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent,1354 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,7
SYSU003-2020,Nail Changes Associated With Chemotherapy and Prevention of Nail Pigmentation by Ice Water Immersion,1034 days,Unknown status,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,120
MS201922_0010,Study of M4344 in Combination With Niraparib,1004 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,0
HR-BLTN-III-MBC-C,A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer,1926 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,590
MC1892,Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy,1096 days,Withdrawn,Interventional,Experimental,"Device, Other",Single Group Assignment,Phase 2,Yes,Yes,0
ZWI-ZW25-202,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,1115 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug",Sequential Assignment,Phase 2,Yes,No,86
MC1734,"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer",1298 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Procedure",Parallel Assignment,Phase 2,Yes,No,200
UW20058,Intraoperative Evaluation of Axillary Lymphatics,392 days,Recruiting,Interventional,Experimental,"Device, Drug",Single Group Assignment,Not Applicable,No,Yes,25
DokuzEUBanuNihan,Diagnostic Contribution of Ultrasonography in Breast Cancer-Related Lymphedema,29 days,Completed,Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,34
202207200MIPB,"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC",1475 days,Recruiting,Interventional,"Experimental, Active Comparator, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,60
2019COIMBRA001,Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer,425 days,Unknown status,Interventional,"Other, Other","Procedure, Procedure",Parallel Assignment,Phase 2,No,No,41
C4391002,A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors,2117 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,144
CPH-2022-10-MHS-2,Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine,328 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,66
HCRN BRE17-141,Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers,560 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,48
YOUNGBC-11,First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients,1146 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,90
C4891018,A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China,652 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,9
P-2020-246,Stick Together - Pilot Intervention Study,485 days,Enrolling by invitation,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,50
YOUNGBC-18,Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC,1004 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,41
SHR-1210-APTN-IIT-TNBC,A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC,994 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,40
FMUUH-BC-2201,PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients,490 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 2,No,No,214
20-153,Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC,2442 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,110
OBU-BC-II-024,Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer,2344 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,104
328717,Effects of a Physical Exercise and Health Education Program for Women With Breast Cancer Undergoing Chemotherapy,1432 days,Unknown status,Interventional,"Placebo Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,136
2066383,Metacognitive Strategy Training in Cancer-related Cognitive Impairment,662 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,44
2021-5644,App for Adverse Events to Oral Chemotherapy - Pilot Study,349 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,30
MC1935,Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer,1461 days,Recruiting,Interventional,"Experimental, Experimental","Radiation, Other, Radiation",Parallel Assignment,Phase 2,No,No,98
19F.265,A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer,2032 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,340
201901698B0,Music Therapy in Patients With Breast Cancer- a Randomized Controlled Trial,121 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,130
2,A Feasibility Study of the Bone@BC App Version 3.0,699 days,Not yet recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,50
MedOPP253,Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer,1210 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,54
S-20180117,Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting,896 days,Completed,Interventional,"Experimental, Placebo Comparator","Procedure, Procedure, Procedure, Biological, Procedure",Parallel Assignment,Phase 2,No,No,80
BZ01/17,Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection,590 days,Terminated,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,10
RC48-C006,A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases,2077 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Crossover Assignment,"Phase 2, Phase 3",No,No,301
KGYY-001,Plasmodium Immunotherapy for Breast and Liver Cancers,1239 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,60
1808852902,"Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets",859 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,14
UHaiArtBC,The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients,1095 days,Completed,Interventional,"Experimental, Sham Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,343
16381,Responsiveness to Acute Changes in Exercise and Relaxation (RACER) Trial,136 days,Completed,Interventional,"Active Comparator, Active Comparator, Experimental","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,40
NL67059.068.18,Microsurgical Treatment of Breast Cancer-related Lymphedema by Lymphaticovenous Anastomosis,1308 days,Recruiting,Interventional,"No Intervention, Experimental",Procedure,Parallel Assignment,Not Applicable,No,No,120
WHUH-BC-001,Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy,1096 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,52
ALRN-6924-1-05,A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer,44 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,6
IRB00223131,Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study,1056 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Behavioral",Sequential Assignment,Phase 2,No,No,55
202111198,Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM),2376 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,42
Shengjing-LCG003,Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy,1777 days,Not yet recruiting,Interventional,"Other, Other","Drug, Drug",Parallel Assignment,Phase 4,No,No,152
AHQU-2022002,Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET),1022 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,234
IC 2019-04,MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery,542 days,Completed,Interventional,"Placebo Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,182
STU00201961B,A Research Study for Latina Women With Breast Cancer,754 days,"Active, not recruiting",Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,58
2-107-05-079,Use of a Remifentanil-propofol Mixture in Patients Undergoing Breast Cancer Surgery,146 days,Completed,Interventional,"Experimental, No Intervention",Combination Product,Parallel Assignment,Not Applicable,No,No,84
2018/781,Pre-operative Hypnosis to Prevent Side Effects After Surgery,975 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,14
2012-090-1182,Shared Decision Making in Surveillance for Distant Metastasis in Breast Cancer,939 days,Enrolling by invitation,Interventional,"Experimental, Other","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,368
IRB00054587,Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases,1602 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Drug",Parallel Assignment,Early Phase 1,Yes,No,19
VSN-18-199,The Effects of Light Therapy to Treat Cancer-related Side Effects,1484 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator, No Intervention","Device, Device",Parallel Assignment,Not Applicable,No,No,240
2022YF035-01,Dalpiciclib Plus Letrozole and Capecitabine,722 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,48
22-544,TRUDI: TDXD+Durva in HER2+/Low IBC,3471 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,63
021-013772,Marker Technique Comparison in Targeted Axillary Dissection,550 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,40
GCO 15-1783,Systematic Light Exposure for Fatigue in Breast Cancer Patients,1556 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,248
1191/2018,"Exercise, Cancer and Cognition: The ECCO-Study",2192 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,126
NCI-2017-01119,Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer,1876 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Procedure, Procedure, Procedure, Drug, Procedure, Drug, Biological, Other, Other, Biological",Parallel Assignment,Phase 3,Yes,No,600
UAB 1794,"Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD",1979 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,17
METIS,ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC,1087 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,180
IUSCC-0616 (1709077419),Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy,249 days,Terminated,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,5
APA-PG1,Adapted Physical Activity (APA) in a Breast Cancer Population.,1460 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,100
26778919.3.0000.0072,Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer,760 days,Unknown status,Interventional,"Experimental, Sham Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
HSM/VGH-2017-01-011AC,Effects of Naturalistic Decision-Making Model-based Oncofertility Care Education,852 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,140
H2207-207-1346,Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor,1096 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,64
CRM-BRE-002,The Malaysian Soy and Mammographic Density Study,560 days,Unknown status,Interventional,"Experimental, Active Comparator, No Intervention","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,282
BC-TATOO-2020,Application of Preoperative Axillary Lymph Node Marking With Nano-Carbon in Breast Cancer Patients Before Neoadjuvant Chemotherapy,1125 days,Recruiting,Interventional,Other,Drug,Single Group Assignment,Not Applicable,No,No,200
ICO-N-2018-03,Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma,1727 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,385
20190511,Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy,548 days,Completed,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Phase 3,No,No,330
RG1121659,Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer,615 days,Recruiting,Interventional,Experimental,"Procedure, Drug, Other",Single Group Assignment,Phase 4,Yes,No,60
17-AKD-186,Erector Spinae Block in Segmental Mastectomy.,393 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,30
Immuno2020-01,A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC,1254 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,46
BGB-A317-ZW25-101,Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab,2471 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Biological, Drug, Biological, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,71
STUDY00011444,Nurse AMIE: Addressing Metastatic Individuals Everyday,550 days,Completed,Interventional,"Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,21
TQB3616-Ⅲ-02,"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Flulvesant Versus Placebo in Combination With Flulvesant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer",1461 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,428
ATOX-2018,Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer,2938 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,284
SHAW001,Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients,1460 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator, Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,40
71306642-5/24,Serratus Plane Plus Pectoral I Block Versus Serratus Plane Block for Perioperative Analgesia in Breast Cancer Surgery,167 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
2021-0077,Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer,1518 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,25
SYSA1501-CSP-005,"DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer",609 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,191
1028595,Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention,553 days,Completed,Interventional,"Active Comparator, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,26
QoLMa,Quality of Life Improvement During Chemotherapy,1248 days,Recruiting,Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,62
CTPR-0015,An Efficacy Study of the Xoft® Axxent® eBx® IORT System® Lite,4383 days,Withdrawn,Interventional,Other,Radiation,Single Group Assignment,Not Applicable,No,Yes,0
FZPL-Ib-105,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC,616 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,32
TDM of TAM,Therapeutic Dose Monitoring (TDM) of Tamoxifen,331 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,40
STUDY20110029,Screening Contrast-Enhanced Mammography as an Alternative to MRI,1080 days,"Active, not recruiting",Interventional,Experimental,"Device, Drug",Single Group Assignment,Phase 4,Yes,Yes,600
ECP 250 - 15/16,Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer,730 days,Unknown status,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Early Phase 1,No,No,104
CTR20220630,Mindfulness Yoga and Sexual Functioning,731 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,78
REC 22/WA/0164,Acceptance and Usability of an App Promoting Healthy Behaviours Amongst Young Women at Increased Risk of Breast Cancer,127 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,35
2019DEPO-TRIGGER001,DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation,425 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Procedure, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,30
OSU-16288,Nipple Aspirate Fluid in Detecting Breast Cancer,1620 days,Recruiting,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,100
20.478.486,Is Breast Massage Necessary to Find Sentinel Lymph Node?,603 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,72
J16146,Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins,1982 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,200
2022-A02337-36,4D CT Scan With Respiratory Gating Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy.,120 days,Not yet recruiting,Interventional,"No Intervention, Experimental",Other,Crossover Assignment,Not Applicable,No,No,13
STUDY00001721,Evaluation of Hydroxychloroquine to Prevent CIPN,549 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,24
H19017,Somatic Acupressure for Symptom Cluster Management in Breast Cancer Patients,492 days,Completed,Interventional,"Experimental, Sham Comparator, Other","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,51
1100903,Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer,302 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Device, Drug",Parallel Assignment,Not Applicable,No,No,72
LAAVA2,Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients,1165 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator","Device, Device",Crossover Assignment,Not Applicable,No,No,70
BXu-1839,The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency,2109 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,200
NABP201801,A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC,587 days,Suspended,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,375
RG1121642,Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer,876 days,Recruiting,Interventional,Experimental,"Biological, Biological, Drug",Single Group Assignment,Phase 1,Yes,No,20
C-plus-Pairs,"A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.",184 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,46
URomLS_4,Metabolomic Evaluation of Psycho-surgical Synergy on Body Image Restoration After Breast Cancer,461 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,80
46.20 PAR ComEt CBM,Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients,1004 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,30
012418QM,Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC,2599 days,"Active, not recruiting",Interventional,"Other, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,146
2020466,PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC,1096 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,49
2021-0031,"An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer",1058 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Other, Other",Single Group Assignment,Not Applicable,No,Yes,100
SYM011,AKY15-HK-301_NEPA Study,2864 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,60
16-0040-02,Pink Warrior 2: Teleconference-based Gaming Support,687 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,20
2022-008,Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C),2922 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,No,No,800
X4P-001-201,"A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC",669 days,Enrolling by invitation,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,24
2017-0479,Comprehensive Lifestyle Change To Prevent Breast Cancer,1246 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
SYSU-2022-01,Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure),477 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Not Applicable,No,No,100
SAKK 21/18,Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC,660 days,Terminated,Interventional,"Experimental, Active Comparator","Drug, Other, Other",Parallel Assignment,Phase 3,No,No,25
736-19,The Patterns of Activity and Cognition During Treatment (PACT) Study,654 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental, Experimental, Experimental","Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,40
198411013011,The Effect of Walking Exercise Based on TOUS on Peripheral Neuropathy and Arthralgia-Myalgia in Women With Breast Cancer,443 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,68
AP1907-50101,Perioperative Analgesic Modalities for Breast Cancer Surgeries,155 days,Completed,Interventional,"Experimental, Experimental, Active Comparator","Procedure, Procedure, Drug",Parallel Assignment,Not Applicable,No,No,75
2021-19,The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC,1568 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,46
RLY-5836-101,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,1021 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,220
BRI-ROL-001,Combination Study of SV-BR-1-GM With Retifanlimab,1932 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,36
RP-PG-1214-20016,What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol,1064 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Sequential Assignment,Not Applicable,No,No,32298
220287,The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies,714 days,Not yet recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,25
PI17/01687,Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity,1308 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,122
BCP-25,Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study),1760 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Phase 3,No,No,256
20210312/2,Neoadjuvant Chemotherapy in Breast Cancer,1114 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Drug",Parallel Assignment,Not Applicable,No,No,1200
2018-1518,"Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain",187 days,Completed,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,6
UCI 18-79 [HS# 2020-5660],Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer,573 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,1
ePOST,Efficacy of Point Of Service Testing in MBC,1878 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,100
URCC16070,Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer,2629 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Other, Drug, Drug, Other, Drug, Other",Parallel Assignment,Phase 3,Yes,No,1600
Shengjing-LJY06,Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy,2556 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,100
Pro00105104,Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477),173 days,Terminated,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,1
202210064DIPD,"LLLT for BCRL: a Randomized, Placebo-controlled Study",624 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,54
PERT.21.001,"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)",836 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Biological, Biological",Parallel Assignment,Phase 3,No,No,268
HCI140278,[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial,1491 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,6
MedOPP068,PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA),1335 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,198
KCT003,A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema,213 days,Recruiting,Interventional,"Experimental, Active Comparator",Device,Crossover Assignment,Not Applicable,No,Yes,50
SILMET_0107665,SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET),1460 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,70
S-20180134,Prevention of Breast Cancer-related Lymphedma With Tacrolimus,918 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,"Phase 1, Phase 2",No,No,60
241379,Carbon Dye Tattooing of Biopsied Axillary Node in Breast Cancer,460 days,Completed,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,100
2021/270,Effect of Nurse-led Supportive Care on Quality of Life,158 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,42
202109031MIPD,"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC",1079 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,56
00048814,Mobile Behavior Change Program for Weight Loss in Breast Cancer Survivors,191 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,30
JD-LK-2022-136-01,"Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)",718 days,Not yet recruiting,Interventional,Experimental,"Drug, Radiation, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,45
2017/12-SBO-GHMG,Autohypnosis and Cancerology,1500 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,120
LYT-100-2020-01,LYT-100 in Healthy Volunteers and BCRL,922 days,Completed,Interventional,"Experimental, Placebo Comparator, Experimental, Placebo Comparator, Experimental, Placebo Comparator, Experimental, Placebo Comparator","Drug, Other, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,50
2017-0328,Development of Exercise Promotion Program Using a Mobile Community,335 days,Completed,Interventional,"Experimental, Experimental",Device,Parallel Assignment,Not Applicable,No,No,64
2179 CE,Music Listening in Radiotherapy Treatment,940 days,Completed,Interventional,"Experimental, Experimental, Other","Other, Radiation",Parallel Assignment,Not Applicable,No,No,60
Pro00117242,Moving Forward Together 4,792 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,68
US-003,Magseed Enabled Long-Term Localization of Axillary Lymph Nodes,1754 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,65
7119-002,Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002),1279 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,25
21-169,Scalp Cooling in MBC,1698 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator","Device, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,Yes,120
2018-002,Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast,1394 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,27
12345,The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer,1095 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,120
GLSI-21-01,Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects,1573 days,Recruiting,Interventional,"Placebo Comparator, Experimental, Experimental","Biological, Biological",Parallel Assignment,Phase 3,Yes,No,598
A221702,Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection,1676 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Procedure, Procedure, Other, Other",Parallel Assignment,Phase 3,No,No,516
22-006606,3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer,777 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Early Phase 1,No,Yes,60
CAPRICE,Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study,1371 days,Terminated,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,57
CT/2019/CANFLAX,Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?,801 days,Unknown status,Interventional,"Experimental, Experimental","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,60
20-754,Axillary Lymph Node Tattoo Marking Study,1279 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,80
URomLS-2019,The Sequelae of Mastectomy and Quadrantectomy Respect to the Reaching Movement in Breast Cancer Survivors,357 days,Completed,Interventional,"Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,65
mavis20023,Application-Enabled Shared Decision-Making,365 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,31
2021-01-075,PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study,2312 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,178
HiFi-APBI,High Five (HiFi) Accelerated Partial Breast Irradiation Study,1552 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,60
Self-compassion FCR,Fear-focused Self-Compassion Therapy for Young Breast Cancer Patients Fear of Cancer Recurrence,807 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,160
20-010751,3D Ultrasound Breast Imaging,1503 days,Recruiting,Interventional,Experimental,"Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,Yes,125
IJB-BC-TDM1BM-2016,Kadcyla In pAtients With bRAin Metastasis,185 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,0
1B-15-6,Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors,145 days,Withdrawn,Interventional,"Experimental, Experimental, Active Comparator","Other, Behavioral, Behavioral, Other, Device, Other, Other",Parallel Assignment,Not Applicable,No,Yes,0
P018,"A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel",976 days,Withdrawn,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,0
CBYL719H12301,Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss,1472 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,137
QUILT 2021-1,The QUILT Study: Quilting Sutures in Patients Undergoing Breast Cancer Surgery,334 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,113
MC18C1,Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer,1469 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Other",Single Group Assignment,Phase 1,Yes,No,2
WSG-AM11,"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC",2646 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 3,No,No,1250
2018-0528,An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction,1317 days,Recruiting,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,25
1024489,Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2),1707 days,Recruiting,Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,100
OBI-822-011,Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC,3312 days,Recruiting,Interventional,"Experimental, Active Comparator","Biological, Device, Other",Parallel Assignment,Phase 3,Yes,Yes,668
MSCW2019,Mindfulness and Self-compassion Focussed Walking,1241 days,Recruiting,Interventional,"Active Comparator, Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,135
2020-12-044-012,Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves,973 days,Recruiting,Interventional,"No Intervention, Experimental",Device,Parallel Assignment,Not Applicable,No,No,72
IJB-PRINTEMPS-2022,Multidisciplinary Approach to Fatigue,1839 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,50
HNCH-BC009,"Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer",882 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,403
c5ZTCN100,A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS,388 days,Completed,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 1,Yes,No,12
CRO-2019-26,Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?,732 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Procedure, Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,68
YM111146EF,Effects of Kombucha Intervention on Emotional Distress and Sleep Quality in Breast Cancer Survivors,1096 days,Recruiting,Interventional,"Experimental, Other",Other,Parallel Assignment,Not Applicable,No,No,60
AP2205-5015,Erector Spinae Plane Block Versus General Anesthesia in Breast Cancer Surgeries,287 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Procedure, Procedure, Drug",Parallel Assignment,Not Applicable,No,No,120
182113,Improving Cognition After Cancer,1606 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,250
LCCC1921,Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer,922 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,56
EC /2018/0996,Pre- or Postoperative Accelerated Radiotherapy,1159 days,Completed,Interventional,"Experimental, Active Comparator",Radiation,Parallel Assignment,Not Applicable,No,No,20
ICO_UCC_202001,SMS Messaging as a Tool to Improve Cancer Screening Programs,837 days,Unknown status,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator, Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,20000
19-008929,Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients,1804 days,"Active, not recruiting",Interventional,Experimental,"Device, Other",Single Group Assignment,Not Applicable,No,Yes,80
19-578,Sacituzumab Govitecan In TNBC,2277 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 2,Yes,No,51
Ref. 070/2018,Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery,760 days,Completed,Interventional,"Active Comparator, Active Comparator, Active Comparator","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,103
2021-04031,Supporting Women With Breast Cancer to Practice DIBH at Home Before Radiation Therapy,2037 days,Not yet recruiting,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,160
PSCI 21-045,Trial Assessing Light Intensity Exercise on the Health of Older Breast Cancer Survivors,709 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,56
AC-TMSQ-2018,Effect of Therapeutic Massage on Sleep Quality and Stress Levels in Women With Breast Cancer,283 days,Completed,Interventional,"Experimental, Sham Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,40
STU-2019-0769,PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer,693 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,14
R-2021-3203-005,Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.,1891 days,Recruiting,Interventional,"Experimental, Active Comparator",Radiation,Parallel Assignment,Not Applicable,No,No,72
CD07_TNBC,Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC,1243 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,48
F16J16000620002,Innovation in Mammography: Tomosynthesis Pathways,1094 days,Unknown status,Interventional,"Active Comparator, Experimental","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,6000
NUR20-0124CRYO,The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer,183 days,Terminated,Interventional,"Active Comparator, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,14
32551/09/2018,Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy,456 days,Completed,Interventional,"Placebo Comparator, Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 4,No,No,83
2017-1535,OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease,1655 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,45
12341234,Brass Mesh Bolus in Rotational Post-Mastectomy Radiation Therapy,365 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,20
Mepitel RCT,Randomized Phase III Trial With Mepitel Film for the Prophylaxis of Radiation Dermatitis in Breast Cancer Patients,1767 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Phase 3,No,No,216
ShandongCHI-07,Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy,2557 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,200
D8532C00005,"A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833",41 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,6
ELIPSE (SOLTI-1905),"Elacestrant in Preoperative Setting, a Window of Opportunity Study",381 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,23
VI-ISRP-026,A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes,578 days,Suspended,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,10
5652-18-SMC,Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients,405 days,Completed,Interventional,"Experimental, Active Comparator","Device, Other",Parallel Assignment,Not Applicable,No,No,136
FEMAL,Comparison of the Efficacy and Tolerability of Femal Versus Placebo,1057 days,Completed,Interventional,"Experimental, Placebo Comparator",Other,Single Group Assignment,Not Applicable,No,No,34
20-30638,Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP),577 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Crossover Assignment,Phase 1,Yes,No,20
R.20.11.1099,Ultrasonographic Axillary Localization,472 days,Unknown status,Interventional,Experimental,"Diagnostic Test, Procedure, Diagnostic Test, Procedure",Single Group Assignment,Not Applicable,No,No,75
IRB00074154,Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients,983 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Dietary Supplement, Other",Parallel Assignment,Phase 2,Yes,No,50
JWCI OBCS WITH IORT,Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.,1508 days,Recruiting,Interventional,Other,"Radiation, Procedure",Single Group Assignment,Not Applicable,No,Yes,30
AAAT8915,Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia,575 days,Recruiting,Interventional,"Experimental, Other","Other, Device",Parallel Assignment,Not Applicable,No,Yes,59
20-513,Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer,1438 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Early Phase 1,No,No,72
IRB00313835,Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic,684 days,Recruiting,Interventional,"Active Comparator, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,196
HE-202012,Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer,2597 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 4,No,No,1072
NCC201804007,Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model,547 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,50
PREVENT,"Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery",2183 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,300
QL-KPTB-150,Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer,47 days,Completed,Interventional,"Active Comparator, Experimental","Drug, Drug",Crossover Assignment,Phase 1,No,No,48
REaCT-Hot Flashes Pilot,Utilizing MyChart to Assess the Effectiveness of Interventions for Vasomotor Symptoms: A Feasibility Study,209 days,Completed,Interventional,Other,Other,Single Group Assignment,Phase 4,No,No,56
COMPLEMENT,Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients,1004 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,136
DHLI-BC/OC-BE-001,Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients,276 days,Recruiting,Interventional,"Active Comparator, Experimental",Drug,Crossover Assignment,Phase 1,No,No,80
GS18/107321,ePainQ - Feasibility Study,602 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,25
2019-003825-56,"Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer",518 days,Unknown status,Interventional,Other,"Drug, Drug",Single Group Assignment,Phase 4,No,No,30
80252,Breast Reconstruction and Neoadjuvant Radiotherapy,670 days,Not yet recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,20
Exo-LCR,Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis (Exo-LCR),1427 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Biological",Single Group Assignment,Not Applicable,No,No,30
MCC-19117,Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer,3207 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Biological, Biological",Parallel Assignment,Phase 2,Yes,No,119
EA1181,CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy,6898 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Procedure, Procedure, Drug, Drug, Biological, Radiation, Biological, Biological",Parallel Assignment,Phase 2,No,No,2156
PAL-ZJCC-02,Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients,799 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,150
GCO 18-1832,Leflunomide in Previously Treated Metastatic Triple Negative Cancers,2360 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,54
T06/024/21,Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3),508 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,28
ES,Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer,454 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,90
Study00145121,Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms,425 days,Terminated,Interventional,"Experimental, Other",Drug,Parallel Assignment,Early Phase 1,Yes,No,11
STU 042018-083,Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod,4085 days,"Active, not recruiting",Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,74
AcuBreast 2020,Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?,668 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,250
A012103,Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab,3674 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Biological, Other, Procedure, Procedure, Other, Other",Parallel Assignment,Phase 3,No,No,1295
HREBA.CC-22-0128,Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women,1457 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,65
A191901,Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy,1689 days,Suspended,Interventional,"Experimental, Experimental, Experimental, Active Comparator","Other, Other, Behavioral, Other, Other, Other",Parallel Assignment,Phase 3,No,No,1180
VICCBRE2257,Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy,1828 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Procedure, Procedure, Biological",Parallel Assignment,Phase 2,Yes,No,120
HCI69515,Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment,2892 days,Recruiting,Interventional,Experimental,"Drug, Drug, Diagnostic Test",Single Group Assignment,Phase 2,Yes,No,15
TX05-03E,Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03,931 days,Completed,Interventional,"Experimental, Active Comparator, Experimental","Biological, Biological",Parallel Assignment,Phase 3,Yes,No,338
2019/639,Effect of Nurse-led Supportive Care on Caregiver Burden and Well-being,270 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,60
PBCST,Precision Breast Conserving Surgery With Guidance.,518 days,Completed,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,92
NEODOC- 2021668610-221,Comparison Trial of Open-tip Pulsed Needle Biopsy and Conventional Core Biopsy in Axillary Lymph Nodes,536 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,320
9785-CL-0018,A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,335 days,Completed,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,24
IRB202202679,Exercise to ReGain Stamina and Energy (The EXERGISE Study),366 days,Not yet recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,24
Arise-FJ-B102,Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer,1461 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,77
453190,Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52,648 days,Unknown status,Interventional,"Experimental, Other","Drug, Behavioral",Parallel Assignment,Phase 4,No,No,150
RenJiH-2018-038,"CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial",310 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,29
202110124,Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women,104 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,156
18-003544,Comparison of Three Methods for Early Detection of Breast Cancer,721 days,Completed,Interventional,Other,"Diagnostic Test, Drug",Single Group Assignment,Early Phase 1,Yes,No,3
MCC-21262,A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV),1069 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,18
CKRC2021-CCV,Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups,1083 days,Enrolling by invitation,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,20
BEXMET,The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC,1002 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,No,No,12
PICC One Day 01 (ET15-123),Iterative PICC Placement Versus Long Term Device,0 days,Withdrawn,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Phase 3,No,No,0
IRB00049061,Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer,933 days,Completed,Interventional,"Experimental, Active Comparator","Procedure, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,23
SOLTI-1710,Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy,826 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Early Phase 1,No,No,22
IJB-SYNERGY-012017,Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC,1738 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,129
IRB00046759,Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer,220 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other, Device",Parallel Assignment,Not Applicable,No,Yes,25
18947,Sentinel Lymph Node Mapping With Near Infrared Fluorescent Markers,1405 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,31
2021-A03027-34,Shared Decision Making on Care Pathways and CAMs: A Pilot Study,334 days,Not yet recruiting,Interventional,"No Intervention, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,100
IRB-44367,Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy,1583 days,Recruiting,Interventional,Experimental,"Device, Other",Single Group Assignment,Not Applicable,No,Yes,10
NEPA-17-05,A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer,187 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,404
SHR6390-III-303,"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative",3836 days,Enrolling by invitation,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,4350
2022-761,Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality,516 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 4,No,No,180
JCL2020,A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast,2270 days,Recruiting,Interventional,Other,"Drug, Radiation",Single Group Assignment,"Phase 1, Phase 2",No,No,20
19-302,"Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer",1067 days,"Active, not recruiting",Interventional,Experimental,"Other, Device, Diagnostic Test",Single Group Assignment,Not Applicable,No,Yes,310
BFH-BC,ESM Versus OM ：A Randomized Controlled Trial,760 days,Unknown status,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,287
RT 1901,Hypofractionated Versus Conventional Fractionation Radiotherapy,519 days,Unknown status,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,80
MC1732,Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery,1826 days,"Active, not recruiting",Interventional,Experimental,Radiation,Single Group Assignment,Phase 2,No,Yes,25
ET19-084 - CICA-RT,Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients,855 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Other",Parallel Assignment,Phase 3,No,No,248
21623,Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer,207 days,Withdrawn,Interventional,"Experimental, Experimental","Other, Procedure, Procedure, Other",Parallel Assignment,Not Applicable,No,No,0
CASE10116,Breast Reconstruction Following Breast Cancer in Very High Risk Patients,1127 days,Withdrawn,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Other",Parallel Assignment,Not Applicable,No,No,0
2021/271,Effect of Laughter Therapy on Perceived Stress and Quality of Life,115 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,42
CASE5Y21,A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose,985 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Device, Other, Other",Parallel Assignment,Not Applicable,No,Yes,90
University in Zielona Gora,Inertial Rehabilitation in Women After Mastectomy,113 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,24
T148/2020,Exercise and Tumor Blood Flow in Breast Cancer Patients,1576 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,20
ISI dV SP - NSM-01,Robotic vs. Open NSM for Early Stage Breast Cancer,1340 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Device, Procedure",Parallel Assignment,Not Applicable,No,Yes,200
ATOPE18,Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program,1217 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,110
ChungnamNU.J1,VR-based Intervention for Cognitive Restoration,1848 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,200
EC/2017/1261,Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes,1903 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,300
EORTC-2129-BCG,TREAT ctDNA Elacestrant,2557 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,220
NCI-2021-11793,Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer,730 days,Recruiting,Interventional,Experimental,"Drug, Drug, Procedure, Procedure, Procedure, Procedure",Single Group Assignment,Phase 1,Yes,No,42
2019-4433,Angiomammography and Neoadjuvant Chemotherapy,2370 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,100
THERMOEDEME,Spa Therapy for Upper Limb Lymphoedema,1260 days,Unknown status,Interventional,"Active Comparator, Sham Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,160
C3621001,Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC,1035 days,Terminated,Interventional,"Experimental, Experimental",Biological,Sequential Assignment,Phase 1,Yes,No,36
LSB-12345,Intraoperative Use of ClearEdge Device in Breast Conserving Surgery,813 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,Yes,288
108511,Breathwork App for Cancer Survivors,560 days,Recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,40
202101421A0,Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy,367 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,30
960-CSP-USA_DenseBreasts_USS1,A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts,380 days,Terminated,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,435
211521,nCCR for Chemotherapy Related Cognitive Impairment Randomized Study,943 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,20
BC-P30(FZQ),Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy,1605 days,Recruiting,Interventional,"Experimental, Other","Device, Drug",Parallel Assignment,Not Applicable,No,No,102
2017-0672,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",2256 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Biological, Biological, Drug, Drug, Biological, Biological, Other, Other",Parallel Assignment,Phase 2,Yes,No,95
22-508,Implantable Microdevice for TNBC - Pilot Study,1950 days,Not yet recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 1,Yes,Yes,24
Pectoral nerve block in breast,Pectoral Nerve Block During Mastectomy,639 days,Not yet recruiting,Interventional,"Active Comparator, Sham Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,40
NU 18B05,Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast,1590 days,Recruiting,Interventional,Experimental,"Drug, Procedure, Other",Single Group Assignment,Phase 2,Yes,No,156
20476,Immune Effects in Patients Treated With Whole Breast Irradiation,517 days,Unknown status,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,50
ICRCTSU/2019/10068,PreOperative Endocrine Therapy for Individualised Care With Abemaciclib,4116 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,2500
EU001,Magseed Pro(R)/ Sentimag(R) Gen3,670 days,Not yet recruiting,Interventional,"Other, Other",Device,Parallel Assignment,Not Applicable,No,No,224
2018-63,Does Chemotherapy Train the Mutation of the Pig-A Gene? (PIGA),731 days,Unknown status,Interventional,Other,Biological,Single Group Assignment,Not Applicable,No,No,30
18-168,"Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue",2175 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,60
2021-A01407-34,Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration,365 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Not Applicable,No,No,100
soh-Med-21-02-05,Modified Pectoral Nerve Block Versus Serratus Plane Block,822 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,No,60
CIMPAX BREAST,Continuous Serrates Plane Block in Axillary Dissection,731 days,Unknown status,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,84
18D.003,"Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence",1553 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Other, Other, Other, Other, Other, Behavioral, Other",Parallel Assignment,Phase 2,No,No,285
20-002505,Mayo Designed Soft Tissue Ultrasound-Detectable Marker,521 days,Completed,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,Yes,8
XianganHXiamenU,NIR Fluorescent Molecular Probe for the Identification of Breast Tissue,346 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,20
201900572,The SONImage Study,2035 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,100
MEDOPP459,Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%,519 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,92
MedOPP485,A PoC Study to Evaluate Treatments Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population,1643 days,Not yet recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 2,No,No,1260
09.2019.866,Ultrasonographic Evaluation of Changes After Complex Decongestive Therapy,162 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
020-008,Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC,1142 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,20
LQiao,HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC,1096 days,Recruiting,Interventional,"Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 2,No,No,92
2021157,Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer,731 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
2020-KY-051,Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction,342 days,Completed,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,No,No,21
BC-09374,LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema,1641 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,80
Shengjing-LCG011,"Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC",2150 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,12
2021-02902,PACED-digitized Support During Adjuvant Endocrine Therapy,1042 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,300
GCO 19-0477,"Vaccination With Flt3L, Radiation, and Poly-ICLC",2157 days,Recruiting,Interventional,Experimental,"Drug, Drug, Radiation, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,56
202100318,Testosterone & Tamoxifen Trial,419 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,6
19-458,A Study of the Use of Text Message Reminders to Take Palbociclib,1461 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,45
S1904,Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE),2830 days,Recruiting,Interventional,"Active Comparator, Experimental","Behavioral, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,415
Seno_Ex_MAC 003,Comparison of Conventional With Sonography Assisted Breast Surgery After Neoadjuvant Chemotherapy,1643 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,340
CL(3204),Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms,659 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,146
211-2018,MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC,936 days,Unknown status,Interventional,"Experimental, No Intervention",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,50
AAAO1760,CBPR - BRCA Genetic Testing Among Orthodox Jews,322 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,50
J17120,"Cancer, Obesity/Overweight and Insomnia Study",902 days,Completed,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,30
1712078374,"Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome",1568 days,Completed,Interventional,Experimental,"Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,Yes,29
D17168,The Prone to Supine Breast MRI Trial,750 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,72
2020-KY-007,The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome,3286 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,234
DELFINO trial,Density Lowering Effect of OFS Add on to TMX(DELFINO Trial),1855 days,Recruiting,Interventional,"No Intervention, No Intervention, Active Comparator",Drug,Parallel Assignment,Phase 3,No,No,224
PRISMA,Primary Hormone-sensitive Breast Cancer: Need-driven Health Care Improvement by Patient-centred Digital Application,943 days,Not yet recruiting,Interventional,"Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,400
3125001,Safety and Pharmacokinetics of ODM-209,1628 days,"Active, not recruiting",Interventional,"Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",No,No,38
ShandongCHI-16,"Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis",424 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,100
ERAS-ABR,ERAS in Autologous Breast Reconstruction: A Pilot RCT,238 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,20
ProFertil,Use of GnRHa During Chemotherapy for Fertility Protection,3228 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,500
MEDOPP240,Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients,1377 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,68
TQB3616-I-0001,A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics,944 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,30
18-00309,Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy,1571 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 2,Yes,No,60
2023-9333,The MARVIN Chatbots to Provide Information for Different Health Conditions,4262 days,Not yet recruiting,Interventional,"Other, Other, Other","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,400
STUDY00020501,"Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study",927 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Behavioral",Parallel Assignment,Not Applicable,No,No,60
[2016]124,Serratus Plane Block in Preventing Postoperative Pain of Mastectomy,487 days,Completed,Interventional,"Placebo Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,50
IIT2018-04-MCARTHUR-NEOHP,Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab,2349 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,174
MCP Study,Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong,1973 days,Recruiting,Interventional,"Other, Other, Other","Diagnostic Test, Diagnostic Test, Diagnostic Test",Factorial Assignment,Not Applicable,No,No,10000
STUDY00000194,"Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases",458 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Other, Drug",Parallel Assignment,Phase 1,Yes,No,0
SIB2232,SMART-ER: Symptom Monitoring With Patient-reported Outcomes,249 days,Recruiting,Interventional,"Other, Other","Other, Other",Single Group Assignment,Not Applicable,No,No,40
KC19EEDT0031,Omitting vs. Doing Intraoperative Frozen Section Biopsy for Margin Status in Breast Conserving Surgery,2076 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,1292
22-008,Onvansertib + Paclitaxel In TNBC,2330 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,50
1807188-16,FUSCC Refractory TNBC Umbrella (FUTURE),1505 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,140
OSU-20429,Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel,1181 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Other, Drug",Parallel Assignment,"Phase 2, Phase 3",Yes,No,100
2020/295,"The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction",2353 days,Recruiting,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,81
SunYatsenU2H-LQ4,"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC",4536 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,260
Phaon1,Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy,1767 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Procedure, Procedure, Procedure",Parallel Assignment,Phase 2,No,No,416
SUGBG-2021002,Premarking of Axillary Nodes Before Start of Neoadjuvant Chemotherapy Using Magnetic Approach,638 days,Recruiting,Interventional,"Other, Other","Drug, Combination Product",Parallel Assignment,Not Applicable,No,No,80
S2018-2450-0001,Distress Reduction by Activity Tracking and Activity Enhancement by Mobile Support Group in Oncology,679 days,Completed,Interventional,"Experimental, Active Comparator","Device, Other",Parallel Assignment,Not Applicable,No,No,202
IIT-0016,Exercise and Compression for Lymphedema,735 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Device, Device, Device, Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,40
N.sativavsRID BreastCancerpt.,Evaluation of the Effect of Nigella Sativa for the Prophylaxis to Radiation Induced Dermatitis in Breast Cancer Patients,433 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,132
00130272,PhysioTouch for Treatment of Radiation Fibrosis,487 days,Withdrawn,Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,0
URCC-18007,Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors,1731 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other, Other, Other",Parallel Assignment,Phase 3,Yes,No,422
jcl2020-2 breast cancer,3D Printed Bolus in Post-mastectomy Radiotherapy,415 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,70
OP-1250-003,Phase 1b Combo w/ Ribociclib and Alpelisib,731 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,60
38285020.8.0000.0072,"Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer",396 days,Completed,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,50
TMP-0315-2018,Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel),1148 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,35
21-3117.cc,Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC,331 days,Withdrawn,Interventional,Experimental,"Drug, Drug, Radiation, Drug",Single Group Assignment,Phase 2,Yes,No,0
IRB00103558,Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors,458 days,Completed,Interventional,"Experimental, Active Comparator","Other, Behavioral",Parallel Assignment,Not Applicable,No,No,28
ICOnnectat-BC,"Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors",545 days,Unknown status,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,193
20-028,Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA),2007 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,40
STU-2022-0091,Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy,695 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,90
2021-0048-B,Erector Spinae Block vs. Placebo Block Study,334 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,60
Breastblock,Regional Anesthesia for Breast Surgery,1099 days,Unknown status,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,150
OMS-I141 (KEYNOTE-890),Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC,2121 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Biological, Device, Drug",Parallel Assignment,Phase 2,Yes,Yes,65
BHP0111,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza),781 days,Completed,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,270
18-001926,Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors,1699 days,Recruiting,Interventional,"Experimental, Experimental","Dietary Supplement, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,20
REDHEMOPACH,Hemopatch Versus Axillary Drainage After Axillary Lymphadenectomy,1080 days,Completed,Interventional,"Other, Active Comparator","Device, Procedure",Parallel Assignment,Not Applicable,No,No,228
PMC_TTAC-0001_06 / KEYNOTE-C14,Olinvacimab With Pembrolizumab in Patients With mTNBC,1795 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,36
INSPIRE-001,Intercostobrachial Nerve Sparing to Reduce Post-Surgical Pain,413 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,50
STUDY00149312,Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC,1092 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,139
IIT2021-10-Giuliano-OmitRT,Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response,2192 days,Not yet recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,25
VICCBRE2256,Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort,5114 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Other, Other",Parallel Assignment,Phase 2,Yes,No,64
EAZ171,Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer,1435 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Other, Other",Parallel Assignment,Phase 2,Yes,No,249
2017/62,Effects of Slow-Stroke Back Massage on CRF,301 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,62
17-001864,SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer,974 days,Completed,Interventional,Experimental,"Device, Procedure",Single Group Assignment,Early Phase 1,No,Yes,27
SCHBCC-N031,An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.,1279 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,138
20429001,Central Obesity and Cancer Prevention for Chinese American Women,412 days,Unknown status,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,30
2000020335,"Lifestyle, Exercise, and Nutrition Study Early After Diagnosis",2189 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,173
KN026-CHN-001,Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer,1808 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,63
Pro00103527,mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients,1199 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,180
CBCRP 23AB-1400,Reducing Breast Cancer Risk in Korean American Women,290 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,48
MC02/04/19,"A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)",1083 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,74
EJERDIETLINF,Reduction of Lymphedema Secondary to Breast Cancer,1096 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,100
22-5074,Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE),1644 days,Not yet recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,15
STUDY00018789,StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients,456 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Other, Other, Drug, Drug",Parallel Assignment,Not Applicable,No,Yes,92
SCHBCC-SOAPET,Sentinel Node Biopsy Vs Observation After Axillary PET,2919 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,1528
ATADEK-2022/08/20,The Effect of Manual Lymph Drainage in the Treatment of Breast Edema,595 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,36
OBU-BC-Ⅱ-077,"Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer",731 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,52
RG1005296,"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer",1897 days,Recruiting,Interventional,Experimental,"Biological, Drug, Biological, Biological",Single Group Assignment,Phase 2,Yes,No,16
RD19/123502,Plant Sterol INtervention for Cancer Prevention (PINC),690 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Dietary Supplement",Crossover Assignment,Not Applicable,No,No,50
091-19,Study on Physical Activitys Relationship With Cancer and Cognition,654 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,30
PR139/21,Axillary Reverse Mapping in Breast Cancer,913 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,30
2021.341,Project Breast47: Effect of an Educational Intervention,162 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,424
17-361,BEFORE Decision Aid Implementation Study,486 days,Unknown status,Interventional,"Other, Experimental, Other","Behavioral, Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,224
Overcome project,"Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases",724 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,58
DS8201-A-A103,DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein,1640 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,12
OBU-BJ-BB-BC-II-007,Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy,1137 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
NU 21B01,"Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study",581 days,Recruiting,Interventional,Experimental,"Procedure, Device",Single Group Assignment,Phase 2,No,Yes,120
COOL-CLIN-2022-01,Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss,578 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,125
2020-1243,Music and Surgery Associated With Relationship and Satisfaction,466 days,Unknown status,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,304
OSU-19085,Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer,425 days,Withdrawn,Interventional,Experimental,"Drug, Drug, Other",Single Group Assignment,Phase 1,Yes,No,0
SYSUCC-012,GM1 Prophylaxis for WBRT Related Cognitive Dysfunction,1691 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,204
UUBreast01,Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ,2860 days,Recruiting,Interventional,"Experimental, Active Comparator","Diagnostic Test, Diagnostic Test",Parallel Assignment,Phase 3,Yes,No,500
IMPACTT,Impact of a Patient Decision Aid Intervention,564 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,274
CBBCT2018CIH,The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer,1095 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,800
30-225 ex 17/18,Laser vs Hyaluronic Acid for GSM in Breast Cancer,1802 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,50
ITSligo SG,Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema,458 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Procedure, Device",Parallel Assignment,Not Applicable,No,No,30
STUDY00003067,Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding,910 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,40
PROICM 2019-02 PRA,Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic  Patient Reported Outcome ) on Breast-related Quality of Life,1736 days,Recruiting,Interventional,"Experimental, Other","Other, Drug",Parallel Assignment,Phase 2,No,No,105
850366,"The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients",731 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,70
2018/13,Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer,1510 days,Completed,Interventional,"Experimental, Other, Experimental, Other","Drug, Procedure",Parallel Assignment,"Phase 1, Phase 2",No,No,17
A095053,Breast Screening - Risk Adaptive Imaging for Density,2713 days,Recruiting,Interventional,"No Intervention, Active Comparator, Active Comparator, Active Comparator","Diagnostic Test, Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,13200
202302077,Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial),550 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,40
2.510.081,PILATES METHOD ON THE UPPER LIMBS FUNCTIONALITY,274 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,22
GX-I7-CA-006,Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899),1832 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,83
R17137,Thermal Suit With Forced-air Warming in Breast Cancer Surgery,136 days,Completed,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,40
2021-395,Efficacy of Cilostazol in Prevention of Peripheral Neuropathy,277 days,Completed,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,71
IC 2018-09,Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR),911 days,Recruiting,Interventional,"Other, Other, Other, Other, Other, Other","Behavioral, Behavioral, Other, Other",Sequential Assignment,Not Applicable,No,No,190
NeoCAT,A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs,1005 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,58
AAAR9515,The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL,1437 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator, Placebo Comparator","Device, Device, Device",Sequential Assignment,Not Applicable,No,Yes,100
RG1007463,"Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",393 days,Terminated,Interventional,Experimental,"Drug, Drug, Drug, Biological, Biological",Single Group Assignment,"Phase 1, Phase 2",Yes,No,1
PA191001001,Pectoral Nerve Block II and Erector Spine Plane Block in Breast Cancer Surgery,428 days,Completed,Interventional,"Experimental, Active Comparator","Procedure, Procedure, Other",Parallel Assignment,Not Applicable,No,No,90
18070604,A Study of Serum Folate Levels in Patients Treated With Olaparib,1411 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,"Phase 2, Phase 3",Yes,No,75
2021198-1,Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer,1371 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,75
PROTOCOL-M7-037,Micrima MARIA Data Collection for Machine Learning Study,428 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,400
201801105,RANKL Inhibition and Breast Tissue Biomarkers,185 days,Completed,Interventional,Experimental,"Procedure, Drug, Procedure, Drug, Drug",Single Group Assignment,Early Phase 1,Yes,No,10
202004120MINB,The Effect of Intraoperative Dexmedetomidine on Postoperative Morphine Requirements After Breast Cancer Surgery,1533 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,60
STUDY00001356,IIT2020-20-SHIRAZIP-WALK: Nature Walks,893 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,40
IC 2020-04,ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery,764 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,292
Remimazolam_recovery,Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol,141 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,66
RECHMPL21_0525,Tridimensional Geometric Modeling of the Breast,610 days,"Active, not recruiting",Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,200
2022037,Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer,700 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
Q122-2001,Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor,686 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,132
S64410,UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research,5388 days,Recruiting,Interventional,Other,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,100
MC1689,"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",1861 days,Suspended,Interventional,Experimental,"Drug, Drug, Drug, Biological, Drug, Drug, Other, Biological, Biological, Biological, Procedure, Biological, Drug, Other, Biological",Single Group Assignment,Phase 1,Yes,No,39
2017-0301,Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers,2588 days,Withdrawn,Interventional,"Experimental, Active Comparator","Radiation, Other",Parallel Assignment,Phase 2,No,No,0
S59396,Cancer Related Cognitive Impairment After Chemotherapy: Evaluation of Potential Therapeutic Interventions,1095 days,Unknown status,Interventional,"Experimental, Active Comparator, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,120
1105/18,The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patients Dream Study,731 days,Completed,Interventional,"Active Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,No,44
SP11631,Trial to Compare the Efficacy and Safety of F-627 and GRAN®,433 days,Completed,Interventional,"Experimental, Active Comparator",Biological,Parallel Assignment,Phase 3,No,No,242
EKNZ 2015-026,Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus,549 days,Withdrawn,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,0
H-37314,Translating Research Into Practice,1760 days,"Active, not recruiting",Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,1224
852666,Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts,357 days,Enrolling by invitation,Interventional,"No Intervention, Experimental, Experimental, Experimental","Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,2000
Three birds with one stone,Three Birds With One Stone,821 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,27099
XZP-3287-1001,A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors,1683 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,300
I 56617,"Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers",1721 days,Terminated,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,7
TAK-676-1003,A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers,892 days,Recruiting,Interventional,Experimental,"Drug, Drug, Radiation",Sequential Assignment,Phase 1,Yes,No,65
STUDY00022229,ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer,732 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,14
CR108557,"A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults",96 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Crossover Assignment,Phase 1,No,No,18
UPCC 25920,Pilot Study of an NTproBNP Guided Strategy of Cardioprotection,1536 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,"Phase 1, Phase 2",No,No,105
MEDOPP243,"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease",1044 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,41
4901,An Enhanced Artificial Intelligence Breast MRI Interpretation System,457 days,Unknown status,Interventional,,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,1526
22-269,Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial),904 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Other",Parallel Assignment,Not Applicable,No,Yes,80
Yvonne Wengstrom,Sensorimotor Training Using Whole Body Vibration Exercise to Reduce Chemotherapy-induced Peripheral Neuropathy,556 days,Recruiting,Interventional,"Experimental, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,44
4-2019-0795,Improvement of Patient Experience and Healthcare Providers Productivity Using Virtual Reality in the Field of Radiation Therapy,567 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,196
20180569-01H,Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study,1307 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,No,70
REaCT-Hold BMA,Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer,1484 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 4,No,No,240
2020-0761,Evaluation of Mailers Promoting Mammogram Screening,368 days,Completed,Interventional,"Active Comparator, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,1342
202005217,Implementing BREASTChoice Into Practice,907 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,412
SBI-CIP 20-002,Fluorescence Imaging of Carcinoma During Breast Conserving Surgery,948 days,Recruiting,Interventional,"Placebo Comparator, Experimental","Drug, Device, Drug",Sequential Assignment,Phase 3,Yes,No,370
DS8201-A-U106,DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer,1481 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,115
A2018-002,Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations,1374 days,Unknown status,Interventional,Other,Drug,Single Group Assignment,Phase 4,No,No,217
STUDY00016221,Nurse AMIE for Echo Show: Randomized Control Trial,391 days,Completed,Interventional,"Experimental, Other",Behavioral,Parallel Assignment,Not Applicable,No,No,42
PR275/20,Impact of Systematic Shaving on Margins,1104 days,Recruiting,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,234
X-PACT 101,"X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma",1151 days,Recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 1,Yes,Yes,12
SHF-WBI,Super Hypofractionated Irradiation For Whole Breast Treatment,2147 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,217
19-07020531,Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study,2375 days,Recruiting,Interventional,Other,Radiation,Single Group Assignment,Phase 2,No,Yes,60
DS8201-A-U105,Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer,1472 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,99
NAUTILUS study,No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography,2663 days,"Active, not recruiting",Interventional,"Experimental, Other","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,1734
BrUOG 387,TAS-116 Plus Palbociclib in Breast and Rb-null Cancer,701 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,27
Instituto Nacional do Câncer,Effectiveness of Compressive Bandage Use in Seroma Prevention,507 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,Yes,270
HP-LY-CL-2063,Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE),2369 days,"Active, not recruiting",Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,39
2008222-12,Accuracy of VABB Elite 10G Versus BARD 14G CNB,606 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Phase 3,No,No,1470
2019-0837-002,Capsular Contracture After PMRT Using Prepectoral Versus Subpectoral Implant-based Breast Reconstruction: PREPER Trial,1855 days,Not yet recruiting,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,114
BCP24,To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes,1349 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,230
IRB00083573,Cardiac Outcomes With Near-Complete Estrogen Deprivation,1916 days,Recruiting,Interventional,Experimental,"Drug, Diagnostic Test, Diagnostic Test, Other, Behavioral",Single Group Assignment,Early Phase 1,Yes,No,90
CCR5199,ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab,1475 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,No,No,48
HVST-HEMO-20,The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage,358 days,Recruiting,Interventional,"Experimental, Other","Device, Other",Parallel Assignment,Phase 4,No,No,118
STUDY00019979,Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology,856 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,30
109489,Time Restricted Eating on Cancer Risk,728 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,44
IIT2019-14-SHIRAZIP-SWEAT,Streaming Web-based Exercise At Home: A Pilot Study,996 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Early Phase 1,No,No,12
SGNTUC-019,Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations,1601 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,270
EORTC-1984-BCG,Chemo-free BRCA-targeted Neoadjuvant Strategy,2727 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,152
H-43277,Wrist Cooling for Hot Flashes Clinical Trial,302 days,Recruiting,Interventional,"Experimental, Experimental","Device, Device, Other",Crossover Assignment,Not Applicable,No,Yes,30
Oncolact2020,Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact,725 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,73
OE20/2020,Effectiveness of Cohesive Bandage on Axillary Web Syndrome After,1056 days,Unknown status,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,90
GNC-035-101（V1.1）,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors",624 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,0
2022-0880,Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation,2037 days,Recruiting,Interventional,"Experimental, Experimental","Radiation, Other",Single Group Assignment,Phase 3,No,No,126
ACT16432,Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors,1386 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,94
AAAT8817,IMPACT Trial: Intervention to iMProve AdherenCe Equitably,1887 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Other",Single Group Assignment,Not Applicable,No,No,350
19-07020533,Prospective Randomized Study of Accelerated Radiation Therapy (PRART),2232 days,Recruiting,Interventional,"Experimental, Experimental","Radiation, Radiation",Parallel Assignment,Phase 3,No,Yes,400
PSIBBR,Prepectoral and Subpectoral Implant-based Breast Reconstruction,698 days,Unknown status,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,300
THRIVORSBH-01,Physical Activity Platform to Improve Bone Health in Cancer Survivors,405 days,Completed,Interventional,"Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,134
20190516,Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib,484 days,Completed,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,No,No,144
RECHMPL20_0614,Assessment of Cryotherapys Analgesic Impact in Anti-aromatase-induced Arthralgia,670 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,70
RD19/121361,Role of ABUS as an Alternative to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy,1043 days,Unknown status,Interventional,Experimental,"Diagnostic Test, Diagnostic Test",Single Group Assignment,Not Applicable,No,No,100
BRAVEHeartV1,Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart,1781 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,45
R/19.08.578,Reconstruction of Partial Mastectomy Defects With Pectoralis Myo-glandular Local Flap.,919 days,Unknown status,Interventional,Experimental,Procedure,Single Group Assignment,Phase 1,No,No,15
DHP107_Bioimaging,A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor,174 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,2
18-5029,Evaluating Positron Emission Mammography Imaging of Suspicious Breast Abnormalities,715 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,100
201902048MINC,Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ,2437 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Radiation",Parallel Assignment,Phase 3,No,No,810
050811,Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer,761 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,24
0594,The Genomic Medicine at VA Study,1901 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,1076
APHP201173,BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS.,731 days,Not yet recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,35
2019-001,Evolution of the Physical Condition in Treated Cancer Patients,623 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,300
2022P000354,Evaluating the Impact of an Equity Focused Dashboard and Clinical Support,463 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention, No Intervention","Other, Other",Crossover Assignment,Not Applicable,No,No,3600
UMCC 2019.125,Altering Lipids for Tolerance of Aromatase Inhibitor Therapy,1007 days,"Active, not recruiting",Interventional,Experimental,Dietary Supplement,Single Group Assignment,Phase 2,Yes,No,77
00001137,Improving Genetic Counseling for BRCA+ Mothers,2009 days,Recruiting,Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,200
C3661001,A Study of PF-06873600 in People With Cancer,2458 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 2,Yes,No,155
4-2020-0430,The Effects of Perioperative PECS Block During Robotic Breast Surgery and Breast Reconstruction,459 days,Completed,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,30
N16PRB,Preoperative Breast Irradiation,150 days,Terminated,Interventional,Other,Radiation,Single Group Assignment,Not Applicable,No,No,4
CASE10119,"Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography",870 days,Recruiting,Interventional,Experimental,"Other, Behavioral",Single Group Assignment,Not Applicable,No,No,100
21-012300,Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain,752 days,Recruiting,Interventional,Experimental,"Other, Behavioral",Single Group Assignment,Not Applicable,No,No,20
KY-Q-2021-182,Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis,1036 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Single Group Assignment,Not Applicable,No,No,380
METC20-099,External Vacuum Expansion: Evaluation in Breast Reconstructive Surgery Evaluation in Breast Reconstructive Surgery,1907 days,Recruiting,Interventional,"Active Comparator, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,90
D8534C00001,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),2340 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,300
NUV-422-03,Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC,1461 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,0
OSU-18094,Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy,577 days,Withdrawn,Interventional,Experimental,"Procedure, Procedure, Other",Single Group Assignment,Not Applicable,No,Yes,0
10840098-604.01.01-E.184,"Effectiveness of PNF Training for Improving for Muscle Strength, Function, and Pain After Axillary Lymph Node Dissection",567 days,Completed,Interventional,"Experimental, Experimental, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,66
Breast Cancer Chemotherapy,Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses,822 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Drug",Single Group Assignment,Not Applicable,No,No,15
STUDY02001039,"21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial",92 days,Not yet recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,60
CSCS,Cognitive Stimulation and Chemobrain. An Innovative Intervention for Cancer Survivors,546 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Sequential Assignment,Not Applicable,No,No,120
2020/6422,"Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.",396 days,Unknown status,Interventional,"Experimental, Experimental, Placebo Comparator","Dietary Supplement, Dietary Supplement, Dietary Supplement",Parallel Assignment,Phase 4,No,No,120
2022-0150,A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care,493 days,Recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Single Group Assignment,Phase 2,No,No,40
2007-0003,Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism,731 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,0
GEN-602-CT-101,Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer,1736 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,127
CASE2119,A Study of the Use of AirXpanders AeroForm in Patients Undergoing Post-Mastectomy Radiation Therapy,1052 days,Withdrawn,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,0
STUDY00000228,RCT Comparing ESPB Solutions in Breast Surgery,1092 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,75
PRESIONA20,Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program,1095 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,25
IPAC,Optimizing the Management of Patients With Oral Therapy,1160 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,406
CTMS# 18-0135,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,2146 days,Suspended,Interventional,Experimental,"Other, Other",Single Group Assignment,Not Applicable,No,No,60
STX-478-101,First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor,1157 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,160
18-486,Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease,1811 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Drug",Parallel Assignment,Phase 2,No,Yes,145
2019-02661,Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions,1154 days,Recruiting,Interventional,"Experimental, No Intervention",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,440
110181,Probiotics and Breast Health,913 days,Completed,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,60
IRB-55153,"Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts",717 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,15
20953,"Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer",1552 days,Withdrawn,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,0
MC1932,TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol,2232 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator",Drug,Parallel Assignment,Phase 2,Yes,No,450
EXPLLN21-01,A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG,670 days,Not yet recruiting,Interventional,Experimental,Diagnostic Test,Parallel Assignment,Not Applicable,No,No,9
22-457,Losartan in Prevention of Radiation-Induced Heart Failure,334 days,Not yet recruiting,Interventional,Experimental,"Drug, Radiation",Single Group Assignment,Early Phase 1,Yes,No,10
GW10029,Assessing the Sensitivity of SureTouch™ in Women Undergoing Diagnostic and Screening Mammography,768 days,Terminated,Interventional,"Experimental, Experimental",Device,Parallel Assignment,Not Applicable,No,No,213
GCC1950,First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies,1721 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 1,Yes,No,77
Erector block after mastectomy,Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.,241 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator","Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,75
2021-0025,Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge,1111 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Drug, Other",Single Group Assignment,Not Applicable,No,Yes,66
HCI148669,Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System,1825 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Early Phase 1,No,Yes,34
21/59848,Lymphaticovenous Anastomosis as Treatment for Lymphedema,630 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,10
221-005,Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®,303 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 1,No,No,87
P.T.REC/012/002615,Aquatic Versus Land Based Exercise on Lymphedema Post Mastectomy,517 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,50
INT31/19,Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases,898 days,Unknown status,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,110
B00394,Automated Low Dose Risk Assessment Mammography (ALDRAM),1455 days,Completed,Interventional,Other,Radiation,Single Group Assignment,Not Applicable,No,No,154
CKMW-1801,Compass Course: Efficacy Study,1156 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Crossover Assignment,Not Applicable,No,No,41
EGC101,A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers,253 days,Completed,Interventional,"Experimental, Active Comparator, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,135
69HCL20_1018,Remediation for Mild Cognitive Deficits After Cancer,1308 days,Recruiting,Interventional,"Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,24
300.08-2018-Samsungmedison-S,Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms,498 days,Unknown status,Interventional,"Active Comparator, Experimental, Experimental","Device, Device, Device, Procedure",Crossover Assignment,Not Applicable,No,No,300
ICO-A-2020-10,Electrotherapy in the Management of Myofascial Syndrome,817 days,Recruiting,Interventional,"Other, Other","Device, Device",Crossover Assignment,Not Applicable,No,No,50
INT157/17,Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial,914 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,100
13155,ciNPT in Autologous Abdominal Tissue Breast Reconstruction,365 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Procedure, Device, Other",Parallel Assignment,Not Applicable,No,Yes,24
IRB20-0528,Low-dose Imaging Technique (LITE),518 days,Unknown status,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,50
BO40933,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",938 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,51
NL67696.068.18,Functional MRI Study Reconstructed Breasts,689 days,Unknown status,Interventional,"Active Comparator, Active Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,No,30
UW17032,Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention,112 days,Terminated,Interventional,Experimental,Device,Single Group Assignment,Phase 2,No,Yes,2
MedOPP321,"ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL",1064 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,160
2017-8737,Post-op Outcomes of Enhanced Energy Delivery Dissection for Mastectomy With Immediate Breast Reconstruction,426 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,15
AP2204-50104,Efficacy of Serratus Anterior Plane Block With Dexmedetomidine During Breast Surgery,380 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental","Procedure, Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,172
IRB-53132,LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy,3186 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,80
5160378,Effect of Resveratrol on Serum IGF2 Among African American Women,1894 days,Suspended,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,50
R.21.11.1523,Comparison of Different Volumes Spread of Erector Spinae Block in Post Mastectomy Pain Syndrome Management,263 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Other,Parallel Assignment,Phase 2,No,No,50
CYP003,A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers,683 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,90
315581,Randomised Trial Comparing Biological Matrices With Synthetic Meshes,1095 days,Not yet recruiting,Interventional,"Active Comparator, Experimental",Procedure,Parallel Assignment,Not Applicable,No,No,60
CTB in Breast surgery,Ultrasound Guided Costotransverse Block for Breast Cancer Surgery,114 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,70
RIS42756,Remote Time-restricted EAting DeliverY,364 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, No Intervention","Behavioral, Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,178
YH32367-101,Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor,1502 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,110
2021.127,Music Intervention for Preoperative Anxiety and Acute Pain Among Mastectomy Patients,295 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,36
ShantouCH,Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery,1229 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Not Applicable,No,No,60
HYACOM,"Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies",629 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Sequential Assignment,Not Applicable,No,No,100
36264PR116/2/23,Vitamin C on Acute and Chronic Post Mastectomy Pain,610 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Not Applicable,No,No,204
00101494,Technology-Based Cancer Screening Intervention,1274 days,Enrolling by invitation,Interventional,"Other, Other, Other",Behavioral,Sequential Assignment,Not Applicable,No,No,22497
ETK00-2020-0103,Effects of Clinical Pilates and Yoga Training in Lymphedema,473 days,Completed,Interventional,"Experimental, Experimental, Other","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,28
DIVA-001,"Randomized, Controlled Trial With Hybrid Fractional Laser",1040 days,Completed,Interventional,"Experimental, Placebo Comparator",Device,Parallel Assignment,Not Applicable,No,Yes,25
PRO00030436,The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure,1114 days,Completed,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator","Other, Other",Single Group Assignment,Not Applicable,No,No,11
JS2021-6-1,Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction,1483 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,57
20180335,An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx System,3855 days,Recruiting,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,Yes,50
DRBX201901/PRO,A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection,172 days,Completed,Interventional,"Experimental, Active Comparator",Drug,Crossover Assignment,Not Applicable,No,No,32
21-04,Performance Assessment of the Fluorescence Technique Alone in the Search for the Sentinel Node in Breast Surgery,588 days,Recruiting,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,350
A221505,Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer,6390 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Radiation, Other, Other, Other, Radiation",Parallel Assignment,Phase 3,No,No,897
UC-0107/1803,Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast,5666 days,Recruiting,Interventional,"Active Comparator, Experimental","Radiation, Other",Parallel Assignment,Not Applicable,No,No,300
SHS-An-1-2022,Nociception Level Monitor (NOL) During Guided Analgesic Delivery in Breast Surgeries,1155 days,Enrolling by invitation,Interventional,"Active Comparator, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,60
R01CA249419,The Engaging Primary Care in Cancer Survivorship (EPICS) Study,1348 days,Enrolling by invitation,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,2450
STU 072016-058,Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity,1704 days,Enrolling by invitation,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Early Phase 1,Yes,No,110
DS1103-074,A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors,1177 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,78
Biofeedback_based_music,Effects of Biofeedback-based Music Program Using a Smart Device Application on Perioperative Sleep Quality.,148 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Device, Other",Parallel Assignment,Not Applicable,No,No,68
IRB-21-28,Can Chronic Post-surgical Pain be Reduced by Preserving Intercostobrachial Nerve During Axillary Lymph Node Dissection? : A Randomized Controlled Trial,244 days,Enrolling by invitation,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,182
BREAST-Pyrotinib,Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC,1644 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,250
L19-065,Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction,1461 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,70
TQB211-III-01,A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.,1055 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,338
AP2110-30111,Erector Spinae Plane Block Versus Serratus Anterior Block on Post Mastectomy Pain Syndrome,424 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental","Procedure, Procedure",Sequential Assignment,Not Applicable,No,No,120
IRB202101449,UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization,332 days,Recruiting,Interventional,"Sham Comparator, Experimental",Device,Parallel Assignment,Not Applicable,No,No,24
IIT2021-01-Shiao-CSF1Ri,Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation,612 days,Not yet recruiting,Interventional,Experimental,"Drug, Radiation, Drug",Single Group Assignment,Phase 2,Yes,No,35
WHITE TEA,White Tea for Prevention of Chemotherapy Induced Mucositis,1032 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,88
2017/15,Study of the Impact of DPD Activity on the Efficacy of Capecitabine,1716 days,Recruiting,Interventional,Experimental,"Other, Drug",Single Group Assignment,Not Applicable,No,No,155
A222101,Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II),2618 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Other, Other, Drug",Parallel Assignment,Phase 2,No,No,98
AP2014-50103,Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia,91 days,Completed,Interventional,"Experimental, Experimental, No Intervention","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,58
21-318,Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery,708 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,88
BXU572940,Doxil/Caelyx BE Study,244 days,Not yet recruiting,Interventional,"Active Comparator, Experimental",Drug,Crossover Assignment,Phase 1,Yes,No,36
62/19-06-18,Guided Imagery & Music in Cancer,914 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,20
ZUH-MICB-UMPR,The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.,740 days,Completed,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,Phase 4,No,No,36
RG1007834,Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy,7234 days,"Active, not recruiting",Interventional,Experimental,"Drug, Procedure, Procedure, Drug, Procedure, Procedure, Other",Single Group Assignment,Phase 2,Yes,No,2
KCT001,"Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study",296 days,Completed,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,Yes,40
HE641269,Efficacy of Parecoxib Combined With Paracetamol in Mastectomy,43 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,60
AIUR trial,The AIUR Trial: Surgical Gloves to Prevent Peripheral Neuropathy,1007 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,104
S-20200094,Lymphedema Screening,361 days,Unknown status,Interventional,"Other, Other","Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,250
ATADEK 2021-14/18,Aromatherapy Methods in Reducing Anxiety Before Breast Biopsy,304 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,150
19-665,CONFIRM: Magnetic Resonance Guided Radiation Therapy,1144 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Radiation,Parallel Assignment,Not Applicable,No,Yes,70
RECHMPL18_0244,Pre Pectoral Implant for Immediate Breast Reconstruction Using Single Port Endoscopy in Prophylactic Indication,2736 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,20
TBio-4101-001,A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors,530 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Drug",Parallel Assignment,Phase 1,Yes,No,30
UCCS19102,Memory and Attention Adaptation Training-Geriatrics (MAAT-G),992 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,39
UCCS20127,Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II,1248 days,Recruiting,Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,85
RCB: 2022-A01349-34,Algology in Oncology Osteopathic Support (ALGOS),697 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,120
211820931,Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis,1380 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,31
CTC-SMMiL-E-1901,Feasibility of a New Technology for Isolating Circulating Tumour Cells,1360 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,76
LCI-BRE-VITD-001,A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation,1172 days,Recruiting,Interventional,"Experimental, Active Comparator","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,128
CLEE011A2412B,Roll-over Study to Allow Continued Access to Ribociclib,2050 days,Recruiting,Interventional,Other,"Drug, Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 4,Yes,No,137
OX2022-203-01,Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors,1501 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,115
2018-0561,"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors",1644 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,32
IRB00180383,e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English,400 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,40
ID-RCB: 2018-A03356-49,Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis,532 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,72
2011684,Radiofrequency Chip for Localization of Non-Palpable Breast Lesions,914 days,Completed,Interventional,"Other, Experimental, Active Comparator","Device, Device, Device",Parallel Assignment,Not Applicable,No,Yes,38
2021/058,Novel Skin Care Product for the Management of Acute Radiodermatitis,485 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,100
CDK-002-101,"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors",829 days,Completed,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",Yes,No,27
SAPB for MRM 2.0,Serratus Anterior Plane Block for Modified Radical Mastectomy: Double-point VS Single-point,211 days,Recruiting,Interventional,"Experimental, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,60
TJ107001STM202,Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors,771 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 2,No,No,133
2015C0090,Tango for Neuropathy Among Breast Cancer Survivors,729 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,52
Study-21-00112,Mammography and Breast Arterial Calcification: An Information-Sharing Trial,1614 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,14875
2020-013-00US3,A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors,935 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,112
NeuroMod-PCCI,Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment,637 days,Recruiting,Interventional,"Experimental, Sham Comparator","Device, Device, Behavioral",Parallel Assignment,Not Applicable,No,No,52
D8530C00004,"A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833",112 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Radiation, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,No,No,32
19-5250.0,Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy,1096 days,Suspended,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,30
STU 2019-1099,Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity,1445 days,Suspended,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Early Phase 1,Yes,Yes,10
2020.253 NL72539.029.20,Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor,565 days,Completed,Interventional,"Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,20
A5481173,Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies,1382 days,Recruiting,Interventional,"Other, Experimental, Other, Other","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,35
RCT Pristina 2/TR,Self-compression Mammography in Clinical Practice,1071 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,502
2021-0568-001,A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia,1415 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Phase 3,No,No,230
STUDY00143316,Sexual Health Empowerment for Womens Health,1602 days,"Active, not recruiting",Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,279
19-238,Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction,1457 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 4,Yes,No,1500
FDRT-BC007,Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery,3652 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,4052
2004-219-1119,Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy,398 days,Completed,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,113
DS1062-A-J101,First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01),2527 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Other",Sequential Assignment,Phase 1,Yes,No,770
CMUH110-REC1-122,Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel,304 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
IIT-ePRO,A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys,550 days,Recruiting,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Phase 3,No,No,128
22-091,Culturally Aware AET Non-Initiation Intervention,212 days,Not yet recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,30
UTK-IRB-22-07195,Womens Interventions for Sexual Health: WISH,283 days,Recruiting,Interventional,"Experimental, Other","Other, Device",Parallel Assignment,Not Applicable,No,Yes,30
PROICM 2018-07 BPR,Memory Perception Assessment in Central/Non-central Nervous System Cancers,1634 days,Recruiting,Interventional,"Other, Other, Other, Other",Other,Factorial Assignment,Not Applicable,No,No,420
5271,SEroma Reduction pOst MAstectomy SEROMA Study,998 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,100
ZG01012019,Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction,912 days,Unknown status,Interventional,"Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,60
PO18091,Per-operative Exploration of the Peri-pancreatic Lymphatic Pathways During Pancreatic Surgical Resection,731 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,20
22-197,The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment,1086 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Procedure, Other",Parallel Assignment,Phase 2,No,No,80
20-5111,The Person-centered Evolution of Radiotherapy Services in Ontario Study,1449 days,"Active, not recruiting",Interventional,"Experimental, Other",Other,Parallel Assignment,Not Applicable,No,No,109
PROICM 2020-06 BIO,Pain Monitoring After Breast Biopsy: Benefit of E-health,903 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,192
IRB-46373,Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma,2293 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Radiation",Parallel Assignment,Not Applicable,No,No,21
2019_NOV_CP_001,Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications,1017 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,200
DEGENCA,"Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the Massive Parallel Sequencing on Circulating Tumor DNA",1083 days,Unknown status,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,20
IRB-2022- 1451,Axillary Versus Primary Breast Approach for Second-stage Breast Reconstruction,731 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental",Procedure,Parallel Assignment,Not Applicable,No,No,136
ASO.RianGen.22.02,Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery,426 days,Enrolling by invitation,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,160
19-00222,Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises,92 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,30
C4431001,A Study of PF-07260437 in Advanced or Metastatic Solid Tumors,1449 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Diagnostic Test",Sequential Assignment,Phase 1,Yes,No,100
M336,Comparison of Erector Spinae Plane Block With Serratus Anterior Plane Block for Breast Surgery,410 days,Completed,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,62
KIA 2018/155,The Effect of Thoracal Paravertebral Block on Seroma Reduction in Breast Surgery,178 days,Completed,Interventional,"No Intervention, Experimental",Procedure,Crossover Assignment,Not Applicable,No,No,40
B-1206-158-005,Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts,394 days,Withdrawn,Interventional,"Experimental, Active Comparator","Biological, Biological",Parallel Assignment,Not Applicable,No,No,0
190311,Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction,893 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Procedure",Parallel Assignment,Not Applicable,No,Yes,120
20-021,Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection,1440 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure, Other, Other",Parallel Assignment,Phase 3,No,No,174
202200395A3,"Effect of Helmet Type, Home-use Low-level Light Therapy Device for Chemotherapy-induced Alopecia",1232 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,88
PECS in Breast Cancer Surgery,PECS Block With Bupivacaine Vs Bupivacaine and Dexmedetomidine in Modified Radical Mastectomy,122 days,Unknown status,Interventional,"Placebo Comparator, Active Comparator, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,45
HREBA.CC-19-0354,Protein Needs Study,1710 days,Recruiting,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,30
Analgesia in breast surgey,Combined PECS II and Transversus Plane Blocks Versus Erector Spinae Block in Modified Radical Mastectomy,661 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,60
159-2019,Magnetic Occult Lesion Localization Instrument (MOLLI) Guidance System for Breast Lesion Localization,959 days,Recruiting,Interventional,"No Intervention, Experimental",Device,Sequential Assignment,Not Applicable,No,No,207
LCCC1920,Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention,950 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,15
MCC-19650,Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1,1187 days,Terminated,Interventional,"Active Comparator, Active Comparator, Experimental, Experimental",Biological,Single Group Assignment,Phase 2,Yes,No,16
2018-05-0009,Living Well After Breast Surgery,844 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,17
DCIS Cryo,Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ,1826 days,Recruiting,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,30
STU00214745,Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage,354 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,30
ENTheR,Exploratory Study on Therapy for Breath Hold in Radiotherapy,260 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,20
Michal Nissim 2,"Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients",1612 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,150
IUSCC-0533,Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias,0 days,Withdrawn,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 2,Yes,No,0
Version 1.1.6,Magnetic Occult Lesion Localization and Imaging (MOLLI),583 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,20
GALENO 1,Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies,804 days,Unknown status,Interventional,"Experimental, Experimental, Experimental","Dietary Supplement, Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,60
MMSTD1Pecs2,Establishing Technique for PECS2 Catheter Insertion,394 days,Completed,Interventional,"Other, Other","Procedure, Procedure, Other",Parallel Assignment,Not Applicable,No,No,80
875329,Training Data Collection & AI Development,253 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,20
ST-067-001,"Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067",1273 days,Recruiting,Interventional,"Experimental, Experimental",Biological,Sequential Assignment,"Phase 1, Phase 2",Yes,No,198
H-40045,Scalable Communication Modalities for Returning Genetic Research Results,453 days,Recruiting,Interventional,"No Intervention, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,2275
SYSKY-2023-122-02,Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge,455 days,Recruiting,Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,60
KOU KAEK 2018/487,Comparison of Bi-level Erector Spine Plane Block and Combined Pectoral I-II Block in Breast Surgery,380 days,Completed,Interventional,"Experimental, Experimental","Other, Other",Crossover Assignment,Not Applicable,No,No,70
TREM-1,Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis,1005 days,Recruiting,Interventional,"Other, Other, No Intervention, No Intervention, No Intervention",Biological,Parallel Assignment,Not Applicable,No,No,20
RC31/17/0335,Quality of Life in Patients With Standard External Compared to Custom-made Breast Prosthesis.,369 days,Unknown status,Interventional,"Other, Other","Device, Device",Crossover Assignment,Not Applicable,No,No,64
201912245RINB,Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia,2109 days,Not yet recruiting,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,30
CUT_DN_02,Prevention of Radiodermatitis in Breast and Head and Neck Cancer Patients in Cyprus,182 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,100
PKUPH10B001,Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physicians Choice,731 days,Unknown status,Interventional,"Active Comparator, Experimental",Combination Product,Parallel Assignment,Early Phase 1,No,No,200
19.58/ONCO19.08,PBMT for the Management of CIA ( HAIRLASER ),927 days,Recruiting,Interventional,"Active Comparator, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,30
CCS1477-01,Study to Evaluate CCS1477 in Advanced Tumours,2048 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,350
CO-338-098,A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR),1029 days,Terminated,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,25
UBP-A103-HER2,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers",393 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Active Comparator","Biological, Biological",Sequential Assignment,Phase 1,No,No,18
UMCC 2021.071,Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study,167 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,18
Pro00040035,Home-Based Physical Activity Intervention for Taxane-Induced CIPN,1508 days,Recruiting,Interventional,"Experimental, Active Comparator",Behavioral,Parallel Assignment,Not Applicable,No,No,312
18-6047,The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease,1451 days,Recruiting,Interventional,"Experimental, Experimental",Radiation,Single Group Assignment,Not Applicable,No,No,100
PI2018068,Peer Support Program in Cancer Patients Elkar Laguntza,1308 days,Recruiting,Interventional,"Experimental, Experimental",Behavioral,Crossover Assignment,Not Applicable,No,No,120
Metimedi-202,OMT-111 for Terminal Stage Solid Tumors,730 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,78
CBCSG-040,Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA),2014 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,450
NUV-422-02,Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors,631 days,Terminated,Interventional,"Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,72
UBT 2022-01,A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection,510 days,Recruiting,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,No,600
2020-A01534-35,A Proximity-incentive Strategy for Cervical Cancer Screening,1262 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,600
181367,Physical Activity Intervention for Young Cancer Survivors,395 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,34
PRO00041443,Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction,1583 days,Recruiting,Interventional,"Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,80
METCZ20190024,The Risk of Postoperative Wound Complications Following the Use of Negative Pressure Wound Therapy in Patients Undergoing Mastectomy,367 days,Completed,Interventional,"No Intervention, Experimental",Device,Single Group Assignment,Not Applicable,No,No,162
22-01024342,Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation,2071 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator",Radiation,Parallel Assignment,Phase 3,No,Yes,380
SY-5609-101,"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors",1621 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,160
MCC-20487,Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease,1422 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Radiation, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,39
2022/73,The Effect of the Motivational Interviewing Technique on Breast and Cervical Cancer Screenings,183 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,120
TBMZ-Radio-boron gel,Preventive Effect of Boron-based Gel on Radiation Dermatitis,320 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,257
BT5528-100,Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression,1881 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,288
REaCT-TEMPO,Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance,2192 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 4,No,No,240
SYSKY-2022-117-01,Endoscopic Breast Conserving Surgery With Intra-operative Navigation System,1065 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,41
PROT-P2-024,M5 vs. M6 Comparison Study With a Sub Study Into the Dielectric Constant of Aspirated Cyst Fluid,338 days,Completed,Interventional,"Other, Other",Device,Parallel Assignment,Not Applicable,No,No,22
2022-0454,Vapocoolant Analgesia for Breast Lymphoscintigraphy,183 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
Pro00101109,Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS),111 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,322
22-071,A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction,709 days,Recruiting,Interventional,"Experimental, Experimental","Procedure, Procedure",Parallel Assignment,Phase 3,No,No,352
ZL-2306-006,A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment,758 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,60
OTT-15-02,"Tumor Bed Dose Delivery Using A Breast Specific Radiosurgery Device, The Gammapod: (A Clinical Feasibility Study)",365 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,20
K 2020-9716,[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors,1134 days,Recruiting,Interventional,Experimental,"Diagnostic Test, Diagnostic Test",Single Group Assignment,Phase 2,No,No,72
NCC20180327,Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion,609 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Not Applicable,No,No,248
3121_MATFIH22,"First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Immediate Breast Reconstruction After Mastectomy for Cancer",1218 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,50
Modi-1-001,"Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer",1545 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Biological, Device",Parallel Assignment,"Phase 1, Phase 2",Yes,Yes,144
20-437,Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement,684 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,125
16-01,Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging,1087 days,Terminated,Interventional,Experimental,"Radiation, Drug",Single Group Assignment,"Phase 2, Phase 3",No,Yes,21
IEO 1002/,Evaluation of the Effectiveness of Prepectoral Breast Reconstruction,1580 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,58
3271,PBI for Breast In Situ Carcinoma of Intermediate Low Risk as Local Adjuvant Treatment,2518 days,Recruiting,Interventional,Experimental,"Radiation, Radiation",Single Group Assignment,Not Applicable,No,No,150
21-559,Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study,823 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,135
LCCC2139,Comparison of CE-DBT and MRI in Patients With Known Breast Lesions,568 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,20
NK-101,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,1062 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,44
1903399639,High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT),487 days,Not yet recruiting,Interventional,Experimental,"Diagnostic Test, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,Yes,100
MCC-19-15167,Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video,790 days,Recruiting,Interventional,"No Intervention, Active Comparator",Behavioral,Parallel Assignment,Not Applicable,No,No,70
CASE5117,Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive,304 days,Withdrawn,Interventional,"Active Comparator, Experimental, Active Comparator","Device, Device, Other",Parallel Assignment,Not Applicable,No,Yes,0
CASE10117,Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction,824 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,0
Medipol Hospital 18,ESPB and RIB for Pain Management Following Mastectomy Surgery,307 days,Completed,Interventional,"Active Comparator, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,60
18-431,Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung,1811 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Radiation, Drug",Parallel Assignment,Phase 2,Yes,No,107
SPI-POZ-203,A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies,827 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 2,Yes,No,1
STUDY21070030,CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study,1734 days,Recruiting,Interventional,Experimental,"Device, Drug",Single Group Assignment,Phase 4,Yes,Yes,1855
E2018124,Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients,1233 days,Unknown status,Interventional,"No Intervention, Experimental, Experimental",Drug,Parallel Assignment,Not Applicable,No,No,291
2140-002,A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002),1042 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,210
21-288,A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer,1096 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,150
RadOnc,Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy,883 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,150
INX-315-01,"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer",1161 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,81
JSKN003-101,First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors,850 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,No,No,45
228012,Impact of Topical Tranexamic Acid in Breast Reconstruction,550 days,Recruiting,Interventional,Experimental,"Drug, Other",Single Group Assignment,Phase 4,Yes,No,150
20-275,Testing a New Imaging Agent to Identify Cancer,1461 days,Recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 1,Yes,No,20
IGAR-TO-007,IGAR-Breast TeleOp Trial,364 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,10
Laser LabCorp #001,Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics,322 days,Suspended,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,100
2020-04936,Mammography Screening With Artificial Intelligence (MASAI),1461 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,100000
IRB-50877,Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution,334 days,Not yet recruiting,Interventional,Experimental,"Drug, Device",Single Group Assignment,Early Phase 1,Yes,Yes,20
PER-19-04,Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.,639 days,Recruiting,Interventional,"No Intervention, Experimental",Device,Parallel Assignment,Not Applicable,No,Yes,333
KL166-I-01-CTP,A Study of A166 in Patients With Advanced Solid Malignant Tumors,1970 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,No,No,120
PROTOCOL-P2-054,The ABC Study: Assessment of Breast Density Classification,257 days,Recruiting,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,No,800
254-18,Reconstructions With Back Donor Site Flaps and Validation of Quality of Life Scales,1978 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,550
B076201420067,Zhongnan Hospital of Wuhan University,656 days,Unknown status,Interventional,"Active Comparator, Experimental",Drug,Parallel Assignment,Not Applicable,No,No,124
MIP-2019-001,BIOpsychosocial Approach of the CAncer-RElated FAtigue (BIOCARE FActory),1247 days,Not yet recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,200
21051,Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults,310 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,75
DE-17-17,Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection,338 days,Completed,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,No,353
201701045,Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach,288 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other, Other",Parallel Assignment,Phase 1,No,No,120
E20210210,Breast Mesh Used in Two-staged Breast Reconstruction,1826 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,300
EMC-0124-18,Evaluation of the SmartBx System for Breast Biopsy,83 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,30
LYL797-101,A Study to Investigate LYL797 in Adults With Solid Tumors,1617 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,54
2834,TIVA Admnistration and Autologous Fat Transfer in Breast Reconstruction,211 days,Completed,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Not Applicable,No,No,46
IC 2021 07,Opioid Free Versus Opioid Based Anaesthesia for Secondary Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.,1194 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 3,No,No,158
GEN1B-01,Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications,742 days,Suspended,Interventional,"Active Comparator, Active Comparator","Device, Device",Sequential Assignment,Not Applicable,No,Yes,4
IIT2018-25-MITA-NEOBREADS,NEOBREADS: Neoadjuvant Breast Diet Study,880 days,Terminated,Interventional,Experimental,"Other, Drug",Single Group Assignment,Phase 1,No,No,2
2020-00493,Red Bull Energy Drink Intake After Autologous Microsurgical Breast Reconstruction,965 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,100
20210817-01H,TAP vs QL for Postoperative Analgesia After DIEP Free Flap Breast Reconstruction,334 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,46
CIRB Ref. No: 2019/2090,Accessible Cancer Care to Enable Support for Survivors Programme,731 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,226
20295,Dermacell ADM Without Basement Membrane,973 days,Unknown status,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,120
TO-TAS0728-101,A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities,1525 days,Terminated,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,19
124.03-2017-GES-0005,Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow,5 days,Completed,Interventional,Other,"Device, Device",Single Group Assignment,Not Applicable,No,Yes,36
IIT2018-21-AMERSI-BREADS,BREADS: Breast Adjuvant Diet Study,1427 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Drug",Parallel Assignment,Phase 2,No,No,40
3-2021-0468,Pectoralis Nerve Block and Quality of Recovery in Mastectomy Patients,1125 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Procedure, Other",Parallel Assignment,Not Applicable,No,No,156
IB 2019-01,Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors,1431 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,247
2022-010,F-Tryptophan PET/CT in Human Cancers,824 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,24
Reader-02 Study,Optoacoustic Images Versus Imagio® Ultrasound,96 days,Completed,Interventional,"Active Comparator, Experimental","Device, Device, Device",Sequential Assignment,Not Applicable,No,Yes,480
20-03,"A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy",531 days,Completed,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,Yes,60
YWBC-002,Prevention and Treatment of Pyrrolitinib-associated Diarrhea,1079 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, No Intervention","Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,470
2019-1176,Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction,809 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Procedure, Other, Other",Parallel Assignment,Not Applicable,No,No,40
2018-4107,Does a Preoperative Prophylactic Antibiotic Reduce Surgical Site Infection Following Wire-localized Lumpectomy,612 days,Completed,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Not Applicable,No,No,326
2021-0290,Effect of Neurotization on QoL and Sensory Restoration,275 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Phase 2,No,No,50
0180910/16,The Combination of PECS II Block and Parasternal Block for Radical Mastectomy,132 days,Completed,Interventional,Experimental,"Procedure, Drug",Single Group Assignment,Not Applicable,No,No,65
INTRUSION,INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701,820 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,60
R.22.09.1830,Comparison of Analgesic Efficacy of Ultrasound Guided Rhomboid Intercostal Block Versus Serratus Anterior Plane Block for Mastectomy Surgery,120 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,"Phase 2, Phase 3",No,No,60
SCOUT2021,Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc ),700 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,500
PROICM 2019-07 PRE,Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction,2363 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,250
2022-A01940-43,Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL,549 days,Not yet recruiting,Interventional,"Placebo Comparator, Experimental","Drug, Other",Parallel Assignment,Phase 2,No,No,60
Reader-01,"Imagio Feasibility Multi-Reader, Multi-Case Study",26 days,Completed,Interventional,"Active Comparator, Experimental","Device, Device, Device",Sequential Assignment,Not Applicable,No,Yes,155
STUDY00025461,Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms,67 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Other, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,44
19D.203,Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings,948 days,Completed,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,107
BCD-178-1,"A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers",541 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 1,No,No,100
SHR6390-I-114,Study of SHR6390 in Renal Insufficiency and Healthy Subjects,284 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 1,No,No,30
2204MDJ,Testing Video Information About Mammography Screening,44 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,400
mastectomy regional anesthesia,Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection,1035 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Phase 3,No,No,13
PECS 2019,The Analgesic Efficacy of the Pectoral Nerves Block Versus Local Anesthetic Infiltration After Mastectomy,607 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Phase 4,No,No,50
R-2017/UEM11,Acute Effect of Chromatic Environment During Chemotherapy,975 days,Unknown status,Interventional,"Experimental, Experimental, Experimental, Experimental","Other, Other",Crossover Assignment,Not Applicable,No,No,20
IBIO-302,Food Effect Study of D-0502 Tablet in Healthy Volunteers,176 days,Completed,Interventional,"Experimental, Experimental",Drug,Crossover Assignment,Phase 1,Yes,No,14
LAE203CN2101,PhI to Solid Tumors and PhII to Locally Advanced or mTNBC,1144 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator, Placebo Comparator","Combination Product, Combination Product, Combination Product, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,101
SN132D CSP final version 6.0,A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer,1195 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,14
2022-1151,Implementation of Population Breast Cancer Genetic Services in Federally Qualified Health Centers (FQHC),1583 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,130
NINTAU,ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence,975 days,Completed,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,85
21-002713,3D Ultrasound Microvessel Imaging for Breast Masses,975 days,Recruiting,Interventional,Experimental,"Other, Procedure",Single Group Assignment,Early Phase 1,No,Yes,50
LIVFOU-930411,Pectoral Nerves Block vs Wound Infiltration for Partial Mastectomy - a Prospective Randomized Trial.,436 days,Completed,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure, Procedure, Drug, Device",Parallel Assignment,Not Applicable,No,No,60
21-BI-1607-01,BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors,1587 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,116
20-378,Researching the Effect of Exercise on Cancer,1461 days,Recruiting,Interventional,"Experimental, Experimental",Other,Sequential Assignment,Not Applicable,No,No,70
2019-A0872-55,Study on Skin Toxicities Induced by Cancer Treatments,1338 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,300
CAAA504A12101,Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.,757 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Early Phase 1,Yes,No,80
D6900C00001,First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies,1351 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,198
HNCH-BC004,A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity,601 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 2,No,No,159
20200491,Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences,1279 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,40
PRO2021-1428,Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer,1825 days,Not yet recruiting,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,91
ZN-A-1041-101,Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors,1354 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,No,No,84
HCC 21-265,"Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community",1176 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,5
HNCH-BC007,GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel,712 days,Withdrawn,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 2,No,No,0
2020-0498,Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome,0 days,Withdrawn,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Other, Other",Parallel Assignment,Not Applicable,No,Yes,0
NBE-002-01,NBE-002 in Patients With Advanced Solid Tumors,1991 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,100
1B-22-2,"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",1096 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Drug, Radiation, Biological",Sequential Assignment,Phase 1,Yes,No,18
PROT002 - Test Plan 01 Rev A,Blue Note Therapeutics Product BNT 103 Usability and User Engagement,121 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,15
Gen 2 - 01,Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System,182 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,38
PROT001,Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment,474 days,Terminated,Interventional,"Active Comparator, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,31
MW05-2020-CP301,Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF,775 days,Completed,Interventional,"Experimental, Experimental, Active Comparator","Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",No,No,586
BYON5667.002,Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985,1086 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,48
UZBRU_VHH2_1,Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT,1243 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",No,No,37
19-007547,"Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial",1582 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,40
Pro00092817,VR Ultrasound Guided Breast Localization,359 days,Completed,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,60
Pro00112215,The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures,381 days,Enrolling by invitation,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,60
5R44CA203608,LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge),1207 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Procedure",Parallel Assignment,Not Applicable,No,Yes,60
M16-573,A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors,1752 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,169
ACROPOLI (SOLTI-1904),Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors,1339 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,73
NL52329.075.15,Intra-individual Comparison of Conventional and Digital PET/CT Scanners,613 days,Completed,Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,225
AAAT2490,AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc,1673 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator","Other, Other, Other, Other",Factorial Assignment,Not Applicable,No,No,240
CMP-001-009,A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer,1923 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,200
SS-SP01-201904,Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents,896 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,60
5890-001,Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001),2441 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Biological, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,202
H19-03343,Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy,1664 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,220
BPI-2358-106 phase 3,Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia,2164 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Drug, Drug, Other, Drug",Parallel Assignment,Phase 3,Yes,No,221
EK 1623/2020,Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection,1248 days,Recruiting,Interventional,"Other, Other","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,100
TRX518-004,A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors,421 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,10
20200110,Study of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer Patients,636 days,Recruiting,Interventional,"Sham Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,No,130
ASPB vs ESBP for mastectomy,Comparison Between Serratus Anterior Plane Block and Erector Spinae Plane Block for Mastectomy,303 days,Completed,Interventional,"Active Comparator, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,25
2018-01,Quantitative Evaluation of the Breasts Morphological Variations During Radiotherapy: MorphoBreast3D,805 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,60
TYKM1602101,A Study of TY-302 in Patients With Advanced Solid Tumors,1089 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,60
BrUOG 351,BrUOG 351: PRE-OPERATIVE APBI USING NIBB,326 days,Withdrawn,Interventional,Experimental,"Radiation, Procedure",Single Group Assignment,Not Applicable,No,No,0
KL264-01,"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies",2103 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,430
Medipol Hospital 26,Different Volumes of Erector Spinae Plane Block for Breast Surgery,427 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Not Applicable,No,No,60
NeoVAB,Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB),815 days,Unknown status,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,67
16-136,Ipilimumab and Nivolumab in Leptomeningeal Metastases,1253 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,18
SGN228-001,A Study of SGN-CD228A in Advanced Solid Tumors,1283 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,88
1612017795,Web-based Family History Tool,1209 days,Completed,Interventional,"No Intervention, Experimental, Experimental",Other,Single Group Assignment,Not Applicable,No,No,250
7902-005,Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005),1774 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Biological, Drug",Parallel Assignment,Phase 2,Yes,No,590
UUBreast02,PREMs on PROMs in Breast Disease (PREMs_PROMs),607 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Phase 3,No,No,230
2021-0842,Single Step Lesion Annotation and Localization of Suspicious Breast Lesions,569 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Early Phase 1,No,Yes,100
GN19HS442,Augmented Reality (AR): The Future of Patient Information Leaflets,485 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Crossover Assignment,Not Applicable,No,No,20
MCC-21622,Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies,1085 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Biological",Sequential Assignment,Phase 1,Yes,No,88
SIBP-03-01,A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.,1095 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,68
IRB00047335,Speeding Recovery From Pain and Opioid Use,578 days,Withdrawn,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Early Phase 1,Yes,No,0
217510,Microbiome and Association With Implant Infections,1555 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,Yes,No,200
RIN20230039,Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure,276 days,Not yet recruiting,Interventional,"Experimental, Experimental",Behavioral,Sequential Assignment,Not Applicable,No,No,30000
UI/EC/20/0275,The Effect of Octreotide on Wound Drainage After Mastectomy,349 days,Completed,Interventional,"Active Comparator, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 4,No,No,41
AB-201-01,A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors,1492 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,133
IOM-040369,Patient Preference for Pegfilgrastim (Neulasta®) Application Forms,442 days,Completed,Interventional,"Experimental, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,404
233,Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting,608 days,Unknown status,Interventional,"Active Comparator, Sham Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,30
TQB3616-I-02,Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects,55 days,Completed,Interventional,"Experimental, Experimental",Drug,Crossover Assignment,Phase 1,No,No,16
MAR-BAS-18-005,The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy,1394 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,No,No,384
107709,Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women,281 days,Terminated,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,Yes,3
20-1456,Improving Cancer Screening and Follow-up in Community Health Centers,182 days,Not yet recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,15
UTN: U1111-1278-1680,CPAP for Motion Management in Breast Radiotherapy; and Lung & Liver SABR,365 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,70
19-104,The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting,791 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Placebo Comparator",Other,Parallel Assignment,Not Applicable,No,No,144
MASCT-I-1003,A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor,804 days,Unknown status,Interventional,Experimental,"Biological, Drug",Single Group Assignment,Phase 1,No,No,28
REC/RCR&AHS/22/0511,Effects Of Lymphatic Drainage on Axillary Web Syndrome,265 days,Recruiting,Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,20
18-264,Enhancing Cancer Prevention and Control Pathways-Native Health Initiative,913 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Crossover Assignment,Not Applicable,No,No,200
KY20202093-F-1,Clinical Study of 68Ga Labeled HER2 Affibody Analogues,548 days,Not yet recruiting,Interventional,,Drug,Single Group Assignment,Early Phase 1,No,No,56
2021-0262,Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study),632 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,80
262180,Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane,1356 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 1,Yes,No,25
H18-02014,CARA Treatment Pilot Study for Breast Positioning,406 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,20
IRB19-2074,Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine),992 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,50
TG1819ONC,A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors,1350 days,Recruiting,Interventional,Experimental,"Biological, Biological, Biological, Biological, Biological, Biological, Biological",Sequential Assignment,"Phase 1, Phase 2",No,No,233
STUDY00018917,The PAI Trial for Breast and Colon Cancer Survivors,0 days,Withdrawn,Interventional,"No Intervention, Experimental",Combination Product,Parallel Assignment,Not Applicable,No,No,0
STUDY00002789,CONTIGO - Informing Latinas About HBOC Risk,1674 days,Enrolling by invitation,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,332
S66520,Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors,1070 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Sham Comparator",Device,Parallel Assignment,Not Applicable,No,No,162
P.T.REC/012/002677,Effectiveness of Low Level Laser Therapy on Insulin Resistance and Inflammatory Biomarkers,1157 days,Recruiting,Interventional,"Active Comparator, Sham Comparator","Device, Other",Crossover Assignment,Not Applicable,No,No,60
ISPY-P1.01,ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer,112 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,0
NCI-2017-01921,Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery,1575 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Other, Other",Parallel Assignment,Phase 1,Yes,No,33
"2016-051-000001, 1835",Investigating Public Enthusiasm for Mammography Screening in Denmark,59 days,Completed,Interventional,"Other, Other",Behavioral,Parallel Assignment,Not Applicable,No,No,768
CF21163B,Clinical Outcome of Extracorporeal Shock Wave Therapy in Patient With Axillary Web Syndrome,1053 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,30
D-FR-01072-002,"Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)",149 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,9
Breast-Nektaria,The Impact of Pecs Blocks on Postmastectomy Pain Syndrome,607 days,Completed,Interventional,"Active Comparator, Sham Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,64
1413727,An Intimacy Intervention for Couples Completing Breast or Prostate Cancer,388 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,14
20200426,Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants,31 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Crossover Assignment,Phase 1,Yes,No,13
VALO-001,START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer,333 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,No,No,15
IMU R204/2017,Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients,917 days,Completed,Interventional,"Active Comparator, Active Comparator, Active Comparator","Dietary Supplement, Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,91
LCCC1915,3-D Super Resolution Ultrasound Microvascular Imaging,859 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Device",Single Group Assignment,Phase 2,Yes,Yes,45
RiphahIU Shafaq,Effects of Active Release Technique (ART) on Pectoralis Minor Tightness in Post Mastectomy Women.,158 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
CRX100-001,Study of CRX100 in Patients With Advanced Solid Tumors,1513 days,Recruiting,Interventional,Experimental,Biological,Sequential Assignment,Phase 1,Yes,No,24
HREBA.CC-20-0077,Time-restricted Eating in Survivors Trial,357 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,22
TST-9-H,Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors,426 days,Withdrawn,Interventional,"Experimental, Active Comparator","Biological, Drug",Parallel Assignment,Phase 1,No,No,0
OCOG-2022-RAPID2,A Randomized Trial of Five Fraction Partial Breast Irradiation,3195 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Phase 3,No,No,910
20181004,Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer,462 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,28
18-571,EHR-embedded OCDT in Breast or GI Cancer,986 days,Completed,Interventional,"Other, Other","Other, Other",Sequential Assignment,Not Applicable,No,No,100
R19-159,Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction,807 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,20
2018B0521,Southeast Asian Womens Health Project,1050 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,540
287482,ARTISS a Single-centre Randomised Control Study,546 days,Recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Other",Parallel Assignment,Phase 4,No,No,138
HR-BLTN-DDI-07,Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects,147 days,Completed,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,No,No,36
201612723,NR in Chemo-induced Peripheral Neuropathy,839 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,5
AWS,Effects of a Manual Therapy Program to Reduce the Evolution Time of Axillary Web Syndrome,733 days,Recruiting,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,46
2022-0328,"Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics",190 days,Recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,1000
20/007-E_TFM,Study of the Effectiveness of Supervised vs. Non-Supervised Therapeutic Exercise in Cancer Patients,518 days,Unknown status,Interventional,"Experimental, Active Comparator",Behavioral,Parallel Assignment,Not Applicable,No,No,58
Internal Code 012-23,"STUDY OF THE EFFECTIVENESS AND SAFETY OF SUPERVISED THERAPEUTIC EXERCISE IN CANCER PATIENTS WITH AND WITHOUT SIMULTANEOUS CHEMOTHERAPY, RADIOTHERAPY OR HORMONAL TREATMENT.",823 days,Not yet recruiting,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,78
0352-2189,"A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis",412 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,30
HCI128055,[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma,1297 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,79
180097,Olaparib in People With Malignant Mesothelioma,833 days,Completed,Interventional,Experimental,"Drug, Device",Single Group Assignment,Phase 2,Yes,Yes,23
190134,Vaccine Response With NT-I7,757 days,Recruiting,Interventional,"Experimental, Active Comparator, Active Comparator","Biological, Biological, Biological",Sequential Assignment,Phase 1,Yes,No,68
TH1902-CTR-0001,TH1902 in Patients With Advanced Solid Tumors,727 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,70
18112,64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy,758 days,Recruiting,Interventional,Experimental,"Procedure, Drug, Other, Procedure",Single Group Assignment,Early Phase 1,Yes,No,6
KY20172047-1,Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction,2710 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Phase 1,No,No,30
mRNA-2752-P101,Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies,2317 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Biological",Parallel Assignment,Phase 1,Yes,No,264
1380800-R,Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments,615 days,Recruiting,Interventional,"Active Comparator, Experimental, Other","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,123
7621,Opening the Conversation Study,1217 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,200
TomBakerCC,Mobile App Postoperative Home Monitoring After Enhanced Recovery Oncologic Surgery,676 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,72
SVIFT Nodal Trial,Breast Fractionation Study - Standard Versus Investigational Fractionation Trial - Nodal Radiation,2404 days,Recruiting,Interventional,"Active Comparator, Other",Radiation,Factorial Assignment,Not Applicable,No,No,132
CASE1Z21,Patient Recall of Cancer Screening and Diagnosis,366 days,Recruiting,Interventional,"No Intervention, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,100
IRB00075787,Mastectomy Flap Temperature Study,367 days,Recruiting,Interventional,Experimental,"Other, Other",Single Group Assignment,Not Applicable,No,No,30
HB-AT-001,Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan,1098 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,14
ART4215C001,A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors,1418 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,330
Duke-NUS,Marital Satisfaction and Sexual Health of Female Cancer Patients in Singapore,1338 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,60
SKNA pilot,Measurement of the Skin Sympathetic Nerve Activity,62 days,Completed,Interventional,"Active Comparator, No Intervention",Drug,Parallel Assignment,Not Applicable,No,No,20
IIT2018-05-ASHER-IMPROV2,LOL: Its All Improv After Cancer!™,2160 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,13
OU-SCC Virtual Reality,Virtual Reality Software to Reduce Stress in Cancer Patients,731 days,Not yet recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,20
2020-A03205-34,"Meditation and Cancer, Pilot Feasibility Study (MAEva Pilot Study)",456 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,40
OPERA2,Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA),365 days,Completed,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,53
201907039,RANKL Inhibition and Mammographic Breast Density,2561 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug, Drug, Drug, Procedure, Procedure",Parallel Assignment,Phase 2,Yes,No,210
TaiHao BR-USCAD VT 20-249,Evaluation of TaiHao Breast Ultrasound Diagnosis Software,78 days,Completed,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator","Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test",Crossover Assignment,Not Applicable,No,Yes,16
UMCC 2021.004,Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors,453 days,Completed,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,30
UPMREB 2021-140-01,Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis,456 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Phase 2,No,No,54
KS01,Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery,153 days,Completed,Interventional,"Active Comparator, Active Comparator",Drug,Parallel Assignment,Phase 4,No,No,70
MS-268-2019,Effectiveness of Ultrasound Guided Erector Spinae Plane Block Against Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy,131 days,Completed,Interventional,"Experimental, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,60
BoCCE,Biopsy of Calcifications Under Contrast Enhancement Guide (BoCCE),495 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,200
875329B,Real-Life Pilot Feasibility Study (LC_RLP_PUC1),273 days,Recruiting,Interventional,"Experimental, Experimental","Device, Device",Single Group Assignment,Not Applicable,No,No,120
MS-536-2021,Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy,455 days,Completed,Interventional,"Experimental, Experimental, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,90
Gyn F-Chem,Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy,1369 days,Terminated,Interventional,"Experimental, Experimental, Placebo Comparator",Other,Parallel Assignment,Not Applicable,No,No,81
PROICM 2019-06 COH,Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session,700 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,53
D3614C00004,A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body,52 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,11
1449,Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction,1591 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,56
CHD22_0002,Interest of Virtual Reality on Anxiety Before the Planning CT Scan in Radiotherapy,666 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,256
CLINP-001001,Motiva Flora Tissue Expander PMCF,913 days,Recruiting,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,No,136
17-VIN-0855,A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition,184 days,Unknown status,Interventional,"Experimental, Active Comparator","Drug, Drug",Crossover Assignment,Phase 1,Yes,No,45
2019-0557,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,85 days,Completed,Interventional,Experimental,Diagnostic Test,Sequential Assignment,Early Phase 1,Yes,Yes,10
D0817C00098,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib,1618 days,Enrolling by invitation,Interventional,Experimental,Drug,Sequential Assignment,Phase 3,Yes,No,292
2017-377,The Effect of Double Injection Erector Spinae Plane Block on Postoperative Pain Following Breast Surgery,32 days,Completed,Interventional,"Active Comparator, Sham Comparator","Other, Device",Crossover Assignment,Not Applicable,No,No,50
IZKSZ3_188408 / 1,The DIALOGUE Study: Swiss-Korean Billateral Collaboration,991 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,228
2018-94,Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Breast Surgery,145 days,Completed,Interventional,"Active Comparator, Active Comparator, Other","Device, Other, Other",Crossover Assignment,Not Applicable,No,No,75
ORIN1001-C1,Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.,1094 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,350
UMCC 2020.041,Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias,656 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,44
H-42207 GAIL-N,C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N),7162 days,Recruiting,Interventional,"Experimental, Experimental",Genetic,Single Group Assignment,Phase 1,Yes,No,94
Esogu Anesthesia,Comparison of Erector Spina Plane Block and Thoracic Epidural Block,79 days,Completed,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,20
TED16925,Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors,1537 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,200
Telerehab CH Feasibility,Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study,233 days,Recruiting,Interventional,"Experimental, Sham Comparator","Device, Other",Parallel Assignment,Not Applicable,No,No,40
RPC006,A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.,919 days,"Active, not recruiting",Interventional,"Other, Placebo Comparator, Active Comparator, Other, Placebo Comparator, Active Comparator, Other, Placebo Comparator, Active Comparator","Dietary Supplement, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,90
BEX15859,"Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women",65 days,Completed,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 1,No,No,6
waitingroom,Anxiety on the First Day of Chemotherapy,487 days,Unknown status,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,106
CP-10-001,In Vivo Smart Biopsy Device Protocol In Radiology,383 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,41
REB16-1463,Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors,822 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,"Phase 2, Phase 3",No,No,128
UF-STO-ETG-003,Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,1124 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,29
UMCC 2020.157,Lighting Intervention for Cancer-related Fatigue,655 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,138
OnkoFit II,Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy,1826 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,201
R7075-ONC-2009,REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors,1927 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,434
CART-TnMUC1-01,A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers,6231 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Biological, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,112
PT06-01,A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors,485 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,60
2019/2944,Cryotherapy in Breast B3 Lesions,395 days,Recruiting,Interventional,,Procedure,Single Group Assignment,Not Applicable,No,No,12
SPI-POZ-501,A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib,2739 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,20
LCB-1801-001,A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers,1250 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,40
PECS vs SAP,Comparing the Quality of Analgesia With Pectoral Nerve Block and Serratus Plane Block in Modified Radical Mastectomy,120 days,Completed,Interventional,"Active Comparator, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,50
2020-000495-37,"Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer",676 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Early Phase 1,No,No,6
2018-0175,Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo,884 days,Unknown status,Interventional,"Experimental, Active Comparator, Placebo Comparator","Drug, Drug, Other",Parallel Assignment,Phase 2,Yes,No,100
012018CONTROL,Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines,1519 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,80
R19258,The LYSA (Linking You to Support and Advice) Trial,902 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,200
2020/03FEV/065,Mechanically-Assisted and Non-Invasive Ventilation for Breathing-related Tumor Motion Mitigation.,819 days,Unknown status,Interventional,"Active Comparator, Experimental, Experimental, Experimental, Other","Device, Other",Parallel Assignment,Not Applicable,No,No,241
2012-001-108,Ramosetron on Late PONV (Postoperative Nausea and Vomiting),318 days,Completed,Interventional,"No Intervention, Experimental, Experimental",Drug,Parallel Assignment,Phase 4,No,No,144
HREC/74777/Alfred-2021,Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial,2015 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,4300
7905,Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief,758 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,40
ARX788-1711,"A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)",2082 days,"Active, not recruiting",Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,106
69HCL18_0492,Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture),656 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,132
BB-1701-101,A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors,1221 days,Recruiting,Interventional,"Other, Experimental, Experimental, Experimental, Experimental",Drug,Single Group Assignment,Phase 1,Yes,No,208
D9720C00001,Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies,1890 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,559
XuanWuH-NK,Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells,1435 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,200
FPX-01-01,A Phase 1/2 Study of [225Ac]-FPI-1434 Injection,2692 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Biological, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,253
RAPA-201-STP-01,RAPA-201 Therapy of Solid Tumors,1248 days,Recruiting,Interventional,Experimental,"Biological, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,22
HC-404-FCP-2011,A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD),1004 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,36
assuitu faculty of medicine,Outcomes of Breast Conservative Surgery for Post Chemotherapy Tumour Size After Response to Neoadjuvant Chemotherapy,1279 days,Recruiting,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,1
STUDY00015358,Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact,1429 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,30
ONCX-NAV-G201,A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors,863 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Biological, Biological",Parallel Assignment,Phase 2,Yes,No,180
CRUKD/22/002,HMBD-001 in Advanced HER3 Positive Solid Tumours,1756 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",No,No,135
042201,Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted,1624 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,60
DCC-2036-01-004,A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors,1399 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,117
NM1F-T1-01,"A First-in-human, Phase I, Open-label, Multicenter Study of NM1F Administered as Monotherapy and in Combination With Pembrolizumab to Patients With Advanced Solid Tumors.",1280 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,38
213409,A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study,1672 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,26
ICO-2020-06,Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ,4562 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,262
OMO-103-01,"Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours",1313 days,"Active, not recruiting",Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,22
849679,RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR),658 days,Recruiting,Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,150
UC-0101/1709,Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours,2385 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",No,No,150
ZN-A-1041-101-US,A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors,1141 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,210
UW21084,Self-administered Acupressure to Improve Cancer-related Fatigue Among Cancer Patients Undergoing Chemotherapy,1065 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,138
TAEK-VAC-HerBy-001,TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer,2121 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Biological,Sequential Assignment,Phase 1,Yes,No,55
C4161001,PF-07104091 as a Single Agent and in Combination Therapy,1939 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,320
MORAb-202-G000-201,"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types",1698 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,55
18-27025,SCOPE-Chinese Women Study,528 days,Completed,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,40
19-652,"Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers",1491 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,220
BESTa,"Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs",671 days,Recruiting,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,No,220
SOLTI-1804,HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a),1829 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,180
M19-037,"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors",1636 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,150
2020-00256; ch18Weber4,Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC,4599 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,372
OSU-21313,A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer,1000 days,Recruiting,Interventional,Experimental,"Behavioral, Other",Single Group Assignment,Not Applicable,No,No,225
AN0025S0103,AN0025 and Pembrolizumab Combination in Advanced Solid Tumors,1926 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,84
Medipol Hospital 9,Pectoral Nerve Block Type-II and Rhomboid Intercostal Block for Pain Management Following Mastectomy Surgery,334 days,Completed,Interventional,"Active Comparator, Active Comparator, No Intervention","Other, Other",Parallel Assignment,Not Applicable,No,No,90
69HCL18_0369,Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients,3318 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,410
200023,Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors,1160 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,64
CHANCES-IPC 2021-008,A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors,887 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,27
17-694,Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia,414 days,Terminated,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,5
SLS17-201/MK3475-770,Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers,1402 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,90
AP2207-30110,Dexmedetomidine vs Dexamethasone as Adjuvant to Bupivacaine in Bilevel Erector Spinae Plane Block in Breast Surgeries,379 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental","Procedure, Procedure, Procedure, Drug",Parallel Assignment,Not Applicable,No,No,60
2015-KAEK-64-22-09,High Intensity vs Low Intensity Resistive Exercise In Patient With Upper Extremity Lymphedema,84 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,36
FZPL-Ⅲ-301-OC,A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients,1341 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,252
2022-0329,Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.,194 days,Recruiting,Interventional,"Other, Other","Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,1000
CLODIS,Local Compression Seroma DIminution Objective (CLODIS),683 days,Unknown status,Interventional,"Experimental, Active Comparator","Device, Procedure",Parallel Assignment,Phase 3,No,No,60
KE-0254/92/2018,ESP in Breast Surgery Due to Cancer,197 days,Completed,Interventional,"Placebo Comparator, Experimental, Sham Comparator","Procedure, Procedure, Procedure, Procedure, Drug, Drug",Parallel Assignment,Phase 4,No,No,75
G423 Multi TP,Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.,258 days,Completed,Interventional,,Other,Single Group Assignment,Not Applicable,No,No,51
2019-001982-34,Measuring Oncological Value of Exercise and Statin,1719 days,Not yet recruiting,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Drug, Other",Parallel Assignment,Phase 3,No,No,240
201803061RIND,Ventilation Efficacy of Size 3 or Size 4 I-gel in Female Patient Weighing 50 to 60 Kilograms,338 days,Unknown status,Interventional,"Active Comparator, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,98
192004,"KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",2288 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,Phase 1,Yes,No,42
22339,Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors,513 days,Not yet recruiting,Interventional,"Experimental, Experimental, Placebo Comparator","Drug, Drug, Drug, Other",Parallel Assignment,Early Phase 1,Yes,No,120
TAS2940-101,A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer,1354 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,42
Bio2738,Shoulder Rehabilitation Using a Mobile App Following Breast Reconstruction,368 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,48
20252,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,475 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,1
STM-IRB-22B-001,Development and Testing of a TTDSS for Cancer Patients,621 days,Recruiting,Interventional,"Experimental, No Intervention","Device, Device",Parallel Assignment,Not Applicable,No,No,136
21-5539,Rehabilitation for People With Advanced Cancer,515 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,117
2018-1361,Physical Activity Promotion for Breast and Endometrial Cancer Survivors,1515 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Other, Other, Other",Sequential Assignment,Not Applicable,No,No,323
MC1713,A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ,1522 days,Recruiting,Interventional,Experimental,"Biological, Biological, Procedure",Single Group Assignment,Phase 1,Yes,No,43
HREBA.CC-18-0028,The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery During Chemotherapy Treatment,2040 days,Recruiting,Interventional,"Experimental, Other",Behavioral,Parallel Assignment,Not Applicable,No,No,178
E-SN@P PROJECT-IPC 2017-029,Assessment of Outpatient Digital Follow-up of Patients Over 70 Years of Age Undergoing Chemotherapy Treatment,1095 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,119
PASCA,A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.,2678 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,858
H-49731,Improving Comprehensive Care of Cancer Patients,1157 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,340
BrUOG 390,BrUOG 390: Neoadjuvant Treatment With Talazoparib,2104 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,1
EC/2018/0315,Hormone Replacement Trial Against ALzheimers Disease,2084 days,Recruiting,Interventional,"Other, Other, Other, Other, Other, Other, Other, Other, Other, Other",Procedure,Parallel Assignment,Not Applicable,No,No,300
CIMS-2019-01,4FMFES-PET Imaging of Endometrial and Ovarian Cancers,1825 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,72
XL102-101,Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101),1329 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,298
Dnr 2019-04151,Exercise as Medicine for People With Cancer Sweden,1025 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,200
2021-001624-17,Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy,2105 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,390
GCO 21-0012,Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials,829 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,1705
2018-0004,Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery,1825 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,80
823981A,Oncology Episode Payment Model in Hawaii,2375 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,7
NIT-110 (KEYNOTE PNA60),NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors,1440 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,238
BT-001.01,A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors,1525 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Biological",Sequential Assignment,"Phase 1, Phase 2",No,No,48
Pro00106186,Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study),1045 days,Recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,50
Laser treatment,Laser Treatment of Genito-urinary Syndrome in Women,1552 days,Not yet recruiting,Interventional,"Active Comparator, Sham Comparator, Active Comparator, Sham Comparator, Active Comparator, Sham Comparator, Active Comparator, Sham Comparator","Procedure, Device, Device",Parallel Assignment,Not Applicable,No,No,160
PROICM 2017-05 BAL,Analysis of Circulating Tumor Markers in Blood,1826 days,Recruiting,Interventional,"Other, Other",Biological,Parallel Assignment,Not Applicable,No,No,620
Breast Biopsy,The Effect of Education Given at Different Times Before a Breast Biopsy,90 days,Completed,Interventional,"Experimental, Experimental, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,60
GOP,Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide,731 days,Unknown status,Interventional,"No Intervention, Experimental",Drug,Parallel Assignment,Phase 2,No,No,100
IRB00167074,Sensory Restoration After DIEP Flap Neurotization,1856 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,156
CDKY709A12101C,Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.,2201 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,99
IRB#21-001169,Postoperative Opt-In Narcotics Treatment in Breast,365 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,240
Pro00102260,Hypertension Management in Cancer Patients,1148 days,Suspended,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,40
19829,"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",1398 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,14
CE3220.,Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.,1461 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Device, Other",Parallel Assignment,"Phase 1, Phase 2",No,No,35
00011271,HeartPhone Cancer Survivors Trial 2019,618 days,Terminated,Interventional,Experimental,"Behavioral, Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,3
METCZ20220056,EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery,303 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Device,Single Group Assignment,Not Applicable,No,No,300
RC31/17/0350,Use of Compression Bandages in the Prevention of Post-mastectomy Lymphoceles,442 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,84
19-179,Acupuncture Pilot Study for Cancer-related Cognitive Function,1461 days,"Active, not recruiting",Interventional,"Experimental, Sham Comparator, Other","Other, Other, Other",Parallel Assignment,Phase 2,No,No,48
180276,Promotora Navigator - Culturally Appropriate Patient Navigator,130 days,Completed,Interventional,"Active Comparator, Experimental, Experimental","Behavioral, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,101
213353,Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer,832 days,Terminated,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,41
ebeddows,Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy,1637 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,40
IFCT-1703,Her2-positive Lung Cancer Treated With Dedicated Drug,1506 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,46
CS001-SA,Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia,367 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,24
MSK8/22,The Effect of Rhomboid Intercostal Block and Serratus Anterior Plane Block on Postoperative Respiratory Functions,61 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,64
JAB-2485-1001,JAB-2485 Activity in Adult Patients With Advanced Solid Tumors,1320 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,102
BA3021-001,CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2),1829 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Biological",Parallel Assignment,"Phase 1, Phase 2",Yes,No,420
2020-05-001B,Regional Anesthesia in Breast Surgery,364 days,Unknown status,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,120
PRT2527-01,A Study of PRT2527 in Participants With Advanced Solid Tumors,655 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,30
13104,Tranexamic Acid for Alloplastic Breast Reconstruction,731 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,106
RECHMPL22_0024,Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC),808 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,63
21-369,A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer,730 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,200
120134,NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT,1126 days,Not yet recruiting,Interventional,"Experimental, Active Comparator",Device,Parallel Assignment,Not Applicable,No,Yes,520
Pro00078230,Erector Spinae Plane Block Versus Paravertebral Block,1064 days,Completed,Interventional,"Active Comparator, Experimental","Procedure, Procedure, Drug, Drug, Drug",Parallel Assignment,Not Applicable,No,No,48
18-000948,Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.,991 days,Completed,Interventional,"Experimental, Placebo Comparator","Dietary Supplement, Other",Parallel Assignment,Not Applicable,No,No,40
20-08,Prospective Case Collection Study for New Mammography Technologies,1452 days,Recruiting,Interventional,"Other, Other",Device,Single Group Assignment,Not Applicable,No,Yes,5400
AP2001-50504,Erector Spinae Block Versus PECS Block Type II for Breast Surgeries,356 days,Completed,Interventional,"Active Comparator, Active Comparator",Other,Parallel Assignment,Not Applicable,No,No,60
FMBSURECS/30042019/Ali,Efficacy of Serratus Anterior Plane Block Mastectomy,208 days,Completed,Interventional,"Active Comparator, Active Comparator",Procedure,Parallel Assignment,Not Applicable,No,No,40
21-192,TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance),457 days,Completed,Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,30
SBT6290-101,A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors,30 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,0
CRYO for Mastectomy (DoD),Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy,1337 days,Enrolling by invitation,Interventional,"Active Comparator, Sham Comparator","Device, Device",Parallel Assignment,Not Applicable,No,Yes,216
FMASUMD45/2021,Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity,730 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,"Phase 2, Phase 3",No,No,100
PT3465,Effect of Thera Band Exercises on Adhesive Capsulitis Post Mastectomy,360 days,Completed,Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,70
Lishui Peoples Hospital,Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors,1052 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,30
HAN2014005-CT02,"Evaluation of the Efficacy and Safety of A High Molecular Weight, Natural Hyaluronic Acid Vaginal Gel in Women With Genitourinary Syndrome of Menopause",895 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,80
SHEBA-19-6136-RS-CTIL,Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors,1040 days,Unknown status,Interventional,"Active Comparator, Active Comparator",Combination Product,Sequential Assignment,Phase 1,No,No,30
GS-US-417-5937,Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants,70 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Crossover Assignment,Phase 1,Yes,No,27
2021/01159,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,1768 days,Not yet recruiting,Interventional,Experimental,"Device, Device, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,10
SOGUG-2016-A-IEC(PRO)-12,Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL),1556 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,16
PPP005-Ph2/3-01,Cannabis Oil and Radiation Therapy for the Management of Pain,261 days,Terminated,Interventional,"Experimental, Placebo Comparator","Radiation, Radiation",Parallel Assignment,Phase 2,No,No,100
AAAS9968,Hair Care Product Use Among Women Of Color,822 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,100
METCZ2019016,Seroma Reduction and Drain Free Mastectomy,1253 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,250
HSL 2016-83,Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.,731 days,Unknown status,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,60
IMM2902-101,"IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors",895 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,135
NOX66-005,A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors,856 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Radiation",Sequential Assignment,"Phase 1, Phase 2",Yes,No,70
CCR5063,Evaluation of an Educational Intervention for Women With Breast Pain,122 days,Unknown status,Interventional,Experimental,"Behavioral, Behavioral",Single Group Assignment,Not Applicable,No,No,15
BGB-3111-108,A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects,25 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,18
2020/14MAI/273,Serum Neurofilament Light (NFL) in Surgery Under General Anaesthesia (GA) Compared to Surgery With Hypno-analgesia (Hyp),910 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,100
B4T2-PRC-IIT-001,A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors,1569 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,36
PROACTIVE,"Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness",1477 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 4,No,No,160
875351,Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project,1063 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Phase 2,No,No,500
CX-839-011,Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors,436 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,33
16-010491,Preventing Lymphedema in Axillary Lymph Node Dissection,2123 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,264
INT17676,A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects,458 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,52
ESG401-101,Study of ESG401 in Adults With Solid Tumors,1295 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",No,No,177
GS-US-382-1587,Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels,439 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,45
20221202,Primary Lesion Treatment for Bone Metastases,1096 days,Not yet recruiting,Interventional,"Experimental, Experimental, No Intervention","Radiation, Procedure",Parallel Assignment,Not Applicable,No,No,400
KSCM-CRD-001,KeraStat(R) Cream for Radiation Dermatitis,209 days,Completed,Interventional,"Other, Experimental","Device, Other",Parallel Assignment,Not Applicable,No,Yes,25
201707042,Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography,2179 days,Recruiting,Interventional,"Experimental, Experimental",Device,Sequential Assignment,Not Applicable,No,Yes,335
201810102MINC,Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle?,714 days,Unknown status,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 4,No,No,300
1237087,A Mind-Body Intervention for Hot Flash Management,1720 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,232
P.T.REC/012/003747,Aerobic Training and Diet on the Immune System in Postmastectomy Patients Receiving Chemotherapy,312 days,Recruiting,Interventional,"Experimental, Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
GIHSYSU-26,"RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer",1106 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,29
GO-1,SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients Own Stem Cells,1418 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug, Device",Single Group Assignment,Phase 1,Yes,Yes,10
BRCA-ACP.2022,Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers,426 days,Not yet recruiting,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,200
JK08.1.01,"A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer",1222 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",No,No,149
NC762-01,A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors,1189 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,170
PARPA-293-001,Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors,1496 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,150
INT 36/18,Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients,1824 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,28
17237,HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases,1826 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,39
MER-XMT-2056-1,A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2,1012 days,Suspended,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,171
ZL-2306-912 ALTER-OC-02,Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors,698 days,Unknown status,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,No,No,52
CEP1:4/2016,BRCA Main Home Nutritional Intervention-random Study,730 days,Unknown status,Interventional,"Experimental, No Intervention",Dietary Supplement,Parallel Assignment,Not Applicable,No,No,300
Chemobrain Study,Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies,914 days,Not yet recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,60
XB002-101,Study of XB002 in Subjects With Solid Tumors (JEWEL-101),1218 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,524
KlusPharma,Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene,1599 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,49
AJIRB-MED-THE-18-236,Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG,869 days,Completed,Interventional,"Experimental, Experimental","Biological, Biological",Single Group Assignment,"Phase 1, Phase 2",No,No,24
JTU-6H-20210227001,Comparison Between IORT and Postoperative Radiotherapy in Breast Conserving Surgery,1460 days,"Active, not recruiting",Interventional,"Experimental, Active Comparator","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,80
69HCL22_0275,Control Cohort CTRL COH,1826 days,Not yet recruiting,Interventional,Other,Biological,Single Group Assignment,Not Applicable,No,No,350
REPLAMOD,Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated Carbon Dioxide (CO2) Laser Treatment,729 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,15
BTC-HER2,Trastuzumab in HER2-positive Biliary Tract Cancer,583 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,4
CASE2117,Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer,731 days,Withdrawn,Interventional,"Active Comparator, Active Comparator, Experimental","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,0
H-38855,Ruxolitinib for Premalignant Breast Disease,2425 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,100
4-2019-0648,Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy,981 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,34
TG-iConquerFear,Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors,884 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,540
TCM-padia001,Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine,365 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,30
GO43860,"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",1107 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,365
C/35/2017,MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour,1361 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,No,No,120
2018-003115-21,Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors,1556 days,Withdrawn,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,0
EC29,Auto-Adjustable MOBIDERM® Autofit NIGHT-time Compression Armsleeve in the Upper Limb LYMphedema in Maintenance Phase,1248 days,Recruiting,Interventional,"Placebo Comparator, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,88
2021/117,Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia,2864 days,Recruiting,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,72
Health consortium maresme,Use of Glubran 2 ® in Axillary Lymphadenectomy Without Drain,1522 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Sequential Assignment,Not Applicable,No,No,134
HS-10502-101,A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors,1279 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,318
STUDY00023183,Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer,530 days,Enrolling by invitation,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,25
DCC-2036-01-003,A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors,1473 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,201
E-19-3943,Erector Spina Plane Block Versus Deep Serratus Anterior Plane Block for Post Mastectomy Analgesia,234 days,Completed,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,80
CASE6118,Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling,1095 days,"Active, not recruiting",Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,30
MCART-006,Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases,793 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,58
PRO1184-001,PRO1184 for Advanced Solid Tumors,999 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,134
ONC-392-001,"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",1567 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,914
BPI-2358-105 phase 3,Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3,986 days,Completed,Interventional,"Active Comparator, Experimental","Drug, Drug, Other, Other",Parallel Assignment,Phase 3,Yes,No,105
HCC 20-064,Telehealth and Memory Study,1535 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,200
E-19-773,"A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan",1500 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention","Other, Other",Parallel Assignment,Not Applicable,No,No,60
STUDY00003387,Exercise and Nutrition Interventions During Chemotherapy K07,1874 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Phase 2,No,No,80
MCART-002,Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis,1025 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Early Phase 1,No,No,18
SBT6050-201,A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers,149 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,2
ARRAY-818-103,Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors,1944 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,56
MC210302,Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer,913 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Drug, Procedure",Single Group Assignment,Early Phase 1,Yes,No,40
QSPainRelief-patientCNS,"QSPainRelief-patientCNS : Clinical Biomarkers of Nociception, Sedation and Cognition",1295 days,Not yet recruiting,Interventional,Experimental,"Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Other",Single Group Assignment,Not Applicable,No,No,180
CARTIER,Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial),2312 days,Recruiting,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,514
The Swedish DIRECT study,Direct Information to At-risk Relatives,2155 days,Enrolling by invitation,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,490
CKAF156A2104,"Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir",222 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Combination Product, Drug, Drug, Drug, Combination Product",Sequential Assignment,Phase 1,No,No,48
Elasto Trial,Comparison of Real-time and Shear Wave Elastography,1766 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Diagnostic Test, Diagnostic Test",Sequential Assignment,Not Applicable,No,No,98
N201810002,Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients,398 days,Completed,Interventional,"Other, Experimental, Experimental",Dietary Supplement,Parallel Assignment,Not Applicable,No,No,75
MastoVit150,Possibilities of Phytomedicine in Monotherapy of Benign Breast Diseases,881 days,Completed,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 4,No,No,150
CASE1219,Incomplete Follow Up After Positive FIT or Stool DNA Testing: A Multimethod Approach,1918 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,30
RELI/19/Der-Rdt/001,Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.,836 days,Completed,Interventional,"Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,No,70
GS-US-467-5643,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies",2420 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,205
PRO00031416,Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors,1490 days,Recruiting,Interventional,"Experimental, Other",Behavioral,Parallel Assignment,Not Applicable,No,No,200
7635,Cannabinoids for Taxane Induced Peripheral Neuropathy,729 days,Terminated,Interventional,"Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 2,Yes,No,12
VAC for HPV,Video-Assisted Counseling for HPV Vaccination,304 days,Unknown status,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,70
ONCB-006-19F,Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer,1443 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,30
70781,Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover,1624 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,Yes,No,60
1407426,Family History Study on Cancer Risk,1887 days,Recruiting,Interventional,"Other, Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,18000
PRS-343-PCS_08_18,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,1045 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,45
NL72939.078.20,Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?,699 days,Recruiting,Interventional,"Other, Other",Procedure,Parallel Assignment,Not Applicable,No,No,21
HCI105691,Fatigue Interventions in Cancer (Exercise Intervention),1801 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Phase 2,No,No,126
AP2007-50104,Comparison of Duloxetine Versus Pregabalin,102 days,Unknown status,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,70
PRO00032593,Virtual Reality Education Program to Reduce Anxiety During Radiation Therapy,246 days,Terminated,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,28
H00020209,Dotarem vs Gadobutrol Contrast for Breast MRI,1094 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Drug",Parallel Assignment,Phase 4,Yes,No,258
BG01-2002,Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors,1072 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,120
Rhomboid,Analgesic Effects of Rhomboid Block,811 days,Recruiting,Interventional,"Experimental, Experimental, Sham Comparator","Procedure, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,72
GC101 TIL-ST-01,A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors,1005 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 1,No,No,60
IM014-032,Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants,85 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 1,Yes,No,22
CEEGOG EX-02,Tracers for Endometrial Cancer Sentinel Node Labeling,1095 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,83
93 /1801/2021,Lifting Effect on Recovery After Mastectomy,822 days,Not yet recruiting,Interventional,"Active Comparator, Placebo Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,50
2020-3627-1407,"SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT.",790 days,Unknown status,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,384
OTH267,Iraqi Trial for Lung Cancer Screening,1400 days,Unknown status,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,500
MF 22-02,Idiopathic Granulomatous Mastitis Combination Therapy,503 days,Recruiting,Interventional,"Active Comparator, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,150
2019-0989,Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physicians Choice (TPC) in Patients With HER2-positive Solid Tumor,0 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,42
UCSD IIT 150729,Histology-Independent Study of Palbociclib in Patients With Advanced Cancer,2041 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,0
P.T.REC/012/003464,Impact of Scapular Mobilization And Strengthening Exercises on Shoulder Function Post Mastectomy,200 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,40
BPX603-201A,Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors,2217 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,220
KEEP-G 07,Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer,1065 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,29
2021-0611,"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",1196 days,Recruiting,Interventional,"Other, Other, Other","Drug, Drug",Single Group Assignment,Phase 2,Yes,No,104
13022260-300-180785,Effect of Exercise in the Management of Peripheral Neuropathy,971 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,60
INCB 123667-101,Study of INCB123667 in Subjects With Advanced Solid Tumors,1486 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,155
ICO-2020-19,Clinico-biological Data Collection Study of Metastatic Lung Cancer,3287 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental",Procedure,Parallel Assignment,Not Applicable,No,No,200
CRUKD/21/004- Treatment Arm 4,"DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations",2400 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 2, Phase 3",No,No,30
NU22-09-00539,Prostate Cancer Screening With Abbreviated MRI Protocol,1340 days,Recruiting,Interventional,Experimental,"Diagnostic Test, Diagnostic Test, Procedure",Single Group Assignment,Not Applicable,No,No,300
2019-A03336-51,Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy,1159 days,Recruiting,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,60
09.2020.125,Efect of Erector Spina Plane Block on Mastectomy,116 days,Completed,Interventional,"Active Comparator, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,42
ANAE-341-19,Improving Tissue Oxygenation in Breast Reconstruction Surgery,1603 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,"Phase 1, Phase 2",No,No,40
01-2/141 27,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,31 days,Completed,Interventional,"Active Comparator, Active Comparator, Active Comparator",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,195
KF2019#1,KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug,234 days,Recruiting,Interventional,"Placebo Comparator, Active Comparator","Drug, Drug, Drug",Crossover Assignment,Phase 1,No,No,10
Vein-project,Training of Arms to Reduce Pain With Peripheral Venous Catheter,1037 days,Recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,84
thoracic sympathectomy,Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study,640 days,Completed,Interventional,"Experimental, Active Comparator","Procedure, Drug",Parallel Assignment,Not Applicable,No,No,70
20-240,Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases,1600 days,Recruiting,Interventional,"Experimental, Experimental","Radiation, Drug, Other",Parallel Assignment,Phase 2,Yes,No,134
Debio 1143-106,Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143,1094 days,Completed,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,46
457,Diagnostic Value of Bronchoscopic and Thoracoscopic Frozen Section Biopsies in Patients With Pleuropulmonary Tumors,563 days,Not yet recruiting,Interventional,Other,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,96
D8410C00001,Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies,1263 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,195
229510,Combination Therapy in Cancers With Mutations in DNA Repair Genes,1735 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,24
Estim Breast,Electrical Stimulation for Improving Postoperative Breast Sensation,792 days,Not yet recruiting,Interventional,"Experimental, Placebo Comparator","Device, Procedure",Single Group Assignment,Not Applicable,No,No,30
YS-RVON-001,Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors,686 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,41
RG1006143,Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization,589 days,Completed,Interventional,Experimental,"Other, Other, Other",Single Group Assignment,Not Applicable,No,No,35
ZL-2306-914,Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma,909 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,83
SNK01-102,Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers,702 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,0
C4551001,Study of PF-07248144 in Advanced or Metastatic Solid Tumors,2183 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,186
ONT-380-011,Effects of Tucatinib on Cardiac Repolarization in Healthy Participants,95 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Crossover Assignment,Phase 1,Yes,No,55
KCSG-ST18-20,AZD8186 and Paclitaxel in Advanced Gastric Cancer,1327 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",No,No,49
HCC 20-117,GIST and Memory and Attention Adaptation Training,1236 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,30
HEM-ONCO-013,CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer,1096 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,10
STUDY00002021,Study of Sulphoraphane in Chronic Kidney Disease,578 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",Yes,No,24
22-501,Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC),1129 days,Enrolling by invitation,Interventional,"Experimental, No Intervention, Experimental, Experimental","Other, Other",Factorial Assignment,Not Applicable,No,No,800
OLATRA,Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma,1497 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,9
ELVN-002-001,ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer,1199 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,178
FN-1501-UP1,A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML,1299 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,67
RBN-2397-19-001,"Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors",1460 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,130
STUDY00000334,Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers,485 days,Completed,Interventional,"Other, No Intervention",Device,Single Group Assignment,Not Applicable,No,Yes,15
OPT-IN Research Protocol,"Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring",426 days,Recruiting,Interventional,,Other,Single Group Assignment,Not Applicable,No,No,100
2017-A02018-45,OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients,1910 days,Unknown status,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,600
CX-5461-04,"Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",997 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,52
MC16C2,Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors,724 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Other, Other, Other",Crossover Assignment,Early Phase 1,Yes,No,2
NL75863.068.21,Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer,853 days,Not yet recruiting,Interventional,"Experimental, Experimental",Device,Parallel Assignment,Not Applicable,No,No,10
20-009,Pre-consultation Compassion Among Patients Referred to a Cancer Center,426 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,470
PUMCH-NM-11/041,68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis,395 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,30
ISU104-001,"Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors",1344 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Drug",Parallel Assignment,Phase 1,No,No,33
BR/2019/487,Binaural Music Study,77 days,Completed,Interventional,"No Intervention, Other, Other",Other,Parallel Assignment,Not Applicable,No,No,57
ATADEK/2022.11,Genital Laser Treatment in Postmenopausal Patients,365 days,Not yet recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,1
60116787-020/34123,Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients,153 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,64
CHUB-Hystocor,Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer,601 days,Withdrawn,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,0
BLU-222-1101,(VELA) Study of BLU-222 in Advanced Solid Tumors,1637 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,366
CHUBX 2015/17,Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After Neo-adjuvant Chemoradiation - RECT,204 days,Completed,Interventional,"Other, Other",Procedure,Parallel Assignment,Not Applicable,No,No,2
1766419-7,Storytelling Intervention for African Americans Living With Hypertension,214 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,60
NUV-868-01,NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,1405 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,246
436,Effects of Clinical Pilates Exercises in Patients With Rheumatoid Arthritis,281 days,Unknown status,Interventional,"Experimental, Experimental, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,30
200155,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta Trap/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)",1284 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Biological, Biological",Sequential Assignment,"Phase 1, Phase 2",Yes,No,12
2021-BRV-004,Scaffold-guided Breast Surgery,1466 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,20
EJC001,Compassion Meditation for Cancer Survivor-Caregiver Dyads,668 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,"Phase 1, Phase 2",No,No,82
PHOX-CLI_001,"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours",1474 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,146
NICSO,NICSO National Study: Physician - Nurse Monitoring Project About Oncological Adverse Events,1432 days,Completed,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,645
BJK-Z-F18HN-202010-YZGK,Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT,430 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Drug",Crossover Assignment,Phase 3,No,No,280
A-ER-109-415,Effect of Reconditioning Exercise on Older Adults With Urinary Tract Cancer Following Curative Surgery,282 days,Recruiting,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,150
2-107-05-162,Investigation of the Strategy of Preventing Post-operative Opioid-induced Hyperalgesia,354 days,Unknown status,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 4,No,No,100
20.60-onco20.07,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,231 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,43
YBCSG-21-04,Granisetron Transdermal Patch for Prophylaxis of Delayed CINV,933 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,No,No,140
SamanRostambeigi,Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity,385 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,80
20190131,Study of AMG 650 in Adult Participants With Advanced Solid Tumors,1071 days,Completed,Interventional,"Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,66
IRB00038262,"The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems",406 days,Terminated,Interventional,"Other, Active Comparator, Active Comparator, Active Comparator, Active Comparator, Active Comparator, Active Comparator, Active Comparator","Drug, Device, Other, Other",Factorial Assignment,"Phase 2, Phase 3",Yes,No,17
IRB00095260,Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors,433 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,8
TapeK_Gesso_ABM_PSO,Taping to Control Edema in Patients With Forearm Plaster for Wrist Fracture.,275 days,Unknown status,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,220
29BRC18-0005 (VinMetAtezo),Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer,1126 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,80
OPTIMUM,Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy,943 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,62
2017-003582-10,Immunotherapy In Locally Advanced Rectal Cancer,1705 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Radiation",Single Group Assignment,Phase 2,No,No,101
2017_43,Impact of Supportive Care on the Experience of Hospitalization of Patients Staying in the Protected Area of the Department of Blood Diseases,1813 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,70
4397,Social Risk Factors and Discrimination in Cancer Survivorship,1609 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,1116
00000001,Effects of Selected Exercise Program on Microcirculation and Lymphedema in Postmastectomy Patients,61 days,Not yet recruiting,Interventional,"Experimental, Other",Combination Product,Parallel Assignment,Not Applicable,No,No,30
IRB-2019-118,Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery,895 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,Yes,126
RGC-1501-001,Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy,730 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,32
20-03021615,FaCT Trial (Facilitated Cascade Testing Trial),833 days,Recruiting,Interventional,"Other, Other","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,600
210026,Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma,2437 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,43
702576,Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo,760 days,Recruiting,Interventional,"Experimental, Placebo Comparator",Drug,Parallel Assignment,Phase 4,Yes,No,100
MT-5111_001,Study of MT-5111 in HER2-positive Solid Tumors,1997 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,178
2020-1255,High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies,1013 days,Recruiting,Interventional,"Experimental, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,60
RC2022_prg.15,Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease),305 days,Recruiting,Interventional,"Experimental, Active Comparator","Dietary Supplement, Dietary Supplement",Parallel Assignment,Not Applicable,No,No,60
UW 19-436,A Resilience Promotion Program for Parents of Children With Cancer,343 days,Completed,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,103
EDGE 000339,"SHIFTPLAN: an RCT Investigating the Effect of a Shift Work Intervention on Fatigue, Sleep and Health.",304 days,Not yet recruiting,Interventional,"Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,176
METCZ20210156,Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients,731 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,40
2000031462,Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases,466 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,24
METCZ20210103,Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients,19 days,Completed,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,6
2017/184 HP,VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer,1280 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,40
20-002000,Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer,1363 days,"Active, not recruiting",Interventional,Experimental,"Behavioral, Other, Other, Other",Single Group Assignment,Not Applicable,No,No,4
18.068,PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer,2192 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Phase 3,No,No,1000
2020-3547,Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments,699 days,Completed,Interventional,"Experimental, Experimental, Active Comparator","Other, Other, Other",Crossover Assignment,Not Applicable,No,No,19
CTM-N2D,Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour,456 days,Unknown status,Interventional,Experimental,Biological,Sequential Assignment,Phase 1,No,No,10
IMT-009-101,Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas,855 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,119
B.30.2.ATA.0.01.00/1/6,Ultrasound-guided Paravertebral Block Versus Mid-point Transverse Process Pleura Block in Mastectomy Surgery,390 days,Completed,Interventional,"Experimental, Active Comparator","Drug, Device, Drug, Drug",Parallel Assignment,Phase 4,No,No,64
SYSKY-2022-019-02,Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC,1461 days,Recruiting,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,70
CHGH-IRB:(864)110-10,The Effect of Nursing Education Intervention on Womens Health Literacy of Plasticizers,303 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,100
PROT-CI2021,US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism,1758 days,Not yet recruiting,Interventional,"Experimental, Experimental, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,Yes,854
CP-MGC018-01,MGC018 With or Without MGA012 in Advanced Solid Tumors,1653 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Biological",Sequential Assignment,"Phase 1, Phase 2",Yes,No,143
RTX-224-01,RTX-224 Monotherapy in Patients With Solid Tumors,322 days,Terminated,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,7
2021-A01625-36,Clinical and Cyto-histological Evaluation of Fractional CO2 Laser Treatment on Genito-Urinary Syndromes of Menopause Related to Vaginal Atrophy,1133 days,Recruiting,Interventional,Other,Device,Single Group Assignment,Not Applicable,No,No,75
SGNB7H4V-001,A Study of SGN-B7H4V in Advanced Solid Tumors,1845 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,375
P130935,"Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy",352 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,12
2000029793,Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma,1983 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,43
794/2020/Farm/IOR,Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse,2313 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,67
SBNK-YJ-2020-016-02,Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas,1823 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,60
ThirdMMUb,Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors,1522 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 2, Phase 3",No,No,57
2693-CL-0307,A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause,683 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 3,No,No,150
2020NZKY-062-01,The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease,546 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 4,No,No,120
2021-13614,Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color,436 days,Recruiting,Interventional,"Experimental, Experimental, No Intervention","Device, Device",Parallel Assignment,Not Applicable,No,Yes,30
MER-XMT-1660-1,A Study of XMT-1660 in Participants With Solid Tumors,1235 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,166
no: P.T.REC/012/002774,"Aerobic Exercise With Diet Induces Hormonal, Metabolic, and Psychological Changes",869 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
SBNK-YJ-2019-006-02,Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas,1386 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,109
2020/900/88,Assessment of the Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause,214 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,42
DF1001-001,Study of DF1001 in Patients With Advanced Solid Tumors,2212 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,490
STUDY00000224,Connecting Families to Overcome Ovarian Cancer,982 days,Recruiting,Interventional,"Experimental, Active Comparator, Experimental, Active Comparator","Behavioral, Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,1240
2693-CL-0304,A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause,909 days,Completed,Interventional,"Experimental, Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,1831
ZUH-ITP-MBCS,ITP Block: Single or Multiple Injection?,7 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Crossover Assignment,Phase 4,No,No,12
1 TP2AH000076-01-00,Evaluation of Momentary Affect Regulation - Safer Sex Intervention,1107 days,Recruiting,Interventional,"Experimental, Sham Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,600
21-007867,Physical Activity Intervention for Hematopoietic Cell Transplant Recipients and Caregivers,665 days,"Active, not recruiting",Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,30
Masters thesis,The Effect of Art-Based Mandala on Mental Health in Bone Marrow Transplant Patients,120 days,Completed,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,46
CPI-006-001,CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers,2777 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,378
RG1001812,Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants,388 days,Completed,Interventional,Experimental,"Dietary Supplement, Procedure, Other",Single Group Assignment,Not Applicable,No,No,21
25922,Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition,472 days,Not yet recruiting,Interventional,Experimental,Other,Sequential Assignment,Not Applicable,No,No,450
2693-CL-0305,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause,764 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,302
2021-A01570-41,Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology,551 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,150
2693-CL-0302,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2,653 days,Completed,Interventional,"Experimental, Experimental, Placebo Comparator, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,501
2693-CL-0301,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause,762 days,Completed,Interventional,"Placebo Comparator, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,527
PUMCH-NM-RR,68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients,502 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Single Group Assignment,Early Phase 1,No,No,90
1-1-7-05-114,Decision Support for the Renal Replacement Therapy With End-stage Renal Disease,285 days,Completed,Interventional,"Experimental, No Intervention",Radiation,Parallel Assignment,Not Applicable,No,No,76
ALXN2040-HV-102,Potential Drug Interaction Between ALXN2040 and Rosuvastatin,63 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,Yes,No,20
NCI-2020-01206,Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer,1265 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Procedure, Procedure, Biological",Single Group Assignment,Phase 1,Yes,No,55
21083,Narrative Exposure Therapy to Reduce Symptoms of Traumatic Stress in Cancer Survivors,546 days,"Active, not recruiting",Interventional,Experimental,Other,Sequential Assignment,Not Applicable,No,No,6
STUDY00144314,KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice,1321 days,Recruiting,Interventional,"Active Comparator, Experimental",Behavioral,Single Group Assignment,Not Applicable,No,No,20
19-068,OPTimizing Treatment Focused Genetic Testing IN Cancer,3300 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,1200
69HCL21_0409,"CAncer, NUtrition and Taste 2",455 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other, Other, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,211
D8532C00003,A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole,85 days,Completed,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 1,No,No,14
UC-0107/1603,Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases,3468 days,Recruiting,Interventional,"Experimental, No Intervention",Radiation,Parallel Assignment,Not Applicable,No,No,196
AK_2021_HP,Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients,562 days,Enrolling by invitation,Interventional,Experimental,"Drug, Drug, Procedure",Single Group Assignment,Phase 2,No,No,15
C4391001,Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors,1969 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Combination Product, Combination Product, Drug, Combination Product",Sequential Assignment,"Phase 1, Phase 2",Yes,No,198
ICO-2020-14,"Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery",702 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral, Drug",Parallel Assignment,Not Applicable,No,No,100
20-2458.cc,Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.,1333 days,Recruiting,Interventional,"No Intervention, Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,300
844554,TumorGlow Intraoperative Molecular Imaging (IMI),753 days,Not yet recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,"Phase 1, Phase 2",Yes,No,500
GCT1047-01,Research Trial to Study Safety of GEN1047 (DuoBody®-CD3xB7H4) in Participants With Malignant Solid Tumors,1145 days,Recruiting,Interventional,Experimental,Biological,Sequential Assignment,"Phase 1, Phase 2",Yes,No,220
659/2017BO1,Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac,3287 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Radiation, Diagnostic Test",Single Group Assignment,Not Applicable,No,No,472
HSC-SPH-20-1117,Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention,683 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,2000
XL092-001,A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors,2053 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,1195
PH-FAPGA-01/22,A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors,275 days,Not yet recruiting,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 1,No,No,20
GCT1029-01,GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors,1261 days,Terminated,Interventional,Experimental,Biological,Sequential Assignment,"Phase 1, Phase 2",Yes,No,48
FPA150-001,FPA150 in Patients With Advanced Solid Tumors,1140 days,Completed,Interventional,Experimental,"Biological, Biological",Single Group Assignment,Early Phase 1,Yes,No,95
HEALED_CPS3,Health and Energy Through Active Living Every Day (HEALED) After Cancer Pilot Intervention for Cancer Survivors,139 days,Unknown status,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,98
IMP7068 - 101,The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors,916 days,Recruiting,Interventional,Other,Drug,Sequential Assignment,Phase 1,Yes,No,350
PY314-1-01,A Study of PY314 in Subjects With Advanced Solid Tumors,1094 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,288
LAUMCRH.YJ1.16/Jul/2019,Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery,915 days,Unknown status,Interventional,"Active Comparator, Experimental",Drug,Parallel Assignment,Phase 4,Yes,No,44
1474/19,Trigger Point Injections for Post-Mastectomy Pain Syndrome,1430 days,Recruiting,Interventional,"Active Comparator, Sham Comparator","Procedure, Procedure, Other",Parallel Assignment,Phase 2,No,No,120
CNZV930X2101,A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.,1552 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental","Other, Other, Drug",Parallel Assignment,Phase 1,Yes,No,127
TirolGESUND,"TirolGESUND: Baseline-controlled Comparison of the Effects of Fasting Dietary Intervention or Smoking Cessation Combined With Exercise in Healthy Female Tyrolean Volunteers Aged 30-60 on Epigenetic and Multi-omic Biomarkers of Health, Ageing, and Disease",832 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,156
R20-3896L,PECS Block in Partial Mastectomy for Postoperative Pain Control,427 days,Unknown status,Interventional,"Experimental, Sham Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,130
69HCL19_0992,Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act,791 days,Recruiting,Interventional,Other,Behavioral,Single Group Assignment,Not Applicable,No,No,66
201805930,Comparison of Pre-op and Post-op Pectoralis Nerve Block,964 days,Completed,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,35
2018-0075,Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery,1971 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 2,Yes,No,24
IRB-300003680,Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy,507 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Early Phase 1,Yes,No,21
HSC-MS-16-0467,Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies,365 days,Withdrawn,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 4,Yes,No,0
2021/03-12,Effects of US-guided SAPB During Breast Surgery,213 days,Completed,Interventional,"Active Comparator, No Intervention",Procedure,Crossover Assignment,Not Applicable,No,No,20
VAR-2021-12,Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy,316 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,30
WVU010518,Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy,1479 days,Suspended,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Not Applicable,No,No,15
NUSMart NM,Evaluating the Relative Effectiveness of Two Front-of-pack Nutrition Labels,125 days,Completed,Interventional,"No Intervention, Experimental, Experimental","Behavioral, Behavioral",Crossover Assignment,Not Applicable,No,No,154
XmAb22841-01,A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors,1359 days,Completed,Interventional,"Experimental, Experimental","Biological, Biological",Sequential Assignment,Phase 1,Yes,No,78
SC103,Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors,1632 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,200
ACE1702-001,ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors,1474 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,36
RP12146-2101,"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors",665 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,60
RG1005815,"Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study",1289 days,Enrolling by invitation,Interventional,"Active Comparator, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,100
MP01,Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours,1096 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,50
5688,Psychosocial Transitional Group Pragmatic Trial,610 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,100
RG1005140,"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer",1624 days,Recruiting,Interventional,Experimental,"Biological, Drug",Single Group Assignment,Phase 1,Yes,No,18
BT8009-100,Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies,1963 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,329
HN20190929,PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma,1096 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,No,No,25
STUDY00018000,EXERCISING TOGETHER for Couples Coping With Cancer,1717 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Behavioral, Behavioral, Other, Other",Parallel Assignment,Not Applicable,No,No,534
00003543,Comorbidities And Reducing inEquitieS,786 days,"Active, not recruiting",Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,63
OSU-19199,Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM),1139 days,Recruiting,Interventional,Experimental,"Procedure, Other, Device",Single Group Assignment,Not Applicable,No,Yes,20
KB-0742-1001,A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma,1757 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,170
GQ1001X2101,Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors,1394 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,96
21820,"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors",1666 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,270
NL 70691.091.19,TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention,7292 days,Recruiting,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,3000
ORM-5029-01-001,Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors,1094 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,87
NCI-2017-01232,PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,2203 days,"Active, not recruiting",Interventional,Experimental,"Drug, Other, Other, Drug",Single Group Assignment,Phase 1,Yes,No,21
PRT3645-01,A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors,705 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,51
HMBD-002-V4C26-01,"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab",1096 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,240
RG1121550,Clinical Outcomes for Offering Genetic Testing in a Tiered Approach,515 days,Completed,Interventional,Experimental,"Other, Other, Behavioral",Single Group Assignment,Not Applicable,No,No,6
KYL[2020091],Surgical Intervention for Refractory Granulomatous Lobular Mastitis,2432 days,Recruiting,Interventional,"Experimental, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,300
TJ004309STM103,A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors,576 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,25
AP1904-50102,Magnesium and Ketamine in Postoperative Analgesia,396 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 4,No,No,90
GCT1044-01,A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors,471 days,Terminated,Interventional,Experimental,Biological,Sequential Assignment,"Phase 1, Phase 2",Yes,No,48
SZMC-0216-22,A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC,2172 days,Not yet recruiting,Interventional,"Experimental, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,50
7465-CL-202,A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202),1605 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,288
ELU-FRα-1,A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα),1279 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,166
D17062,Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity,1446 days,Completed,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,Yes,7
SGNPDL1V-001,A Study of SGN-PDL1V in Advanced Solid Tumors,1528 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,315
SAIL-002,Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity,176 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 4,No,No,30
101,CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors,1398 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Biological",Parallel Assignment,Phase 1,Yes,No,48
ASN004-101,Study of ASN004 in Patients With Advanced Solid Tumors,1572 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,43
C3881001,PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors,1273 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,49
TT420X1103,Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,505 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Combination Product",Parallel Assignment,"Phase 1, Phase 2",Yes,No,225
RP2-001-18,Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors,1353 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Biological",Sequential Assignment,Phase 1,No,No,36
STUDY00020679,SMMART Adaptive Clinical Treatment (ACT) Trial,1216 days,Not yet recruiting,Interventional,Experimental,"Procedure, Procedure, Biological, Drug, Biological, Biological, Drug, Drug, Biological, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Other",Single Group Assignment,Phase 2,Yes,No,131
21-508,Video Education With Result Dependent dIsclosure,1489 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,1020
CPG-01-001,COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.,1912 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,140
TJCC-LC-20190108,Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC,641 days,Unknown status,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 4,No,No,45
2000026840,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC,823 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Combination Product",Single Group Assignment,Phase 2,Yes,No,24
INCB 106385-102,INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors,1059 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,230
GCT1046-01,GEN1046 Safety Trial in Patients With Malignant Solid Tumors,2028 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Biological, Biological, Biological",Sequential Assignment,"Phase 1, Phase 2",Yes,No,752
127-CL-01,Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors,1420 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Combination Product, Combination Product",Sequential Assignment,Phase 1,No,No,60
KY1044-CT01,Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer,2104 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,280
UAB30,A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer,1400 days,Recruiting,Interventional,"Active Comparator, Placebo Comparator","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,84
MCC-20086,Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance,603 days,Completed,Interventional,"No Intervention, Experimental, No Intervention",Behavioral,Sequential Assignment,Not Applicable,No,No,60
Oncoplastic breast surgeries,The Role of Lipofilling After Oncoplastic Breast Surgeries : Evaluation of Outcomes and Patient Satisfaction,622 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,20
XmAb20717-01,A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors,1519 days,Completed,Interventional,Experimental,Biological,Sequential Assignment,Phase 1,Yes,No,150
PBC017,Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer,1531 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,40
NCI-2017-01979,"Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery",0 days,Withdrawn,Interventional,Experimental,"Drug, Biological, Other, Biological, Other",Single Group Assignment,"Phase 1, Phase 2",Yes,No,0
Pro20170001392,"Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability",2034 days,Recruiting,Interventional,Experimental,"Other, Biological",Single Group Assignment,Phase 2,Yes,No,40
A005D-E01-201,[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR),367 days,Terminated,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,19
TAP_Sett17,Kinesio Tex Tape in Reducing Edema and Seroma After Complex Reconstructive Breast Surgery,820 days,Unknown status,Interventional,"Experimental, No Intervention",Device,Parallel Assignment,Not Applicable,No,No,60
CPO-100-US-101,Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors,1438 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,126
20-117,Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors,1452 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Other","Radiation, Radiation, Other, Other",Parallel Assignment,Phase 2,No,Yes,102
19-002006,Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer,1325 days,"Active, not recruiting",Interventional,Experimental,"Procedure, Other, Other, Other",Single Group Assignment,Early Phase 1,No,No,250
Plasticity Longitudinal cANcer,Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET),1399 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Biological,Parallel Assignment,Not Applicable,No,No,500
2021-025,Ask Questions (ASQ):Implementation of a Communication Intervention,706 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,225
ATRC-101-A01,A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies,1845 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Biological, Drug",Sequential Assignment,Phase 1,Yes,No,240
ST101-101,A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors,1279 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,162
190143,Non-Viral TCR Gene Therapy,2444 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Biological",Single Group Assignment,Phase 2,Yes,No,210
CYT-0851-01,A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors,1514 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,320
MC210102,"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study",1061 days,Recruiting,Interventional,Experimental,"Drug, Biological, Biological, Biological",Single Group Assignment,Phase 1,Yes,No,36
17573,A Study of Lasmiditan in Healthy Volunteers,141 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,96
NCI-2020-13883,"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",1852 days,Recruiting,Interventional,Experimental,"Drug, Biological",Single Group Assignment,Phase 1,Yes,No,15
TT00420CN04,To Evaluate Efficacy and Safety of TT-00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,841 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,114
ONCR-177-101,"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",2964 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Biological",Parallel Assignment,Phase 1,Yes,No,132
SGNSTNV-001,A Study of SGN-STNV in Advanced Solid Tumors,1898 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,315
2021-0299,Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax,1586 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Drug, Drug, Procedure",Parallel Assignment,Phase 1,Yes,Yes,36
SKL27969C001,"Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients",720 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,96
ACE-Pan tumor-02,ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02),166 days,Withdrawn,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,0
HCC 20-266,Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC),2956 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,61
D9090C00003,A Study to Assess the Effect of Multiple Doses of AZD5462 on the Pharmacokinetics (PK) of Drugs in Healthy Participants,74 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,32
FT500-101,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,1369 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,37
17364,A Study of LY3435151 in Participants With Solid Tumors,129 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,2
NCI-2020-06906,Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations,1067 days,Recruiting,Interventional,Experimental,"Procedure, Drug",Single Group Assignment,Phase 2,Yes,No,36
IDE161-001,A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors,915 days,Not yet recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,68
AK2018_1,18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer,319 days,Completed,Interventional,Experimental,"Drug, Other",Single Group Assignment,Phase 1,No,No,10
FT536-101,FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors,1766 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Combination Product, Combination Product, Combination Product, Combination Product, Combination Product, Combination Product, Combination Product, Drug",Sequential Assignment,Phase 1,Yes,No,322
STUDY00000719,Adaptive Symptom Self-Management Immunotherapy Study,1553 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Sequential Assignment,Not Applicable,No,No,400
JZP712-201,Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors,843 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,60
TMPS-101,Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors,1204 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,110
CancerDyads,Improving Survivorship Among Minority Cancer Dyads,1279 days,Withdrawn,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,0
00000441,Same-Day Discharge After Nipple-sparing Mastectomy or Skin-sparing Mastectomy With Breast Reconstruction,731 days,Unknown status,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,60
CCI-2003,Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC),1347 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,18
SGNB6A-001,A Study of SGN-B6A in Advanced Solid Tumors,1606 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Single Group Assignment,Phase 1,Yes,No,572
MLB-PK-001,A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer,731 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,6
XmAb23104-01,A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3),2315 days,Recruiting,Interventional,"Experimental, Experimental","Biological, Biological",Sequential Assignment,Phase 1,Yes,No,300
2020-0439,Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors,1475 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,50
CYH33-G102,Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.,1217 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,350
20-410,Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer,1042 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,210
202101,Comprehensive Outcomes for After Cancer Health,526 days,Recruiting,Interventional,"Experimental, Other","Behavioral, Device",Crossover Assignment,Not Applicable,No,No,500
NB-ND021 (NM21-1480)-101,A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors,1596 days,Recruiting,Interventional,Experimental,Biological,Sequential Assignment,"Phase 1, Phase 2",Yes,No,406
SBT6050-101,A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors,857 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,58
17-262-01,REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies,1516 days,Terminated,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,64
UC-IMM-2101,Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO,1095 days,Recruiting,Interventional,"Experimental, No Intervention",Drug,Parallel Assignment,Phase 3,No,No,646
ADCT-301-103,Study of ADCT-301 in Patients With Selected Advanced Solid Tumors,1490 days,Terminated,Interventional,"Experimental, Experimental, Experimental","Drug, Biological",Sequential Assignment,Phase 1,Yes,No,78
170177,Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer,523 days,Terminated,Interventional,Experimental,Biological,Single Group Assignment,Phase 2,Yes,No,1
TPST-1120-001,TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers,1922 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,138
180032,Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,936 days,Completed,Interventional,"Experimental, Experimental","Biological, Biological, Biological",Sequential Assignment,Phase 1,Yes,No,11
VICC SUPP 2112,Improving Care After Inherited Cancer Testing,2310 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Other, Other, Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,720
IB2022-03,Streamlined Geriatric and Oncological Evaluation Based On IC Technology,1006 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Sequential Assignment,Not Applicable,No,No,720
PR148/21,Axillary Lymph Node Dissection vs Axillary Radiotherapy in Positive Sentinel Node After Neoadjuvant Therapy,1826 days,Recruiting,Interventional,"Experimental, Active Comparator","Radiation, Procedure",Parallel Assignment,Not Applicable,No,No,1666
A9001502,Treatment Resistance Following Anti-cancer Therapies,670 days,Terminated,Interventional,Other,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,38
2020-117,DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer,1663 days,Recruiting,Interventional,"Other, Other, Other","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,260
NCI-2020-05428,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",1063 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,74
2021-0175,Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors,0 days,Withdrawn,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,0
CCT303-406-mST01,A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors,1724 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,15
6B-20-1,18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases,1461 days,"Active, not recruiting",Interventional,Experimental,"Procedure, Drug, Procedure, Procedure",Single Group Assignment,Early Phase 1,Yes,No,10
NRG-BN009,Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery,3334 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Other, Other, Radiation, Radiation",Parallel Assignment,Phase 3,No,No,350
TCR2-21-01,A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer,1989 days,Recruiting,Interventional,Experimental,"Biological, Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",Yes,No,115
NCI-2020-05956,Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV,1824 days,Recruiting,Interventional,Experimental,"Procedure, Drug, Procedure, Procedure, Biological",Single Group Assignment,Phase 1,Yes,No,18
CA052-002,A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors,1937 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,665
IMX-110-001,IMX-110 in Patients With Advanced Solid Tumors,1976 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,70
IIR 17-127,Measuring and Improving the Safety of Test Result Follow-Up,1796 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,11
WPH 2201,A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads,411 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,12
IRB20-0462,The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care,2244 days,Recruiting,Interventional,"No Intervention, Experimental",Other,Parallel Assignment,Not Applicable,No,No,860
XmAb808-01,"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors",1813 days,Recruiting,Interventional,Experimental,"Biological, Biological",Sequential Assignment,Phase 1,Yes,No,220
2019-1091,Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases,1567 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug, Other",Single Group Assignment,"Phase 1, Phase 2",Yes,No,10
VAR-2022-04,Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy,304 days,Not yet recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,40
Phase 1 SV-101,Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors,333 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,20
NYPC ERC# 2019-002,Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors,1803 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, No Intervention",Radiation,Single Group Assignment,Not Applicable,No,Yes,1800
TTX-080-001,TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers,1418 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,240
P.T.REC/012/003744,Endermologie Versus Negative Pressure Therapy on Postmastectomy Lymphedema,337 days,Recruiting,Interventional,"Experimental, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,68
P.T.REC/012/004199,Effect of Wii-console Based Exercise on Shoulder Range of Motion for Post-mastectomy Lymphedema Patients,212 days,Recruiting,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,40
Doaa Atef,Virtual Reality Versus Proprioceptive Neuromuscular Facilitation on Postmastectomy Lymphedema,427 days,Completed,Interventional,"Active Comparator, Active Comparator","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,30
0752-20-HMO,Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers,2099 days,Recruiting,Interventional,Experimental,"Drug, Drug, Biological, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,3
OCEL-01,A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,756 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Single Group Assignment,"Phase 1, Phase 2",No,No,80
ILBS-VASMPCa-103,Effectiveness of Video Assisted Self Management Program on Chemotherapy Related Side Effects .,34 days,Completed,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,60
NuTide:303,NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours,700 days,Not yet recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,91
IC 2020-11_ALCINA4,Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4,2013 days,Recruiting,Interventional,"Other, Other, Other, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,820
AMT-151-01,AMT-151 in Patients With Selected Advanced Solid Tumours,644 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,30
MDNA11-01,A Beta-only IL-2 ImmunoTherapY (ABILITY) Study,1221 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,100
SGNTGT-001,A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer,1797 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,429
PT199X1101,Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor,557 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,41
GB1275-1101 (KEYNOTE-A36),GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma,972 days,Terminated,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,61
INCAGN 2385-101,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,842 days,Completed,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,22
IB 2017-01,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,2798 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,747
INCAGN 2390-101,A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies,1059 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,40
NU04,.Exercise and Follow-up After a Mastectomy,210 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,60
STUDY00001436,Enhance the Use of Genetic Counseling and Testing in Latinas,707 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Other",Parallel Assignment,Not Applicable,No,No,61
20430,HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics,1097 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Other, Other, Other, Procedure, Other",Parallel Assignment,Not Applicable,No,No,435
STUDY00015588,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial,2158 days,Recruiting,Interventional,Experimental,"Drug, Drug, Drug, Biological, Drug, Procedure, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Biological, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Biological, Drug, Drug, Drug, Drug, Drug, Drug, Biological, Drug, Drug, Drug, Drug, Biological, Biological, Drug, Other, Drug, Drug, Drug, Drug, Drug, Drug, Biological, Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,40
IRB00092505,Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy,1766 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Sequential Assignment,Not Applicable,No,No,244
NX-1607-101,A Study of NX-1607 in Adults With Advanced Malignancies,1248 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,268
GLP-CDK-1009,Evaluation of GLR2007 for Advanced Solid Tumors,744 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,19
Teleclub_cam,Telerehabilitation in Oncology Patients,153 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Crossover Assignment,Not Applicable,No,No,30
HZDH20-002,Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.,727 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 1,No,No,98
Pro00100029,Calming Alternatives Learned During MRI-Guided Breast Biopsy,247 days,Completed,Interventional,"No Intervention, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,58
2022-0712,Feasibility Study: IGNITE-TX (Identifying Texans at Risk for Hereditary Cancer) Intervention,1584 days,Not yet recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Factorial Assignment,Not Applicable,No,No,80
2018-0439,Genetic Education in BRCA Families,1521 days,Enrolling by invitation,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,426
CR109080,A Study of Lazertinib (JNJ-73841937) in Healthy Participants,146 days,Completed,Interventional,Experimental,"Drug, Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,20
GIMI-IRB-20004,4SCAR-CD44v6 T Cell Therapy Targeting Cancer,1308 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",No,No,100
2020-0079-E,Evaluation of the Effectiveness and Implementation of the BETTER Women Peer Health Coaching Program,1022 days,Recruiting,Interventional,"Experimental, Other","Other, Behavioral",Parallel Assignment,Not Applicable,No,No,408
EOC317X1101,Study of EOC317 in Chinese Patients With Advanced Solid Tumors,915 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,No,No,140
IRB00056774,Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors,1253 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,645
EAQ202,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,1185 days,Recruiting,Interventional,"Other, Other",Other,Parallel Assignment,Early Phase 1,No,No,400
V937-013,A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013),1006 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,185
10000045,"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",1489 days,Recruiting,Interventional,Experimental,"Drug, Drug, Biological, Drug",Single Group Assignment,Phase 1,Yes,No,100
19-006717,Cancer Genetic Testing in Ethnic Populations,1402 days,Recruiting,Interventional,Experimental,"Procedure, Other",Single Group Assignment,Not Applicable,No,No,800
ATLAS-101,A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies,872 days,Recruiting,Interventional,Experimental,"Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,80
19-151,Personalized Disease Prevention,1183 days,Recruiting,Interventional,"No Intervention, Active Comparator",Behavioral,Parallel Assignment,Not Applicable,No,No,660
21-00715,Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain,1366 days,Recruiting,Interventional,"Active Comparator, Active Comparator, Placebo Comparator","Drug, Drug, Other",Parallel Assignment,Phase 3,Yes,No,750
TAC01-HER2-03,TAC T-cells for the Treatment of HER2-positive Solid Tumors,1384 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",Yes,No,70
UW17009,Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer,1689 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Radiation",Single Group Assignment,Early Phase 1,Yes,No,30
UMCC 2021.076,Methods for Increasing Genetic Testing Uptake in Michigan,1775 days,Recruiting,Interventional,"Active Comparator, Experimental, Experimental","Other, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,759
H19-04010,Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity,1567 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,200
F/N-R19-3893L,Effect of Hemp-CBD on Patients With CIPN,1039 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Other",Parallel Assignment,Phase 2,Yes,No,56
CRUKD/21/005,TT-702 in Patients With Advanced Solid Tumours.,1321 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",No,No,114
YXLL-KY-2022(057),Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer Patients,184 days,Completed,Interventional,"Active Comparator, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,270
ISI dV Xi-NSM,Robotic-Assisted da Vinci Xi Prophylactic Nipple-Sparing Mastectomy,2836 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,145
16712,A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,907 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,172
HREBA.CC-20-0098,EXCEL: Exercise for Cancer to Enhance Living Well,2676 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,1500
IPO/PI134,Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer,0 days,Unknown status,Interventional,"Experimental, Experimental, Other","Behavioral, Behavioral, Other",Parallel Assignment,Not Applicable,No,No,108
IMM2520-001,"IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors",948 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,48
OM-GRPR-02,Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors,741 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,50
17493,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,1899 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,100
LOXO-IDH-20002,Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations,927 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,200
1623168,Healthy Moms: Prenatal Counseling for Postpartum Health,864 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,451
PACT-0101,A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors,1136 days,Suspended,Interventional,"Experimental, Experimental, Experimental","Biological, Biological, Biological",Sequential Assignment,Phase 1,Yes,No,21
PROICM 2021-05 SER,Quantifying Systemic Immunosuppression to Personalize Cancer Therapy,603 days,Withdrawn,Interventional,Experimental,Diagnostic Test,Single Group Assignment,Not Applicable,No,No,0
IRB-300002068,Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health,1641 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Behavioral, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,652
0000-0001-5580-7256,Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.,851 days,Unknown status,Interventional,"Experimental, No Intervention",Other,Crossover Assignment,Not Applicable,No,No,40
2017-0319,Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF,2205 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Radiation, Radiation, Procedure, Procedure",Single Group Assignment,Phase 1,Yes,No,120
ATOS-016R,Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density,1471 days,Recruiting,Interventional,"Placebo Comparator, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,240
Pro00104093,Assessing the Immunogenicity of pING-hHER3FL,1602 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,24
VNC-236-101,Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer,677 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,24
Metabolic Cancer 001,"Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer",1949 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 3,No,No,0
19-000756,Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues,4364 days,Recruiting,Interventional,Experimental,"Procedure, Radiation, Radiation, Procedure, Radiation",Single Group Assignment,Early Phase 1,Yes,Yes,30
7339-002,"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)",2546 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,390
2018-001744-62,Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors,2181 days,Suspended,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,1000
20-533,Pembrolizumab And Lenvatinib In Leptomeningeal Metastases,633 days,Recruiting,Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,19
D9950C00001,First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours,987 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Drug, Biological",Sequential Assignment,Phase 1,Yes,No,61
19-011472,"Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study",1476 days,"Active, not recruiting",Interventional,Experimental,"Procedure, Other, Other, Other",Single Group Assignment,Phase 1,No,No,230
7684A-005,MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005),1985 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Biological, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,610
2017-0719,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,2275 days,Recruiting,Interventional,Experimental,"Drug, Biological, Drug",Single Group Assignment,Phase 1,Yes,No,18
CBX-12-101,Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors,1064 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,130
1801,9-ING-41 in Patients With Advanced Cancers,2493 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,350
IJB-IRAES-2020,Immunological Variables Associated to ICI Toxicity in Cancer Patients,822 days,Recruiting,Interventional,,Drug,Single Group Assignment,Phase 2,No,No,441
IRB00229163,Behavioral Weight Loss Program for Cancer Survivors in Maryland,1011 days,"Active, not recruiting",Interventional,"Other, Other, Other","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,300
ON-1002,"A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer",832 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,30
SGN47M-001,A Safety Study of SGN-CD47M in Patients With Solid Tumors,425 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,16
P-MUC1C-ALLO1-001,P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors,6254 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Drug",Sequential Assignment,Phase 1,Yes,No,100
NTI1GSA,"Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid",699 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Biological, Drug",Sequential Assignment,Phase 1,No,No,12
FT538-102,FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,1390 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Combination Product, Combination Product",Sequential Assignment,Phase 1,Yes,No,189
OHSN-REB#20170381-01H,Randomized Trial of eOncoNote,1108 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,181
H-43405 VISTA,"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",6590 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,45
QUILT-2.025,QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,873 days,Unknown status,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,16
ZZTIL-012,Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors,5113 days,Recruiting,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,40
20201421,"With Love, Grandma (Con Cariño, Abuelita) Pilot Study",464 days,Recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,80
YSCH-01-0000,Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study,761 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,No,No,28
SNB101P01,"Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors",1166 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,No,No,36
1224/2018,Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy,1461 days,Recruiting,Interventional,"Active Comparator, Active Comparator",Device,Parallel Assignment,Not Applicable,No,No,196
438-IO-101,Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,752 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,71
831-IO-101,Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,976 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Single Group Assignment,Phase 1,Yes,No,79
BHP0120,A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation,1401 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Phase 2,No,No,1500
CDX527-01,A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies,970 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,27
Meet-URO 12,Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy,736 days,Completed,Interventional,"Experimental, Other","Drug, Other",Parallel Assignment,Phase 2,Yes,No,58
NC318-01,A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors,1646 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,109
STR-004-001,Strata PATH™ (Precision Indications for Approved Therapies),2922 days,Recruiting,Interventional,"Other, Other, Other, Other, Other","Drug, Drug, Drug, Drug, Drug",Single Group Assignment,Phase 2,Yes,No,700
Pro00103249,Symptom Management for YA Cancer Survivors,2079 days,Recruiting,Interventional,"Experimental, Active Comparator",Behavioral,Crossover Assignment,Not Applicable,No,No,120
21850,Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors,2048 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Device, Drug, Drug",Parallel Assignment,Phase 1,Yes,Yes,32
180049,Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer,3486 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Drug, Biological, Drug",Parallel Assignment,Phase 2,Yes,No,270
ARC-5 (AB928CSP0005),A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,1137 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,48
201809177,PROactive Evaluation of Function to Avoid CardioToxicity,1450 days,Terminated,Interventional,"Experimental, Active Comparator",Device,Parallel Assignment,Phase 2,No,Yes,49
2020-2110,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,203 days,Completed,Interventional,"Active Comparator, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,27
IIT2020-24-SHIRAZIP-BURN,The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors,789 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,20
PY159-2-01,A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors,878 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,343
C3651010,Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia,455 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,18
Palliach,Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care,515 days,Unknown status,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,80
TAK-500-1001,A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors,1059 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,118
PRT1419-02,A Study of PRT1419 in Patients With Advanced Solid Tumors,544 days,Completed,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,Yes,No,26
IIT2020-13-GRESHAM-ELLY,Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients,583 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,100
2018-0663,Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients,910 days,Recruiting,Interventional,Experimental,"Procedure, Drug",Single Group Assignment,Phase 1,Yes,No,40
C3441037,A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors,578 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug, Drug",Crossover Assignment,Phase 1,Yes,No,73
CE 07-14-2020,Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer,1401 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,200
ELVCAP-001-01,Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors,975 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,Yes,No,75
143631,"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.",498 days,Withdrawn,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,0
ZZITICI-004,Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors,5479 days,Recruiting,Interventional,"Experimental, Active Comparator",Drug,Parallel Assignment,"Phase 2, Phase 3",Yes,No,200
QBS-72S-1001,"Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S",885 days,Completed,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,No,No,15
2440LM-002,DNX-2440 for Resectable Colorectal Liver Metastasis,1049 days,Recruiting,Interventional,"Experimental, Experimental, Experimental",Biological,Sequential Assignment,Phase 1,Yes,No,30
DB-1303-O-1001,A Study of DB-1303 in Advanced/Metastatic Solid Tumors,1339 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Biological,Single Group Assignment,"Phase 1, Phase 2",Yes,No,360
VISTA-101,A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101),669 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,314
ZZICI3-015,Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors,1459 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,100
ALS-6000-101,"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours",714 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,80
AA1809,Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors,1129 days,Completed,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,13
PMV-586-101,The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE),2084 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,181
AMXT1501-102,Oral AMXT 1501 Dicaprate in Combination With IV DFMO,488 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,56
201909133,Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers,988 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,25
FPI-1966-101,A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours,1686 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug, Biological",Sequential Assignment,"Phase 1, Phase 2",Yes,No,155
JAB-3312-1002,A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China,1269 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,No,No,24
707-IO-101,Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies,1483 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Factorial Assignment,"Phase 1, Phase 2",Yes,No,179
UW18101,Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction,1004 days,Completed,Interventional,Experimental,Dietary Supplement,Single Group Assignment,Phase 3,No,No,125
JAB-3312-1001,"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors",1618 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,24
PAL-E602-001,Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01),1206 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Biological, Biological",Sequential Assignment,"Phase 1, Phase 2",Yes,No,273
340-74,CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC),900 days,Withdrawn,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,Yes,No,0
PRO17070414,Self-Advocacy Serious Game in Advanced Cancer,826 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,78
MAPreminder1,UCLA Health Patient Health Maintenance Text Reminder,465 days,Not yet recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,24000
MFLeong,RCT of Acceptance and Commitment Therapy Versus Mindfulness-based Stress Reduction in Head and Neck Cancer,1095 days,Not yet recruiting,Interventional,"Experimental, Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,90
1100,NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy,3422 days,Recruiting,Interventional,Experimental,"Drug, Radiation, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,145
MAPinitial,UCLA Health Patient Health Maintenance Outreach Text Message,479 days,Enrolling by invitation,Interventional,"Experimental, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,48000
MAPreminder2,UCLA Health Patient Health Maintenance With Interactive Text Reminder,404 days,Not yet recruiting,Interventional,"No Intervention, Experimental, Experimental, Experimental","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,24000
G190165,Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites,1354 days,"Active, not recruiting",Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,20
JSKN003-102,To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors,1036 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,Phase 1,No,No,365
RAIN-3202,Milademetan in Advanced/Metastatic Solid Tumors,1004 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,65
56160922.7.3001.5274,Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds,366 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,No,No,106
A222001,Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer,579 days,Recruiting,Interventional,"Experimental, Experimental, Placebo Comparator, Placebo Comparator","Drug, Drug, Other, Other",Crossover Assignment,Phase 2,Yes,No,87
CH1701,CH1701 for Prevention and Treatment of Radiation Burns,515 days,Unknown status,Interventional,"Placebo Comparator, Placebo Comparator, Active Comparator, Placebo Comparator, Placebo Comparator, Placebo Comparator, Placebo Comparator","Drug, Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",No,No,92
D0816C00020,Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients,1500 days,Completed,Interventional,Experimental,Drug,Single Group Assignment,Phase 3,No,No,279
K01CA190659,Culturally Appropriate Nutrition Communication for Mexican American Women,1371 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Other,Parallel Assignment,Not Applicable,No,No,800
TOS-358-001,A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors,1020 days,Recruiting,Interventional,Experimental,Drug,Single Group Assignment,Phase 1,Yes,No,241
UW19-183,"The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence",893 days,Recruiting,Interventional,"Experimental, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,174
SI-B003-101,"A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",902 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,Phase 1,No,No,159
PROT004,Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer,280 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator","Device, Device",Parallel Assignment,Not Applicable,No,Yes,352
EK 1612/2018,Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing,1337 days,Completed,Interventional,"Other, Other",Procedure,Parallel Assignment,Not Applicable,No,No,406
202006168,Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome,935 days,Recruiting,Interventional,"No Intervention, Experimental",Other,Sequential Assignment,Not Applicable,No,No,150
BO41929,A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,357 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,1
IRB202201399 -N-R,A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials,1703 days,Not yet recruiting,Interventional,"Experimental, Experimental",Behavioral,Parallel Assignment,Not Applicable,No,No,350
FLX475-02,Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab,1893 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,375
2019-A02135-52,Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine,3308 days,Recruiting,Interventional,"Other, Other, Other, Other, Other, Other, Other, Other",Genetic,Single Group Assignment,Phase 2,No,No,1644
18-504,Smartphone Technology to Alleviate Malignant Pain (STAMP),1277 days,Completed,Interventional,Other,Behavioral,Single Group Assignment,Not Applicable,No,No,20
DB-1305-O-1001,First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors,1077 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Single Group Assignment,"Phase 1, Phase 2",Yes,No,235
TAS0612-101,A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer,1325 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Single Group Assignment,Phase 1,Yes,No,242
IIT2021-07-Atkins-CARMA,Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial,694 days,"Active, not recruiting",Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,20
1948-CL-0101,"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors",1824 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,190
CO-338-100,A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes,967 days,Terminated,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,83
STUDY00020629,Identifying and Caring for Individuals With Inherited Cancer Syndrome,3745 days,Recruiting,Interventional,Other,"Procedure, Other, Other, Other",Single Group Assignment,Not Applicable,No,No,27500
E7766-G000-101,Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101,883 days,Completed,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,24
NRG-GU006,BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER,3840 days,"Active, not recruiting",Interventional,"Placebo Comparator, Experimental","Drug, Radiation, Other",Parallel Assignment,Phase 2,Yes,No,311
BBI-20201001,A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors,2441 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,390
ZWI-ZW49-101,A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers,2300 days,Recruiting,Interventional,Experimental,Drug,Parallel Assignment,Phase 1,Yes,No,174
BVAC-B-P1,Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care,441 days,Completed,Interventional,Experimental,Biological,Single Group Assignment,Phase 1,No,No,8
IDE397-001,Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion,1173 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,382
MDK-703-102,A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors,936 days,Recruiting,Interventional,"Experimental, Experimental","Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,150
19-011444,Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ,1984 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,"Phase 2, Phase 3",Yes,No,104
ATTCK-34-01,Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers,365 days,Terminated,Interventional,Experimental,"Biological, Drug",Single Group Assignment,Phase 1,Yes,No,6
BDTX-189-01,"A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",1002 days,Terminated,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,91
DB-1310-O-1001,A Study of DB-1310 in Advanced/Metastatic Solid Tumors,1242 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,287
NRG-GU009,"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial",4764 days,Recruiting,Interventional,"Active Comparator, Experimental, Active Comparator, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Other, Other, Radiation, Drug",Parallel Assignment,Phase 3,Yes,No,2478
17504,A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer,886 days,Completed,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 1,Yes,No,52
DGD-44-065,Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years,2839 days,Recruiting,Interventional,"Experimental, Experimental, Other","Procedure, Procedure, Procedure, Procedure, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 4,Yes,No,2076
22-OBU-SH-CA-II-019,Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy,670 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 1,No,No,80
20220586-01H,Reexamining Her Cardiovascular Risk - Ottawa WomeNs Longitudinal Cohort Study,403 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Diagnostic Test,Parallel Assignment,Not Applicable,No,No,210
D8532C00004,"Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers",183 days,Completed,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 1,Yes,No,59
CLIN-17-008,Study of the Safety and Effectiveness of Motiva Implants®,5442 days,"Active, not recruiting",Interventional,"Other, Other, Other, Other",Device,Single Group Assignment,Not Applicable,No,Yes,800
Ad-p53-002,Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.,1552 days,Unknown status,Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,40
TUMAGNOSTIC(CP506-001),Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI,1126 days,Not yet recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",No,No,126
20210104,A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression,1404 days,Recruiting,Interventional,"Experimental, Experimental",Drug,Sequential Assignment,Phase 1,Yes,No,303
217228,First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors,1378 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,162
FT516-102,FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,872 days,Completed,Interventional,Experimental,"Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,12
IMC-F106C-101,Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors,2168 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug",Sequential Assignment,"Phase 1, Phase 2",Yes,No,170
TK-Onko,Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses,656 days,Completed,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,100
Pro00103812,Neoadjuvant Immunotherapy in Brain Metastases,225 days,Terminated,Interventional,"No Intervention, Experimental","Drug, Drug",Single Group Assignment,Phase 2,Yes,No,1
17894,Taking Time to Connect: A Study of Programs for Hispanic Mothers Diagnosed With Cancer and Their Children,1263 days,Completed,Interventional,"Experimental, Other","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,43
M19-345,"Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors",1876 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,260
21-00072,Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy,337 days,Completed,Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 4,Yes,No,31
20246,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",280 days,Completed,Interventional,"Experimental, Experimental","Drug, Drug",Crossover Assignment,Phase 1,Yes,No,14
UW21090,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,447 days,Completed,Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,118
18-222,GENetic Education Risk Assessment and TEsting Study,3159 days,"Active, not recruiting",Interventional,"Experimental, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,1000
4830-001,Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001),2673 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Biological",Parallel Assignment,Phase 1,Yes,No,442
2020-002766-14,Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab,2154 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,Phase 2,No,No,112
AG0315OG/CTC0140,RegoNivo vs Standard of Care Chemotherapy in AGOC,1826 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Biological, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,450
63646,Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer,1574 days,Recruiting,Interventional,"Active Comparator, Experimental","Other, Behavioral",Parallel Assignment,Not Applicable,No,No,2996
201617079.3,Accelerated Hypofractionated Whole Breast Irradiation Plus Sequential Boost Versus Concomitant Boost Following BCS,1125 days,Unknown status,Interventional,"Active Comparator, Experimental","Radiation, Radiation",Parallel Assignment,Not Applicable,No,No,185
C4221015,A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer,2155 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Active Comparator, Experimental, Active Comparator","Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,815
ARRAY-818-202,An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer,1853 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,Yes,No,98
03.CP.0.3,Study to Evaluate VORTX Rx (Theresa),483 days,Completed,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,8
0482-001,A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001),2072 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Biological, Biological, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,230
GO42144,"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",1585 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug, Drug, Drug, Drug, Drug, Drug",Sequential Assignment,Phase 1,Yes,No,498
Ordu55,Nutrition Education and Quality of Life in Cancer Cachexia,306 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,80
ORDU551,"Slimming Myokines, Cancers,Nutritional and Psychology Support",731 days,Not yet recruiting,Interventional,"Other, Other, Other, Other","Other, Other, Other, Other",Crossover Assignment,Not Applicable,No,No,240
ONO-4059-09,Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study),1645 days,Recruiting,Interventional,"Experimental, Experimental, Experimental","Drug, Drug, Drug",Parallel Assignment,Phase 2,Yes,No,112
19741,"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",1289 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Sequential Assignment,Phase 1,Yes,No,56
JTX-8064-101,"Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors",1084 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental","Drug, Drug",Parallel Assignment,"Phase 1, Phase 2",Yes,No,281
IBC0966-I/IIa,Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors,1553 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental, Experimental, Experimental, Experimental",Biological,Sequential Assignment,"Phase 1, Phase 2",No,No,228
LCH-112020,Subzero and Scorpion Trial,1019 days,Recruiting,Interventional,,Procedure,Single Group Assignment,Phase 2,No,No,20
"019/026/ICI, CEI/1330/18",Effect of Two Cognitive-Behavioral Interventions on Cervical Cancer Patients,715 days,Unknown status,Interventional,"Experimental, Active Comparator","Other, Other, Other, Other",Parallel Assignment,Not Applicable,No,No,92
HP-00070946,Exercise Effect on Chemotherapy-Induced Neuropathic Pain,1918 days,"Active, not recruiting",Interventional,"Other, Experimental, Experimental","Behavioral, Other, Behavioral",Parallel Assignment,Not Applicable,No,No,60
FGCL-4592-898,A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies,422 days,Recruiting,Interventional,"Experimental, Active Comparator","Drug, Drug",Parallel Assignment,Phase 3,No,No,146
2000034075,Buprenorphine Integration Research and Community Health,1223 days,Recruiting,Interventional,Experimental,Behavioral,Single Group Assignment,Not Applicable,No,No,20
APHP180586,Evaluating Effectiveness of a Communication Facilitator : A Randomized Trial,517 days,Unknown status,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,400
NCI-2020-07841,Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer,1273 days,Recruiting,Interventional,Experimental,"Procedure, Procedure, Drug, Biological",Single Group Assignment,Phase 1,Yes,No,55
S60857,FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study,2485 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,200
T30-0002,Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood,242 days,Unknown status,Interventional,Experimental,Device,Single Group Assignment,"Phase 1, Phase 2",No,Yes,100
CAMH2_1001,"A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer",1221 days,Recruiting,Interventional,Experimental,Drug,Sequential Assignment,"Phase 1, Phase 2",Yes,No,70
CIRB Ref. No: 2019/2135,Health-related Quality of Life-intervention in Survivors of Breast and Other Cancers Experiencing Cancer-related Fatigue Using Traditional Chinese Medicine: The HERBAL Trial,959 days,Unknown status,Interventional,"Experimental, Placebo Comparator","Other, Other",Parallel Assignment,Phase 2,No,No,80
Nigeria World Cancer Walk 2022,"Step up to Health, Nigeria! Impact of 2022 World Cancer Day Walk on Health Behaviors Among Nigerians",0 days,Not yet recruiting,Interventional,"Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,527
NRG-HN010,"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer",2131 days,Recruiting,Interventional,"Active Comparator, Experimental","Drug, Other, Biological, Biological",Parallel Assignment,Phase 2,Yes,No,116
D081SC00001Sub,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort),1741 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,108
D081SC00001,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer,1460 days,"Active, not recruiting",Interventional,"Experimental, Placebo Comparator","Drug, Drug",Parallel Assignment,Phase 3,Yes,No,796
H18-02052,BREAST ADM Trial for Alloplastic Breast Reconstruction,401 days,Unknown status,Interventional,"Active Comparator, Active Comparator, Active Comparator, Active Comparator","Device, Device, Device, Device",Parallel Assignment,Not Applicable,No,No,328
REG-114-2019,Histopathologic Effect of Calcium Electroporation on Cancer in the Skin,1382 days,Recruiting,Interventional,Experimental,Combination Product,Single Group Assignment,Phase 2,No,No,24
20-0270-E,Family History App in Personalized Medicine,802 days,"Active, not recruiting",Interventional,"Experimental, No Intervention",Other,Parallel Assignment,Not Applicable,No,No,627
PRO00104179,Onco-primary Care Networking to Support TEAM-based Care,1021 days,Recruiting,Interventional,"Experimental, Experimental","Behavioral, Behavioral, Behavioral",Sequential Assignment,Not Applicable,No,No,800
SJHH_PSPM,Post SBRT Pulmonary Metastasectomy (PSPM) Trial,1265 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,39
823871-iGame,Digital Intervention for the Modification of Lifestyles (iGame),757 days,Not yet recruiting,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,48
2018-0419,Pediatric Reporting of Adult-Onset Genomic Results,1313 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Genetic, Genetic, Genetic",Parallel Assignment,Early Phase 1,No,No,705
2019-00965,The SERENITY Study: Online Mindfulness-Based Cancer Recovery for Patients With Gynecological Cancer,1016 days,Completed,Interventional,"Experimental, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,62
COALESE/2021/103,Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy,547 days,Recruiting,Interventional,"Experimental, No Intervention","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,50
2017_71,PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Pagets Disease of the Vulva (EMPV).,1801 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,24
PYC001,The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments,715 days,Unknown status,Interventional,"Experimental, Experimental, Experimental, Experimental","Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement",Crossover Assignment,Not Applicable,No,No,40
22-01516,NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation,1279 days,Not yet recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,2160
2U01HG007292-05,Cancer Health Assessments Reaching Many,1964 days,"Active, not recruiting",Interventional,"Active Comparator, Experimental","Other, Other",Parallel Assignment,Not Applicable,No,No,967
20201224,Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate,1310 days,Not yet recruiting,Interventional,Experimental,"Drug, Drug, Drug",Single Group Assignment,Phase 2,No,No,50
CTMS# 19-0069,Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0,1417 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Early Phase 1,Yes,No,26
E2019453,Bovine Pericardial Patch and TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction.,1095 days,Unknown status,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,176
21-103,A Study to Develop a Strategy to Increase Lung Cancer Screening in Women Who May Be at Risk for Lung Cancer,1096 days,"Active, not recruiting",Interventional,Experimental,Behavioral,Single Group Assignment,Early Phase 1,No,No,30
ABCSG C08,ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer,2847 days,Recruiting,Interventional,"Experimental, Other","Other, Other",Parallel Assignment,Not Applicable,No,No,788
PCA001,Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer,1522 days,Recruiting,Interventional,,"Biological, Biological",Single Group Assignment,"Phase 1, Phase 2",Yes,No,137
CASE1121,Prepectoral vs Partial Subpectoral Two-Stage Implant-Based Breast Reconstruction,91 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,62
Nigeria Cancer Walk,"Step up to Health, Nigeria! Impact of World Cancer Day Walk on Health Behaviors Among Nigerians",0 days,Completed,Interventional,"Active Comparator, No Intervention",Behavioral,Parallel Assignment,Not Applicable,No,No,527
20-565,Comparing Two Different Surgical Techniques for Breast Reconstruction,333 days,Withdrawn,Interventional,"Experimental, Active Comparator","Procedure, Procedure",Parallel Assignment,Phase 3,No,No,0
Arabic BREAST-Q,Validity and Reliability of Arabic Version of Breast Questionnaire,91 days,Not yet recruiting,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,87
UPCC 11919,Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients,1232 days,Recruiting,Interventional,"Experimental, Experimental, Experimental, Experimental","Other, Other, Other",Parallel Assignment,Not Applicable,No,No,560
segmental thoracic TEA-spinal,US-guided Thoracic Spinal Epidural Anesthesia VS GA for Abdominal and Breast Surgeries,227 days,Completed,Interventional,"Active Comparator, No Intervention",Procedure,Parallel Assignment,Not Applicable,No,No,63
IRB-22-34,Comparison of Patient Satisfaction in Post-operative Breast Surgery Patients Having Physical Clinic and Tele Clinic Follow up: A Randomized Controlled Trial,243 days,Enrolling by invitation,Interventional,"Active Comparator, Active Comparator","Other, Other",Parallel Assignment,Not Applicable,No,No,202
PSCI-19-112,Diminish Chemotherapy Related Side Effects Through Patient Education,1012 days,Recruiting,Interventional,Experimental,Other,Single Group Assignment,Not Applicable,No,No,50
2016-0463,REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction,1270 days,Completed,Interventional,"Experimental, Experimental","Other, Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,20
IIT-0013,MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1),708 days,Recruiting,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,100
BND and RND,Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection,364 days,Unknown status,Interventional,"Experimental, Experimental","Device, Device",Parallel Assignment,Not Applicable,No,No,10
TheNethersole,Effects of Music Intervention Combined With Progressive Muscle Relaxation in Cancer Patients,155 days,Completed,Interventional,"Experimental, No Intervention","Other, Other",Parallel Assignment,Not Applicable,No,No,84
N-111012422,Diet Effect on Cancer Treatment Outcome,428 days,"Active, not recruiting",Interventional,"Active Comparator, Active Comparator, Placebo Comparator, Placebo Comparator, No Intervention, No Intervention","Dietary Supplement, Other",Parallel Assignment,Phase 1,No,No,160
302,"177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)",853 days,Withdrawn,Interventional,Experimental,Biological,Single Group Assignment,"Phase 1, Phase 2",Yes,No,0
MC01/01/19,Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE),1068 days,Unknown status,Interventional,Experimental,"Procedure, Procedure",Single Group Assignment,Not Applicable,No,No,35
LCCC1748,Academic-Industrial Partnership for Translation of Acoustic Angiography,792 days,Completed,Interventional,"Experimental, Experimental","Device, Drug",Sequential Assignment,Phase 4,No,Yes,20
69HCL22_0466,Lung Cancer Screening Implementation Among Employees at Lyon Hospital,730 days,Not yet recruiting,Interventional,Experimental,"Behavioral, Other",Single Group Assignment,Not Applicable,No,No,600
IMPACNEO,IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in HIV Patients,1327 days,Recruiting,Interventional,"Active Comparator, Experimental","Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,4638
GCO 19-2707,To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,1095 days,Withdrawn,Interventional,"Active Comparator, Active Comparator","Drug, Drug",Parallel Assignment,Phase 2,Yes,No,0
RECO_CT29A,Investigation of Urinary Biomarkers for the Detection of Prostate Cancer,275 days,Suspended,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,No,200
INT 292/20,Lung Cancer Prevention Screening Programme in Italy,1445 days,Recruiting,Interventional,"Experimental, Experimental","Diagnostic Test, Other",Parallel Assignment,Not Applicable,No,No,7324
STUDY21020095,Efficacy of a Self-advocacy Serious Game Intervention,1470 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,336
D967MC00001,A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations,2574 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,102
UHHeidelberg,Decision Aid to Support Advanced Cancer Patients,1278 days,Recruiting,Interventional,"No Intervention, Other",Other,Sequential Assignment,Not Applicable,No,No,70
R01CA205025,Understanding the Post-Surgical Non-Small Cell Lung Cancer Patients Symptom Experience,1763 days,Recruiting,Interventional,"Experimental, Experimental, Active Comparator","Behavioral, Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,279
HCB/2021/0130,Mapping Sentinel Lymph Node in Initial Stages of Ovarian Cancer,850 days,Recruiting,Interventional,Experimental,Procedure,Single Group Assignment,Not Applicable,No,No,62
S1614,Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors,2929 days,"Active, not recruiting",Interventional,"Experimental, Experimental, Experimental","Other, Drug, Drug, Drug",Parallel Assignment,Phase 3,Yes,No,444
TMHPO1763,A Pilot Study on HPV and Cervical Cancer Screening in Mumbai,30 days,Unknown status,Interventional,Other,Other,Single Group Assignment,Not Applicable,No,No,227
APHP210359,Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer (HRPCa-II),1857 days,Not yet recruiting,Interventional,Other,Procedure,Single Group Assignment,Not Applicable,No,No,880
M16VIB,Vinorelbine in Advanced BRAF-like Colon Cancer,731 days,Unknown status,Interventional,"Experimental, Experimental",Drug,Parallel Assignment,Phase 2,No,No,82
EPOC1903,Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer,1278 days,"Active, not recruiting",Interventional,Experimental,"Drug, Drug",Single Group Assignment,Phase 2,No,No,30
CASE2118,Integrated Imaging System for In Vivo Visualization of Free Flap Perfusion Using Indocyanine Dye,1348 days,Suspended,Interventional,Experimental,Device,Single Group Assignment,Not Applicable,No,Yes,25
PARALUC,Pneumonitis After Radiotherapy for Lung Cancer,1369 days,Recruiting,Interventional,Experimental,"Diagnostic Test, Other",Single Group Assignment,Not Applicable,No,No,98
CTC20200417,Influence of Opioids on Circulating Tumor Cells in Radical Cystectomy,233 days,Completed,Interventional,"Active Comparator, Experimental","Procedure, Procedure",Parallel Assignment,Not Applicable,No,No,44
CASE4119,The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction,791 days,Recruiting,Interventional,"Active Comparator, Experimental","Procedure, Behavioral",Parallel Assignment,Not Applicable,No,No,20
29BRC20.0021,Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism,2922 days,Recruiting,Interventional,"Active Comparator, Experimental","Diagnostic Test, Diagnostic Test",Parallel Assignment,Not Applicable,No,No,1276
CRUKD/21/004 - Treatment Arm 2,"DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition",2375 days,Not yet recruiting,Interventional,Experimental,Drug,Single Group Assignment,"Phase 2, Phase 3",No,No,30
20201491,Culturally Tailored Nurse Coaching Study for Cancer Symptom Management,615 days,Recruiting,Interventional,"Experimental, Active Comparator","Behavioral, Behavioral",Parallel Assignment,Not Applicable,No,No,98
32900654326,"TPVB, PECSB, ESPB for Postmastectmy Pain",853 days,Completed,Interventional,"Placebo Comparator, Active Comparator, Active Comparator, Active Comparator","Procedure, Drug",Parallel Assignment,Not Applicable,No,No,80
ReDA 13176,A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.,2192 days,Not yet recruiting,Interventional,"Active Comparator, Experimental","Radiation, Drug, Drug, Drug, Drug, Other, Radiation, Procedure, Other, Radiation",Parallel Assignment,Phase 3,No,No,180
64121317.4.1001.5330,Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial),1369 days,"Active, not recruiting",Interventional,Experimental,Drug,Single Group Assignment,Phase 2,Yes,No,38
3-2020-0038,Intraoperative Radiation Therapy for Resectable Pancreatic Cancer,2190 days,Recruiting,Interventional,Experimental,Radiation,Single Group Assignment,Not Applicable,No,No,80
